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Abstract 
 
Background 
Cardiovascular disease (CVD)-related events such as myocardial infarction and stroke remain 
the world’s leading cause of death. The incidence of CVD-related events is expected to rise in 
the future due to the increase in the global prevalence of obesity and diabetes, in addition to 
less economically developed countries adopting a western style diet. Atherosclerosis is a 
chronic inflammatory disease which is the underlying cause of CVD and characterised by the 
build-up of fatty deposits within the walls of medium and large arteries. Macrophages play 
critical roles during the pathogenesis of atherosclerosis, including the uptake of modified low-
density lipoproteins to form foam cells. CardioWise is a dietary supplement developed by 
Cultech Limited which contains the anti-inflammatory compounds ω-3 PUFAs, flavanols and 
phytosterols. The aim of this project was to assess the cardiovascular protective effects of 
CardioWise and its individual components in isolation using in vitro and in vivo model systems. 
Results 
Foam cell formation was attenuated in human THP-1 macrophages treated with CardioWise. 
In addition, CardioWise reduced pro-inflammatory gene expression, monocyte recruitment and 
M1 macrophage phenotype polarisation. CardioWise was also found to increase HDL 
cholesterol levels and attenuate circulating levels of pro-inflammatory cytokines in wild type 
mice. Further investigation identified (+)-catechin within CardioWise as a key beneficial 
molecule to explore in greater detail. In vitro experiments demonstrated that catechin reduced 
monocyte migration and reactive oxygen species generation. Wild type mice treated with 
catechin were also found to receive anti-atherogenic benefits such as increased HDL 
cholesterol levels and reduced pro-inflammatory cytokine levels. 
Conclusion 
The findings of this study show that CardioWise and catechin are capable of exerting strong 
anti-inflammatory effects on several stages of atherosclerosis disease development in vitro. 
Furthermore initial in vivo studies using wild type mice revealed that both treatments are also 
capable of exerting several cardiovascular protective effects. Reasons for these beneficial 
effects have been proposed in this thesis and future studies outlined. 
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Chapter 1: Introduction 
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1.1 Prevalence of atherosclerosis 
The World Health Organisation (WHO) has estimated that one in three global deaths are due 
to the total number of cardiovascular disease (CVD)-related events, such as myocardial 
infarction (MI) and stroke (WHO 2017). The global number of CVD-related deaths in 2015 was 
estimated to be 17.7 million (WHO 2017). Furthermore during 2013 in England and Wales, 
there were 142,000 registered CVD-related deaths, equating to 28% of the total number of 
deaths that year (ONS 2014). The levels of CVD-related events have remained consistent in 
England and Wales since 2011 (ONS 2012; ONS 2013; ONS 2014) whereas the global 
incidence of CVD is predicted to increase significantly due to rises in the rates of obesity and 
diabetes in combination with the uptake of a westernised diet in developing countries. Obesity 
and diabetes are two major risk factors for CVD and therefore increased prevalence of these 
two conditions will result in a rise in the number of reported CVD-related events (Lavie et al. 
2016; Dongerkery et al. 2017). Atherosclerosis is a chronic inflammatory disease which is the 
underlying cause of CVD and therefore therapeutic strategies that can attenuate disease 
development must be pursued further in order to reduce its prevalence. Atherosclerosis is 
triggered by the dysfunctional transportation of lipids and the resulting build-up of cholesterol 
within the walls of medium and large arteries. 
 
1.2 Lipid dysfunctions in atherosclerosis 
Cholesterol can be obtained from two sources, de novo synthesis and dietary intake, with both 
sources requiring transport around the body to the liver or peripheral tissues (McLaren et al. 
2011a). Due to the hydrophobic nature of lipids, there are several hydrophilic lipoproteins 
which each have a different function and allow lipids to be transported in the blood (Fig. 1.1; 
Table 1.1). Newly synthesised triacylglycerols (TGs) in the liver can be transported to 
peripheral tissues by very low density lipoproteins (VLDL), whereas TGs synthesised in the 
intestine from the digestion products of dietary fats are transported to the liver or peripheral 
tissues by chylomicrons (McLaren et al. 2011a). Low density lipoproteins (LDL) are the most 
abundant lipoprotein found in the bloodstream and transports cholesterol from the liver to the 
peripheral tissues, whereas intermediate density lipoproteins (IDL) are found at very low levels 
and forms an intermediate step between VLDL and LDL. VLDL can receive apolipoprotein 
(Apo)-E, -A and -C from high density lipoproteins (HDL) and transfers phospholipids in return. 
The TGs in VLDL can then be hydrolysed by lipoprotein lipase (LPL) and hepatic lipase (HL) 
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altering the VLDL into an IDL particle. LDL can be formed from IDL following further HL-
mediated TG hydrolysis and the transfer of apolipoproteins out of the IDL (McLaren et al. 
2011a). LDL particles enter cells primarily by receptor-mediated endocytosis using the LDL 
receptor (LDLr). The key role LDL plays during atherosclerosis development can be 
demonstrated in studies focusing on patients with mutations in their LDLr gene, a condition 
known as familial hypercholesterolemia (Buckley and Ramji 2015; Kovacic and Bakran 2012). 
It is thought that approximately one in a million people are heterozygous sufferers of the 
condition and are at a greater risk of MIs at an earlier age than non-sufferers due to their 
plasma LDL levels being six to ten times greater than non-sufferers (Kovacic and Bakran 
2012). 
Table 1.1. The major lipoproteins/apolipoproteins and their functions. 
Molecule Major function Reference 
ApoA1 The major protein present in HDL. Induces cholesterol efflux 
within cells via ABCA1 and allows nascent HDL to collect free 
cholesterol. 
McLaren et al. 2011a 
ApoB The primary apolipoprotein found in CM, VLDL, IDL and LDL 
particles. 
Piepoli et al. 2016 
ApoC-III Prevents the removal of ApoB rich lipoproteins from the blood 
stream. 
Sacks 2015 
ApoE Combines with cholesterol within HDL molecules to reduce 
its mobility and aid in transportation of cholesterol back to the 
liver for excretion. 
van der Velde 2010 
CM Transports triacylglycerols synthesised in the intestine from 
digested food to the liver or peripheral tissues. 
McLaren et al. 2011a 
CMR Peripheral tissues hydrolyse the triacylglycerols within CM via 
LPL into Fas and 2-monoacylglycerol which are then 
transported to the liver by CMR. 
McLaren et al. 2011a 
HDL Transports surplus cholesterol from the peripheral tissues to 
the liver for removal in a process known as RCT. 
McLaren et al. 2011a 
IDL Forms upon the degradation of VLDL and can be further 
degraded into LDL. 
McLaren et al. 2011a 
LDL Transports cholesterol from the liver to the peripheral tissues. 
It is the most abundant lipoprotein within the blood stream. 
McLaren et al. 2011a 
VLDL Transports triacylglycerols synthesised in the liver to 
peripheral tissues. 
McLaren et al. 2011a 
 
Apo, apolipoprotein; CM, chylomicrons; CMR, CM remnants; FAs, fatty acids; HDL, high density lipoprotein; IDL, 
intermediate lipoprotein; LDL, low density lipoprotein; LPL, lipoprotein lipase; RCT, reverse cholesterol transport; 
VLDL, very low density lipoprotein.  
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Fig. 1.1. Cholesterol metabolism. Several lipoprotein particles are involved in the transport of cholesterol and 
other lipids around the body through the bloodstream. Triacylglycerols absorbed in the intestine from dietary intake 
are transported to the liver and peripheral tissues by chylomicrons, whereas triacylglycerols synthesised de novo 
are transported from the liver to the peripheral tissues by VLDL. IDL bridges the gap between the VLDL and LDL 
pathways. LDL particles can be formed when the triacylglycerols in VLDL particles are hydrolysed by LPL and HL. 
Cholesterol is transported from the liver to the peripheral tissues via LDL. The CEs are then hydrolysed into free 
cholesterol and FFAs by LAL. The excess cholesterol in the peripheral tissues can either be transported out of the 
cells or stored. The free cholesterol can be re-esterified to CEs by ACAT-1 and stored within the cells as lipid 
droplets. The remaining cholesterol is transported back to the liver by HDL for excretion in bile through the reverse 
cholesterol transport pathway (indicated by the blue arrows). However some of the cholesterol esters can be 
transferred to VLDL and other lipoprotein particles by CETP-mediated processes. The stored CEs can be 
hydrolysed back into free cholesterol by NCEH. LCAT is an enzyme that is able to re-esterify free cholesterol into 
CEs and sequester it in a nascent HDL particle, causing a one way reaction, to form a newly synthesised HDL 
particle. ACAT-1, acyl-coenzyme A acyltransferase 1; CETP, cholesterol ester transfer protein; CEs, cholesteryl 
esters; FFAs, free fatty acids; HDL, high density lipoproteins; HL, hepatic lipase; IDL, intermediate density 
lipoproteins; LAL, lysosomal acid lipases; LCAT, lecithin-cholesterol acyltransferase; LDL, low density lipoproteins; 
LPL, lipoprotein lipase; NCEH, neutral cholesterol ester hydrolase; VLDL, very low-density lipoproteins. Figure 
adapted from McLaren et al. (2011a). 
In order to maintain a balance in cholesterol metabolism, HDL transports excess cholesterol 
from the peripheral tissues back to the liver for excretion by a process known as reverse 
cholesterol transport (RCT; McLaren et al. 2011a). Initially HDL and ApoA1 stimulate 
cholesterol efflux in cells within the peripheral by stimulating the transporter ATP-binding 
cassette A1 (ABCA1; McLaren et al. 2011a). Therefore increased levels of ApoA1 is seen as 
a marker of increased cholesterol efflux. ApoA1 also allows nascent HDL particles to collect 
the released cholesterol for transportation. To reduce the mobility of cholesterol being 
transported by HDL, it is esterified and combined with ApoE to decrease its net electrical 
polarity (van der Velde 2010). Some of the cholesteryl esters (CEs) are transferred to VLDL 
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particles via cholesterol ester transfer protein (CETP)-mediated processes, while the rest are 
delivered to the liver (McLaren et al. 2011a). Once the HDL particles reach the liver, CEs 
detach in a process involving HDL particles briefly binding to the cell membrane of hepatocytes 
via scavenger receptor (SR)-B1 and releasing the esterified cholesterol into the cytosol of 
these cells (van der Velde 2010; Bhatt and Rohatgi 2016). The esterified cholesterol is 
processed into bile salts which are then excreted into the small intestine (van der Velde 2010). 
However only 5% of the biliary cholesterol is excreted in faeces as the rest is reabsorbed in 
the intestine as they are used to emulsify lipid droplets formed within the intestine following 
dietary intake (van der Velde 2010). This rotation of bile salts is known as the enterohepatic 
circulation. Sufferers of a genetic disease called Tangier disease have mutations in their 
ABCA1 gene, which plays a key role in cholesterol efflux, and as a result have low plasma 
levels of HDL and develop atherosclerosis much earlier compared to the general population 
(Van Eck 2014). The association of high HDL plasma levels and cardiovascular protective 
effects has been demonstrated in both human and animal studies (Van Eck 2014; Rader and 
Hovingh 2014; Kingwell et al. 2014; Calabresi et al. 2015). Recent human and murine studies 
have suggested that rather than the concentration of circulating levels of HDL cholesterol, it is 
its ability to induce cholesterol efflux which results its cardiovascular protective effects (Bhatt 
and Rohatgi 2016). This has led to the cholesterol efflux capacity (CEC) of the RCT system 
being investigated as a potential therapeutic target. 
During normal healthy conditions, the metabolism and transport of cholesterol is highly 
regulated and the influx and efflux of cholesterol in cells is well balanced. The development of 
atherosclerosis can begin when these transport systems become unbalanced in favour of 
increased cholesterol influx or decreased efflux (discussed in greater detail in Section 1.3). 
High LDL and low HDL serum levels have been associated with reduced endothelium function 
such as induction of a pro-inflammatory state, increased pro-thrombotic effects and attenuated 
vasodilation (Vogel 1997; Rajendran et al. 2013). Therefore increased LDL levels are thought 
of as being pro-atherogenic whereas elevated HDL levels are considered to be anti-
atherogenic (Vogel 1997). It is important that therapies for atherosclerosis aim to lower plasma 
LDL levels as well as increase the efflux capacity of the RCT system through HDL.  
Naturally mice do not develop atherosclerosis but LDLr and ApoE deficient mouse models 
have been developed which are prone to atherosclerosis lesion formation while on their natural 
diet, however this can be accelerated by feeding them a high fat or high cholesterol diet. Mice 
lacking the LDLr develop atherosclerosis due an increase in the circulating levels of VLDL and 
LDL as they cannot be cleared by the liver (Kapourchali et al. 2014). ApoE deficient mice 
develop atherosclerotic lesions as the HDL molecules cannot be removed from the blood 
stream and they are eventually metabolised into VLDL and LDL particles, resulting in 
atherosclerosis disease development (Kapourchali et al. 2014). Mouse model systems have 
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significantly improved our understanding of the pathology of atherosclerosis disease 
progression. 
1.3 Pathophysiology 
Atherosclerosis is often characterised by the build-up of fatty deposits and the formation of 
plaque structures in the walls of large and medium arteries, as well as a strong immunological 
response to the fatty deposit accumulation (Fig. 1.2). The initial fatty deposit build up in the 
intima of arteries, often referred to as a fatty streak, is composed of ApoB containing 
lipoproteins, in particular LDL, and other lipoprotein remnants (McLaren et al. 2011a). Vascular 
cells produce reactive oxygen species (ROS) which are thought to act as secondary 
messengers in vascular homeostasis (Vara and Pula 2014). During aerobic metabolism, ROS 
are generated as a product of the electron transport chain as well as being produced by a 
variety of enzymes including cyclooxygenase (COX) and nitric oxide synthase (NOS; Vara and 
Pula 2014). However ROS can also modify the LDL by oxidation to oxidised LDL (oxLDL; 
McLaren et al. 2011a). LDL can also undergo under several other modifications to form a 
variety of modified LDL molecules including aggregated LDL and glycated LDL (gLDL; Alique 
et al. 2015). The later modification occurs in diabetics who are at an increased risk of forming 
gLDL, which increases their risk of developing atherosclerosis (Rashid et al. 2006). 
An inflammatory response is then generated by the presence of oxLDL in the neighbouring 
endothelial cells (ECs) which start to produce pro-inflammatory cytokines and chemokines 
(McLaren et al. 2011a; Lusis 2000; Ramji and Davies 2015). The role of different chemokines 
and cytokines has been extensively reviewed and can be generally classified as either pro- or 
anti-inflammatory (Buckley and Ramji 2015; Ramji and Davies 2015; Moss and Ramji 2016a). 
Pro-inflammatory cytokines include interferon (IFN)-γ, tumour necrosis factor (TNF)-α, 
interleukin (IL)-1β and IL-18, whereas anti-inflammatory cytokines include IL-10, IL-33 and 
transforming growth factor (TGF)-β (Ramji and Davies 2015; Moss and Ramji 2016a; Moss 
and Ramji 2015). However this distinction is not always possible with some cytokines and 
chemokines capable of exerting both pro- and anti-inflammatory effects; for example 
macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-
CSF; Ramji and Davies 2015).  
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Fig. 1.2. The progress of an atherosclerotic plaque formation. Initially circulating LDL within the lumen of the 
artery passively diffuses into the intima where it becomes modified, usually by oxidation into oxidised LDL. The 
presence of modified LDL triggers an inflammatory response in the neighbouring endothelial cells causing them to 
express cell adhesion molecules on their surface. These cell adhesion molecules allow monocytes to roll and 
adhere to the wall of the artery at the affected site. The monocytes then proceed to migrate into the intima of the 
artery, where they differentiate into macrophages and begin to take up the modified LDL causing their 
transformation into lipid laden foam cells. Over time these foam cells undergo apoptosis or necrosis as accumulation 
of intracellular cholesterol is toxic. Foam cells then release their lipid contents into the wall of the artery which 
accumulate and form a lipid-rich necrotic core. The necrotic core continues to add to the initial inflammatory 
response by triggering inflammasome activation due to lipid and cholesterol accumulation. Inflammasome activation 
results in the continuous recruitment and formation of foam cells. As the lipid-rich necrotic core grows in size it can 
become unstable. Smooth muscle cells migrate from the media of the artery to the top of the necrotic core and 
deposit collagen and other proteins to form a fibrous cap to provide the plaque with extra stability. Eventually the 
fibrous cap deteriorates and ruptures due to a build-up of matrix metalloproteinases and other proteases capable 
of degrading the ECM. Once ruptured the internal components of the plaque become exposed to the lumen. This 
triggers a thrombotic reaction and the formation of a blood clot due to the aggregation of platelets, which can block 
the artery and depending on the location of the plaque can result in either a myocardial infarction or stroke. 
One of the major pro-atherogenic chemokines released by the activated ECs is monocyte 
chemotactic protein (MCP)-1, which guides the circulating monocytes and T-lymphocytes 
towards the oxLDL build-up. Atherosclerotic mouse models lacking MCP-1 or its receptor 
(CCR2) have been shown to develop smaller lesions (Gu et al. 1998; Boring et al. 1998; 
Öhman et al. 2010; Liu et al. 2012b; Olzinski et al. 2010; Majmudar et al. 2013), highlighting 
the importance of MCP-1 in the development of this disease. The presence of oxLDL further 
enhances the inflammatory response by inhibiting the production of nitric oxide (NO), possibly 
by reducing the availability of its precursor L-arginine (Knowles et al. 2000; Wang et al. 2011b). 
Due to the role of NO in vasodilation, inhibiting its production leads to an increase in blood 
pressure and enhances atherosclerosis in mouse models (Knowles et al. 2000). Furthermore, 
oxLDL has been shown to directly induce endothelial dysfunction and reduce vasorelaxation 
by stimulation of endothelial cell death as well as enhancing the expression of the cytoplasmic 
adapter protein TNF receptor associated factor 3 interacting protein 2 (TRAF3IP2; sometimes 
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referred to as CIKS or Act1; Valente et al. 2014). TRAF3IP2 is known to regulate the 
expression of nuclear factor-kappa B (NF-κB) and Janus kinase (JNK; Leonardi et al. 2000; Li 
et al. 2000), both of which are capable of modulating the immune response and contributing 
towards atherosclerosis progression. The activated ECs also express cell adhesion markers 
on their cell surface, such as P- and E-selectins, vascular cell adhesion molecule (VCAM)-1 
and intercellular adhesion molecule (ICAM)-1 (McLaren et al. 2011a). These cell surface 
molecules bind to the corresponding receptors and ligands expressed on the surface of 
circulating monocytes, allowing them to roll and adhere to the site of activation in the 
endothelium, aiding their migration to the oxLDL accumulation in the arterial walls (Dong et al. 
1998; Collins et al. 2000; Shih et al. 1999). Pro-inflammatory cytokines and chemokines, 
including IFN-γ, IL-1β and TNF-α, have been shown to aid cellular recruitment to the 
atherosclerotic lesion by inducing the expression of VCAM-1, ICAM-1 and MCP-1 in activated 
ECs (Charo and Taubman 2004; Blankenberg et al. 2003; Chung et al. 2002; Kirii et al. 2003; 
Xiao et al. 2009). Mouse models deficient in IFN-γ, IL-1β and TNF-α have reduced lesion sizes 
due to a decrease in the number of macrophages (Kirii et al. 2003; Gupta et al. 1997; Whitman 
et al. 2000; Whitman et al. 2002; Koga et al. 2007b; Koga et al. 2007a; Chamberlain et al. 
2009; Branen et al. 2004; Ohta et al. 2005; Xiao et al. 2009). Mice deficient in a variety of 
chemokines and cytokines have been shown to have reduced or enhanced atherosclerotic 
plaque formation depending on whether they are pro- or anti-inflammatory. These are 
extensively reviewed by Ramji and Davies (2015). 
Once the monocytes have migrated into the intima of the arteries, they become exposed to M-
CSF and differentiate into macrophages, a process that is associated with increased 
expression of pattern recognition receptors on their cell surface (McLaren et al. 2011a; Lusis 
2000). These receptors allow macrophages to identify foreign bodies during an innate immune 
response, however they are cable of recognising domains found within modified LDL. 
Research continues to emerge which suggests that macrophages are capable of polarising 
into broad classes, either the pro-inflammatory M1 phenotype or the anti-inflammatory M2 
phenotype (Geeraerts et al. 2017; Rojas et al. 2015; Komohara et al. 2016). The factors which 
affect macrophage phenotype polarisation are discussed in Chapter 3. 
Macrophages are able to uptake oxLDL via SR-mediated endocytosis, macropinocytosis or 
phagocytosis (Li and Glass 2002; Bobryshev 2006). Although there are several SRs, SR-A 
and CD36 are thought to be of particular importance and play a significant role in oxLDL uptake 
as shown by mouse models deficient in either receptor developing smaller atherosclerotic 
lesions (Febbraio et al. 2000; Kuchibhotla et al. 2008; Mäkinen et al. 2010). Both SR-A and 
CD36 are thought to be responsible for 90% of macrophage oxLDL uptake (Chistiakov et al. 
2016). The uptake of LDL via the LDLr is under a negative feedback loop which is tightly 
regulated by intracellular cholesterol levels (Zhang et al. 2016). The proteins sterol regulatory 
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element-binding protein 2 (SREBP2) and SREBP cleavage-activating protein (SCAP) are 
essential for the expression of the LDLr. These two proteins form a dimer which is transferred 
from the endoplasmic reticulum (ER) to the golgi apparatus for maturation. Once in the golgi, 
SREBP2 is cleaved by proteases and separated from SCAP to form the active nuclear SREBP 
(nSREBP), which is then able to bind to the promotor region of the LDLr gene and induce its 
transcription (Zhang et al. 2016). Increased intracellular cholesterol levels induce SCAP to 
undergo a conformation change which results in the SREBP2/SCAP dimer unable to transfer 
from the ER to the golgi leading to the attenuation of LDLr gene expression as well as 
cholesterol uptake (Zhang et al. 2016). On the other hand, oxLDL uptake via SRs is 
unregulated and not controlled by a negative feedback loop and therefore results in the 
continuous uptake of oxLDL (Stephen et al. 2010). Constant uptake of oxLDL leads to the 
formation of CE lipid droplets in the cytoplasm of macrophages, giving them a foamy 
appearance and induce the development of foam cells (Yu et al. 2013). 
Pro-inflammatory cytokines are capable of inducing foam cell formation by altering cholesterol 
homeostasis in macrophages to lower cholesterol efflux and increase the uptake and retention 
of oxLDL, and are thought to mediate these effects by regulating the expression of key 
cholesterol metabolism and transport genes including ApoE, ABCA1, acetyl-CoA 
acyltransferase 1 (ACAT1) and SR-A (McLaren et al. 2011a; Ramji and Davies 2015; Harvey 
and Ramji 2005; Panousis and Zuckerman 2000; Wuttge et al. 2004; Ohta et al. 2005). The 
formation of foam cells is summarised in Fig. 1.3. Foam cells then begin to accumulate and 
form an initial lesion that can be seen as a fatty streak in arteries which then matures into an 
atherosclerotic plaque. 
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Fig. 1.3. Foam cell formation. The mechanism of cholesterol homeostasis and the cholesterol transport processes 
used to prevent foam cell formation by balancing cholesterol uptake and efflux (A). The uptake of LDL via the LDL 
receptor (LDLr) is precisely controlled by a negative feedback loop. The intracellular cholesterol is stored as free 
cholesterol and effluxed via ApoE and the cholesterol efflux transporters ATP-binding cassette (ABC)A1 and 
ABCG1. When macrophage homeostasis becomes imbalanced to favour cholesterol uptake and reduced 
cholesterol efflux, foam cells begin to form (B). Modified LDL is taken up via scavenger receptors (SRs), SR-A and 
CD36, as well as macropinocytosis and phagocytosis. SR-mediated uptake of modified LDL is not under a negative 
feedback loop and therefore results in the continuous uptake of modified LDL. The efflux of cholesterol is also 
attenuated which results in an increase of intracellular cholesterol levels. The free cholesterol is esterified into 
cholesteryl esters, leading to an increase in lipid droplet formation and macrophages developing into foam cells. 
Red arrows indicate processes which are increased, blue arrows indicate processes which are attenuated. ACAT-
1, acyl-coenzyme A acyltransferase 1; Apo, apolipoprotein; FFAs, free fatty acids; HDL, high density lipoprotein; 
NCEH, neutral cholesterol ester hydrolase; TGs, triacylglycerols. Figure adapted from McLaren et al. (2011a). 
During atherosclerosis lesion maturation, the accumulated foam cells begin to undergo 
apoptosis and necrosis as increased cholesterol accumulation is toxic and results in ER stress 
(Sozen and Ozer 2017). Foam cell death causes them to release their fatty contents, including 
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components from the metabolism of oxLDL such as cholesterol, into the intima of the arteries. 
The apoptotic cells and the fatty contents accumulate to form a lipid-rich necrotic core. The 
accumulated lipids within the core, including oxLDL and cholesterol crystals, are capable of 
exacerbating the inflammatory response by triggering inflammasome activation (Hoseini et al. 
2017). The inflammasome is a multi-protein complex capable of enhancing the innate immune 
response and can be triggered by a variety of stimuli including pathogen-associated molecular 
patterns (PAMPs) and danger-associated molecular patterns (DAMPs; Hoseini et al. 2017). 
The activated inflammasome is involved in the maturation and activation of the pro-
inflammatory cytokines IL-1β and IL-18. This has led to inflammasome activation being 
associated with atherosclerosis disease progression (Guo et al. 2015). Patients considered to 
be at high risk of suffering a CVD-related event (hypercholesterolaemic, diabetic, hypertensive 
and smokers) often have an increased level of inflammasomes in their aortas (Zheng et al. 
2013). Furthermore silencing the NACHT, LRR and PYD domains-containing protein 3 
(NLRP3) inflammasome leads to improved plaque stability in ApoE deficient mice (Zheng et 
al. 2014). Additionally all mechanisms which activate inflammasomes are also involved in 
atherosclerosis disease progression (Hoseini et al. 2017). Therefore the inflammasome 
represents a possible link between aberrant lipid metabolism and inflammation in 
atherosclerosis (Hoseini et al. 2017). 
The necrotic core can be covered by a fibrous cap formed by the extracellular matrix (ECM) 
produced by the vascular smooth muscle cells (VSMCs; McLaren et al. 2011a; Katsuda and 
Kaji 2003). During the latter stages of plaque progression, macrophages, endothelial cells and 
T-cells stimulate VSMC proliferation and migration towards the oxLDL accumulation and form 
a fibrous cap over the lipid core (McLaren et al. 2011a; Chistiakov et al. 2015). This process 
occurs when the phenotype of the VSMCs is altered from an inactive quiescent state to an 
active contractile one, triggered by pro-inflammatory factors which induce the expression of 
integrins on the surface of VSMCs that are then able to bind to fibronectin in ECM and allow 
VSMC migration (Rudijanto 2007; Schonbeck et al. 2000; Barillari et al. 2001). The CD40 
receptor is expressed on antigen presenting cells, including macrophages and T-cells, and its 
activation has been linked with the release of chemokines and pro-inflammatory cytokines 
(Legein et al. 2013). Furthermore, CD40 activation has been shown to stimulate ECM 
degradation and remodelling, allowing the VSMCs to migrate more easily from the media to 
the intima to form the fibrous cap (McLaren et al. 2011a). Atherosclerotic mouse models 
deficient in CD40 have smaller and less inflammatory atherosclerotic lesions (Lusis 2000; 
Lutgens et al. 2010), stressing its important role in plaque progression. 
The fibrous cap provides the lesion with stability, therefore the balance of ECM deposition and 
degradation is a key element in the clinical complications of atherosclerosis. ECM degrading 
enzymes are released from macrophages during an inflammatory response as well as when 
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they undergoing apoptosis, shifting the balance towards ECM degradation and increasing the 
risk of a plaque rupture (Newby 2006; McLaren et al. 2011a). Matrix metalloproteinases 
(MMPs), a class of proteases capable of degrading ECM proteins, have been shown to be 
produced by macrophages and VSMCs during inflammatory conditions (Schonbeck et al. 
1997). Murine studies have also demonstrated that the levels and activity of MMP-2 and MMP-
9 are increased within advanced atherosclerotic plaques, highlighting their key role in plaque 
stability (Wågsäter et al. 2011). No external symptoms of plaque development are observable 
until the plaque ruptures. Once ruptured a thrombotic reaction is generated and platelet 
aggregation occurs, which can quickly impede or obstruct blood flow though the artery (Lusis 
2000). Due to the global prevalence of CVD and its economic burden on healthcare services 
around the world, many therapeutic strategies have been/are being developed to retard 
atherosclerosis progression. The benefits and limitations of these therapeutics will be 
discussed below in greater detail. 
 
1.4 Aetiology 
An individual’s risk of developing atherosclerosis can be affected by both their life style and 
genetic predisposition (Lusis 2000). The life style of the patient can often be modified to reduce 
their risk of a CVD-related event, however a family history of CVD and other unmodifiable 
factors can indicate whether an individual is genetically susceptible to atherosclerosis 
(McLaren et al. 2011a). 
One of the major modifiable life style risk factors is smoking. The susceptibility of LDL to 
oxidation, vasoconstriction and platelet aggregation, all of which are involved in the 
development of a CVD-related event, are all promoted by nicotine (Vogel 1997). Indeed in 
those who quit smoking there was an improvement in endothelial function within 1 year 
(Johnson et al. 2010). Furthermore serum levels of LDL and HDL cholesterol can be influenced 
both directly and indirectly by a high fat diet and obesity (McGill et al. 2002), therefore obesity 
is another key risk factor in determining whether an individual will suffer a CVD-related event. 
Additionally, a lack of exercise is associated with an increased risk of developing 
atherosclerosis as improved endothelial function has been observed in patients following 
regular exercise (Hambrecht et al. 2003; Beck et al. 2014). 
There are many unmodifiable genetic factors which can lead to a predisposition to CVD 
including family history, age and gender. Those with a family history of CVD-related events 
such as MI, stroke, aortic disease and peripheral arterial disease are more likely to develop 
atherosclerosis (Vogel 1997). Age is strongly correlated with increased vasoconstriction and 
build-up of cholesterol within atherosclerotic plaques and therefore it is also correlated with an 
increased risk of suffering a CVD-related event (Vogel 1997; Niccoli and Partridge 2012). 
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Furthermore men are more likely to suffer a CVD-related event than aged matched pre-
menopausal women, leading to what is known as the ‘gender gap’ (Frink 2009). This ‘gender 
gap’ narrows in post-menopausal women. As previously discussed, the genetic conditions 
familial hypercholesterolemia and Tangier disease cause patients to have mutations in their 
LDLr and ABCA1 genes respectively (Kovacic and Bakran 2012; Van Eck 2014; Buckley and 
Ramji 2015). As a result these patients have increased circulating LDL cholesterol levels or 
reduced plasma levels of HDL cholesterol compared to non-sufferers, giving them a higher risk 
of developing atherosclerosis (Kovacic and Bakran 2012; Van Eck 2014). 
There are many modifiable and unmodifiable risk factors that can influence an individual’s risk 
of suffering a CVD-related event, therefore it is key that doctors can accurately identify high 
risk patients (McLaren et al. 2011a). It is essential that educational drives to help individuals 
recognise their risk factors start much earlier to allow early intervention rather than wait until 
advanced atherosclerosis disease development has occurred. Once high risk patients have 
been identified, their risk can be reduced by developing strategies that either modify their 
lifestyle or involve the use of pharmaceuticals such as statins. 
 
1.5 Current and emerging therapeutics: Benefits and limitations 
The most commonly and successfully used cholesterol lowering class of pharmaceutical 
therapies are statins, which inhibit the enzyme involved in the rate limiting step during 
cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase, resulting in 
a reduction in circulating LDL cholesterol (Schonbeck 2004; Haslinger-Loffler 2008). However 
there is still a discernible residual risk of a CVD-related event in patients taking statins, in 
addition to a significant minority of individuals who are unable to achieve target plasma 
cholesterol levels despite receiving the maximum recommended dosage (McLaren et al. 
2011a; Leitersdorf 2001). The maximum reduction in CVD mortality that can be attributed to 
statins is approximately 30%, stressing the need to develop alternative therapies to target the 
remaining 70% (McLaren et al. 2011a). Approximately for every 6% reduction in plasma LDL 
levels past the baseline achieved with the initial statin treatment levels, the dosage needs to 
be doubled (Knopp 1999). However high-dose statin therapy is known to exert side effects 
such as nose bleeds, non-allergic rhinitis, headaches, muscle pain and an increased risk of 
developing diabetes (Parker et al. 2013; Ridker et al. 2008; NHS 2016). This highlights the 
significant need to develop new therapeutics that can either be taken alone or in combination 
with statins (McLaren et al. 2011a; Leitersdorf 2001). 
Ezetimibe therapy in combination with statins is providing some hope for lowering LDL 
concentrations in those individuals that are unable to achieve target levels whist receiving the 
maximal dose of statins. It is designed to inhibit the Niemann-Pick C1-like protein (NPLC1L1) 
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in the intestine and reduce cholesterol uptake. Ezetimibe in combination with statins reduces 
LDL levels by approximately 23% compared to statin therapy alone (Ballantyne et al. 2004; 
Morrone et al. 2012). Two recent trials known as Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT) and Plaque Regression With Cholesterol Absorption 
Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound (PRECISE-IVUS) which 
involved 18,144 and 229 participants respectively, have shown that ezetimibe plus statin 
therapy lowered patient LDL cholesterol levels and improved cardiovascular outcomes 
(Cannon et al. 2015; Tsujita et al. 2015). However a previous study involving 3,827 individuals 
found no evidence that ezetimibe therapy in combination with statins significantly reduced 
mortality compared to the statin only group (Patel et al. 2013), thereby implicating the need for 
more larger clinical trials to evaluate efficacy. 
Another emerging strategy involves targeting proprotein convertase subtilisin/kexin type 9 
(PCSK9) with human monoclonal antibodies at present and possibly specific inhibitors in the 
future. PCSK9 is able to bind to the LDLr and direct it towards the lysosome for degradation 
during LDLr metabolism and results in increased plasma LDL cholesterol levels (Giugliano and 
Sabatine 2015). Loss-of-function in PCSK9 leads to protection against cardiovascular events 
regardless of other risk factors by increasing LDLr expression. This results in a reduction in 
the circulating LDL cholesterol levels, making it an exciting emerging therapeutic target 
(Giugliano and Sabatine 2015). Phase I and II clinical trials have shown that inhibition of 
PCSK9 by human monoclonal antibodies reduced circulating LDL levels without exerting any 
severe side effects (Giugliano and Sabatine 2015; Zhang et al. 2015). Phase III clinical trials 
are currently underway or completed recently using three antibodies, evolocumab, alirocumab 
and bococizumab, in trials known as FOURIER (Further Cardiovascular Outcomes Research 
with PCSK9 Inhibition in Subjects with Elevated Risk), ODYSSEY Outcomes (Study to 
Evaluate the Effect of Alirocumab on the Occurrence of Cardiovascular Events in Patients Who 
Have Experienced an Acute Coronary Syndrome), SPIRE (Studies of PCSK9 Inhibition and 
the Reduction of Vascular Events)-1 and SPIRE-2 involving 28,000, 18,000, 17,000 and 
10,000 participants respectively (U.S. National Institutes of Health 2017b; Ridker et al. 2017b; 
Sabatine et al. 2017). The ODYSSEY trial is expected to be completed in 2018. The FOURIER 
trial found evolocumab was able to reduce patients LDL cholesterol levels by 59% when 
compared to those receiving the placebo without exerting any adverse effects (Sabatine et al. 
2017). However evolocumab failed to lower an individual’s risk of suffering a CVD-related 
event. The efficacy of bococizumab was assessed in both low risk patients (SPIRE-1) and high 
risk individuals (SPIRE-2; Ridker et al. 2017b). These studies were prematurely stopped as 
other trials involving bococizumab showed it was capable of inducing the development of high-
titer antidrug antibodies (Ridker et al. 2017b). Despite this, pooled data from both SPIRE 
studies demonstrated that bococizumab resulted in a decrease in circulating LDL levels by 
56% after 14 weeks. This reduction in LDL levels was maintained throughout the study period. 
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High risk patients treated with bococizumab were found to have a reduced CVD-related event 
risk, however no reduction was observed in low risk patients (Ridker et al. 2017b). These trials 
show that PCSK9 inhibitors are capable of further reducing LDL levels in patients already 
receiving statins, however due to the high cost of this treatment and potential adverse effects 
the use of these therapies should be limited to high risk patients. Indeed alirocumab has 
already been approved for high risk patients in both USA and Europe (FDA 2015; EMA 2015b), 
whereas as the use of evolocumab has only been granted in Europe (EMA 2015a). 
A number of other targets have been explored for therapeutic intervention of atherosclerosis 
though most have proved disappointing at the clinical level. For example, despite the extensive 
evidence associating increased plasma HDL levels with reduced risk of CVD, clinical trials 
using orally active, HDL raising agents have largely failed (Rader and Hovingh 2014; Kingwell 
et al. 2014; Cimmino et al. 2015; Kaur et al. 2014). Other trails with agents that are known to 
augment HDL levels in addition to other beneficial effects at the pre-clinical level, such as 
niacin and fibrates, have also been disappointing (Sando and Knight 2015). This probably 
reflects the complex roles of HDL, its heterogeneity and its interactions with numerous proteins 
(Rader and Hovingh 2014; Kingwell et al. 2014; Cimmino et al. 2015). Future research is 
focusing on attaining a deeper understanding of HDL biology and enhancing its capacity to 
stimulate cellular cholesterol efflux and RCT. CETP is involved in the bidirectional transfer of 
cholesteryl esters in HDL for TGs in ApoB containing lipoproteins such as LDL and VLDL 
(Sando and Knight 2015; Ladeiras-Lopes et al. 2015). Inhibition of CETP should therefore be 
beneficial, as this would increase the cholesteryl ester content of HDL for RCT and reduce that 
in pro-atherogenic LDL particles. However, initial large-scale clinical trials with two CETP 
inhibitors, torcetrapip and delcetrapib, were disappointing due to off target effects (Sando and 
Knight 2015; Ladeiras-Lopes et al. 2015). Ongoing clinical trials are evaluating the efficacy of 
two more potent CETP inhibitors, anacetrapib and evacetrapib (Sando and Knight 2015; 
Ladeiras-Lopes et al. 2015). Other approaches such as inducing the levels of ApoA1, the major 
apolipoprotein in HDL, HDL mimetics and microRNAs that modulate plasma HDL levels 
together with agents that augment the levels/activities of proteins involved in cellular 
cholesterol efflux are being evaluated (Sando and Knight 2015; Ladeiras-Lopes et al. 2015). 
As atherosclerosis is an inflammatory disorder, approaches that dampen inflammation are also 
being pursued. Members of the phospholipase A2 (PLA2) are involved in producing 
atherogenic lipids via their actions on lipoprotein remodelling (Ladeiras-Lopes et al. 2015). 
Inhibitors of these enzymes therefore represent a promising avenue for limiting 
atherosclerosis. However, clinical trials with an inhibitor of a lipoprotein-associated PLA2 
(Derapladib) and secretory PLA2 (Verespladib) have been disappointing (Ladeiras-Lopes et 
al. 2015). Based on the beneficial effects of low dose methotrexate in other inflammatory 
disorders such as arthritis, CIRT (Cardiovascular Inflammation Reduction Trial) is evaluating 
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its potential in limiting cardiovascular events in patients with prior MI and either type II diabetes 
or metabolic syndrome (Ridker 2013). The outcomes of the CIRT trial will clearly open up 
further avenues for limiting inflammation and the actions of other cytokines. Another approach 
is focussed on IL-1β given that it is a major cytokine involved in the disease and produced by 
the inflammasome that is activated by modified LDL and cholesterol crystals (Ramji and Davies 
2015). The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial 
evaluated the potential of an IL-1β neutralising antibody in reducing cardiovascular events in 
patients with prior MI (Ridker 2016). Despite no changes in lipid levels or the rate of all-cause 
mortality, treatment with 150 mg of canakinumab every 3 months was found to reduce an 
individual’s risk of a recurrent CVD-related event when compared to those receiving the 
placebo (Ridker et al. 2017a). It should however be noted that because of the risks associated 
with manipulating systemic inflammation, such as predisposition to infections, these 
approaches will have to be restricted to high risk patients until effective technologies to target 
them to the atherosclerotic lesions are developed. The use of nanoparticles and other drug 
delivery systems have been explored as possible options to directly target cytokines and their 
receptors within atherosclerotic plaques (Chacko et al. 2011; Jayagopal et al. 2010; Lewis et 
al. 2011; Chung 2016). Although these drug delivery systems have been used to deliver 
antibodies to atherosclerotic lesions to enhance imaging techniques, their use in therapeutic 
drug delivery remains largely unexplored (Chacko et al. 2011; Jayagopal et al. 2010; Lewis et 
al. 2011). A recent study has shown that nanoparticle-directed drug was capable of improving 
plaque stability in LDLr deficient mice in comparison to the control mice (Fredman et al. 2015). 
However until anti-cytokine and anti-chemokine antibodies and molecules can be targeted 
within atherosclerotic plaques, it is important that further research is carried out on alternative 
approaches that limit inflammation and other pro-atherogenic changes in the disease.  
One potential avenue being explored for novel therapeutics for the prevention of 
atherosclerosis are natural products, known as nutraceuticals, which are thought to have anti-
inflammatory properties. Unless there is genetic evidence, it is often difficult to predict the 
safety profiles of pharmaceuticals as patients receive them for several years, whereas 
nutraceuticals are natural products which are generally considered safe. Therefore 
nutraceuticals may represent effective treatments to provide to patients before traditional 
pharmaceuticals. Nutraceuticals can be broken down into two broad classes, functional foods 
or dietary supplements. There are several nutraceuticals being explored as potential anti-
atherogenic therapies which are comprehensively reviewed in Moss and Ramji (2016b), 
however a summary of the preclinical and human studies are presented in Tables 1.2 and 1.3. 
Diets which are rich in fruit, vegetables, fish, cereal grains or olive oil have all been associated 
with cardiovascular health benefits (Slavin and Lloyd 2012; Wall et al. 2010; Granados-
Principal et al. 2010; Moss and Ramji 2016b). The aim of this study is to assess the key 
nutraceutical components ω-3 PUFAs, flavanols and phytosterols in order to determine their 
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potential uses for the prevention of atherosclerosis development. Therefore these 
nutraceuticals are discussed in greater detail in Sections 1.6 – 1.8. 
Table 1.2 The potential anti-atherogenic effects of key nutraceuticals from pre-clinical studies. 
Nutraceutical Cardiovascular health benefits References 
   
Allicin - Murine macrophages stimulated with LPS have reduced 
expression of pro-inflammatory cytokines (IL-1β, IL-6 and 
TNF-α). 
Lee et al. 2012 
 - Reduced leukocyte adherence and inflammatory response 
in murine models. 
Zanardo 2006 
 - Reduced foam cell formation due to attenuated expression 
of SR-A, ACAT-1 and CD36 in human monocyte-derived 
macrophages. 
Zhao et al. 2011 
 - Dietary supplementation retards atherosclerosis 
development in ApoE deficient mice by reducing lesion size. 
Zhang et al. 2012 
   
Berberine - Reduces MCP-1, iNOS, IL-1β and IL-6 gene expression in 
mouse macrophages. 
Jeong et al. 2009 
 
- Attenuates monocyte recruitment. Cheng et al. 2015 
 
- Attenuates intracellular accumulation of oxLDL in human 
macrophages by increasing ABCA1 gene expression. 
Lee et al. 2010a 
 
- Lowers total cholesterol serum levels and the number of 
atherosclerotic lesions in ApoE deficient mice. 
Hu and Davies 
2010; Wang et al. 
2011a 
   
Butyrate - Reduces pro-inflammatory cytokine and nitric oxide 
production in murine macrophages. 
Liu et al. 2012a 
 - Decreases monocyte and macrophage migration in ApoE 
deficient mice resulting in reduced plaque size. 
Aguilar et al. 2014 
   
Carnosine - Protects against foam cell formation in vitro. Rasid et al. 2007 
 - Improves atherosclerotic plaque stability in murine diabetes-
associated atherosclerosis models. 
Brown et al. 2014 
   
Coenzyme 
Q10 
- Induces macrophage reverse cholesterol transport and slow 
the development of atherosclerosis possibly via miR-378 in 
ApoE deficient mice. 
Wang et al. 2014a 
   
Curcumin - Reduces pro-inflammatory cytokine (MCP-1, IL-1β and 
TNF-α) production in primary human monocytes. 
Abe et al. 1999 
 - Induces an anti-inflammatory M2 macrophage phenotype in 
vitro. 
Gao et al. 2015 
 - Decreases oxidative stresses and LDL oxidation in addition 
to reducing aortic fatty streak development in rabbits. 
Ramírez-Tortosa et 
al. 1999; Quiles et 
al. 2002 
 - ApoE and LDLr double knockout mice had reduced 
atherosclerotic plaque development. 
Olszanecki et al. 
2005 
   
Flavanols - Decreases atherosclerotic plaque size in ApoE*3-Leiden 
mice. 
Morrison et al. 2014 
 - Reduces endothelial exocytosis (the process of releasing 
pro-inflammatory cytokines and chemokines into the 
extracellular space) in HUVECs 
Yamakuchi et al. 
2008 
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Hydroxytyrosol - The expression of the pro-inflammatory adhesion proteins 
VCAM-1 and ICAM-1 is attenuated in HUVECs. 
Dell’Agli et al. 2006 
 - Increased plasma HDL levels and lower LDL plasma levels 
in Wistar rats compared to control rats. 
Mangas-Cruz et al. 
2001; Gorinstein et 
al. 2002 
 - Attenuates atherosclerotic plaque formation in hyperlipemic 
mice. 
González-Santiago 
et al. 2006 
   
ω-3 PUFAs - The expression of several key atherosclerotic markers in 
both human and murine macrophages is reduced. 
Hughes et al. 1996; 
Miles et al. 2000 
 - Induces the expression of “cholesterol efflux” genes as well 
as decreasing the expression of “LDL uptake” genes. 
Song et al. 2013 
 - Raises plasma HDL levels and attenuates atherosclerotic 
lesion formation in LDLr deficient mice. 
Brown et al. 2012; 
Nakajima et al. 
2011 
   
ω-6 PUFAs - PGE1, a metabolite of DGLA, is capable of improving 
plaque stability in atherosclerosis in rabbits by increasing the 
thickness of the fibrous cap. 
Bai et al. 2012 
 - Decreased blood pressure in hypertensive rats. Engler 1993 
 - Attenuates atherosclerotic plaque formation in mice. Takai et al. 2009 
   
Phytosterols - Enhanced cholesterol efflux in human THP-1 macrophages. Sabeva et al. 2011 
 - Reduced atherosclerotic plaque formation and plasma LDL 
levels in ApoE deficient mice. 
Moghadasian 2006; 
Nashed et al. 2005 
   
Resveratrol - Attenuates oxidation of LDL in vitro. Frankel et al. 1993 
 - Enhanced cholesterol efflux in human THP-1 macrophages 
resulting in reduced foam cell formation. 
Voloshyna et al. 
2013 
 - Reduced atherosclerotic lesion formation by approximately 
50% in ApoE*3-Lieiden.CEPT mice. 
Berbée et al. 2013 
   
Vitamin C - Improved eNOS activity and restored endothelium function 
in ApoE deficient mice. 
d’Uscio 2002; 
Matsumoto et al. 
2003 
 
ACAT-1, acyl-CoA acetyltransferase-1; ApoE, apolipoprotein E; CHD, coronary heart disease; CVD, cardiovascular 
disease; DGLA, dihomo-γ-linolenic acid; DHA, docosahexaenoic acid; eNOS, endothelial nitric oxide synthase; 
EPA, eicosapentaenoic acid; GLA, γ-linolenic acid; H2S, hydrogen sulphide; HDL, high density lipoprotein; 
HUVECs, human umbilical vein endothelial cells; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; LDL, 
low density lipoprotein; LDLr, LDL receptor; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; miR, 
micro RNA; MMP, matrix metalloproteinases; NO, nitric oxide; oxLDL, oxidised LDL; PGE1, prostaglandin E1; 
PUFAs, polyunsaturated fatty acids; SR-A, scavenger receptor-A; TNF-α, tumour necrosis factor α; VCAM-1, 
vascular cellular adhesion molecule-1. 
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Table 1.3. Summary of the major findings on nutraceuticals from human studies. 
Nutraceutical Number of 
participants 
Study 
type 
Major Findings References 
     
Fibre 116 CL No additional benefit when 
combined with other lipid lowering 
therapies. 
Ramos et al. 
2011 
 46,032 EP Increased fibre intake associated 
with reduced peripheral arterial 
disease risk. 
Merchant et 
al. 2003 
 78,779 EP Increased fibre intake reduced the 
risk of stroke in women. 
Oh et al. 
2005a 
 39,876 EP Increased fibre consumption was 
correlated with reduced CVD risk. 
Liu et al. 2002 
     
Flavanols 90 CL Reduced blood pressure and lipid 
peroxidation. 
Mastroiacovo 
et al. 2015 
 100 CL Increased FMD and HDL plasma 
levels. 
Decreased blood pressure, arterial 
stiffness, total and LDL cholesterol 
levels. 
Sansone et 
al. 2015 
 7,172 EP Increased flavanol intake correlated 
with reduced CVD risk. 
Tresserra-
Rimbau et al. 
2014a 
 57 CL Improved FMD and reduced blood 
pressure. 
Rassaf et al. 
2016 
     
ω-3 PUFAs 11,324 CL 15% reduction in total number of 
deaths and non-fatal CVD-related 
events. 
45% reduction in sudden cardiac 
deaths. 
Anon. 1999 
 18,645 CL 19% reduction in major CVD-related 
events. 
Most effective as a secondary 
preventative. 
Yokoyama et 
al. 2007 
 600 CL Lowered TG, VLDL and oxLDL 
levels. 
No additional benefit to those 
already taking lipid lowering 
therapies. 
Franzese et 
al. 2015 
 3,851 CL No cardiovascular protective effects 
observed after 1 year follow-up. 
Rauch et al. 
2010 
 12,536 CL No cardiovascular protective effects 
observed after 6 years follow-up. 
The ORIGIN 
Trial 
Investigators 
2012 
 229 CL Lowered TG levels. Bays et al. 
2011 
 702 CL Lowered TG, non-HDL, LDL and 
total cholesterol levels in statin 
receiving patients. 
Ballantyne et 
al. 2012 
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ω-6 PUFAs 258 CL Optimisation of Omega 6:3 ratio to 
3:1 reduces triglyceride and LDL 
levels. 
Griffin et al. 
2006 
 401 CL No cardiovascular protective effects 
observed. 
Sluijs et al. 
2010 
 340,000 EP Replacement of saturated fats with 
PUFA reduces CVD risk. 
Katan 2009 
 78,778 EP Inverse relationship between PUFA 
and CVD in women with BMI over 
25. 
Oh et al. 
2005b 
 2,682 EP Linoleic acid is cardio protective and 
reduces overall mortality. 
Laaksonen 
2005 
 2,206 EP Serum CRP levels correlate with 
increased omega-6 serum levels 
present.  
Tomiyama et 
al. 2011 
     
Polyphenols 200 CL Correlation between polyphenol 
intake and HDL plasma levels 
Reduced TG and oxidative stress 
levels. 
Covas et al. 
2006 
 134 CL Reduced blood pressure. Tjelle et al. 
2015 
 101 CL Reduced blood pressure and 
improved lipid profile in 
haemodialysis patients. 
Shema-Didi 
et al. 2014 
 117 CL Improved inflammatory and 
oxidative condition of metabolic 
syndrome patients. 
Panahi et al. 
2015 
 70 CL No change in blood pressure. Ras et al. 
2013 
 78 CL No change in blood pressure. Bondia-Pons 
et al. 2014 
 7,447 CH Increased polyphenol intake 
resulted in a reduced mortality risk. 
Tresserra-
Rimbau et al. 
2014b 
 200 CH Polyphenol intake reduced blood 
pressure and increased NO plasma 
levels. 
Medina-
Remón et al. 
2015 
 573 CH Reduced blood pressure in elderly 
individuals. 
Decreased TG levels but no 
changes in total, HDL or LDL levels. 
Guo et al. 
2016 
 1,139 CH Reduced plasma levels of several 
inflammatory biomarkers. 
Medina-
Remón et al. 
2017 
     
Vitamins 14,641 CL No positive effects of Vitamins C or 
E on any major CVD outcomes. 
Vitamin E increased risk of stroke. 
Sesso 2008 
 
 1,302 CL Vitamin C and E increased number 
of plaques and decreased pulse 
wave velocity. 
Zureik 2004 
 353 CL No cardiovascular protective effects 
observed following vitamin E 
supplementation. 
Hodis 2002 
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 520 CL Vitamin C and E reduced carotid 
artery atherosclerosis in smoking 
men. 
Salonen et al. 
2000 
 39,876 CL 24% reduction in CVD mortality in 
women receiving vitamin E. 
Lee et al. 
2005 
 840 EP High serum carotenes is protective 
in early atherosclerosis. 
Karppi et al. 
2011 
 
CH, cohort study; CL, clinical trial; EP, epidemiological study. 
 
1.6 Omega-3 polyunsaturated fatty acids 
Polyunsaturated fatty acids (PUFAs) are fatty acids which contain at least two carbon-carbon 
double bonds. PUFAs can be classified by the position of the nearest carbon-carbon double 
bond to the methyl terminus of the fatty acid (Wall et al. 2010). During normal physiological 
conditions, PUFAs play important roles in influencing both blood clotting and blood pressure 
(Wall et al. 2010). More importantly PUFAs are also capable of manipulating the production of 
key regulators of inflammation, known as eicosanoids and resolvins, which play key roles in 
enhancing or attenuating the inflammatory response respectively (Fig. 1.4; Wall et al. 2010; 
Fredman and Tabas 2017). It is essential that diets are rich in both ω-3 and ω-6 PUFAs as 
they cannot be synthesised in vivo and therefore must be acquired from exogenous sources. 
Nuts, flax seeds and especially oily fish are key sources of ω-3 PUFAs, whereas animal fats 
and vegetable oils are able to provide ω-6 PUFAs (Wall et al. 2010). 
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Fig. 1.4. The structure and metabolism of ω-6 and ω-3 PUFAs. The metabolism of ω-6 PUFAs leads to the 
formation of a variety of compounds which can result in an increased inflammatory state, whereas the metabolism 
of ω-3 PUFAs results in compounds which can improve inflammation resolution. See text for more details. COX, 
cyclooxygenase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LOX, lipoxygenase. Figure adapted 
from Adkins and Kelley (2010). 
The cardiovascular protective effects of ω-3 PUFAs have been known for the last 60 years. 
The Inuit population of Greenland were found to have a lower incidence rate of CVD and other 
CVD-related events despite having a diet consisting mainly of fish and whale meat and lacking 
fruit and vegetables, meaning their diets were rich in saturated fats (Bang and Dyerberg 1980). 
Since this initial epidemiological observation, the findings that ω-3 PUFAs may exert 
cardiovascular health benefits has been repeated in numerous epidemiological and clinical 
trials (Table 1.3; Lee et al. 2008; Lavie et al. 2009; Moss and Ramji 2016b). Both 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are considered the two most 
potent ω-3 PUFAs and exert the greatest cardiovascular protective effects (Moss and Ramji 
2016b). 
Although both ω-3 and ω-6 PUFAs are essential within the diet, they must be consumed in the 
correct proportion. A ratio of 1:4 for ω-3:ω-6 is considered to be ideal, however since the 
introduction of vegetable oils (which are rich in ω-6 PUFAs) in Western countries for the use 
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in cooking, it is thought the current ratio is closer to approximately 1:15 (Simopoulos 2003). 
Over the last few decades in Europe the incidence of inflammatory based diseases has 
increased significantly, correlating with the increased dietary intake of ω-6 PUFAs which has 
risen by approximately 50% (Sanders 2000). Diets which are low in ω-3 but rich in ω-6 PUFAs 
have been associated with increased expression of pro-inflammatory eicosanoids (James et 
al. 2000). Furthermore an increased sensitivity of LDL to oxidation into oxLDL ex vivo has been 
linked to diets with high levels of ω-6 PUFA intake (Tsimikas et al. 1999). Despite the 
association of ω-6 PUFAs with enhancing the pro-inflammatory nature of atherosclerosis 
disease progression, some ω-6 PUFAs, such as dihomo-γ-linolenic acid (DGLA), have been 
shown to exert anti-inflammatory effects and provide cardiovascular protective effects. 
However the anti-inflammatory effects of DGLA do not fall within the scope of this project and 
further discussion of its potential health benefits can be found in Moss and Ramji (2016b). 
The ability of ω-3 PUFAs to attenuate atherosclerosis disease development has been 
demonstrated in several in vitro and in vivo studies performed in both murine and human 
participants. The expression of pro-atherogenic markers, including ICAM-1 and SR-A, in both 
murine and human macrophages can be significantly reduced following treatment with fish oil 
(Hughes et al. 1996; Miles et al. 2000). The use of human THP-1 macrophages in vitro has 
shown that ω-3 PUFA treatment is capable of attenuating cholesterol uptake while 
simultaneously enhancing cholesterol efflux, resulting in reduced intracellular cholesterol 
accumulation (McLaren et al. 2011b; Lada et al. 2003). These changes in cholesterol 
accumulation can be explained by the upregulation in the expression of genes involved in 
cholesterol efflux and a reduction in the expression of “LDL uptake” genes (Song et al. 2013). 
The recruitment of monocytes to the activated ECs and their subsequent migration into the 
intima of the artery to the site of modified LDL build up is one the key processes in 
atherosclerosis disease progression. Studies performed in vitro and in vivo have shown that 
treatment with ω-3 PUFA results in reduced monocyte migration (Brown et al. 2012), which 
highlights the possible use of ω-3 PUFAs to attenuate one of the key initial stages of plaque 
formation. 
The use of mouse model systems have greatly enhanced our knowledge of the effects of ω-3 
PUFA dietary supplementation on atherosclerosis disease progression. The use of fish oil 
dietary supplementation in LDLr deficient mice while they received a high fat diet for 16 weeks 
resulted in a decrease of approximately 50% in monocyte migration to the atherosclerotic 
lesion (Brown et al. 2012). In contrast to the control mice, those receiving ω-3 PUFAs 
developed smaller atherosclerotic plaques and had significantly reduced plasma cholesterol 
levels (Brown et al. 2012). Conversely when the study was repeated using ApoE deficient mice 
no significant differences in monocyte migration or lesion size was observed between the 
control group and those receiving fish oil dietary supplementation (Brown et al. 2012). However 
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it should be noted that ApoE deficient mice are a more aggressive model of atherosclerosis 
disease progression and therefore a shorter time point was possibly required in order to study 
any possible differences (Getz and Reardon 2016). Encouraging results have also been seen 
in a plaque regression study. After 8 weeks of feeding LDLr deficient mice a high fat diet they 
were switched to a standard chow diet in the presence or absence of 5% EPA for 4 weeks 
(Nakajima et al. 2011). Compared to the control mice, those that received the EPA 
supplementation had increased serum HDL levels and their plaques were approximately 
20.9% smaller (Nakajima et al. 2011). The study also found that the EPA receiving mice had 
attenuated expression of pro-inflammatory genes such as ICAM-1, IL-10, IFN-γ and TNF-α 
within the atherosclerotic plaques (Nakajima et al. 2011), indicating that EPA dietary 
supplementation may exert strong anti-atherogenic effects. 
The mechanisms behind the anti-inflammatory effects of ω-3 PUFA rich diets are slowly being 
uncovered (Calder 2015). Both EPA and DHA can be metabolised via COX, lipoxygenase 
(LOX) and CYTP450 pathways to form anti-inflammatory molecules capable of attenuating 
inflammation known as resolvins (Calder 2015; Fredman and Tabas 2017). Both human and 
murine studies have shown levels of resolvins in the blood to increase following diets rich in 
ω-3 PUFAs (Hong et al. 2003; Mas et al. 2012). Another anti-inflammatory effect of ω-3 PUFA 
dietary supplementation is the reduced production of pro-inflammatory cytokines and adhesion 
molecules (Nakajima et al. 2011; Calder 2015). ω-3 PUFAs are thought to achieve these 
effects by attenuating the expression of the pro-inflammatory transcription factor NF-κB and 
upregulating the action of the anti-inflammatory transcription factor peroxisome proliferator-
activated receptor (PPAR)-γ (Calder 2013; Calder 2015). These transcription factors influence 
the expression of several genes involved in resolvin formation as well as cytokine and cell 
adhesion molecules (Calder 2015). Upon further investigation it was found that the G-protein 
coupled receptor (GPR)120 is also capable of binding to PUFAs in addition to attenuating the 
expression of NF-κB (Oh et al. 2010; Calder 2015). Indeed GPR120 agonists have been shown 
to induce similar anti-inflammatory effects that are normally associated with ω-3 PUFA dietary 
supplementation (Oh et al. 2014). Therefore GPR120 appears to be a key receptor involved in 
the anti-inflammatory properties of ω-3 PUFA dietary supplementation. 
As previously mentioned achieving a better ω-3:ω-6 ratio is considered key for reducing the 
speed of atherosclerosis development. ApoE mice which also expressed the Fat-1 gene from 
Caenorhabditis elegans have been used to demonstrate the importance of the ω-3:ω-6 ratio 
(Wan et al. 2010). In theory these mice should achieve a tissue ω-3:ω-6 ratio of approximately 
1:1 due to the ability of Fat-1 to metabolise ω-6 into ω-3 PUFAs by an ω-3 fatty acid desaturase 
(FAD; Wan et al. 2010). The ApoE deficient/Fat-1 mice developed smaller atherosclerotic 
plaques in addition to attenuated expression of IFN-γ and MCP-1 in comparison to ApoE 
deficient only mice following 14 weeks of high fat diet feeding (Wan et al. 2010). Despite these 
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changes neither serum LDL, HDL or total cholesterol levels were altered. This study reinforces 
the idea of using EPA and DHA dietary supplements in order to achieve a ω-3:ω-6 ratio which 
is closer to the ideal 1:4 to attenuate atherosclerosis disease progression and reduce an 
individual’s risk of suffering a CVD-related event. 
Relevant clinical data in humans 
During the last 30 years, there have been three large robust trials which used either EPA, DHA 
or both dietary supplementation in high risk patients. These trials are known as the DART (Diet 
and Reinfarction Trial), GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’ Infarto 
Miocardico)-Prevenzione and the JELIS (Japan EPA Lipid Intervention Study) trials (Burr et al. 
1989; Anon. 1999; Yokoyama et al. 2007). Approximately 2,000 men who had recently suffered 
a MI were involved in the DART trial (Burr et al. 1989). The participants were then randomised 
to receive three different diets for 2 years and compared to a control group. The diets being 
assessed were either increased cereal fibre intake; improved ratio of polyunsaturated to 
saturated fat by reducing the amount of dietary fat; or using oily fish or fish capsules to increase 
ω-3 PUFAs intake (Burr et al. 1989). The participants receiving the enhanced ω-3 PUFAs 
intake diet were found to have a 29% reduction in all-cause mortality, almost completely due 
to a substantial decrease in the number of CVD-related events (Burr et al. 1989). However no 
significant reduction in the mortality rates was observed in the participants receiving the other 
diets (Burr et al. 1989). This study highlights the possible benefits of using ω-3 PUFAs as 
secondary preventatives to reduce an individual’s risk of suffering a subsequent CVD-related 
event following their initial MI. 
During the GISSI-Prevenzione trial, 11,323 patients were recruited and all participants had 
recently suffered a MI (Anon. 1999). The participants randomly received either ω-3 PUFA 
dietary supplementation or continued to only receive traditional care for CVD (Anon. 1999). 
After a 6 month follow up, there were no significant changes in total, LDL or HDL cholesterol 
levels in the patient’s serum (Anon. 1999). Despite these disappointing results at the 6 month 
time point, at the 1 year follow up participants on the ω-3 PUFA supplemented diet showed a 
45% reduction in sudden cardiac death when compared to the control group (Anon. 1999). 
This reduction in cardiac death contributed to the observed 15% decrease in all-cause mortality 
and non-fatal CVD-related events in the ω-3 PUFA receiving group (Anon. 1999). 
The JELIS trial involved 18,645 hypercholesterolaemic individuals who were randomly 
assigned to receive either statin only therapy or a combination of statin and EPA 
supplementation (Yokoyama et al. 2007). During the average follow up time point of 4.6 years, 
no changes in serum HDL or LDL levels were observed in those receiving the additional EPA 
supplementation compared to those receiving statins only. However the extra dietary intake of 
EPA was associated with a 19% relative reduction in major CVD-related events (Yokoyama et 
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al. 2007). Further evidence of the cardiovascular protective effects of ω-3 PUFA dietary 
supplementation has been generated in a recent study involving 95 patients who had been 
treated with a high dose of statins for at least 6 months before also being given an EPA 
supplement for 6 months (Niki et al. 2016). A reduction in the levels of pro-inflammatory 
cytokines, such as MCP-1, was found in the participants receiving EPA compared to those on 
the statin only therapy (Niki et al. 2016). Furthermore EPA supplementation appeared to 
improve plaque stability by reducing the amount of lipid build up within the lesion and 
enhancing collagen deposition in the fibrous cap, indicating a reduction in the risk of a plaque 
rupturing and therefore reducing the chance of a CVD-related event (Niki et al. 2016). The 
evidence observed in these trials indicates that increasing an individual’s dietary intake of ω-3 
PUFAs, in particular EPA and DHA, either alone or as a combination with statins can provide 
cardiovascular protective effects which may reduce an individual’s risk of a major CVD-related 
event. 
A reduction in the markers of atherothrombotic risk was observed in 600 Caucasian men with 
CVD following dietary fish oil supplementation (Franzese et al. 2015). In a study involving 29 
patients who received daily ω-3 PUFA supplementation for 12 weeks, there was a significant 
improvement in endothelial function and arterial stiffness as assessed by flow-mediated 
dilation (FMD) and pulse wave velocity (PWV; Tousoulis et al. 2014). This observation was 
confirmed by a later epidemiological study involving 160 Japanese patients which found a 
correlation between low serum levels of DHA and attenuated endothelium function when 
measured by FMD (Yagi et al. 2015).  
Even though many studies provide evidence for the cardiovascular protective effects of 
increased ω-3 PUFA dietary intake, their effectiveness is still debated in the literature with 
several meta-analysis studies failing to find an association between ω-3 PUFA intake and a 
reduced risk of CVD-related events. One meta-analysis involving a total of 36,913 individuals 
across 48 randomised studies failed to find any significant reduction in CVD-related mortality 
following 6 months of ω-3 PUFA supplementation (Hooper et al. 2006). Another study 
investigating 14 randomised double blind trials and 20,485 total participants with a history of 
CVD, found no correlation between ω-3 PUFA supplementation and any cardiovascular 
protective effects (Kwak et al. 2012). These findings have also been shown in another study 
involving 68,680 patients in 20 randomised clinical trials, in which ω-3 PUFA supplementation 
did not alter patient’s risk of either all-cause or CVD-related mortality (Rizos et al. 2012). ω-3 
PUFA supplementation also failed to reduce the number of CVD-related events in individuals 
with peripheral arterial disease (Enns et al. 2014). Furthermore a recent clinical trial involving 
74 patients with atherosclerotic vascular disease and type 2 diabetes failed to find any changes 
in the inflammatory state of participants following daily treatment of EPA and DHA for 3 months 
(Poreba et al. 2017). 
 Chapter 1: Introduction  
26 
 
Recent trials did not observe any additional cardiovascular protective effects from taking ω-3 
PUFAs in combination with traditional pharmaceuticals. The MAGMA (Magnetic Resonance 
Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis) trial 
failed to find any further reductions in the levels of TG, VLDL and oxLDL following fish oil 
supplementation when patients were already receiving traditional therapy (Franzese et al. 
2015). However fish oil supplementation was shown to be effective at lowering these factors 
within the general population. A total of 3,851 and 12,536 high risk patients were recruited for 
the OMEGA and ORIGIN (Outcome Reduction with an Initial Glargine Intervention) trials 
respectfully (Rauch et al. 2010; The ORIGIN Trial Investigators 2012). Neither of these studies 
found any benefits from ω-3 PUFA dietary supplementation, however these trials used 
relatively low doses of ω-3 PUFAs and conducted the trial in patients with typical TG serum 
levels (a risk factor for CVD; Bhatt et al. 2017; Nordestgaard 2016). 
To assess the effect of ω-3 PUFA dietary supplementation in patients with raised TG levels, 
two studies known as the MARINE (Multi‐centre, Placebo‐controlled, Randomized, Double‐
blind, 12‐week study with an open‐label Extension) and ANCHOR trials were conducted (Bays 
et al. 2011; Ballantyne et al. 2012). These preliminary studies observed a reduction in serum 
TG levels as well as a decrease in a variety of inflammatory markers without increasing LDL 
levels following EPA ethyl ester treatment (Bays et al. 2013). These preliminary trials formed 
the basis of the large international trial known as REDUCE-IT (Reduction of Cardiovascular 
Events with EPA – Intervention Trial; Bhatt et al. 2017; U.S. National Institutes of Health 
2017a). The REDUCE-IT trial is expected to involve 8,000 participants and investigate the 
effect of Vascepa® (icosapent ethyl) in combination with statins on the incidence rate of CVD-
related events (U.S. National Institutes of Health 2017a). Vascepa® is a purified ethyl ester of 
EPA and has been designed to treat hyperglyceridaemia. Another large international study 
known as the STRENGTH (Statin Residual Risk Reduction With EpaNova in HIGh CV Risk 
PatienTs With Hypertriglyceridemia) trial involves 13,000 individuals and is establishing 
whether a combined treatment of statins and Epanova® (ω-3 carboxylic acids) can reduce the 
number of CVD-related events compared to those receiving statins only (U.S. National 
Institutes of Health 2017c). It is hoped these studies will provide greater evidence on whether 
additional ω-3 PUFA supplementation taken in combination with statins is capable of exerting 
enhanced cardiovascular protective effects. 
When drawing conclusions from the results of clinical trials, caution must be taken due to the 
heterogeneity in the experimental design of the studies (Enns et al. 2014). Trials often differ in 
how the ω-3 PUFA supplementation is provided and whether it is given alone or in combination 
with statins and therefore the combined therapy may exert synergistic effects. Furthermore 
trials can differ in their dose and length of ω-3 PUFA dietary intervention. The biggest 
difference within the trials are the populations which are selected. For example, dietary intake 
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of ω-3 PUFAs is estimated to be roughly 15 times higher in the Japanese population when 
compared to their Western counterparts (Iso 2006; Kobayashi et al. 2003). Therefore this may 
alter the outcomes of these trials as the Western population is more likely to see health benefits 
of extra ω-3 PUFA dietary supplementation in contrast to the Japanese population. These key 
differences in the designs of the studies may result in the different outcomes observed within 
the clinical trials and meta-analysis. 
 
1.7 Flavanols 
The cardiovascular protective effects of diets with high intakes of fruit and vegetables has long 
been known (Slavin and Lloyd 2012; Moss and Ramji 2016b). Flavonoids are a class of plant 
secondary metabolites which are commonly found in fruit and vegetables. Flavanols, a 
subclass of flavonoids, have the possibility to be used as a nutraceutical therapy for 
atherosclerosis and therefore their potential must be explored in greater detail (Falcone 
Ferreyra et al. 2012). Catechin (Fig. 1.5) is a common flavanol found within green tea and 
cocoa and has been shown to reduce endothelial exocytosis in human umbilical vein 
endothelial cells (HUVECs; Yamakuchi et al. 2008). Activated ECs release stored pro-
inflammatory cytokines and chemokines from intracellular endothelial granules into the 
extracellular space via a process called endothelial exocytosis. Therefore catechin and its 
isomers may be capable of attenuating vascular inflammation during the initial atherosclerotic 
lesion formation, highlighting the need to develop a greater insight into the effects and potential 
of this compound. 
 
Fig. 1.5. The chemical structure of catechin. Catechin is a major flavanol found within green tea and cocoa and 
shows promising cardiovascular protective effects. 
The size of severe lesions in ApoE*3-Leiden mice were found to be significantly smaller 
following 20 weeks of a high fat diet supplemented with 0.1% epicatechin (Morrison et al. 
2014). The mice receiving the epicatechin supplement were found to have altered expression 
of 173 genes, including 77 that had their expression reversed when compared to the mice 
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receiving the high fat diet only. Furthermore a large number of the 173 genes played a role in 
cell recruitment (Morrison et al. 2014), indicating that epicatechin may reduce lesion size by 
attenuating one of the key steps during early atherosclerosis lesion formation. 
Relevant clinical data in humans 
NO production was increased in 27 healthy individuals who received a flavanols-rich cocoa 
(epicatechin and catechin) diet for 5 days (Fisher et al. 2003). The increased NO production 
was also accompanied by an increase in vasodilation, highlighting the possibility of using 
catechin to reduce an individual’s blood pressure which is a risk factor for CVD-related events 
(Fisher et al. 2003). Subsequent studies have also found an improvement in vasodilation 
following 5 weeks of green tea extract dietary supplementation as well as a reduction in serum 
oxLDL levels (Babu et al. 2008; Tinahones et al. 2008). Increased dietary intake of catechin in 
obese and near-obese children resulted in a significant reduction in the levels of circulating 
LDL after 24 weeks of daily supplementation (Matsuyama et al. 2008). FMD was improved in 
57 patients with end stage renal disease, a population at high risk of developing CVD, following 
30 days of cocoa flavanol-rich dietary supplementation (Rassaf et al. 2016). The vascular 
function of 100 healthy individuals without any previously reported cases of CVD was also 
improved after 30 days of cocoa flavanol consumption (Sansone et al. 2015). The use of cocoa 
flavanol dietary supplementation for 14 days in 22 young and 20 elderly patients resulted in 
decreased arterial stiffness and increased FMD in both participant groups (Heiss et al. 2015). 
This study highlights the use of flavanols in order to reduce blood pressure in the elderly, a 
high risk population for suffering a CVD-related event. These trials indicate that the use of 
flavanols may not only be used as a preventative in healthy individuals but it may also provide 
cardiovascular protective effects in high risk patients. 
The levels of several pro-inflammatory mediators including soluble TNF-receptor 2, IL-6 
receptor, IL-8, Fas ligand and neutrophil-activating peptide (NAP)-2 were reduced following 
catechin treatment, highlighting its anti-inflammatory properties (Hsu et al. 2007). A small trial 
involving 17 healthy men receiving a daily catechin treatment for 3 weeks observed a 
significant reduction in the total:HDL cholesterol ratio compared to the control group, however 
other cardiovascular risk factors, including blood pressure were unaffected (Frank et al. 2009). 
A later study also failed to find a significant improvement in blood pressure or FMD after 4 
weeks of daily cocoa flavanol supplementation in 30 overweight adults, however there was a 
significant reduction in arterial stiffness within the women subgroup (West et al. 2014). The 
lack of reduction in blood pressure in these studies contradicts the decreases found in the 
previously mentioned studies (Fisher et al. 2003; Babu et al. 2008; Tinahones et al. 2008). 
These differences in outcomes may be partly due to the limited number of trial participants and 
therefore larger and more robust clinical trials are required to provide stronger conclusions 
about the benefits of catechin supplementation (Moss and Ramji 2016b). 
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The three largest studies investigating the potential cardiovascular health benefits of flavanol 
dietary supplementation are known as CoCoA (Cocoa, Cognition, and Aging) study, the 
Flaviola Health study and the PREDIMED (Prevención con Dieta Mediterránea) trial 
(Mastroiacovo et al. 2015; Sansone et al. 2015; Tresserra-Rimbau et al. 2014a). The CoCoA 
study observed a significant reduction in the amount of lipid peroxidation, in addition to an 
improvement in blood pressure and insulin resistance in 90 elderly participants who had 
received either a high or intermediate dose of daily flavanols for 8 weeks compared to those 
that only received a low dose (Mastroiacovo et al. 2015). These results were also found in the 
subsequent Flaviola Health study which involved 100 healthy individuals with no prior history 
of CVD receiving cocoa flavanol dietary supplementation for 1 month (Sansone et al. 2015). 
Those receiving the flavanols showed improvements in FMD and HDL levels as well as a 
reduction in blood pressure, serum LDL levels and arterial stiffness compared to the control 
group (Sansone et al. 2015). The PREDIMED trial is a large dietary intervention study which 
ran for 4 years and recruited 7,172 participants (Tresserra-Rimbau et al. 2014b). After 
controlling for other risk factors and nutrients together with lipid lowering pharmaceutical 
usage, the PREDIMED study found a significant correlation between flavanol intake and an 
individual’s risk of suffering a CVD-related event (Tresserra-Rimbau et al. 2014a). Despite 
these larger studies showing associations between flavanol intake and cardiovascular health 
benefits such as lowering an individual’s blood pressure and circulating LDL levels, two CVD 
risk factors, the efficacy of flavanol treatment needs to be assessed further in both in vitro and 
in vivo studies. 
 
1.8 Phytosterols 
Phytosterols are almost identical in structure to cholesterol but are derived from plant sources 
instead of animal sources (Fig. 1.6). Due to their similar structure, phytosterols are able to 
compete with cholesterol within the intestine during dietary and biliary cholesterol uptake and 
therefore reduce an individual’s cholesterol level and provide cardiovascular health benefits 
(Andersson et al. 2004). Indeed low serum LDL levels have been associated with diets 
containing high levels of phytosterols (Katan et al. 2003; Andersson et al. 2004). An in vitro 
study observed an increase in the expression of the “cholesterol efflux” gene ABCA1 as well 
as a decrease in LDLr expression in murine macrophages (Sabeva et al. 2011). These 
changes in gene expression correlated with increased ApoA1- and HDL-mediated cholesterol 
efflux from human THP-1 macrophages following phytosterols treatment (Sabeva et al. 2011). 
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Fig. 1.6. The chemical structure of cholesterol and phytosterols. The structure of cholesterol is almost identical 
to the phytosterols sitosterol, campesterol and stigmasterol. Due to their similar structure it is hoped that 
phytosterols can be used to lower an individual’s cholesterol level by out competing it in the gut and preventing 
cholesterol uptake. 
The anti-inflammatory potential of phytosterols has also been demonstrated in in vivo studies. 
After 20 weeks of a high fat diet supplemented with a 2% phytosterols mixture, ApoE mice 
developed atherosclerotic plaques which were approximately 50% smaller than the mice which 
received a high fat only diet (Moghadasian et al. 1999). The same study also observed a 
decrease in serum LDL levels in addition to a moderate increase in HDL levels in the mice 
which had received the phytosterols supplement (Moghadasian et al. 1999). Later studies also 
observed smaller lesion formation and reduced serum LDL levels in ApoE deficient mice 
following 12 and 14 weeks of a 2% phytosterol supplemented diet when compared to the 
control mice (Yeganeh et al. 2005; Moghadasian 2006). The levels of pro-inflammatory 
cytokines, IL-6 and TNF-α, were reduced whereas there was an increase in the anti-
inflammatory cytokine IL-10 within the spleen of ApoE mice fed a 2% phytosterol supplemented 
high fat diet for 2 weeks (Nashed et al. 2005). These mice also developed lesions which were 
approximately 60% smaller in the mice receiving the phytosterol supplemented diet (Nashed 
et al. 2005). A study involving ApoE deficient mice found that 132 genes were differentially 
expressed, including several genes implicated in the control of sterol metabolism such as 
FAD1, FAD2, PPAR-γ coactivator 1β (Ppargc1B) and hydroxysteroid (17-beta) 
dehydrogenase 7 (Hsd17b7), after receiving a 2% phytosterol supplemented diet when 
compared to the control group (Xu et al. 2008).  
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Relevant clinical data in humans 
A recent clinical trial involving 233 patients receiving phytosterol dietary supplementation for 
12 weeks found a decrease in their serum LDL levels compared to the control group, however 
there were no changes in FMD or PWV (Ras et al. 2015). Furthermore low serum LDL levels 
were associated with higher dietary intake of phytosterols in an epidemiological study involving 
22,256 men and women (Andersson et al. 2004). Despite the potential cardiovascular 
protective effects of phytosterols discussed so far, there are still several studies which indicate 
that high dietary intake of phytosterols may exert adverse effects and further impact on 
atherosclerosis development (Chan et al. 2006). One trial found that an increased serum 
phytosterol:cholesterol ratio was associated with a greater risk of developing coronary heart 
disease (CHD) when assessed in 48 postmenopausal women with existing disease 
(Rajaratnam et al. 2000). However several of studies which have concluded that phytosterols 
actually exert pro-atherogenic effects, and increase an individual’s risk of suffering a CVD-
related event, often lack appropriate controls or fail to match risk factors between those 
receiving the phytosterols and the control group. Therefore caution should be taken when 
interpreting the findings (extensively reviewed by Chan et al. (2006)). In one study, serum 
phytosterol levels were significantly higher in 159 patients who had suffered a MI or sudden 
cardiac death in contrast to 318 control individuals (Assmann et al. 2006). However a major 
flaw in this study was the failure to account for differences in total cholesterol, TG and LDL 
levels, as well as blood pressure, all of which are considered risk factors for CVD-related 
events, between the two sets of participants (Chan et al. 2006). All of these risk factors were 
found to be higher in the CVD-related event group. Additionally the serum 
phytosterol:cholesterol ratio between the two groups was not significant, consequently this 
study does not provide any substantial evidence which directly links increased phytosterol 
levels with increased risk of CVD-related events (Chan et al. 2006).  
 
1.9 Project aims 
Due to the adoption of a westernised diet in many developing countries around the world and 
the expected rise in diabetes and obesity worldwide, CVD-related events are predicted to 
continue their increase in global prevalence. As atherosclerosis, the primary cause of CVD, is 
a chronic inflammatory disease, novel therapeutics that are able to reduce many of the 
inflammatory stages involved in disease progression are required. These key inflammatory 
stages include; the recruitment of immune cells to the affected area, the expression of key pro-
inflammatory genes and the formation of foam cells. Therefore novel therapies that are able to 
attenuate these steps may be helpful in reducing the global incidence of CVD-related events 
by reducing atherosclerosis development. 
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The main hypothesis of this study was that CardioWise, as well as its constituent components, 
are capable of attenuating key steps in atherosclerosis development in vitro and in vivo by 
exerting anti-inflammatory effects. Initial experiments were performed using monocytes and 
macrophages in vitro as they are involved in all of the major steps in atherosclerosis 
progression and therefore any anti-atherogenic effects observed would denote an encouraging 
therapeutic avenue to pursue. Once a potential anti-atherogenic nutraceutical was identified, 
it was then used in an initial in vivo study to determine its effects in wild type C57/BL6 mice. 
The major project objectives are outlined below and in Fig. 1.7: 
 Research started with CardioWise as it is a unique combination of nutraceuticals 
produced by Cultech Ltd with no previous studies on atherosclerosis. Its effect on 
several macrophage processes associated with atherosclerosis development such as 
MCP-1 and ICAM-1 gene expression, cholesterol efflux and M1 macrophage 
phenotype formation was therefore investigated (Chapter 3). 
 Chapter 4 describes the effects of CardioWise dietary supplementation in wild type 
C57/BL6 mice for 3 weeks while being fed a high fat diet. The potential anti-
inflammatory effects of CardioWise were determined by analysing circulating 
cholesterol and cytokine levels, gene expression studies and investigating the 
proportion of haematopoietic stem/progenitor cells within the bone marrow. 
 Investigation of the efficacy of various ingredients present in CardioWise on a key pro-
atherogenic process, monocyte migration, identified a major role of the flavanol (+)-
catechin (Chapter 5). 
 Chapter 6 describes studies on the anti-inflammatory effects of catechin on several 
pro-atherogenic processes including gene expression changes, ROS generation and 
MMP activity. 
 The anti-atherogenic effects of catechin dietary supplementation was assessed in wild 
type C57/BL6 mice fed a high fat diet for 3 weeks (Chapter 7). The cardiovascular 
protective effects of catechin were determined by monitoring circulating cholesterol and 
cytokine levels, gene expression analysis and the proportion of haematopoietic 
stem/progenitor cells within the bone marrow. 
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Fig. 1.7. An overall summary of the aims addressed within this project. Further details on the specific methods 
used to assess the anti-inflammatory properties of CardioWise and catechin, as well as the rationale for each 
experiment, can be found in Chapter 2 – 7. 
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Chapter 2: Materials and Methods 
Materials and Methods 
 
2.1 Materials 
A list of all the suppliers and materials used in this project have been outlined below in Table 
2.1. 
Table 2.1. The materials used to carry out the project and their suppliers. 
Supplier Material 
Abcam, UK Annexin V-FITC apoptosis detection kit; DCFDA Cellular ROS Detection 
Assay Kit; MMP Activity Assay Kit (Fluorometric - Green); HDL and 
LDL/VLDL cholesterol assay kit; Triacylglycerol quantification assay kit 
Amersham, UK [4-14C]cholesterol 
BD Bioscience, UK FITC-conjugated anti-mouse CD34 
Biolegend, USA APC-conjugated anti-mouse c-Kit; PE-conjugated anti-mouse Sca-1; 
FITC-conjugated anti-mouse CD48; PE/Cy7-conjugated anti-mouse 
CD150; APC/Cy7-conjugated anti-mouse Sca-1; PE/Cy7-conjugated anti-
mouse CD16/32; BV650-conjugated anti-mouse CD127 
Biotrend, Germany Acetylated LDL; Dil-oxLDL 
Cayman Chemical, USA EPA; DHA; β-sitosterol; Campesterol 
Cell Biolabs, USA OxiSelect in vitro ROS/RNS Assay kit (green fluorescence); OxiSelect 
TBARS Assay Kit (MDA Quantification) 
Cultech Limited, UK CardioWise; CardioWise Plus 
Dutscher, UK 40/70 μm sterile cell strainer 
Fisher Scientific, UK  Agarose 
Helena Biosciences, UK Cell scrappers 
Jackson Laboratory, USA Male C57 black 6 wild type mice 
Life Technologies, UK TBE; Penicillin; Streptomycin; Foetal calf serum; miRNA probes and 
Taqman master mix; Amplex Red kit; qPCR plate seals 
Lonza, UK RPMI 1640 with L-Glutamine media 
Nycomed, Switzerland Lymphoprep 
Peprotech, UK IFN-γ, MCP-1; M-CSF; TNF-α 
Promega, UK dNTPs; MMLV reverse transcriptase; RNasin ribonuclease inhibitor; 
random primers; MMLV RT 5x buffer 
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Qiagen, UK Atherosclerosis RT2 Profiler PCR Arrays (human and mouse) 
R&D Systems, UK Human CCL2 DuoSet ELISA; Human IL-1β DuoSet ELISA; DuoSet 
ancillary reagent kit 2 
Sigma-Aldrich, UK Phorbol-12-myristate-13-acetate (PMA): SYBR Green; Dimethyl sulfoxide 
(DMSO); RAW264.7 cells; Ethylenediaminetetraacetic acid (EDTA); 
Ethanol; PCR primers; Isopropanol; Ipegal; Bovine serum albumin (BSA); 
Hexane; Tissue culture flasks; 12/24/96-well plates; 10/25ml strippets; 
15/50ml Falcon tubes; Cell culture plates; Crystal violet; THP-1 cells; 
Apolipoprotein A-I; 5-Bromo-2′-deoxy-uridine Labeling and Detection Kit 
III; Lucifer yellow CH dipotassium salt (LY); Stigmasterol; (+)-Catechin; 
Catechin hydrate; Accuspin tubes 
Special Diets Services, UK High fat diet [21% (w/w) pork lard and 0.15% (w/w) cholesterol] 
Starlabs, UK qPCR 96-well plates 
Thermo Scientific, UK  Micro BCA™ Protein Assay kit; 2x RNA loading dye; RiboRuler high 
Range RNA ladder; Pierce lactate dehydrogenase (LDH) cytotoxicity 
assay kit; Streptavidin; Cryomolds; OCT 
VWR Jencons, UK Falcon® cell culture inserts (8 μm pore size); Falcon® 12-well companion 
plates 
APC, allophycocyanin; Cy7, cyanine7; DCFDA, 2’7’-dichlorofluorescin diacetate; DHA, docosahexaenoic acid; 
EPA, eicosapentaenoic acid; FITC, fluorescein isothiocyanate; HDL, high density lipoprotein; IFN, interferon; LDL, 
low density lipoprotein; MCP-1, monocyte chemotactic protein-1; M-CSF, macrophage colony-stimulating factor; 
MDA, malondialdehyde; MMLV, moloney murine leukaemia virus; oxLDL, oxidised LDL; PCR, polymerase chain 
reaction; PE, phycoerythrin; RNS, reactive nitrogen species; ROS, reactive oxygen species; Sca-1, stem cell 
antigen-1; TBARS, thiobarbituric acid reactive substances; TBE, tris/borate/EDTA buffer; TNF-α, tumour necrosis 
factor α; VLDL, very low density lipoprotein. 
 
2.2 CardioWise Composition 
CardioWise is a unique combinational product supplied by Cultech Limited containing a variety 
of nutraceuticals thought to exert anti-inflammatory effects. In order to create the different 
treatment dosages of CardioWise used in this study (Table 2.2), stock CardioWise was diluted 
(1:10 v/v) in culture media. Culture media consists of RPMI 1640 with L-Glutamine media, 10% 
(v/v) heat-inactivated (56ºC for 30 minutes) foetal calf serum (HI-FCS), as well as penicillin 
and streptomycin (both 100 μg/ml). To preserve the sterility of the media, the HI-FCS, penicillin 
and streptomycin were passed through a sterile filter (0.2 μm) before being added to the media. 
The doses initially used in the study ranged from 0.25x to 4x physiological dose, with 1x 
physiological dose based on the reported levels of each component found in the blood stream 
following consumption (Garaiova et al. 2007; Batta et al. 2006; Manach et al. 2005). 
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Table 2.2. Dosages of CardioWise used in the study. 
Compound 0.25x PD 0.5x PD 1x PD 2x PD 4x PD 
EPA (µg/ml) 7.5 15.0 30.0 60.0 120.0 
DHA (µg/ml) 5.0 9.9 19.7 39.4 78.8 
Total Phytosterol Esters (µg/ml) 14 28 56* 112 224 
Flavanols (µmol/ml) 1.25 2.50 5.00 10.00 20.00 
FA free BSA (µg/ml)** 25 50 100 200 400 
 
FA, fatty acid; PD, physiological dose. * Stigmasterol: 10 µg/ml, Campesterol: 13.9 µg/ml, β-sitosterol: 27.2 µg/ml, 
Brassicasterol: 1.672 µg/ml. ** used as an emulsifier and protein carrier unless stated otherwise. 
 
2.3 Cell Culture Techniques 
2.3.1 Cell Lines Utilised 
The RAW264.7 and THP-1 cell lines were predominately used throughout the study. The 
RAW264.7 cell line is a mouse macrophage-like cell line which was originally from a tumour 
developing in a BALB/c IgH strain of BAB/14 mouse which had been injected with Abelson 
murine leukaemia virus (Hartley et al. 2008). Since their first discovery 35 years ago, the 
RAW264.7 cell line has become one of the most common mouse macrophage-like cell lines 
used in atherosclerosis research for gene expression and macrophage function studies 
(Hartley et al. 2008). These cells can also be efficiently transfected with exogenous DNA and 
therefore extensively used in promoter analysis studies (Hartley et al. 2008). 
In order to make the results of this study more applicable to humans, experiments were also 
performed using the THP-1 human monocytic leukaemia cell line. Unlike the RAW264.7 cells 
which are adherent to tissue culture dishes, THP-1 monocytes grow in suspension and require 
treatment with phorbol-12-myristate-13-acetate (PMA) for at least 24 hours in order to 
differentiate into macrophages. PMA differentiated THP-1 macrophages make ideal cell 
models for atherosclerosis gene expression, macrophage function and cell signalling studies 
as they exhibit similar traits to human monocyte-derived macrophages (HMDMs) both in vitro 
and in vivo (Auwerx 1991; Qin 2012; Chanput et al. 2014). For this reason the THP-1 cell line 
has become well established and makes for an excellent in vitro model of HMDMs. 
Some assays were also performed using primary HMDMs from buffy coats in order to rule out 
the possibility that the results achieved were due to the use of a cell line. HMDMs were 
obtained from buffy coats using the following protocol. The National Blood Service Wales 
provided the human blood buffy coats and the white blood cells were separated using 
Lymphoprep. In order to place the Lymphoprep in the bottom of a 50 ml Accuspin tube, 15 ml 
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of Lymphoprep was centrifuged at 1000 x g for 60 seconds at room temperature. Subsequently 
25 ml of blood was added to the tube and centrifuged at room temperature at 800 x g for 10 
minutes. No brake was used to slow the centrifuge at this step. The mononuclear layer of cells 
was aspirated and placed in a fresh Falcon tube where an equal volume of ice cold 0.4% (w/v) 
tri-sodium citrate phosphate buffered saline (PBS) was added. The mixture was centrifuged at 
1000 x g for 5 minutes at room temperature. Red blood cells were lysed by re-suspending the 
cell pellet in 10 ml of 0.2% (w/v) saline and placed on ice for 30 seconds before addition of an 
extra 10 ml of 1.6% (w/v) saline to the mixture. It was then centrifuged at 1000 x g for 5 minutes 
at room temperature. In order to remove platelets, the resulting pellet was re-suspended in ice 
cold 0.4% (w/v) tri-sodium citrate PBS and centrifuged at 800 x g for 5 minutes at room 
temperature 6 – 10 times. The final cell pellet could be re-suspended in culture media and 
seeded into 12 well plates and incubated at 37ºC in 5% (v/v) CO2. The monocytes required 10 
days to differentiate into HMDMs before they could be used experimentally. The HMDMs were 
washed before use in order to remove non-adhering leukocytes. The primary human 
macrophages were utilised in the same way as the THP-1 macrophages, therefore the 
following methods will only refer to THP-1 monocytes/macrophages. 
2.3.2 Thawing Frozen Cells 
For long term storage of the cell lines they were either stored in liquid nitrogen or at -80ºC, 
therefore careful thawing of the frozen stock was required when fresh cells were needed. The 
cells were warmed to 37ºC using a water bath and once thawed, the cells were immediately 
added to 10 ml of pre-incubated culture media and centrifuged at 250 x g for 5 minutes at room 
temperature. Once centrifuged the supernatant was aspirated and a further 5 ml of pre-
incubated culture media was used to re-suspend the cells, which were then maintained and 
sub-cultured according to the instructions outlined further in Section 2.3.3. 
2.3.3 Cell Line Maintenance and Sub-culturing of Cells 
Cell lines were maintained and incubated in culture media at 37ºC in 5% (v/v) CO2 in either 
tissue culture dishes (RAW264.7 due to their adherent nature) or tissue culture flasks (THP-1 
cells as they grow in suspension). When the RAW264.7 or THP-1 cells became confluent (80% 
or 60% respectively) they were sub-cultured. A cell scraper was used to remove the adherent 
RAW264.7 cells from the surface of the tissue culture dishes to create a cell suspension. Both 
of the RAW264.7 and THP-1 cell suspensions were then transferred to a Falcon tube and 
centrifuged at room temperature at 250 x g for 5 minutes. The supernatant was then removed 
and the cell pellet re-suspended in 5 ml of fresh pre-warmed culture media and split in a ratio 
of approximately 1:30. The freshly split cells were then maintained at 37ºC in 5% (v/v) CO2 
until the process needed to be repeated. Cells between passage 3 and 12 were used in 
experiments. 
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2.3.4 Counting Cells 
In order to accurately seed the correct number of cells for each experiment a haemocytometer 
was used. The surface of the haemocytometer is covered in a 5 x 5 grid which can be used to 
count the number of cells by adding 7.5 μl of either the RAW264.7 or THP-1 cell suspension 
and using a glass cover slip over the surface of haemocytometer to evenly spread the 
suspension. The average number of cells in the four corners and centre of the grid was 
multiplied by 104 in order to calculate the number of cells/ml. 
2.3.5 Cytokine stimulation 
RAW264.7 and THP-1 cells were seeded at 5.13 x 104 cells/cm2 and 1.28 x 105 cells/cm2 
respectively in total volumes of 2 ml and 1 ml of culture media unless stated otherwise. Due to 
their adherent nature, the RAW264.7 cells could be left for 24 hours to allow them to “stick” to 
the surface of the experimental plate at 37ºC and 5% (v/v) CO2. However THP-1 monocytes 
required the culture media to be supplemented with 0.16 μM PMA for 24 hours at the same 
incubation conditions as the RAW264.7 cells to induce macrophage differentiation. Following 
their 24 hour PMA differentiation, the THP-1 cells were washed using 0.5 ml of PBS (x1, pH 
7.4). The required cytokine could be then added to the cells for the desired length of time to 
induce the expression of the target genes. The concentrations of the cytokines used are listed 
below in Table 2.3 as previous optimisation studies in the laboratory had shown these 
concentrations to be effective (Gallagher 2016). 
Table 2.3. The concentrations of cytokines used in the study (unless stated otherwise). 
Cytokine Concentration 
IFN-γ 250 U/ml 
IL-4  20 ng/μl 
LPS 100 ng/μl 
MCP-1 20 ng/ml 
TNF-α 100 ng/ml 
IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MCP, monocyte chemotactic protein-1; TNF-α, tumour 
necrosis factor α. 
 
2.4 Cell Based Assays 
2.4.1 Cell Viability 
The effect of nutraceuticals on cell viability was assessed in THP-1 cells for 24 hours using the 
Pierce lactate dehydrogenase (LDH) cytotoxicity and crystal violet assays simultaneously. This 
time frame was chosen as it corresponds to the longest assay time used in other cell based 
assays in this study. Initially, THP-1 monocytes (4.11 x 105 cells/cm2) were plated per well of 
 Chapter 2: Materials and Methods  
39 
 
a 96-well plate and differentiated into macrophages using 0.16 µM PMA and incubation at 
37°C and 5% (v/v) CO2 for 24 hours. The culture media was aspirated and substituted with 
200 µl of culture media encompassing a nutraceutical along with both a negative (vehicle) and 
positive control (complete lysis) and returned to the incubator for a further 24 hours. 
After 24 hours, 20 µl of 10x lysis buffer (provided in kit) was added to the positive control wells 
to create a maximum LDH release control. In order to compensate for the increased volume in 
the positive control wells, 20 µl of dH2O was added to all of the other wells. The plate was then 
incubated for 45 minutes using the conditions listed above. Subsequently, 50 µl of supernatant 
from each well was transferred to a new 96-well plate to which 50 µl of reaction mixture 
(provided in kit and made according to manufacturer’s instructions) was added and incubated 
for 30 minutes. LDH is an intracellular enzyme whose function is to catalyse the conversion of 
lactate and NAD+ to pyruvate and NADH. Upon cell membrane rupture (cell death or damage), 
LDH is released into the surrounding media and is then able to freely react with the lactate and 
NAD+ in the reaction mixture. The reaction mixture also contains the water soluble salt 2-(4-
iodophenyl)-3-94-nitrophenyl)-5-phenyl-2H-tetrazolium chloride (INT), which is reduced to an 
insoluble red formazan salt by NADH. Therefore the darker the red colour the more LDH 
leakage has occurred and indicating a reduction in cell viability (Korzeniewski and Callewaert 
1983; Decker and Lohmann-Matthes 1988). After the final incubation, 50 µl of stop solution 
(provided in kit) was added to each well. 
Once the supernatant was removed from the original 96-well plate, the remaining media was 
removed and the cells washed with 50 µl PBS (1x, pH 7.4). A 0.2% (w/v) crystal violet solution 
(which also contained 10% (v/v) ethanol) was prepared and 100 µl added to each well for 5 
minutes at room temperature to stain the cells. The crystal violet solution was removed and 
the cells washed three times with 50 µl PBS (1x, pH 7.4). Then 100 μl solubilisation buffer (0.1 
M NaH2PO4 in 50% ethanol) was added to every sample. Crystal violet is a dye capable of 
binding to DNA within a cell (Feoktistova et al. 2016). Therefore the darker the purple colour 
the more viable cells are present as unviable cells will have become detached and removed 
during the assay. As crystal violet binds to DNA it can also be used to assess the level 
proliferation occurring within the cells. The absorbance of both the LDH and crystal violet plates 
were read in a microplate reader at 570 nm. The negative vehicle control was arbitrarily 
assigned as 100% cell viability and all other samples standardised to it. 
2.4.2 Cell Proliferation 
Cell proliferation was assessed using three different methods including crystal violet assay 
(see Section 2.4.1 for further details), counting the number of cells and a bromouridine 
enzyme-linked immunosorbent assay (ELISA). The simplest way to measure cell proliferation 
is count the changes in cell numbers over a prolonged period of time. To determine the effect 
of (+)-catechin on cell proliferation by cell counting, 200,000 undifferentiated THP-1 monocytes 
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were grown at 37ºC in 5% (v/v) CO2 for 7 days. The cells were cultured in complete cell media 
with the vehicle control or in culture media also containing the desired nutraceutical. The media 
was replaced every 24 hours for the first 4 days. The cell number was determined using a 
haemocytometer (see Section 2.3.4 for further details) on days 0, 1, 2, 3, 4 and 7.  
As bromouridine is simply a uridine with one of its carbon substituted with a bromine, it is 
incorporated into RNA just as regular uridine would be. Higher levels of RNA would indicate 
an increase in the number of cells and therefore increased cell proliferation. Bromouridine can 
be detected using fluorescently labelled antibodies, consequently an increase in the 
fluorescent signal would suggest an increase in cell proliferation. To assess cell proliferation 
by bromouridine ELISA, PMA differentiated THP-1 macrophages (4.11 x 105 cells/cm2) were 
incubated at 37ºC at 5% (v/v) CO2 for 24 hours in either complete media with the vehicle control 
or complete media containing the nutraceutical. Following initial incubation, 10 μM 
bromouridine labelling solution (provided by the manufacturer) was added and the cells 
returned to the incubator for a further 3 hours. The media was then carefully aspirated and the 
cells washed twice with complete media. Pre-cooled fixative (0.5 M HCl in 70% (v/v) ethanol) 
was added to the cells which were then incubated at -20ºC for 30 minutes, before being 
washed a further three times with complete media. After the final wash when all media had 
been removed, the cells were kept at 4ºC overnight. The following morning the cells were 
washed once with complete media and then incubated with nuclease solution (provided by the 
manufacturer) at 37ºC at 5% (v/v) CO2 for 30 minutes. The cells were then washed three times 
with complete media and returned to the incubator for 30 minutes in anti-BrdU-POD, Fab 
fragments solution (provided in kit and made according to manufacturer’s instructions). A 
washing buffer (provided by the manufacturer) was used to wash the cells three times before 
they were incubated in peroxidase substrate solution (provided by the manufacturer) at room 
temperature in the dark for 30 minutes. Fluorescence was measured in a fluorescence 
microplate reader at 405 nm with a secondary reference wave-length of 490 nm. The vehicle 
control was then arbitrarily assigned as 1.0 and all other data were presented relative to this. 
2.4.3 Cell Apoptosis 
PMA differentiated THP-1 macrophages (4.11 x 105 cells/cm2) were used to assess the effect 
of nutraceuticals on apoptosis. To induce apoptosis cells were subjected to a combination of 
serum starvation (by using culture media lacking HI-FCS) and TNF-α stimulation for 3 hours. 
Cells were incubated during that time at 37ºC in 5% (v/v) CO2 in the presence of either the 
vehicle control or nutraceutical of choice. Following the induction of apoptosis, the 96-well plate 
was centrifuged at 250 x g for 5 minutes and the media aspirated. The cells were then gently 
washed with PBS (x1, pH 7.4) and 100 μl of annexin V-FITC solution (made according to 
manufacturer’s instructions from the reagents provided) was added and the cells incubated at 
room temperature in the dark for 5 minutes. Annexin V is protein capable of binding to markers 
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of apoptosis and therefore the levels of apoptosis can be assessed by using a fluorescently 
labelled annexin V protein. After incubation, fluorescence was measured in a fluorescence 
microplate reader, with excitation at 485 nm and emission detected at 535 nm. The vehicle 
control was then arbitrarily assigned as 1.0 and all other data were presented relative to this. 
2.4.4 Monocyte Migration 
2.4.4.1 Setting Up the Boyden Chamber 
Monocyte migration was determined using a modified Boyden chamber (Fig. 2.1), which 
involved using a porous membrane to act like the endothelium layer in the artery. Cells were 
placed on one side of the membrane and the levels of migration determined by the percentage 
of cells which moves across the membrane in response to a chemoattractant. To assess 
monocyte migration, Falcon® cell culture inserts and Falcon® 12-well companion plates were 
used. The cell culture inserts contained a membrane with pore sizes of 8 µm (mimicking the 
arterial wall) and were used to split the wells of the companion plate into separate halves but 
still allowing monocytes to migrate. To induce migration, the chemokine MCP-1 was added in 
a total of 1 ml of culture media to the bottom half of all the wells except for the control (No 
MCP-1). Undifferentiated THP-1 monocytes (1.28 x 105 cells/cm2) were added to the top half 
of the well. The top halves of the wells were then made up to a total volume of 0.5 ml using 
culture media either containing the vehicle control or nutraceutical. The modified Boyden 
chambers were then incubated at 37°C in 5% (v/v) CO2 for 3 hours. 
 
Fig. 2.1. The experimental set up of the modified Boyden chambers used to assess monocyte migration. 
Monocytes within the control group are not exposed to the chemoattractant MCP-1 in the bottom half of the chamber 
and therefore basal or limited migration should occur. Migration was induced within the MCP-1 control group by 
using culture media supplemented with MCP-1 in the bottom half of the chamber. As the THP-1 monocytes in the 
top half of the chamber are treated with vehicle control a significant level of migration across the membrane should 
occur. The final group were also exposed to MCP-1 within the bottom half of the chamber, however the cells are 
suspended in culture media containing the nutraceutical of choice. A successful nutraceutical treatment would result 
in a reduction in the percentage of monocytes migrating from the top to the bottom half of the chamber. 
2.4.4.2 Assessing Migration 
After 3 hours of migration, the media in the top half of the wells was removed and the underside 
of the membrane washed with 0.5 ml of PBS (x1, pH 7.4) into the bottom well to remove any 
adherent cells. The media in the bottom of the wells was then transferred to a 10 ml Falcon 
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tube and centrifuged at 250 x g for 5 minutes at room temperature. The supernatant was 
aspirated and the cells resuspended in 2 ml of culture media and counted using the 
haemocytometer (Section 2.3.4). The number of cells that had migrated from the top to the 
bottom half of the well was calculated and expressed as a percentage of the number of cells 
originally added. 
2.4.5 MMP Activity 
To assess MMP activity, PMA differentiated THP-1 macrophages (4.11 x 105 cells/cm2) were 
cultured for 3 or 24 hours with either culture media containing vehicle control or the 
nutraceutical of choice at 37ºC in 5% (v/v) CO2. These time points were chosen to assess both 
short term and long term effects of nutraceuticals on MMP activity. Following the desired 
incubation time period, 50 μl of the media was transferred to a new plate for analysis. An equal 
volume of MMP green substrate solution (provided by the manufacturer) was added to each 
well and the plate returned to the incubator for a further 30 minutes. The substrate solution 
contains a fluorescent resonance energy transfer (FRET) peptide consisting of two subunits, 
an emitter and a quencher. When the peptide is intact, the quencher prevents the emitter from 
releasing a fluorescent signal upon excitation. However the FRET peptide has been designed 
to be broken down by MMPs, causing the separation of the emitter and quencher. Once 
separated from the quencher, the fluorescence of the emitter is recovered. Therefore a 
reduction in MMP activity would result in more FRET peptides remaining intact and a reduced 
fluorescent signal detected. Following incubation, fluorescence was measured in a 
fluorescence microplate reader, with excitation at 485 nm and emission detected at 535 nm. 
The vehicle control was then arbitrarily assigned as 1.0 and all other data were presented 
relative to this. 
2.4.6 ROS Production 
To assess whether nutraceuticals possessed any anti-oxidant properties a 2’7’-
dichlorofluorescin diacetate (DCFDA) Cellular ROS Detection Assay Kit was used. DCFDA is 
a non-fluorogenic compound capable of passively diffusing into cells where it is deacetylated 
by cellular esterases. This new molecule is oxidised by ROS into a highly fluorescent 
compound. Therefore the higher the fluorescent signal, the more ROS generation which has 
occurred within the cell. Undifferentiated THP-1 monocytes and PMA differentiated THP-1 
macrophages (4.11 x 105 cells/cm2) were added per well of a 96-well plate in 50 µl. Culture 
media containing 2x concentration of the desired nutraceutical were also added to the cells in 
a volume of 50 µl, resulting in a 1x concentration in a total volume of 100 µl. Tert-butyl hydrogen 
peroxide (TBHP) was used as a positive control as it is capable of stimulating ROS production 
in cells. The nutraceuticals were used in combination with TBHP to assess whether they were 
capable of reducing ROS production. All reagents were supplied as part of the DCFDA Cellular 
ROS Detection Assay Kit unless stated otherwise. 
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Before cell treatment could begin, the cells were washed using 1x buffer before being stained 
with 20 µM DCFDA in 1x buffer for 30 or 45 minutes (for monocytes or macrophages 
respectfully) in the dark at 37°C in 5% (v/v) CO2. A longer incubation period is required for 
macrophages as it takes more time for the DCFDA compound to diffuse into adherent cells. 
Once the cells had been stained, they were washed once with 1x buffer before being 
transferred to a 96-well plate in 50 µl of culture media. The different treatment groups were 
then added to the wells of the plate which was incubated at 37°C in 5% (v/v) CO2 for 3 hours. 
After incubation, fluorescence was measured in a fluorescence microplate reader, with 
excitation at 485 nm and emission detected at 535 nm. The vehicle control was then arbitrarily 
assigned as 1.0 and all other data were presented relative to this. 
2.4.7 ELISAs for Pro-inflammatory Cytokines/Chemokines 
PMA differentiated THP-1 macrophages (1.28 x 105 cells/cm2) were stimulated with IFN-γ in 
the presence or absence of a variety of nutraceuticals in 0.2% (w/v) bovine serum albumin 
(BSA) cell culture media for 24 hours. Cell culture media containing BSA was used as it is 
present in the blocking buffer and used as a carrier for other substrates during this assay. As 
a result BSA media was used in order to avoid any possible interference from HI-FCS 
containing media. A DuoSet ELISA kit was used to determine the levels of MCP-1 and IL-1β 
secreted from the cells into the surrounding media. Initially a capture antibody, which is fixed 
to the surface of microplate, binds to the target cytokine/chemokine present in the aspirated 
cell media. A detection antibody, which contains biotin, is then added and also binds to the 
target antigen. Streptavidin is protein which has a high affinity to biotin. By attaching the 
enzyme horseradish-peroxidase (HRP) to streptavidin, it means the more target 
cytokine/chemokine captured from the aspirated cell media the more HRP will be present at 
the end of the assay. A substrate solution is then added which undergoes a colour change in 
the presence of HRP. Therefore the more colour change which occurs, the more target 
cytokine/chemokine was secreted by the cells into the surrounding media. 
A microplate was incubated with the desired capture antibody (provided in kit) overnight at 
room temperature to allow adequate time for adhesion. The following morning, the microplate 
was washed three times with wash buffer (provided in kit) which was then aspirated and blotted 
on a paper towel to ensure it was completely dry. All subsequently described washing steps 
used the same procedure. Once dry, a blocking buffer (provided in kit) was added for 1 hour 
at room temperature, followed by further washing and drying. The samples and standard curve 
(100 μl) were then incubated with the adhered capture antibody for 2 hours at room 
temperature, before being washed and subsequently incubated with the detection antibody 
(provided in kit) for a further 2 hours. The standard curve consisted of known concentrations 
of the target cytokine/chemokine and made according the manufacturer’s instructions from 
reagents provided in the kit. The MCP-1 ELISA has an assay range of 15.6 pg/ml to 1000 
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pg/ml, whereas the IL-1β ELISA has an assay range of 3.91 pg/ml to 250 pg/ml. Samples being 
assessed were diluted if they exceeded this maximum limit of detection. After being washed 
again, the following steps were considered light sensitive and therefore all further incubation 
periods were carried out in the dark. A conjugate of streptavidin and HRP (provided in kit) was 
added to the microplate and left at room temperature for 20 minutes. After another wash, the 
microplate was then incubated with substrate solution (provided in kit) for an additional 20 
minutes before the stop solution (provided in kit) was added. The absorbance of the microplate 
was read in a microplate reader using wavelength correction with the first reading measured 
at 450 nm and a second reading at 590 nm. Wavelength correction is a process by which more 
accurate absorbance readings are achieved. A second wavelength is used to determine the 
level of background interference and remove it from the desired primary wavelength readings. 
 
2.5 Nucleic Acid Based Techniques 
2.5.1 RNA Extraction 
As mRNA is produced by activated genes, it can extracted and the amount of target mRNA 
can be determined in order to assess gene expression levels. Prior to RNA extraction, the 
culture media was aspirated and the cells washed with 0.5 ml of PBS (x1, pH 7.4). RiboZol™ 
(1 ml) was added to the cells which were then lysed by passing them several times through 
the tip of a pipette. The mixture was then left to stand for 10 minutes at room temperature to 
guarantee the complete dissociation of nucleoprotein complexes. To isolate the RNA in the 
mixture, 200 μl of chloroform was added to the samples and shaken for 15 seconds and then 
centrifuged at 12,000 x g for 15 minutes at 4ºC. This process separates the mixture into three 
phases: a lower red, phenol-chloroform phase; a white interphase; and a colourless upper 
phase where the RNA is present. In order to avoid contaminating the RNA phase, 
approximately only 80% of the RNA phase was transferred to a clean RNase-free tube. The 
RNA was then precipitated using isopropanol (500 μl) and incubated at -80ºC for at least one 
hour and subsequently centrifuged at 12,000 x g at 4°C for 10 minutes. The supernatant was 
removed and the RNA pellet washed three times using 1 ml 75% (v/v) ethanol and vortexing 
the samples before centrifugation at 7,500 x g for 5 minutes at 4ºC. Following the final RNA 
pellet wash, the pellet was left to air dry for 10 minutes at room temperature before re-
suspending the pellet in 15 μl of RNase-free water and incubating the samples at 55-60ºC for 
10 minutes. A NanoDrop 2000 spectrophotometer was used to determine the quality and 
concentration of the extracted RNA. A result between 1.8 – 2.1 for the A260/A280 and the 
A230/A260 ratios indicated high quality RNA. Gel electrophoresis was also used to assess the 
quality of a small quantity of the extracted RNA (Section 2.5.4). 
 Chapter 2: Materials and Methods  
45 
 
2.5.2 Reverse Transcription 
In order to be able to assess gene expression, the extracted RNA had to be reverse transcribed 
into cDNA for quantitative polymerase chain reaction (qPCR; Section 2.5.3). The initial step 
involved adding 0.5 μl of random hexamer primers (200 pmol) to 500 or 1000 ng of extracted 
RNA (depending on the yield) and ddH2O in a total volume of 13.5 μl. The samples were then 
heated to 70ºC for 5 minutes and immediately afterwards placed on ice to prevent RNase 
activity. The reagents listed in Table 2.4 were then added and the reaction mixture incubated 
at 37ºC for 1 hour with a final enzyme inactivation phase of 90ºC for 2 minutes. Following 
reverse transcription, ddH2O was added until a final concentration of 10 ng/μl of cDNA was 
achieved. The cDNA could then be kept at 4ºC for short-term storage or -20ºC if long-term 
storage was required. 
Table 2.4. Composition of the master mix used in the reverse transcription reaction.  
Reagent 1x Master Mix (µL) 
100mM dNTPs mixture 1.0 
5x MMLV buffer 4.0 
RNase inhibitor (40 U/µl) 0.5 
MMLV reverse transcriptase (200 U/µl) 0.5 
 
 MMLV, moloney murine leukaemia virus. 
2.5.3 qPCR 
qPCR is a technique that allows for the quantification of gene expression by simultaneously 
amplifying and quantifying target cDNA. This technique achieves this because the amount of 
PCR product produced in the reaction is proportional to the starting amount of cDNA during 
the exponential phase of PCR amplification. In this study SYBR Green JumpStart™ Taq 
Readymix™ was used as it is a fluorescent dye that is only detectable when bound to double 
stranded DNA, therefore the strength of the fluorescent emission is proportional to the amount 
of cDNA template. The method determines when the strength of the fluorescent emission 
reaches a pre-set threshold value (CT value), and compares this value for the target gene of 
interest to a housekeeping gene (whose expression should not alter under the experimental 
conditions) using the comparative CT (∆∆CT) method (Schmittgen and Livak 2008). The 
housekeeping genes used in this study were β-actin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) for RAW264.7 and THP-1 cells respectively as their expression has 
been shown to be stable under different experimental conditions (Mehta et al. 2010), in addition 
to their extensive use previously in the laboratory (McLaren et al. 2010a; Li et al. 2010). During 
the project two forms of qPCR were utilised, the first will be referred to as ‘regular qPCR’ and 
was performed using the method outlined above and sequence of the primers employed can 
be found in Table 2.5. The second form of qPCR will be referred to as ‘qPCR array’. Unless 
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stated otherwise, all primers used for regular qPCR were designed by members of the 
laboratory to be intron spanning to avoid genomic DNA amplification.  
qPCR arrays use specialist plates (Atherosclerosis RT2 Profiler PCR Arrays) which contain the 
primers for 84 atherosclerotic and 5 housekeeping genes as well as 3 negative, 3 positive and 
1 genomic DNA contamination controls. The advantage of the qPCR arrays is that they are 
able to provide a large volume of data compared to regular qPCRs in the same time frame. 
The cycling conditions for the qPCRs can be found in Tables 2.6 and 2.7. A reverse 
transcriptase negative control was included in all regular qPCR experiments to confirm that 
there was no genomic DNA contamination. Melting curve analysis was used for both regular 
qPCRs and qPCR arrays to ensure the primers produced a single product. 
Table 2.5. Sequences of qPCR primers and their targets. 
Species Target 
Gene 
Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Mouse β-actin* ACACCCGCCACCAGTTCGCCAT CACACCCTGGTGCCTAGGGCGGCC
CACGATG 
MCP-1* GCTCAGCCAGATGCAGTTAACG GCTTGGTGACAAAAACTACAGCTTC 
ICAM-1* ACGTGCTGTATGGTCCTCGG GTCCAGTTATTTTGAGAGTGGTACA
GTA 
Arg2# ATATGGTCCAGCTGCCATTCGAGA CCACTTCAGCCAGTTCCTGGT 
iNOS## CAGTTCTGCGCCTTTGCTCAT GGTGGTGCGGCTGGACTTT 
 IL-6 GAGGATACCACTCCCAACAGACC AAGTGCATCATCGTTGTTCATACA 
 IL-1β GAGGACATGAGCACCTTCTTT GCCTGTAGTGCAGTTGTCTAA 
Human GAPDH CTTTTGCGTCGCCAGCCGAG GCCCAATACGACCAAATCCGTTGAC
T 
MCP-1 CGCTCAGCCAGATGCAATCAATG ATGGTCTTGAAGATCACAGCTTCTTT
GG 
ICAM-1 GACCAGAGGTTGAACCCCAC GCGCCGGAAAGCTGTAGAT 
 ABCA1 AGTGGAAACAGTTAATGACCAG GCAGCTGACATGTTTGTCTTC 
 ABCG1 GGTGGACGAAGAAAGGATACAAGA
CC 
ATGCCCGTCTCCCTGTATCCA 
 
* Previous work in my MRes has shown these primers to produce a single PCR product of the target gene by 
sequence analysis (Moss 2014). # primers from Jin et al. (2015). ## primers from Chang et al. (2010). All other 
primers were designed by members of the laboratory. 
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Table 2.6. Composition of the qPCR master mix for gene expression.  
Reagent 1x Master Mix for regular 
qPCR (µL) 
1x Master Mix for qPCR 
array (µL) 
SYBR Green JumpStart™ Taq Readymix™ 
for quantitative PCR 
13.75 12.5 
Forward Primer (100 µM) 0.55 - 
Reverse Primer (100 µM) 0.55 - 
cDNA (10 ng/μl) 1.10 0.26 
ddH2O 11.55 12.24 
The master mix was prepared in excess before 25 µl was transferred to the qPCR plate. 
Table 2.7. The qPCR conditions used for gene expression. 
 Regular qPCR  qPCR array 
PCR step Temperature (°C) Time (s) aa Temperature (°C) Time (s) 
Preincubation 94 120  95 600 
Melting 95 30  95 15 
Annealing 60 60  60 60 
Extension 72 60    
Melt curve 95 10  95 10 
 60 60  60 60 
 97* 2  97* 2 
The regular qPCR is a three step amplification process and cycles 40 times, whereas the qPCR array involves a 
two-step amplification (as the annealing and extension steps occur simultaneously) and cycles 45 times. * Increased 
from 55°C by 0.5°C per cycle over 74 cycles. 
2.5.4 Agarose Gel Electrophoresis 
A 2% (w/v) agarose gel was used to determine the integrity of the extracted RNA. Agarose 
was dissolved in 1x Tris/borate/EDTA (TBE; 89 mM Tris-borate, 89 mM Boric acid, 2 mM 
EDTA, pH 8.3) buffer by heating it in a microwave. Initially, 10 μl of the RNA samples were 
added to 10 μl 2x RNA Loading Dye and heated at 70°C for 10 minutes and then immediately 
transferred to ice for 3 minutes. Electrophoresis was carried out using a horizontal gel unit at 
100 V in 1x TBE for 45 minutes. The size of RNA products were determined using a RiboRuler 
High Range RNA Ladder. UV light was used to picture the gel using a Sygene Gel 
Documentation system. 
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2.6 Cholesterol Homeostasis 
2.6.1 Cholesterol Uptake 
Reduced cholesterol uptake can also be a sign of decreased foam cell formation, therefore 
nutraceuticals which are capable of attenuating cholesterol uptake would represent potential 
anti-atherogenic therapies. Using fluorescently labelled lipoprotein, the amount of uptake into 
cells can be assessed by flow assisted cell sorting (FACS) analysis as the stronger the 
fluorescent signal, the more cholesterol uptake has occurred. PMA differentiated THP-1 
macrophages (1.28 x 105 cells/cm2) were incubated with a fluorescently labelled oxLDL known 
as Dil-oxLDL (5 μg/ml) for 24 hours in the presence of vehicle or nutraceuticals in media 
containing 0.2% (v/v) fatty acid free BSA. HI-FCS containing media was not used during this 
assay due to its ability to induce cholesterol efflux. Following incubation, the media was 
aspirated and the cells washed with PBS (x1, pH 7.4) and the cells “lifted” from the plate using 
Trypsin EDTA (0.05% w/v) for 10 minutes at 37 °C. Once the cells were in suspension, they 
were centrifuged at 9000 x g for 5 minutes at room temperature. The supernatant was removed 
and the pellet re-suspended in 2% (w/v) paraformaldehyde (PFA) in order to fix the cells for 
FACS analysis. A BD FACS Canto flow cytometer was then used to assess Dil-oxLDL uptake. 
At least 10,000 counts were captured for each sample. 
2.6.2 Macropinocytosis 
Macropinocytosis is another mechanism by which cholesterol may be taken up into 
macrophages during foam cell formation. Lucifer yellow (LY) is a fluorescent dye which enters 
cells via macropinocytosis. Therefore measuring the fluorescent signal within macrophages 
treated with LY by FACS analysis can be used as a maker for the level of macropinocytosis 
which has occurred within the cells. Cholesterol crystals are primarily taken up by 
macrophages via micropinocytosis (Moore et al. 2013). Therefore a macropinocytosis assay 
was carried out to determine the effect of nutraceuticals on PMA differentiated THP-1 cells 
(1.28 x 105 cells/cm2). Once differentiated, the THP-1 cells were incubated at 37°C with 5% 
CO2 (v/v) for 1 hour with either 1 ml of media only (for both the negative and positive control) 
or media containing the nutraceutical. Due to the effect of HI-FCS on cholesterol efflux, media 
containing 0.2% (v/v) fatty acid free BSA was used throughout this assay. Following incubation 
for 1 hour, LY (100 µg/ml) was added to both the positive control and nutraceutical treated 
cells and incubated for 24 hours. 
After incubation with the LY, the media was removed and the cells washed with PBS (1x, pH 
7.4). Subsequently, 0.5 ml Trypsin EDTA (0.05% w/v) was then added to each well and 
incubated for 10 minutes at 37°C. Culture medium (0.5 ml) was added to each well to inactivate 
the Trypsin EDTA to prevent cell lysis. The resulting mixture was then pipetted up and down 
several times to ensure the cells were no longer adherent to the surface of the well. The cell 
suspension was then centrifuged at 12,000 x g for 5 minutes. The resulting pellet was washed 
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with PBS and centrifuged again and the subsequent pellet resuspended in 500 µl 2% (w/v) 
PFA. LY uptake was determined using at least 10,000 detection events for each sample with 
a FACS flow cytometer. 
2.6.3 Cholesterol Efflux 
Cholesterol efflux can be measured using radioactively labelled cholesterol. Cells are allowed 
to take up the radioactive cholesterol during foam cell formation for 24 hours before its efflux 
is stimulated by ApoA1 into the surrounding media. The more radioactive cholesterol found 
within the media compared to the amount found within the cell indicates increased cholesterol 
efflux and therefore a possible reduction in foam cell formation. The following cholesterol efflux 
assay was adapted from a previously reported protocol (McLaren et al. 2010a). Initially, THP-
1 macrophages (1.28 x 105 cells/cm2) were incubated with acetylated LDL (acLDL; 25 μg/ml) 
and [4-14C]cholesterol (0.5 mCi/ml) in media containing 0.2% (v/v) fatty acid free BSA for 24 
hours before subsequent treatment with ApoA1 (10 mg/ml) with vehicle or the desired 
nutraceutical in 0.2% (v/v) BSA media. No HI-FCS was used in the culture media once the 
cells had differentiated due to the ability of FCS to stimulate cholesterol efflux from the cells 
and therefore affecting the accuracy of the assay. After 24 hours, the media was collected and 
0.2 M NaOH (100 μl) was used to solubilise the cells. A liquid scintillation counter was used to 
measure the radioactivity within the supernatant and cellular fractions. Radioactivity was 
determined by the number of disintegrations per minute (dpm) within the samples. Cholesterol 
efflux was calculated as the percentage radioactivity in the supernatant versus total 
radioactivity (cells and supernatant).  
 
2.6.4 Lipid Analysis 
2.6.4.1 Lipid extraction 
As well as determining the effect of nutraceuticals on cholesterol homeostasis, their effects on 
intracellular lipids was also assessed. Once intracellular lipids have been extracted, the major 
classes can be separated by thin layer chromatography (TLC) and quantified (Section 2.6.4.2). 
Previous work within the laboratory has shown RAW264.7 to produce a high quantity of 
intracellular lipids compared to THP-1 macrophages (which only contain very low levels of 
cholesteryl esters), improving the sensitivity of the data (Gallagher 2016). For this reason 
RAW264.7 macrophages were used for TLC analysis. Initially, RAW264.7 macrophages (2.08 
x 105 cells/cm2) were cultured for 24 hours in culture media at 37ºC in 5% (v/v) CO2 to allow 
the cells to adhere. Once adhered, the macrophages were treated for 24 hours with either the 
vehicle control or nutraceutical of choice in the presence or absence of acLDL (25 μg/ml) and 
[14C]acetate (1 μCi/ml). Following treatment, the media was aspirated and the cells washed 
once with PBS (x1, pH 7.4). The macrophages were collected by scrapping the wells using 
PBS (x1, pH 7.4) and transferred into Eppendorf tubes. Cells were pelleted by centrifugation 
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at 9000 x g for 5 minutes and resuspended in 1 ml of dH2O and transferred into a glass tube 
to prevent the adherence of lipids to a plastic surface. Once in the glass tube, 2 ml of 
chloroform:methanol (2:1, v/v) solution was added and the mixture vortexed and incubated at 
room temperature for 15 minutes. Following incubation, 1 ml of chloroform and 2 ml of Garbus 
solution (2M KCl in 0.5 M potassium phosphate buffer, pH 7.6; Garbus et al. 1963) was added 
and the resulting mixture vortexed and centrifuged at 220 x g for 5 minutes in order to separate 
the chloroform and aqueous layers. A glass pipette was used to transfer the chloroform 
aqueous layer into a clean glass tube and subsequently evaporated under nitrogen and 
resuspended in 300 μl of chloroform. 
2.6.4.2 TLC 
A 10 x 10 cm silica gel G Merck plate was used to separate the different lipid classes during 
TLC. In order to separate total polar lipid (TPL), free cholesterol (FC), free fatty acid (FFA), TG 
and CE lipid classes from one another, a solution of hexane: diethyl ether: acetic acid (80:20:1, 
v/v/v) was used. A solvent mixture of chloroform: methanol: ammonium hydroxide (65:35:4, 
v/v/v) was used for one dimensional separation on the TLC silica gel plate. Following 
separation, the plates were left to dry before being sprayed with 8-anilino-4-naphthosulphonic 
acid (ANSA; 0.05% v/v in methanol). ANSA solution allows the lipids to become detectable 
under UV light. The location of the bands was then marked on the plates which were 
subsequently sprayed with water for scrapping into liquid scintillation vials. The radioactivity of 
each band was measured by a liquid scintillation counter. 
 
2.7 In Vivo Techniques 
2.7.1 Feeding and weighing 
Once CardioWise and catechin were found to exert anti-inflammatory effects in the in vitro 
models of atherosclerosis disease development, an initial in vivo study involving high fat fed 
wild type mice was established. This study was designed to determine whether the benefits 
associated with CardioWise and catechin treatment in vitro were also observed in vivo.  
To assess the effects of CardioWise and catechin in vivo, 8 week old male C57 black 6 
(C57BL/6) wild type mice were used. The mice were housed in a light and temperature 
controlled facility (lights on 7 am to 7 pm, 22°C). Based upon previously published studies by 
Cultech Limited (Michael et al. 2017) and others in the literature (Schreyer et al. 1998; Shimizu 
et al. 2014; Zanotti et al. 2013), it was found that group sizes of 6 to 8 are required to calculate 
significant differences between our various parameters at the p<0.05 levels with a power of 
0.8 (standard deviation ~30% and differences between groups ~40%). However, the number 
of mice used during the studies were based on the number of wild type mice available at the 
time of experiments. As a result during the CardioWise study, 6 mice were designated to 
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receive the vehicle control and 7 mice to receive CardioWise. A total of 16 mice were used to 
assess catechin with 8 in both the vehicle and catechin treatment groups. 
The number of mice used during the studies were based on the number of wild type mice 
available at the time of experiments. All mice in the study received a high fat diet [21% (w/w) 
pork lard and 0.15% (w/w) cholesterol] for 3 weeks based on previous unpublished 
experiments performed in laboratory and previous studies within the field (Michael et al. 2017). 
During the feeding period, the mice were gavaged daily with their respective treatments. A 1x 
human equivalent dose of CardioWise was calculated based on the surface area of the mice 
and consisted of 410 mg/kg of EPA/DHA, 410 mg/kg of phytosterols as well as 41 mg/kg of 
catechin (Nair and Jacob 2016). To prevent the fish oil separating from the rest of the 
treatment, xanthan gum was used as an emulsifying agent, which was therefore also used as 
the vehicle control. Based on a similar study which gavaged rats every day for 3 weeks, a 
concentration of 200 mg/kg of catechin hydrate was chosen (Potenza et al. 2007). Catechin 
hydrate was used in this study due to the extremely high cost of using pure (+)-catechin. In 
vitro studies were used to confirm that (+)-catechin and catechin hydrate exert similar effects 
in experiments (Fig. 7.3). The catechin hydrate was dissolved in PBS which was also used as 
the vehicle control. 
Body weight was measured at the start of the study and then approximately every 2 days. At 
the end of the study, all mice were sacrificed under anaesthesia by cardiac puncture and death 
confirmed by an absence of a pulse. All studies and protocols were approved by the Cardiff 
University Institutional Ethics Review Committee and the United Kingdom Home Office, and 
experiments were performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (NIH Publication No. 85–23, revised 1996; Experimental licence 30/3365). 
2.7.2 Blood and tissue collection 
Blood from cardiac puncture was collected into Eppendorfs containing heparin and the plasma 
obtained by centrifugation (12,000 x g) for 5 minutes. Rear legs were removed and placed into 
Falcon tubes containing PBS supplemented with 10% (v/v) HI-FCS for cell population analysis 
(Section 2.7.7). The fat pads and organs were placed in weighing-boats and weighed on an 
electronic scale. Samples from the fat pads, spleen, perivascular aortic tissue and liver were 
placed in cryomolds, covered in OCT and placed on dry ice. The remainder of the fat pads and 
liver, along with the brain, intestine and heart were snap frozen in liquid nitrogen. All samples 
were then stored at -80°C. 
2.7.3 Serum cholesterol levels 
As high levels of LDL cholesterol and low levels of HDL cholesterol are considered to be pro-
atherogenic, it was essential to determine the effect of CardioWise and catechin treatment 
exerted on cholesterol levels in wild type mice receiving a high fat diet. Cholesterol levels were 
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determined with a HDL and LDL/VLDL cholesterol assay kit. To assess total cholesterol levels 
no additional preparation of the collected serum was required, however additional steps were 
needed to separate the HDL and LDL/VLDL fractions. The serum was mixed with precipitation 
buffer (provided by the manufacturer) in order to separate the LDL/VLDL fraction from the rest 
of the serum. The mixture was then incubated at room temperature for 10 minutes. The sample 
was then centrifuged at 2,000 x g for 10 minutes. The HDL fraction is located in the 
supernatant, which was removed and placed in to a clean Eppendorf tube. The remaining 
sample was re-centrifuged under the same conditions and any remaining supernatant 
aspirated. The pellet was resuspended in PBS (1x, pH 7.4), this is the LDL/VLDL fraction. The 
levels of free and total cholesterol was measured in all three fractions and compared to a 
standard curve which was prepared according to manufacturer’s instructions. The absorbance 
was measured in a microplate reader at 570 nm. The assay is designed to detect up to 1 μg 
of cholesterol. As a result, samples being assessed were diluted if they exceeded this 
maximum limit of detection. 
2.7.4 Serum TG levels 
TG levels were determined with a triacylglycerol quantification assay kit. During the assay, all 
TGs within the serum were broken down into FFAs and glycerol. The glycerol is then oxidised 
to produce a product which is capable of interacting with target probe and induce a colour 
change. Therefore the greater the colour change, the more TGs are present in the serum. 
Initially the serum samples were mixed with lipase for 20 minutes at room temperature in order 
to convert the TGs into glycerol and fatty acids. The samples were then combined with an 
assay buffer, probe and enzyme mix according to manufacturer’s instructions and incubated 
at room temperature for 1 hour while protected from light. The colour change was measured 
in all samples and compared to a standard curve which was prepared according to 
manufacturer’s instructions. The absorbance was measured in a microplate reader at 570 nm. 
The assay is designed to detect between 2 pmol and 10 nmol of TG. As a result, samples 
being assessed were diluted if they exceeded this maximum limit of detection. 
2.7.5 Oxidative Stress State 
2.7.5.1 ROS Levels 
To assess the levels of ROS production in the mice following treatments, an OxiSelect in vitro 
ROS/reactive nitrogen species (RNS) Assay kit (green fluorescence) was used. The principle 
of the assay is similar to that described in Section 2.4.6. A dichlorodihydrofluorescin (DCFH) 
probe is oxidised by ROS into a highly fluorescent probe and therefore the stronger the 
fluorescent signal detected the more ROS were present in the serum. No additional steps were 
required in the preparation of the samples and 50 μl of the sample and H2O2 standard curve 
(made according to manufacturer’s instructions) were transferred to a 96-well plate. An equal 
volume of catalyst solution (provided in kit) was added to each well and the plate incubated for 
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an additional 5 minutes at room temperature while protected from light. The samples were then 
mixed with a DCFH solution (provided in kit), a probe which is broken down in the presence of 
H2O2 into a fluorescent form, for 30 minutes in the dark. After incubation, fluorescence was 
measured in a fluorescence microplate reader, with excitation at 485 nm and emission 
detected at 535 nm, and compared to the H2O2 standard curve. The vehicle control was then 
arbitrarily assigned as 1.0 and all other data were presented relative to this. The assay has a 
sensitivity limits of 10 pM. 
2.7.5.2 MDA Levels 
Lipid peroxidation is a useful indicator of the level of oxidative stress which is occurring. One 
product of lipid peroxidation is malondialdehyde (MDA) and therefore measuring its levels 
using an OxiSelect thiobarbituric acid reactive substances (TBARS) Assay Kit can reveal 
useful insights into the oxidative stress state of the mice. Thiobarbituric acid reacts with MDA 
to produce a fluorescent molecule, as a result the strength of the fluorescent signal produced 
by this reaction can be an indicator for the level of lipid peroxidation which has occurred. Initially 
to prevent further oxidation, 0.05% (v/v) butylated hydroxytoluene solution was added to the 
samples. An equal volume of SDS lysis solution was added to the samples and incubated at 
room temperature for 5 minutes. Thiobarbituric acid (TBA) was added to the mixture and the 
samples were subsequently incubated at 95°C for 30 minutes before being cooled to room 
temperature on ice. Samples were then centrifuged at 500 x g for 15 minutes. The supernatant 
was transferred to a 96-well plate and fluorescence was measured in a fluorescence microplate 
reader, with excitation at 535 nm and emission detected at 590 nm. The levels of MDA 
measured in all samples were compared to a standard curve (prepared according to 
manufacturer’s instructions). The assay is designed to detect between 0 μmol and 125 μmol 
of MDA. As a result, samples being assessed were diluted if they exceeded this maximum limit 
of detection. 
2.7.6 Plasma cytokine levels 
Plasma cytokine levels were determined by the Central Biotechnology Services at the school 
of Medicine using a V-PLEX Plus Pro-inflammatory Panel1 Mouse Kit and 25 μl of serum from 
each mouse. 
2.7.7 Liver gene expression 
Approximately 50 mg of liver was placed in a mortar along with 1 ml of RiboZol™ and the 
tissue samples were homogenised with a pestle. RNA was then extracted following the method 
outlined in Section 2.5.1. The RNA was then used in a reverse transcription reaction (Section 
2.5.2) before gene expression was assessed by a qPCR array (Section 2.5.3). 
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2.7.8 Cell populations within the bone marrow analysis 
Previous studies have shown that a high fat diet is capable of altering the proportion of 
haematopoietic stem/progenitor cells within the bone marrow (Chan et al. 2012; Wu et al. 2013; 
Adler et al. 2014; van den Berg et al. 2016). The bone marrow of wild type mice was collected 
following treatment with either CardioWise or catechin hydrate or appropriate control (see 
Section 2.7.2) to determine whether either nutraceutical was capable of preventing high fat 
diet induced changes in haematopoietic cell populations.  
The day after collection, the tibia and fibia were placed in a mortar along with 10 ml of PBS 
(1x, pH 7.4) which was supplemented with HI-FCS (2% v/v). The bones were then crushed 
until no visible bone marrow remained in the bones and the extracted marrow had been 
homogenised. The mixture was placed on a sterile filter (pore size of 70 μm) and allowed to 
pass through into a large Falcon tube. Further 2% (v/v) PBS was added to the filter until a final 
volume of 30 ml had been collected in the Falcon tube. The total number of cells was then 
calculated and either 10 or 8 million cells were placed in separate Falcon tubes to analyse the 
signalling lymphocytic activation molecule (SLAM) and progenitor cell populations respectively. 
As the SLAM and progenitor cells form a small proportion of the total number of cells extracted, 
these large cell numbers were required to ensure a sufficient number of target cells were 
detected during FACS analysis. The cells were then centrifuged at 5,000 x g for 5 minutes at 
4°C (these setting were used for centrifugation unless stated otherwise). 
Cells from the bone marrow were stained at 4°C for 30 minutes with a biotinylated mix of 
lineage marker antibodies present within the SLAM and progenitor cell populations. To analyse 
the SLAM cell population the following antibodies were used: phycoerythrin (PE)/cyanine7 
(Cy7)-conjugated anti-mouse CD150; FITC-conjugated anti-mouse CD48; allophycocyanin 
(APC)-conjugated anti-mouse c-Kit; and PE-conjugated anti-mouse stem cell antigen (Sca)-1. 
The progenitor cell population was analysed using the following antibodies: BV650-conjugated 
anti-mouse CD127; PE/Cy7-conjugated anti-mouse CD16/32; FITC-conjugated anti-mouse 
CD34; APC-conjugated anti-mouse c-Kit; and APC/Cy7-conjugated anti-mouse Sca-1. After 
initial staining, the cells were washed with 2% (v/v) PBS and resuspended in PerCP-Cy5.5-
conjugated streptavidin and incubated for a further 15 minutes at 4°C. The SLAM and 
progenitor cell populations were now ready to be analysed by FACS. 
While the SLAM and progenitor cell populations are being primed for FACS analysis, the 
preparation of lineage cell population was carried out simultaneously. Cells were incubated at 
4°C for 20 minutes with APC-conjugated anti-mouse B220, FITC-conjugated anti-mouse CD3, 
PE/Cy7-conjugated anti-mouse Gr1, PE-conjugated anti-mouse Mac1 and APC/Cy7-
conjugated anti-mouse Ter119. All markers of the haematopoietic cell populations analysed in 
this study are presented in Table 2.8. Following incubation, the cells were washed and 
resuspended in 2% (v/v) PBS. 
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Table 2.8. Markers used to identify haematopoietic cell populations within the bone marrow. 
Class Cell type Identifiable marker 
SLAM LSK Lin- Sca-1+ c-Kit+ 
 HSC CD150+ CD48- LSK 
 MPP CD150- CD48- LSK 
 HPC I CD150- CD48+ LSK 
 HPC II CD150+ CD48+ LSK 
   
Progenitor LK Lin- Sca-1- c-Kit+ 
 CMP CD34+ CD16/32- LK 
 MEP CD34- CD16/32- LK 
 GMP CD34+ CD16/32+ LK 
 CLP CD127+ 
   
Lineage Granulocytes GR1+ Mac1- 
 Macrophages GR1- Mac1+ 
 MDSCs GR1+ Mac1+ 
 B-cells B220+ 
 T-cells CD3+ 
 RBCs Ter119+ 
 
HSC, haematopoietic stem cell; MPP, multipotent progenitors; HPC, hematopoietic progenitor cell; CMP, common 
myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor; MDSC, 
myeloid-derived suppressor cells; CLP, common lymphoid progenitor; SLAM, signalling lymphocytic activation 
molecule. 
Before the samples could be analysed on the FACS machine, they were vortexed and filtered 
(pore size 40 μm) to prevent the cells from clumping together. Due to the high concentration 
of cells within the SLAM and progenitor samples, extra 2% (v/v) PBS was added. DAPI stain 
was added to all of the SLAM, progenitor and lineage samples in order to identify viable cells. 
A BD FACS Canto flow cytometer was then used to assess the composition of the cell 
populations and all possible cell counts were collected from each sample. The gating strategy 
used in this assay is summarised in Fig. 2.2 and the overall assay is summarised in Fig. 2.3. 
The process of backgating was performed to ensure the accuracy of the gating strategy. This 
is achieved by overlaying the final gated population over the preceding parent populations in 
order to determine whether all of the target cells had been isolated correctly. 
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Fig. 2.2. An example of the gating strategy used during this study to identify and quantify the different haematopoietic cell populations within the bone marrow of 
wild type mice. The arrows indicate how each haematopoietic stem/progenitor cell population can be identified within the preceding gating strategy. The axis represent the 
various stains used to separate the cell populations (see Table 2.8 for further details). The forward scatter (FSC-A) is a measurement of cell size by determining the amount of 
light which passes around it. The side scatter (SSC-A) is a measurement of the amount of light which is reflected by particles within the cells and therefore can be used to 
determine the granularity of cells. HSC, haematopoietic stem cell; MPP, multipotent progenitors; HPC, hematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, 
megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor; MDSC, myeloid-derived suppressor cells; CLP, common lymphoid progenitor; LIN, lineage; WBC, 
white blood cell.
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Fig. 2.3. Overall summary of the assay used to determine haematopoietic cell populations within the bone 
marrow of wild type mice. Further details such as antibodies used, incubation periods and cell extraction can be 
found within the main text and Table 2.8. FACS, flow assisted cell sorting; SLAM, signalling lymphocytic activation 
molecule. 
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2.8 Data Analysis 
Normality of the data sets was tested using Shapiro-Wilk test, histograms and Q-Q plots and 
any data transformations have been stated. Data values outside two standard deviations of 
the mean were classed as outliers and removed before statistical analysis. To compare the 
means of two groups either a t-test (normal data distribution) or a Mann-Whitney test (non-
normal distribution) were used. To compare the means of multiple groups a one-way analysis 
of variance (ANOVA) was used with a variety of post-hoc tests which were determined by the 
variation within the data. If there was equal variation between the different test groups either a 
Tukeys or Dunnett post-hoc analysis was performed, whereas Dunnett T3 or Games-Howell 
post-hoc tests were utilised in cases of unequal variation. In cases where a combination of 
continuous and categorical variables were assessed simultaneously a generalised linear 
model (GLM) was used. Where necessary a generalised linear mixed model (GLMM) was used 
to avoid pseudoreplication. All data analysis was performed in the R statistical software 
package (R Core Team 2015). Each independent experiment contained three technical 
replicates for all in vitro assays (except for qPCR array which were only performed once). Data 
are presented as the average of all experiments. Significance was defined as p≤0.05.  
 Chapter 3: CardioWise  
59 
 
Chapter 3: CardioWise can attenuate key processes in atherosclerosis development in vitro 
CardioWise can attenuate key processes in atherosclerosis 
development in vitro 
 
3.1 Introduction 
CardioWise is a unique emulsion of nutritionally active compounds which are thought to exert 
strong anti-inflammatory effects (Moss and Ramji 2016b), therefore it represents a promising 
nutraceutical combinational therapy for the prevention and treatment of atherosclerosis and 
must be investigated further. It contains the two major ω-3 PUFAs EPA and DHA, derived from 
fish oil, as well as cocoa flavanols in the primary form of catechin. As previously discussed the 
health benefits of ω-3 PUFAs have long been known while flavanols are rapidly emerging as 
potential anti-oxidants for use in atherosclerosis (Moss and Ramji 2016b). Initially CardioWise 
was designed to either contain or not contain phytosterols. Although there is some promising 
cardiovascular health benefits associated with phytosterols, there is still a concern about their 
possible adverse effects (Moss and Ramji 2016b; Köhler et al. 2017). Therefore two forms of 
CardioWise were utilised to discern any detrimental effects in vitro following the inclusion of 
phytosterols. 
CardioWise has been designed as a convenient way for an individual to boost their ω-3 PUFA 
intake and achieve current guidelines. The current advice given by the UK government and 
WHO is that individuals should be consuming two portions of fish every week with at least one 
being considered rich in ω-3 PUFAs (SACN 2004; WHO 2007). A fish containing 200-500 mg 
of EPA and DHA are considered to be one portion of fish (WHO 2007). Increasing an 
individual’s EPA and DHA dietary intake through supplementation represents the easiest way 
to achieve target levels (Garaiova et al. 2007). It is essential easy solutions are found to 
increase ω-3 PUFA intake as the majority of the UK public consume less than one portion of 
fish every week (SACN 2004). Nutraceutical combinational therapies have previously been 
shown to improve lipid parameters in patients, therefore the combination of anti-inflammatory 
nutraceuticals within CardioWise make it a promising therapy (Pirro et al. 2016; Spigoni et al. 
2017). However any potential health benefits must be assessed using in vitro atherosclerotic 
model systems before moving on to in vivo analysis. 
A variety of doses and model systems were used to analyse the efficacy and safety of 
CardioWise in the presence or absence of phytosterols. Initially a range of physiological doses 
of CardioWise were used to assess the effect of CardioWise on cell viability (Table 2.2; Manach 
et al. 2005; Batta et al. 2006; Garaiova et al. 2007). As CardioWise is a new product and a 
novel combination of nutraceuticals, it is important to determine whether it exerts any adverse 
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effects. Cell viability was determined using two independent assays, the first was a crystal 
violet stain which binds to protein and DNA (Feoktistova et al. 2016). As the assay was 
conducted in adherent cells, those that underwent apoptosis or necrosis would become 
detached and removed during the assay procedure. Consequently the amount of crystal violet 
stain present is proportional to amount of DNA present and therefore cell viability and cell 
proliferation. To confirm these results, cell viability was also determined using a LDH assay. 
LDH is normally localised within the cytoplasm of the cell, however when cells undergo 
apoptosis or necrosis their membranes can become leaky or lyse causing the secretion of LDH 
into the surrounding media (Chan et al. 2013). Therefore the amount of LDH present in the 
media surrounding the cells correlates to the amount of cell death which has occurred. 
After determining that CardioWise did not exert any adverse effects on cell viability, its effects 
on IFN-γ induced pro-inflammatory gene expression was determined. Due to their role in 
immune cell recruitment to the site of oxLDL accumulation during early atherosclerosis lesion 
formation, MCP-1 and ICAM-1 have become two robust markers of atherosclerosis. Their 
expression is also tightly regulated by IFN-γ. The expression of nearly 25% of genes can be 
induced in macrophages by IFN-γ (McLaren and Ramji 2009). IFN-γ is often considered a 
master regulator of atherosclerosis disease progression due to its ability to influence all three 
major stages of plaque development including immune cell recruitment, foam cell formation 
and plaque stability (see Moss and Ramji (2015) for more detail). A 60% reduction in lipid 
accumulation within atherosclerotic lesions in addition to a general attenuation in disease 
development was observed in ApoE deficient mice when the IFN-γ receptor was knocked out, 
highlighting the important role of IFN-γ in atherosclerosis (Gupta et al. 1997). Therefore being 
able to attenuate IFN-γ induced gene expression with CardioWise would signal strong anti-
inflammatory effects. In this assay both a 1x and 2x physiological dose was used to determine 
whether any adverse effects would occur if someone accidentally took double the 
recommended dosage, once it was determined safe only a 1x dose was used for the remaining 
assays. 
Another key step in atherosclerosis disease development is the migration of monocytes from 
the artery lumen into the wall of artery at the site of oxLDL accumulation. Monocyte recruitment 
was assessed using a modified Boyden chamber, which involves monocytes crossing a porous 
membrane. The membrane mimics the endothelial layer in the artery by having pores which 
monocytes can pass through towards a chemoattractant. MCP-1 was used as the 
chemoattractant due to its major role in the initial stages of lesion formation (Moss and Ramji 
2016a; Ramji and Davies 2015). The importance of MCP-1 has been demonstrated in 
atherosclerotic mouse models where smaller atherosclerotic lesions formed in animals that 
were either deficient in the cytokine or its receptor (Öhman et al. 2010; Yadav et al. 2010). 
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Decreasing monocyte recruitment, the initial step in lesion formation, with CardioWise would 
represent a promising preventative therapy for atherosclerosis. 
The formation of foam cells occurs when cholesterol homeostasis becomes disrupted in favour 
of reduced cholesterol efflux and enhanced cholesterol uptake, resulting in higher levels of 
intracellular cholesterol (Lusis 2000; McLaren et al. 2011a; Buckley and Ramji 2015). The 
effect of CardioWise on the cholesterol efflux potential of human macrophages was determined 
using radioactively labelled cholesterol. Stimulating the efflux of radioactive cholesterol from 
preloaded macrophages with ApoA1 into the surrounding media allows determination of the 
cholesterol efflux capability. Increasing the radioactivity in the surrounding media with 
CardioWise would indicate an increase in cholesterol efflux and therefore a reduction in foam 
cell formation. Furthermore increased levels of ROS are associated with an increase in oxLDL 
levels (Lusis 2000; McLaren et al. 2011a; Buckley and Ramji 2015). In the presence of ROS 
the non-fluorescent probe DCFDA is broken down into a highly fluorescent molecule which 
can be measured on a microplate reader. Therefore a reduction in the fluorescent signal 
following CardioWise treatment would mean it is capable of attenuating ROS generation. 
Increasing cholesterol efflux and reducing ROS production as a result of CardioWise treatment 
would mean it exerted strong anti-atherogenic effects. 
More recently greater emphasis has been placed on the differing roles of macrophage 
phenotypes during atherosclerosis plaque formation. As research continues to emerge in this 
area it appears the situation is relatively complex with a large variety of subclass whose roles 
are not always well defined or easily disguisable. However there is broad agreement that two 
of the major classes of macrophages which exist can be defined as those which are classically 
activated (M1 phenotype) or those that are alternatively activated (M2 phenotype; Geeraerts 
et al. 2017; Rojas et al. 2015; Komohara et al. 2016). M1 macrophages play a key role in 
enhancing an inflammatory reaction in the innate immune system in response to bacterial 
infection, whereas the M2 macrophages are able to influence inflammatory resolution and 
repair (Leitinger and Schulman 2013). This has led to the consensus that M1 macrophages 
are pro-inflammatory whereas M2 macrophages are anti-inflammatory. The formation of M1 
macrophages can be induced by a variety of pro-inflammatory cytokines including IFN-γ and 
IL-1β, and they are able to exert their harmful effects by secreting pro-inflammatory cytokines 
such as TNF-α, IL-6 and IL-12 (Moss and Ramji 2016a). The anti-inflammatory cytokines IL-4 
and IL-13 are capable of inducing M2 macrophage phenotype formation, leading to the release 
of anti-inflammatory cytokines TGF-β and IL-10 (Moss and Ramji 2016a). Other macrophage 
phenotypes including M2b, M2c, M2d and M4 have been identified but their function remains 
inadequately defined (Moss and Ramji 2016a). Due to the critical role macrophages play during 
atherosclerosis disease progression, targeting their phenotype formation may represent an 
ideal therapeutic target. If the balance can be influenced to reduce M1 phenotype while 
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simultaneously enhancing M2 formation, it may result in a retardation in plaque formation. As 
the M1 and M2 phenotypes have unique cell surface markers it is possible to assess the effect 
of CardioWise on M1 macrophage phenotype formation by assessing the gene expression 
levels of identifiable markers inducible NOS (iNOS) and arginase 2 (Arg2). 
 
3.2 Experimental Aims 
Details of specific methodologies for each experimental aim are outlined in Chapter 2 and the 
experimental strategies for Chapter 3 are presented in Figs. 3.1 – 3.6. 
 
Fig. 3.1. Cell viability experimental strategies. LDH, lactate dehydrogenase. A 24 hour time point was chosen 
for this assay to ensure sufficient time for determination of changes in the level of cell proliferation. 
 
Fig. 3.2. Strategy for assessing gene expression. Previous studies have suggested that differentiating THP-1 
monocytes into macrophages with PMA can result in an established M1 phenotype (Park et al. 2007). For this 
reason the murine RAW264.7 macrophages were used to assess the effect of catechin on M1 macrophage 
phenotype formation in this study. A 24 hour time point was chosen to ensure sufficient time for determination of 
changes in the level of cholesterol efflux and M1 phenotype gene expression. A 3 hour time point has previously 
been shown to be sufficient to study pro-inflammatory gene expression levels (Moss 2014). ABC, ATP-binding 
cassette; Arg2, arginase 2; ICAM, intercellular adhesion molecule; IFN, interferon; iNOS, inducible nitric oxide 
synthase; LPS, lipopolysaccharide; MCP, monocyte chemotactic protein. 
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Fig. 3.3. Monocyte migration experimental strategy. A 3 hour time point has previously been shown to be 
sufficient to study monocyte migration levels (Moss 2014). MCP, monocyte chemotactic protein.  
 
Fig. 3.4. Experimental strategy for determining cholesterol efflux. A 24 hour time point was chosen to ensure 
sufficient time for cholesterol efflux to occur. AcLDL, acetylated LDL; ApoA1, apolipoprotein A1.  
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Fig. 3.5. Strategy for assessing macropinocytosis. A 24 hour time point was chosen to ensure sufficient time 
for Lucifer Yellow to be taken up by the cells. FACS, flow assisted cell sorting.  
 
Fig. 3.6. ROS detection experimental strategy. A 3 hour time point has previously been shown to be sufficient to 
study ROS generation in macrophages (Moss 2014). DCFDA, 2’7’-dichlorofluorescin diacetate; TBHP, Tert-butyl 
hydrogen peroxide.  
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3.3 Results 
3.3.1 The viability of human macrophages is unaffected by CardioWise in vitro 
The viability of human THP-1 monocyte-derived macrophages was determined by either a 
crystal violet assay or a LDH assay. Furthermore due to the possible adverse effects of 
phytosterols, CardioWise was assessed in the presence or absence of phytosterols. As shown 
in Fig. 3.7 there were no significant differences in cell proliferation (Fig. 3.7A and 3.7C; crystal 
violet assay) or cell viability (Fig. 3.7B and 3.7D; LDH assay) following treatment of the cells 
with either the complete CardioWise or CardioWise without phytosterols for 24 hours in 
comparison to the vehicle control.  
 
Fig. 3.7. No detrimental effects were observed in human macrophages following treatment with 
physiologically relevant doses of CardioWise. Crystal violet (A and C) or lactate dehydrogenase (B and D) 
assays were used to asses cell viability in PMA differentiated THP-1 macrophages that were treated with vehicle 
(vehicle control) or various doses of the complete CardioWise formulation (+PS) or various doses of CardioWise 
lacking phytosterols (-PS) for 24 hours. Data were normalised to the vehicle control that has been arbitrarily 
assigned as 100%. The data are presented as the mean ± SEM from three independent experiments. Statistical 
analysis was performed using one-way ANOVA with Dunnett T3 post-hoc analysis. 
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3.3.2 CardioWise attenuates the expression of pro-inflammatory genes following IFN-γ 
stimulation in human macrophages  
IFN-γ is capable of inducing the expression of two key markers of inflammation, MCP-1 and 
ICAM-1, which also play major roles in the development of atherosclerosis development (Moss 
and Ramji 2016a; Li et al. 2010). The expression of MCP-1 in human PMA differentiated THP-
1 macrophages was significantly increased by 7.83 and 10.13 fold (p<0.001 and p<0.001) 
following IFN-γ stimulation (250 U/ml) for 3 hours (Fig. 3.8A and 3.8C). Furthermore the 
transcript levels of ICAM-1 were increased by 2.55 and 1.99 fold (p=0.014 and p=0.001) when 
compared to the vehicle control (Fig. 3.8B and 3.8D). When treated with either a 1x or 2x 
physiological dose of the complete CardioWise formulation, the IFN-γ stimulated MCP-1 
expression was attenuated by 71.3% (p=0.004) and 73.6% (p=0.001) respectively (Fig. 3.8A). 
A non-significant trend of decrease (51.1%; p=0.108) in IFN-γ induced expression of ICAM-1 
was observed when cells were incubated with 1x dose of complete CardioWise, whereas the 
2x dose reduced ICAM-1 expression by 57.5% (p=0.010; Fig. 3.8B). Similar observations were 
seen in human THP-1 monocyte-derived macrophages which were treated with CardioWise in 
the absence of phytosterols (Figs. 3.8C and D). The expression of IFN-γ induced MCP-1 
expression was reduced by 79.1% (p=0.001) and 78.2% (p=0.002) when treated with the 1x 
or 2x physiological dose respectively (Fig. 3.8C). In comparison to the IFN-γ stimulated cells, 
the expression of ICAM-1 was attenuated in the presence of CardioWise lacking phytosterols 
at the 1x and 2x dose by 52.8% (p<0.001) and 64.7% (p<0.001) respectively (Fig. 3.8D). These 
results were confirmed in primary HMDM (see Section 3.3.3). Furthermore similar observations 
were seen in murine RAW264.7 macrophages (Supplementary Fig. S.1). 
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Fig. 3.8. CardioWise can inhibit the IFN-γ induced expression of MCP-1 and ICAM-1 at physiologically 
relevant doses in human macrophages. The expression of MCP-1 (A and C) and ICAM-1 (B and D) were 
assessed in PMA differentiated THP-1 macrophages that were either treated with vehicle (vehicle control) or with 
IFN-γ (250 U/ml) or IFN-γ (250 U/ml) in the presence of the complete CardioWise formulation (+PS; A and B) or 
with IFN-γ (250 U/ml) in the presence of CardioWise lacking phytosterols (-PS; C and D) for 3 hours. Gene 
expression levels were assessed using qPCR and calculated using the comparative Ct method and normalised to 
GAPDH levels with values from vehicle treated cells given an arbitrary value of 1. The data are presented as the 
mean ± SEM from three independent experiments. Statistical analysis was performed using a one-way ANOVA 
with Dunnett T3 post-hoc analysis on log-transformed data where * p <0.05, ** p <0.01 and *** p <0.001. 
3.3.3 CardioWise can attenuate pro-inflammatory gene expression in primary human 
macrophages 
To rule out the possibility that the results observed in THP-1 macrophages were due to the cell 
line used, gene expression analysis was repeated in primary cultures of HMDMs. IFN-γ 
stimulation (250 U/ml for 3 hours) significantly increased the transcript levels of MCP-1 (Fig. 
3.9A; 3.13-fold increase (p<0.001)) and ICAM-1 (Fig. 3.9B; 1.75-fold increase (p=0.016)) in 
primary HMDMs when compared to the vehicle control. However in the presence of 1x dose 
of CardioWise with phytosterols, significant 30.7% (p=0.011) and 62.9% (p=0.002) reductions, 
in IFN-γ induced MCP-1 and ICAM-1 transcript levels respectively were observed when 
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compared to cells treated with IFN-γ alone. Likewise, 28.2% (p=0.025) and 50.6% (p=0.013) 
reductions respectively were seen in IFN-γ induced MCP-1 and ICAM-1 expression in 
response to treatment with the formulation lacking phytosterols.  
 
Fig. 3.9. A physiologically relevant dose of CardioWise inhibits pro-inflammatory gene expression in 
primary human macrophages. Gene transcript levels of MCP-1 (A) and ICAM-1 (B) were assessed in HMDMs 
that were either treated with vehicle (vehicle control) or IFN-γ (250 U/ml) or IFN-γ (250 U/ml) in the presence of the 
complete CardioWise formulation (+PS) or IFN-γ (250 U/ml) in the presence of the formulation lacking phytosterols 
(-PS) for 3 hours. Gene transcript levels were calculated using the comparative Ct method and normalised to 
GAPDH levels with values from vehicle treated cells given an arbitrary value of 1. The data are presented as the 
mean ± SEM from three (A) or four (B) independent experiments. Statistical analysis was performed on the log-
transformed data using a one-way ANOVA with either a Tukeys (A) or Dunnett T3 (B) post-hoc analysis where * p 
<0.05, ** p <0.01 and *** p <0.001. 
3.3.4 The migration of human monocytes is prevented by CardioWise 
During the progression of atherosclerosis disease development, the recruitment of monocytes 
to the affected area is a key mechanism in lesion formation. The chemokine MCP-1 (20 ng/ml 
for 3 hours) is capable of recruiting monocytes and this was confirmed in our in vitro model as 
a significant 6.84 fold increase (p<0.001) in monocyte migration was observed in comparison 
to the vehicle control (Fig. 3.10). A 1x physiological dose of the complete CardioWise 
formulation reduced MCP-1 driven monocyte recruitment by 37% (p=0.019) in comparison to 
MCP-1 only. A similar decrease in monocyte recruitment (38%; p=0.001) was observed in cell 
treated with CardioWise in the absence of phytosterols. There was no significant difference in 
monocyte recruitment between the cells receiving CardioWise with or without phytosterols. 
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Fig. 3.10. The migration of human monocytes towards MCP-1 is inhibited by physiologically relevant doses 
of CardioWise. THP-1 monocytes were treated with vehicle (vehicle control) or treated with MCP-1 (20 ng/ml) 
alone or with MCP-1 (20 ng/ml) in the presence of CardioWise (+PS) or with MCP-1 (20ng/ml) in the presence the 
CardioWise lacking phytosterols (-PS) for 3 hours. Monocyte migration was then determined as described in Section 
2.4.4. Data were normalised to the percentage of cells that migrated from the apical compartment of the modified 
Boyden chamber into the basolateral compartment in response to MCP-1 only treatment (arbitrarily assigned as 1). 
The data are presented as the mean ± SEM from four independent experiments. Statistical analysis was performed 
using a one-way ANOVA with a Games-Howell post-hoc analysis where * p <0.05, ** p<0.01 and *** p <0.001.  
3.3.5 The efflux of cholesterol from human macrophages is increased following 
CardioWise treatment 
Human PMA differentiated THP-1 macrophage foam cells, pre-loaded with cholesterol, were 
treated with ApoA1 (10 μg/ml) for 24 hours to stimulate the efflux of their intracellular 
radiolabelled cholesterol. Following ApoA1 only stimulation, the THP-1 macrophages were 
able to release approximately 20% of their cholesterol into the surrounding media, and this 
was arbitrarily assigned as 1 and the remaining data normalised to this (Fig. 3.11). Treatment 
with either a 1x physiological dose of CardioWise in the presence or absence of phytosterols 
significantly increased cholesterol efflux by 1.61 (p=0.002) and 1.53 (p=0.001) fold 
respectively. The effects on cholesterol efflux from the two forms of the CardioWise formulation 
were not significantly different from one another. 
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Fig. 3.11. CardioWise can induce cholesterol efflux from human macrophage foam cells at physiologically 
relevant doses. PMA-differentiated THP-1 cells were loaded with [4-14C]cholesterol and acLDL for 24 hours prior 
to a further 24 hour treatment with ApoA1 (10 µg/ml) in the presence of vehicle or ApoA1 in the presence of 
CardioWise (+PS) or ApoA1 in the presence of CardioWise lacking phytosterols (-PS). The vehicle control (ApoA1) 
was arbitrarily assigned as 1 and remaining data normalised to this. The data are presented as the mean ± SEM 
from three independent experiments. Statistical analysis was performed using a one-way ANOVA with Dunnett T3 
post-hoc analysis where ** p <0.01. 
3.3.6 CardioWise can attenuate macropinocytosis in human macrophages 
The uptake of cholesterol via macropinocytosis is an important early step in the development 
of atherosclerosis. Upon the inclusion of CardioWise in the absence of phytosterols (1x), 
macropinocytosis was significantly reduced (22.8%, p<0.001) when compared to cells treated 
with vehicle control (Fig. 3.12). However, no significant difference in macropinocytosis was 
observed between the complete CardioWise formulation and vehicle control. 
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Fig. 3.12. A physiologically relevant dose of CardioWise can attenuate macropinocytosis in human 
macrophages. Macropinocytosis was assessed in PMA differentiated THP-1 macrophages that were either treated 
with vehicle (vehicle control) or with complete CardioWise (+PS) or with CardioWise lacking phytosterols (-PS) for 
1 hour. Following pre-treatment, Lucifer yellow (LY; 100 μg/ml) was also added to all cells for a further 24 hours. 
LY uptake was measured using a BD FACS Canto flow cytometer and at least 5,000 counts were measured for 
each sample. LY uptake in the vehicle control was given an arbitrary value of 100%. The data are presented as the 
mean ± SEM from three independent experiments. Statistical analysis was performed using a one-way ANOVA 
with Dunnett T3 post-hoc analysis where *** p <0.001. 
3.3.7 The expression of two cholesterol efflux genes is attenuated by the formulation 
ABCA1 and ABCG1 are both cholesterol efflux genes and therefore changes in their 
expression may correlate to possible changes in foam cell formation. As the effect of 
CardioWise on cholesterol efflux was assessed after 24 hours (Fig. 3.11), the expression of 
ABCA1 and ABCG1 was also determined after 24 hours. In the presence of 1x doses of 
CardioWise, there was a trend of decreased ABCA1 (Fig. 3.13A) and ABCG1 (Fig. 3.13B) 
expression of 44.4% and 54.7% respectively when compared to cells treated with vehicle 
control. Likewise, 43.4% and 57.8% reductions were observed in ABCA1 and ABCG1 
expression in response to treatment with the formulation lacking phytosterols. However these 
results are based on PMA differentiated THP-1 macrophages, rather than THP-1 macrophages 
loaded with acLDL in order to form foam cells. Furthermore the results are from one 
independent experiment and therefore must be repeated using human macrophage foam cells 
before any firm conclusions can be drawn. 
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Fig. 3.13. A physiologically relevant dose of CardioWise appears to reduce the expression of two 
cholesterol efflux genes in human macrophages. Gene transcript levels of ABCA1 (A) and ABCG1 (B) were 
assessed in PMA differentiated THP-1 macrophages that were either treated with vehicle (vehicle control) or with 
CardioWise (+PS) or with the formulation lacking phytosterols (-PS) for 24 hours. Gene transcript levels were 
calculated using the comparative Ct method and normalised to GAPDH levels with values from vehicle treated cells 
given an arbitrary value of 1. The data are presented as the mean from one independent experiment performed in 
triplicate. 
3.3.8 CardioWise can induce ROS production in human macrophages 
The formation of ROS is a key step in the generation of oxLDL and therefore foam cell 
formation. The production of ROS can be induced in macrophages by treating them with tert-
Butyl hydroperoxide (TBHP; 50 μM for 3 hours) and this was confirmed in our system as a 
significant 1.56-fold induction (p<0.001) in the formation of ROS in cells treated with TBHP 
alone was observed when compared to the vehicle control (Fig. 3.14). Upon the inclusion of 
the complete CardioWise formulation (1x), ROS production in response to TBHP was 
significantly increased (21.3%, p=0.026) when compared to cells treated with TBHP alone. 
Similarly, incubation with CardioWise lacking phytosterols resulted in a 77.7% (p<0.001) 
increase in ROS formation when compared to TBHP treated cells. However ROS production 
in the cells treated with the complete formulation was 31.7% lower (p<0.001) compared to 
those which has received the formulation lacking phytosterols. 
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Fig. 3.14. A physiologically relevant dose of CardioWise can induce ROS production in human 
macrophages. ROS production was assessed in PMA differentiated THP-1 macrophages that were either treated 
with vehicle (vehicle control) or tert-Butyl hydroperoxide (TBHP; 50 μM) or TBHP (50 μM) in the presence of 
CardioWise (+PS) or TBHP (50 μM) in the presence of CardioWise lacking phytosterols (-PS) for 3 hours. ROS 
production was measured in a fluorescence microplate reader, with excitation at 485 nm and emission detected at 
535 nm. Vehicle control was given an arbitrary value of 1. The data are presented as the mean ± SEM from three 
independent experiments. Statistical analysis was performed using a one-way ANOVA with Tukeys post-hoc 
analysis where * p <0.05 and *** p <0.001 when compared to TBHP. ### p <0.001 when comparing +PS to –PS. 
3.3.9 CardioWise attenuates the expression of M1 phenotype markers in murine 
macrophages 
Due to the possibility of PMA differentiating THP-1 monocytes resulting in an established M1 
macrophage phenotype, murine RAW264.7 macrophages were used during this assay (Park 
et al. 2007). Previous studies have demonstrated that a combined treatment of IFN-γ and 
lipopolysaccharide (LPS) is capable of inducing M1 macrophage polarisation and both iNOS 
and Arg2 are robust markers of the M1 phenotype (Khallou-Laschet et al. 2010; Dugo et al. 
2017). For this reason the expression of iNOS and Arg2 was determined following co-
stimulation with IFN-γ and LPS (250 U/ml and 100 ng/ml respectively for 24 hours) to determine 
the effect of CardioWise on macrophage polarisation. The expression of iNOS (Fig. 3.15A; 
p<0.001) and Arg2 (Fig. 3.15B; p<0.001) was significantly increased following co-stimulation 
treatment. Incubation with the complete CardioWise formulation resulted in a decrease in the 
expression of both iNOS and Arg2 by 48% (p=0.004) and 42% (p=0.015) respectively. Similar 
results were observed in cells treated with CardioWise lacking phytosterols, where a significant 
decrease in iNOS expression (45%; p=0.002) and a trend of decrease in Arg2 expression 
(37%; p=0.056) was seen when compared to the IFN-γ and LPS co-stimulation only group. 
The presence or absence of phytosterols had no significant effect on either iNOS or Arg2 
expression. 
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Fig. 3.15. M1 polarisation in murine macrophages is inhibited by a physiologically relevant dose of 
CardioWise. The expression of iNOS (A) and Arg2 (B) were assessed in murine RAW264.7 macrophages that 
were either treated with vehicle (vehicle control); with IFN-γ (250 U/ml) and LPS (100 ng/ml); with IFN-γ (250 U/ml) 
and LPS (100 ng/ml) in the presence of the complete CardioWise formulation (+PS) or with IFN-γ (250 U/ml) and 
LPS (100 ng/ml) in the presence of CardioWise lacking PS (-PS) for 24 hours. Gene expression levels were 
assessed using qPCR and calculated using the comparative Ct method and normalised to β-actin levels with values 
from IFN-γ and LPS treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from 
five independent experiments. Statistical analysis was performed using a one-way ANOVA with Dunnett T3 post-
hoc analysis on square root-transformed data where * p <0.05, ** p <0.01 and *** p <0.001. 
 
3.4 Discussion 
The various atherosclerosis-associated assays used for the different experiments in this 
chapter demonstrate the ability of the unique nutraceutical combination, known as CardioWise, 
to attenuate the expression of IFN-γ induced pro-atherogenic genes, reduce monocyte 
recruitment, enhance cholesterol efflux while simultaneous decreasing macropinocytosis and 
attenuate the polarisation of macrophages into their pro-inflammatory M1 phenotype. Although 
CardioWise did increase ROS generation, overall it appears to exert strong anti-atherogenic 
effects. This unique combination of ω-3 PUFAs, flavanols and phytosterols has been shown 
to work on a variety of pro-inflammatory processes associated with atherosclerosis in vitro, 
highlighting its possible use as a preventative during early atherosclerotic lesion formation. 
Previous studies have not investigated the effects of a nutraceutical combination consisting of 
fish oils, cocoa extracts and phytosterols either in vitro or in vivo. Several studies focusing on 
the individual nutraceuticals have observed potential anti-inflammatory effects. However a 
variety of studies have also found fish oils, cocoa extracts and especially phytosterols to be 
capable of either exerting adverse effects and contributing to atherosclerosis lesion formation 
or having no observable anti-atherogenic properties (reviewed in Moss and Ramji 2016b). 
There are many reasons why these negative observations may have been made including: a 
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single agent being tested which does not take into consideration the possible synergistic 
effects between nutraceuticals that may occur during dietary intake; pure forms of the 
compounds being utilised rather than the naturally and most abundant forms which ignores 
possible beneficial metabolic by-products produced by side chains not present on the pure 
molecule; nutraceuticals being used at dosages that are unrealistic and unachievable from 
dietary absorption; differences in the genetic makeup of clinical trial participants; presence or 
absence of other risk factors such as high blood pressure, increased cholesterol levels and 
age; and patients also receiving high levels of pharmaceutical therapies such as statins. In 
order to try and account for some of these limitations, this study used the nutraceuticals in their 
most widely occurring natural forms rather than the pure compound, as previous studies have 
shown them to be capable of influencing macrophage function (Oh et al. 2010; Sabeva et al. 
2011; Byun et al. 2014). The study also used the nutraceuticals at doses that have been 
previously observed following dietary intake (Manach et al. 2005; Batta et al. 2006; Garaiova 
et al. 2007). This makes the observations seen in this study more translatable and more 
representative of the effects which may occur following CardioWise consumption. THP-1 
monocytes and macrophages were used in this study due to their significant role in all stages 
of atherosclerosis disease progression and also because the responses observed in THP-1 
cells are highly conserved in HMDM and in vivo studies (Michael et al. 2012b; McLaren et al. 
2010a; McLaren et al. 2010b). Indeed the key finding of attenuated IFN-γ-induced expression 
of MCP-1 and ICAM-1 (Fig. 3.8) was directly confirmed in primary HMDM cultures (Fig. 3.9). 
As CardioWise is a novel formulation it was essential to initially confirm it did not exert any 
detrimental effects on either cell proliferation or viability of human macrophages in vitro (Fig. 
3.7). These results also confirm the alterations in gene expression and cell functions observed 
in other assays were as a result of CardioWise rather than as a consequence of altered cell 
viability. The primary function of phytosterols is to reduce dietary cholesterol uptake from the 
lumen of the intestine, however they are also known to cross the gut-blood barrier at extremely 
low levels (Chan et al. 2006; Gylling et al. 2014). Furthermore individual phytosterols have 
been found to cause adverse effects on macrophages in vitro, including the phytosterols 
sitosterol and stigmasterol, which are present in CardioWise (Sabeva et al. 2011). Therefore 
during this study, CardioWise in the presence or absence of phytosterols was used in all of the 
assays to ensure no detrimental effects were observed following exposure of the cells to the 
total dose of phytosterols. The inclusion of phytosterols did not alter the effect of CardioWise 
on cell viability (Fig. 3.7), pro-inflammatory gene expression (Figs. 3.8 and 3.9), monocyte 
migration (Fig. 3.10), cholesterol efflux (Fig. 3.11), “cholesterol efflux” gene expression (Fig. 
3.13) and M1 macrophage polarisation (Fig. 3.15), providing no evidence to support its removal 
from the formulation. However the inclusion of phytosterols did affect macropinocytosis and 
ROS production (Figs. 3.12 and 3.14 respectively; reasons for this are discussed in greater 
detail later). 
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IFN-γ is a major pro-inflammatory cytokine which is considered to be one of the key 
orchestrators of atherosclerosis disease progression (Moss and Ramji 2016a; Moss and Ramji 
2015; Ramji and Davies 2015). Several immune cells found within atherosclerotic plaques, 
such as macrophages, natural killer T-cells and T-lymphocytes, produce and release IFN-γ at 
prominent levels (van Boxel-Dezaire and Strak 2007; Kleemann et al. 2008). Furthermore due 
to its role in all stages of atherosclerotic plaque formation, IFN-γ is thought of as a potential 
therapeutic target (Moss and Ramji 2015; Moss and Ramji 2016a). Previous work in the 
laboratory has shown that IFN-γ is capable of stimulating the expression of the pro-
inflammatory genes MCP-1 and ICAM-1 (Li et al. 2010). Products of these genes are capable 
of significantly driving monocyte recruitment during early atherosclerosis lesion formation at 
the site of oxLDL accumulation. In this study we show that a physiologically relevant dose of 
CardioWise in the presence or absence of phytosterols is capable of reducing IFN-γ-mediated 
expression of MCP-1 and ICAM-1 in PMA differentiated THP-1 macrophages (Fig. 3.8), 
primary HMDMs (Fig. 3.9) and murine macrophages (Supplementary Fig. S.1). These results 
highlight the possibility of using CardioWise in order to attenuate monocyte migration to the 
activated endothelium during the early stages of atherosclerosis disease progression. The pro-
inflammatory stimuli induced expression of ICAM-1 and MCP-1 has also been reduced in a 
variety of cell types following individual treatment with ω-3 PUFAs, flavanols and phytosterols 
in other studies (Hughes et al. 1996; Miles et al. 2000; Nakanishi et al. 2010; Wang et al. 
2014b; Bustos et al. 2008). 
In addition to attenuating MCP-1 gene expression, a 1x physiological dose of CardioWise was 
also capable of decreasing the recruitment of monocytes towards a MCP-1 stimulus (Fig. 3.10). 
In theory these results suggest that a physiological dose of CardioWise would be doubly 
effective at reducing the size of atherosclerotic lesions. Firstly it is capable of reducing the 
levels of MCP-1 produced by activated cells and secondly it then decreases the responsive of 
monocytes to move towards the MCP-1 stimuli. This makes CardioWise an extremely 
promising anti-atherogenic therapy. Previous studies using ω-3 PUFAs, flavanols and 
phytosterols individually have also observed reductions in monocyte recruitment (Brown et al. 
2012; Melgarejo et al. 2009; Bustos et al. 2008). The alterations observed in MCP-1 gene 
expression (Figs. 3.8 and 3.9) may mechanistically explain the changes seen in monocyte 
migration (Fig. 3.10). These results imply that CardioWise may reduce the number of 
macrophages which accumulate at the site of oxLDL build-up in atherosclerotic lesions and 
therefore result in a smaller lesion. However this hypothesis still requires extensive in vivo 
investigation in mouse models of atherosclerosis which was unfortunately not performed 
during this study due to time limitations. 
The unbalancing of cholesterol homeostasis towards increased cholesterol uptake and 
reduced efflux within macrophages leads to the formation of foam cells, which form the initial 
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fatty streak in atherosclerosis disease progression. Following treatment with CardioWise in the 
presence or absence of phytosterols, there was a significant increase in ApoA1-mediated 
cholesterol efflux from cholesterol laden human macrophage foam cells (Fig. 3.11), indicating 
a possible attenuation in foam cell formation. These results correlate with previous in vitro 
studies which assessed the effects of individual nutraceuticals on cholesterol efflux (Lada et 
al. 2003; Bursill and Roach 2006; Sabeva et al. 2011). Macropinocytosis is the mechanism by 
which cholesterol crystals are taken up by macrophages (Bobryshev 2006). Cholesterol 
crystals are able to activate inflammasomes, an intracellular multi-protein complex in the innate 
immune response which is capable of converting the pro-inflammatory cytokines IL-1β and IL-
18 into their mature forms (Hoseini et al. 2017). In the absence of phytosterols CardioWise 
was able to decrease macropinocytosis uptake (Fig. 3.12), showing it is capable of increasing 
cholesterol efflux while simultaneously reducing cholesterol uptake. However the effect of 
CardioWise on receptor-mediated cholesterol uptake remains to be assessed. In contrast, 
CardioWise with phytosterols showed a non-significant trend of increased macropinocytosis. 
This is the first result in which the addition of phytosterols altered the effect of CardioWise, this 
may be due to the fact that phytosterols and cholesterol have almost identical structures. The 
PMA differentiated THP-1 macrophages may have recognised the presence of phytosterols in 
the same way it recognises cholesterol, which in turn triggered a slight increase in 
macropinocytosis. As the vast majority of phytosterols will not be taken up from the intestine 
and therefore unlikely to come into contact with macrophages in atherosclerotic lesions, the 
trend of increase in macropinocytosis seen is this in vitro study is not of concern but should be 
kept in mind when analysing future in vivo studies. 
The expression of two “cholesterol efflux” genes, ABCA1 and ABCG1, was reduced following 
CardioWise treatment (Fig. 3.13). This result is unusual because it shows the opposite result 
of the cholesterol efflux assay (Fig. 3.11), however it is worth noting that the gene expression 
assay is only based on one independent experiment and therefore requires repeating in order 
to draw firm conclusions. Furthermore mRNA expression levels do not always match protein 
abundance levels (Vogel and Marcotte 2012), so it is possible to have reduced mRNA 
expression levels but increased ABCA1 and ABCG1 protein levels, this would have to 
determined using a western blot. Furthermore there are a variety of other cholesterol efflux 
genes including liver X receptors (LXRs) and ApoE which may have their expression increased 
following CardioWise treatment and therefore their expression levels should be assessed. 
Previous in vitro studies have observed increases in “cholesterol efflux” gene expression 
following treatment with ω-3 PUFAs and phytosterols (Song et al. 2013; Sabeva et al. 2011). 
The normal physiological function of vascular cells, including VSMC contraction and 
endothelial homeostasis, are reliant on ROS for cell signalling (Chen et al. 2017c). Failure to 
maintain a balance in ROS formation can have serious detrimental effects and increased ROS 
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production has been associated with increased cell damage, lipid peroxidation, immune cell 
recruitment and MMP activation (Chen et al. 2017c). Therefore reducing ROS formation 
represents a potential therapeutic avenue for attenuating atherosclerosis disease progression. 
In this study both forms of CardioWise significantly increased hydrogen peroxide-induced ROS 
formation (Fig. 3.14), however ROS levels were significantly higher following treatment with 
CardioWise in the absence of phytosterols when compared to the formulation containing 
phytosterols. These results imply that the addition of phytosterols provides a level of anti-
oxidant protection that is not present in the base formulation, indeed a previous in vitro study 
has demonstrated that β-sitosterol (a phytosterol present in CardioWise) is capable of 
increasing the activity of superoxide dismuatase (SOD; Vivancos and Moreno 2005). 
Superoxide dismutase is an anti-oxidant enzyme which converts oxygen free radicals into 
oxygen molecules or hydrogen peroxide. However as previously mentioned, only a small 
amount of the phytosterols will be absorbed in the intestine and therefore CardioWise without 
phytosterols is a more accurate indication of the effect it will exert on macrophages within 
atherosclerosis lesions. This is the first assay which indicates that CardioWise may exert 
detrimental pro-inflammatory effects, this results needs to be confirmed in vivo. 
Due to the pro-atherogenic role of M1 macrophages, it is important to target macrophage 
polarisation in order to reduce the levels of M1 macrophages within lesions. Furthermore it is 
emerging that M1 macrophages also contribute to plaque instability and rupture after it was 
found they tend to be localised within the rupture prone shoulder regions of atherosclerotic 
plaques (Stöger et al. 2012). Following the treatment of murine macrophages with CardioWise 
in the presence or absence of phytosterols, the expression of two robust markers of the M1 
phenotype, iNOS and Arg2, was significantly attenuated (Fig. 3.15). These results indicate that 
CardioWise may be able to stabilise mature atherosclerotic plaques and reduce the risk of 
them rupturing, however this hypothesis needs to be scrutinised in vivo. The findings in this 
study are similar to previous in vitro studies which have found that ω-3 PUFAs and flavanols 
are capable of reducing M1 polarisation and activation (De Boer et al. 2014; Chang and 
Deckelbaum 2013; Dugo et al. 2017). 
Overall this is the first in vitro study which has demonstrated that a unique combination of ω-3 
PUFAs, flavanols and phytosterols exerts strong anti-atherogenic effects at several key 
atherosclerosis disease progression steps. CardioWise was found to significantly attenuate 
pro-inflammatory gene expression, monocyte recruitment, M1 macrophage polarisation as well 
as enhancing cholesterol efflux (summarised in Fig. 3.16). As CardioWise is a combination of 
nutraceuticals it is important to also assess them individually to identify the most effective 
compounds (Chapter 5). The results of this in vitro study provides support for the use of 
CardioWise in an initial in vivo feeding study. Indeed Chapter 4 discusses the anti-atherogenic 
effects of CardioWise treatment in wild type mice fed a high fat diet for 3 weeks. 
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Fig. 3.16. Summary of the anti-atherogenic properties of CardioWise. The steps reduced in atherosclerosis 
disease progression following CardioWise treatment are highlighted in green whereas those increased by 
CardioWise are highlighted in red. 
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Chapter 4: The effects of CardioWise in wild type mice fed a high fat diet 
The effects of CardioWise in wild type mice fed a high fat 
diet  
 
4.1 Introduction 
The results produced by the full CardioWise formulation in the in vitro assays covered in 
Chapter 3 justified its use in an initial mouse study to further explore its potential as an anti-
atherogenic nutraceutical. The use of in vivo models allows for a greater understanding of the 
effect of novel treatments that cannot currently be replicated in vitro, due to the potential 
unknown effects which a whole body system may exert. To ensure the results of the preclinical 
study were more translatable to human subjects, the mice were treated with a 1x human 
equivalent physiological dose based on a body surface area calculation (Nair and Jacob 2016). 
The exact concentrations of the components of CardioWise can be found in Section 2.7.1. Wild 
type mice fed a high fat diet for 21 days were used as previous work in the laboratory has 
shown these conditions to induce markers of atherosclerosis development (Wijdan Al-Ahmadi 
personal communication). These markers include weight gain, changes in plasma cholesterol 
and TG levels, levels of pro-inflammatory cytokines within the serum, as well as changes in 
gene expression in the liver. Furthermore a study using wild type mice found that a high fat 
diet also raised the levels of these markers after just 14 days (Michael et al. 2017), indicating 
our study period is sufficient to observe potential anti-atherogenic effects of nutraceuticals. 
Therefore this in vivo model was utilised to assess the potential cardiovascular protective 
effects of CardioWise. 
Initially, basic physical and physiological parameters were measured to ensure no detrimental 
effects occurred as a result of CardioWise treatment. Weight gain was assessed using a 
GLMM in order to determine the effects of both time, treatment and their interaction 
simultaneously. Furthermore as the study involved repeatedly measuring the same mice over 
the 21 day trial period, it suffered from a phenomenon known as pseudoreplication. In this 
study the weight of the 13 mice was measured 10 times. However traditional statistical 
methods, such as an ANOVA, would inappropriately interpret the data as 130 independent 
measurements rather than 13, making the p values associated with the ANOVA meaningless. 
Therefore to avoid pseudoreplication each mouse was given a unique ID tag and this tag was 
included within the random model portion of the GLMM. 
The weight of the different fat pads within the mice was also measured to determine whether 
CardioWise affected fat accumulation or the location where the fat was stored. This is because 
recent studies have found white fat, brown fat and perivascular adipose tissue (PVAT) to 
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potentially have different roles in the progression of atherosclerosis (Gómez-Hernández et al. 
2016; Hoeke et al. 2016; van Dam et al. 2017). White fat, such as subcutaneous, inguinal, 
gonadal and renal fat are used by the body to store excess dietary fat for organs to use as 
energy when required (van Dam et al. 2017). On the other hand, brown fat has been shown to 
be used by the body for maintaining body temperature by combusting fatty acids for heat 
generation (van Dam et al. 2017). PVAT is unique due to its location surrounding systemic 
blood vessels (van Dam et al. 2017). Unlike white and brown fat, PVAT maintains the normal 
function of blood vessels by providing structural support. During obesity and inflammatory 
disorders, white fat releases fatty acids into the plasma making it pro-atherogenic, whereas 
brown fat begins to store circulating TG in lipid droplets indicating it is anti-atherogenic (van 
Dam et al. 2017). The role of PVAT during atherosclerosis remains unclear as it has been 
shown to be both pro- and anti-atherogenic (van Dam et al. 2017). Therefore if CardioWise 
affects the proportion of white fat, brown fat and PVAT, it may imply that it is capable of exerting 
cardiovascular protective effects. 
Previous studies have shown that ω-3 PUFAs, catechin and phytosterol consumption is 
capable of altering an individual’s lipid profile (Franzese et al. 2015; Matsuyama et al. 2008; 
Ras et al. 2015). We therefore assessed the effect of CardioWise treatment on the plasma 
levels of total, LDL and HDL cholesterol. It has long been established that elevated LDL levels 
are associated with an increased risk of CVD whereas low HDL levels are considered pro-
atherogenic (Buckley and Ramji 2015). CardioWise would be considered a strong anti-
atherogenic nutraceutical combination if it was capable of lowering LDL levels as well as 
increasing HDL levels. However plasma concentrations of LDL and HDL in isolation are not 
always ideal predictors of an individual’s risk of CVD and often the ratio of total/HDL cholesterol 
and LDL/HDL cholesterol are more useful as clinical risk indicators (Millán et al. 2009). The 
effect of CardioWise on the total/HDL, total/LDL and LDL/HDL cholesterol ratios was also 
determined. TG levels within the blood are another lipid parameter which can be used as an 
indicator of an individual’s risk of suffering a CVD-related event (Talayero and Sacks 2011). 
Furthermore the ratio of TG/HDL cholesterol has been previously shown to be strongly 
associated with CVD (da Luz et al. 2008). Therefore it was expected that CardioWise would 
lower TG levels and TG/HDL cholesterol ratio in the plasma of wild type mice fed a high fat 
diet for 21 days. 
During our in vitro studies CardioWise was found to potentially increase ROS generation (Fig. 
3.14), therefore it was vital to assess the effect of CardioWise on ROS production in vivo. 
Furthermore the levels of lipid peroxidation were also measured to determine the full effect of 
CardioWise on ROS generation and its consequences as increased oxidative stress is 
associated with increased lipid peroxidation (Ayala et al. 2014; Chen et al. 2017c). Previous 
studies have shown that unregulated lipid peroxidation results in reducing the strength of the 
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arterial wall and increasing the risk of formation of an aneurysm by triggering the apoptosis of 
aortic cells (Kinnunen et al. 2012; Ayala et al. 2014). MDA is a major by-product of lipid 
peroxidation found within the blood, consequently measuring the effect of CardioWise on MDA 
levels can be used as an indicator for its effects on ROS damage and lipid peroxidation (Ayala 
et al. 2014).  
The circulating concentrations of pro- and anti-inflammatory cytokines were also assessed in 
the plasma from wild type mice fed a high fat diet for 21 days following CardioWise treatment. 
The roles of the cytokines in atherosclerosis disease development are outlined in Table 4.1 
and extensively reviewed by Moss and Ramji (2016) and Ramji and Davies (2015). These pro-
inflammatory cytokines are key contributors to atherosclerosis progression and therefore it is 
hoped that CardioWise treatment is able to attenuate their secretion into the blood. 
Table 4.1. The role of pro- and anti-inflammatory cytokines analysed during this study. 
Cytokine Role in atherosclerosis  Reference 
CXCL1 Produced by macrophages and has been found to be 
increased in patients with CVD. LDLr deficient mice also 
lacking CXCL1 were found to develop smaller 
atherosclerotic lesions. 
 Boisvert et al. 2006; 
Breland et al. 2008 
IFN-γ Genetic deletion in ApoE deficient mice results in reduced 
atherosclerotic lesion size and lipid accumulation. 
 Whitman et al. 2002; 
Koga et al. 2007a 
IL-1β ApoE mice which are also IL-1β deficient have reduced 
expression of pro-inflammatory genes and attenuated 
atherosclerosis development. 
 Kirii et al. 2003; Bhaskar 
et al. 2011 
IL-2 Blocking IL-2 signalling in ApoE deficient mice retards 
atherosclerosis, whereas IL-2 injections enhances 
disease progression. 
 Dinh et al. 2012; 
Upadhya et al. 2004 
IL-4 Induces a pro-inflammatory state in vascular endothelium. 
Deficiency in ApoE mice resulted in smaller plaque 
formation. 
 Davenport and Tipping 
2003; Lee et al. 2010c 
IL-5 Transplanting IL-5 deficient bone marrow into LDLr 
deficient mice resulted in accelerated atherosclerosis. 
 Binder et al. 2004 
IL-6 IL-6 injections in ApoE deficient mice resulted in increased 
pro-inflammatory cytokine levels and plaque size. 
However other studies have shown that both ApoE and 
LDLr mice which also lack IL-6 suffer from enhanced 
atherosclerosis. 
 Schuett et al. 2012; 
Madan et al. 2008 
IL-10 Genetic deletion in ApoE mice enhanced atherosclerosis 
disease development. 
 Potteaux et al. 2004; 
Eefting et al. 2007 
TNF-α Deficiency in ApoE mice reduced atherosclerosis 
development by decreasing foam cell formation and the 
expression of multiple pro-inflammatory genes. 
 Xiao et al. 2009; 
Xanthoulea et al. 2009 
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In order to determine whether the changes in physical and physiological parameters were as 
a result of altered gene expression, the expression of genes in the liver of wild type mice fed 
a high fat diet for 21 days was assessed by qPCR array. Furthermore, gene expression 
changes were measured within the liver due to the critical role it plays during metabolic 
disorders (Pietrangelo 2009). One of the major advantages of using qPCR arrays over regular 
qPCRs is that they produce more data in a shorter space of time, this is due to the plate being 
able to determine mRNA expression levels of 84 genes simultaneously. As different mice were 
used for the vehicle control group and the CardioWise treatment group, an average base line 
of gene expression had to be established for all the vehicle control treated mice rather than an 
independent base line for each mouse. Any p value of approximately 0.1 or lower was 
considered to show a trend of change and was included and discussed in the results section. 
It should be noted that due to the low expression levels of some genes, obtaining a Ct value 
was not achievable for every repeat. Mice with undetectable Ct readings were removed before 
statistical analysis and need to be investigated in future experiments by possibly increasing 
the starting amount of cDNA. 
Stem and progenitors cells are capable of self-renewal and give rise to all the other cell types 
within the body. The haematopoietic stem cells (HSCs) give rise to all types of blood cells. 
Previous studies have observed changes in the stem and progenitor cell populations within the 
bone marrow of mice following a high fat diet (Chan et al. 2012; Wu et al. 2013; Adler et al. 
2014; van den Berg et al. 2016). Alteration in bone marrow cell populations are also associated 
with atherosclerosis disease progression (Lang and Cimato 2014; Murphy et al. 2014; Ma and 
Feng 2016). For example an increase in HSC proliferation and differentiation has been 
observed in hypercholesterolaemic conditions (Lang and Cimato 2014; Ma and Feng 2016). 
Other cells such as the myeloid derived suppressor cell (MDSC) population is associated with 
chronic inflammatory diseases such as atherosclerosis and is often found in increased 
numbers during disease development (Foks et al. 2016). However the current role of MDSCs 
during atherosclerosis remains unclear. The formation of all other cell types from HSCs is 
outlined in Fig. 4.1. Using CardioWise treatment may represent a novel way of restoring the 
cell populations to their natural state during atherosclerosis. 
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Fig. 4.1. The formation of haematopoietic cells from a haematopoietic stem cell. HSC, haematopoietic stem 
cell; MPP, multipotent progenitors; HPC, haematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, 
megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage progenitor; MDSC, myeloid-derived 
suppressor cells; LMPP, lymphomyeloid progenitor; CLP, common lymphoid progenitor. 
 
4.2 Experimental Aims 
Details of the specific in vivo methodologies are outlined in Chapter 2 and a brief experimental 
strategy for Chapter 4 is presented in Fig. 4.2. 
 
Fig. 4.2. Experimental strategy used to assess the effect of CardioWise in vivo. 
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4.3 Results 
4.3.1 CardioWise had no effect on weight gain in wild type mice receiving a high fat diet 
Mouse weight gain was positively correlated with time (Fig. 4.3), with mice gaining 
approximately 0.09 g per day resulting in a total average increase in weight of 1.89 g (p<0.001; 
adj-R2=0.86). However there was no significant effect observed for CardioWise treatment or 
interaction between time and treatment type. 
 
Fig. 4.3. The rate of weight gain in wild type mice fed a high fat diet was not altered by CardioWise. The 
weight of mice was measured every 2 or 3 days for the entire duration of the study (21 days). Mice were fed a high 
fat diet which was either supplemented with vehicle control (circle) or a 1x human equivalent physiological dose of 
CardioWise (triangle). The prediction of the average rate of weight gain, as calculated by a generalised linear mixed 
model with a Gamma error distribution and identity link function, is displayed from 13 mice (control 6; CardioWise 
7). To avoid pseudoreplication the identity of each mouse was included within the model as a random term. The 
raw data from each mouse is also presented to provide a visual representation of the spread within the data. 
4.3.2 The weight of fat pads in wild type mice fed a high fat diet was not significantly 
affected by CardioWise 
As shown in Fig. 4.4, there were no significant differences in the weight of subcutaneous (Fig. 
4.4A), inguinal (Fig. 4.4B), gonadal (Fig. 4.4C) or total (Fig. 4.4G) fat pads observed following 
CardioWise treatment in wild type mice fed a high fat diet in comparison to the vehicle control. 
The weight of renal fat and PVAT showed a non-significant trend of increase of 20.8% 
(p=0.139) and 79.9% (p=0.105) respectively following CardioWise treatment (Fig. 4.4D and F), 
whereas the brown fat pad weight was non-significantly reduced by 38.3% (p=0.217) when 
compared to the vehicle control (Fig. 4.4E).
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Fig. 4.4. No changes in fat pad weight were observed in wild type mice following feeding of a high fat diet and treatment with CardioWise. Subcutaneous (A), inguinal 
(B), gonadal (C), renal (D), brown (E), PVAT (F) and total (G) fats from wild type mice were weighed after 21 days of a high fat diet and treatment with either a vehicle control or 
a 1x human equivalent physiological dose of CardioWise. The data are presented as the mean ± SEM from 13 mice (control 6; CardioWise 7). Statistical analysis was performed 
using a t-test (equal variance) on either untransformed data (C, D, E and F) or log-transformed data (A, B and G).
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4.3.3 CardioWise increases HDL cholesterol levels in wild type mice fed a high fat diet 
The levels of HDL within the plasma of the mice were increased by 1.60 fold (p=0.054) 
following 21 days of CardioWise treatment (Fig. 4.5B). The levels of total cholesterol were also 
non-significantly increased (Fig. 4.5A), whereas no changes in LDL levels were observed in 
contrast to the vehicle control treated mice (Fig. 4.5C). The ratios of total cholesterol/HDL, total 
cholesterol/LDL and LDL/HDL were also assessed. CardioWise treatment did not affect the 
total cholesterol/HDL and total cholesterol/LDL ratio (Fig. 4.5D and E). However a non-
significant trend of decrease of 38% (p=0.091) was observed in the ratio of LDL/HDL 
cholesterol in the mice receiving CardioWise (Fig. 4.5F). This result means that CardioWise 
resulted in more HDL per LDL cholesterol molecule in comparison to the vehicle control mice.  
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Fig. 4.5. Wild type mice on a high fat diet and treated with CardioWise had increased HDL cholesterol levels. 
Total cholesterol (A), HDL (B) and LDL (C) from wild type mice were measured after 21 days of a high fat diet and 
treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. The ratios of 
total cholesterol/HDL (D), total cholesterol/LDL (E) and LDL/HDL (F) were also assessed. The data are presented 
as the mean ± SEM from 13 mice (control 6; CardioWise 7). Statistical analysis was performed using either a t-test 
(equal variance; A, B, C, E and F) or a Mann-Whitney test (D) on untransformed data (B, D and E), reciprocal-
transformed data (A), square rooted-transformed data (C) or log-transformed data (F). 
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4.3.4 CardioWise increases TG levels in wild type mice fed a high fat diet 
Increased serum TG levels can be seen as a risk factor for developing atherosclerosis and 
CVD-related events. CardioWise treatment significantly increased TG levels by 96% (p<0.001) 
in wild type mice fed a high fat diet for 21 days (Fig. 4.6A). The ratios of TG/total cholesterol, 
TG/HDL and TG/LDL were also assessed. The level of TGs to total or LDL cholesterol levels 
showed significant increases of 43% and 71% (p=0.046 and p=0.032) respectively following 
CardioWise treatment when compared to the vehicle control (Fig. 4.6B and D). A non-
significant trend of increase of 39% (p=0.193) was observed for the TG/HDL cholesterol ratio 
in the mice which had received the CardioWise treatment (Fig. 4.6C). These results show that 
CardioWise treatment increases the levels of TG within the plasma in relation to the levels of 
the various types of cholesterol. 
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Fig. 4.6. CardioWise in wild type mice increased TG levels while receiving a high fat diet. TG levels (A) from 
wild type mice were measured after 21 days of a high fat diet and treatment with either a vehicle control or a 1x 
human equivalent physiological dose of CardioWise. The ratios of TG/total cholesterol (B), TG/HDL cholesterol (C) 
and TG/LDL cholesterol (D) were also assessed. The data are presented as the mean ± SEM from 13 mice (control 
6; CardioWise 7). Statistical analysis was performed using a t-test (equal variance) on either untransformed data 
(A, B and C) or log-transformed data (D) where * p≤0.05 and *** p≤0.001. 
4.3.5 CardioWise increases lipid peroxidation in wild type mice fed a high fat diet 
Upon treatment with a human equivalent physiologically relevant dose of CardioWise the levels 
of ROS generation did not significantly differ from the mice receiving the vehicle control (Fig. 
4.7A). However the levels of MDA, a by-product of lipid peroxidation, were increased by 2.07 
fold (p=0.053) in mice receiving CardioWise treatment in contrast to the mice receiving the 
vehicle control (Fig. 4.7B). 
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Fig. 4.7. CardioWise shows a trend of induction for lipid peroxidation in wild type mice fed a high fat diet. 
ROS production (A) and MDA levels (B) were assessed in wild type mice after 21 days of a high fat diet and 
treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. ROS production 
was measured in a fluorescence microplate reader, with excitation at 485 nm and emission detected at 535 nm. 
Vehicle control was given an arbitrary value of 1. MDA levels were measured in a fluorescence microplate reader, 
with excitation at 535 nm and emission detected at 590 nm. The data are presented as the mean ± SEM from six 
control mice and either six (B) or seven (A) CardioWise treated mice. Mice with undetectable assay readings were 
removed before statistical analysis. Statistical analysis was performed using a t-test (equal variance) on either 
untransformed data (B) or log-transformed data (A). 
4.3.6 CardioWise reduces the levels of several pro- and anti-inflammatory cytokines in 
the plasma of wild type mice fed a high fat diet 
The protein levels of pro- and anti-inflammatory cytokines IFN-γ, IL-1β, IL-2, IL-5, IL-6, IL-10, 
TNF-α and chemokine (C-X-C motif) ligand (CXCL)1 (see Table 4.1 for further details) were 
assessed in the plasma of wild type mice fed a high fat diet that was supplemented with either 
vehicle control or a human equivalent physiological dose of CardioWise for 21 days (Fig. 4.8). 
Following CardioWise treatment, a non-significant trend of decrease was observed for CXCL1 
of 18.1% (p=0.106). Although the levels of IL-2, IL-5, IL-6, IL-10 and TNF-α were found to be 
reduced these changes were found not to be significant, 61.9%, 42.9% (p=0.426), 46.5% 
(p=0.275), 21.1% (p=0.210) and 15.4% (p=0.414) respectively. No changes in IFN-γ or IL-1β 
levels were seen in mice receiving CardioWise in contrast to the vehicle control. 
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Fig. 4.8. Wild type mice on a high fat diet and treated with CardioWise had a trend of reduced levels of several cytokines. CXCL1 (A), IFN-γ (B), IL-1β (C), IL-2 (D), IL-5 
(E), IL-6 (F), IL-10 (G) and TNF-α (H) levels within the plasma of wild type mice were measured after 21 days of a high fat diet and treatment with either a vehicle control or a 1x 
human equivalent physiological dose of CardioWise. The data are presented as the mean ± SEM from four (D), five (A and C) or six (B, E, F, G and H) control mice and either 
one (D), five (B) or six (A, C, E, F, G and H) CardioWise treated mice. Mice with undetectable assay readings were removed before statistical analysis. Statistical analysis was 
performed using a t-test (equal variance) either on untransformed data (A, C and G) or log-transformed data (B, E, F and H). 
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4.3.7 The expression of all genes present on the qPCR array following CardioWise 
treatment in wild type mice fed a high fat diet 
Fig. 4.9 shows the global significant and non-significant gene expression changes in the livers 
of wild type mice fed a high fat diet for 21 days following treatment with a human equivalent 
physiological dose of CardioWise compared to vehicle control treated mice. The housekeeping 
genes: β-actin; β-2-Microglobulin (B2M); GAPDH; β-Glucuronidase (GUSB); and Heat shock 
protein HSP 90-β (HSP90AB1); were found to be stable during the assay and were therefore 
used to calculate gene expression fold changes induced by CardioWise. A total of 49 genes 
were found to have their expression altered by at least 10% and 8 of those genes were found 
to be significantly altered. The genes have been classed by their function (according to the 
literature provided by Qiagen which accompanied the Atherosclerosis RT2 Profiler PCR Arrays) 
and will be explored in greater detail in the subsequent sections. 
 
Fig. 4.9. Volcano plot showing global gene expression changes in the liver of wild type mice treated with 
CardioWise vs vehicle control. Gene transcript levels of 84 genes were assessed in the livers of wild type mice 
after 21 days of a high fat diet and treatment with either a vehicle control or a 1x human equivalent physiological 
dose of CardioWise. The data are presented as the mean CardioWise induced fold change when compared to the 
vehicle control treated mice. Results are based on at least three control and three catechin treated mice. All genes 
present on the Qiagen RT2 profiler PCR Array were plotted. The log fold change in the treated cells versus the 
vehicle control cells is represented on the x-axis. The y-axis shows the -log10 of the p value. A p value of 0.05 
(dashed line) and a fold changes of ±10% (solid lines) are indicated. Significantly altered gene expressions are 
indicated by a black triangle and non-significant trends of change (approximately p<0.1) are indicated by a black 
square. 
4.3.8 CardioWise affects the expression of genes involved in the regulation of apoptosis 
in wild type mice fed a high fat diet 
Both BCL2 related protein A1 (BCL2A1A) and CASP8 and FADD-like apoptosis regulator 
(CFLAR) are two genes involved in the regulation of cell apoptosis. Following treatment with 
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CardioWise there was a trend of decrease in the expression of BCL2A1A in the liver of wild 
type mice of 53.1% when compared to the vehicle control treated mice (p=0.086; Fig. 4.10A). 
On the other hand, the expression of CFLAR was found to be significantly increased by 35.0% 
(p=0.009) within the livers of CardioWise treated mice (Fig. 4.10B). 
 
Fig. 4.10. CardioWise alters the expression of genes involved in apoptosis regulation. Gene transcript levels 
of BCL21A (A) and CFLAR (B) were assessed in the livers of wild type mice after 21 days of a high fat diet and 
treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. Gene transcript 
levels were calculated using the comparative Ct method and normalised to five housekeeping genes (β-actin, B2M, 
GAPDH, GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value of 1. The data 
are presented as the mean ± SEM from six control and six CardioWise treated mice. Mice with undetectable Ct 
readings were removed before statistical analysis. Statistical analysis was performed using a t-test (unequal 
variances) where ** p≤0.01. 
4.3.9 CardioWise attenuates the expression of cell adhesion molecules in wild type mice 
fed a high fat diet 
The recruitment and migration of immune cells can be influenced by a variety of genes 
including CD44, CXCL1, integrin subunit (ITG)A5, ITGB2 and selectin P ligand (SELPLG), 
therefore attenuating their expression may lead to reduced atherosclerosis plaque formation. 
The expression of CD44, ITGB2 and SELPLG showed trends of decrease following 
CardioWise treatment of 23.0% (p=0.051), 15.8% (p=0.108) and 25.8% (p=0.069) respectively 
when compared to the vehicle control treated cells (Fig. 4.11A, D and E). The expression of 
ITGA5 showed a trend of increase of 28.1% in the presence of CardioWise (p=0.108; Fig. 
4.11C). CardioWise treatment significantly attenuated the expression of CXCL1 in the liver of 
wild type mice fed a high fat diet for 21 days by 36.9% (p=0.049) in comparison to the vehicle 
control receiving mice (Fig. 4.11B). 
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Fig. 4.11. CardioWise decreases the expression of cell adhesion molecules in vivo. Gene transcript levels of 
CD44 (A), CXCL1 (B), ITGA5 (C), ITGB2 (D) and SELPLG (E) were assessed in the livers of wild type mice after 
21 days of a high fat diet and treatment with either a vehicle control or a 1x human equivalent physiological dose of 
CardioWise. Gene transcript levels were calculated using the comparative Ct method and normalised to five 
housekeeping genes (β-actin, B2M, GAPDH, GUSB and HSP90AB1) with values from the vehicle treated cells 
given an arbitrary value of 1. The data are presented as the mean ± SEM from six control mice and either five (B) 
or six (A, C, D and E) CardioWise treated mice. Mice with undetectable Ct readings were removed before statistical 
analysis. Statistical analysis was performed using a t-test (unequal variances) where * p≤0.05. 
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4.3.10 CardioWise reduces the expression of cell growth and proliferation regulators in 
wild type mice fed a high fat diet 
Colony stimulating factor (CSF)2, basic fibroblast growth factor (FGF2) and IL-3 are three pro-
inflammatory genes capable of influencing cell growth and proliferation, whereas leukaemia 
inhibitory factor (LIF) is an anti-inflammatory gene which plays a key role in the terminal 
differentiation of myeloid leukemic cells. CardioWise treatment resulted in a trend of decreased 
expression of CSF2, FGF2 and IL-3 in the livers of wild type mice by 23.3%, 34.4% (p=0.078) 
and 62.3% respectively (Fig. 4.12A, B and C). The expression of LIF was significantly 
attenuated by CardioWise treatment by 57.8% (p=0.027) compared to the vehicle control mice 
(Fig. 4.12D). 
 
Fig. 4.12. CardioWise decreases the expression of cell growth and proliferation regulators. Gene transcript 
levels of CSF2 (A), FGF2 (B), IL3 (C) and LIF (D) were assessed in the livers of wild type mice after 21 days of a 
high fat diet and treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. 
Gene transcript levels were calculated using the comparative Ct method and normalised to five housekeeping genes 
(β-actin, B2M, GAPDH, GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value 
of 1. The data are presented as the mean ± SEM from four (A and C) or six (B and D) control mice, and either two 
(A and C) or five (B and D) CardioWise treated mice. Mice with undetectable Ct readings were removed before 
statistical analysis. Statistical analysis was performed using a t-test (unequal variances) where * p≤0.05. 
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4.3.11 CardioWise treatment increases the expression of a lipid transport and 
metabolism gene in wild type mice fed a high fat diet 
The LYPLA1 gene controls the expression of acyl-protein thioesterase 1 (APT1), a lipase 
involved in lipid metabolism. The expression of LYPLA1 within the livers of wild type mice was 
significantly increased by 16.7% (p=0.011) following CardioWise treatment when compared to 
the vehicle control mice (Fig. 4.13). 
 
Fig. 4.13. CardioWise increases the expression of a gene involved in the regulation of lipid transport and 
metabolism. Gene transcript levels of LYPAL1 were assessed in the livers of wild type mice after 21 days of a high 
fat diet and treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. Gene 
transcript levels were calculated using the comparative Ct method and normalised to five housekeeping genes (β-
actin, B2M, GAPDH, GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value of 
1. The data are presented as the mean ± SEM from six control and six CardioWise treated mice. Mice with 
undetectable Ct readings were removed before statistical analysis. Statistical analysis was performed using a t-test 
(unequal variances) where * p≤0.05. 
4.3.12 CardioWise alters the expression of genes involved in stress responses in wild 
type mice fed a high fat diet 
IFN-γ, IL-1β and TNF-α are all major pro-inflammatory cytokines capable of influencing the 
progression of atherosclerosis disease progression and the development of atherosclerotic 
plaques. SOD1 is an enzyme capable of metabolising ROS, therefore increasing its expression 
may represent a level of protection against ROS formation. The expression of IFN-γ was 
significantly reduced following treatment with CardioWise by 58.4% (p=0.013) when compared 
to the vehicle control mice (Fig. 4.14A). A non-significant trend of decreased expression of IL-
1β and TNF-α (36.9% and 44.3%; p=0.060 and p=0.101 respectively) was also observed in 
the livers of mice which had received CardioWise (Fig. 4.14B and D). CardioWise treatment 
also resulted in a significant increase in the expression of SOD1 by 23.0% (p=0.003; Fig. 
4.14C). 
 Chapter 4: In Vivo study - CardioWise  
98 
 
 
Fig. 4.14. CardioWise exerts anti-inflammatory effects on the expression of genes involved in stress 
responses. Gene transcript levels of IFN-γ (A), IL-1β (B), SOD1 (C) and TNF-α (D) were assessed in the livers of 
wild type mice after 21 days of a high fat diet and treatment with either a vehicle control or a 1x human equivalent 
physiological dose of CardioWise. Gene transcript levels were calculated using the comparative Ct method and 
normalised to five housekeeping genes (β-actin, B2M, GAPDH, GUSB and HSP90AB1) with values from the vehicle 
treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from five (A) or six (B, C and 
D) control mice, and either four (A), five (D) or six (B and C) CardioWise treated mice. Mice with undetectable Ct 
readings were removed before statistical analysis. Statistical analysis was performed using a t-test (unequal 
variances) where * p≤0.05 and ** p≤0.01. 
4.3.13 CardioWise increases the expression of transcriptional regulators in wild type 
mice fed a high fat diet 
Nuclear receptor subfamily 1 group H member 3 (NR1H3) and PPAR-γ are two anti-
inflammatory regulators of transcription, therefore increasing their expression with CardioWise 
treatment would represent a strong anti-inflammatory effect. CardioWise treatment caused a 
significant increase in the expression of NR1H3 and PPAR-γ within the livers of wild type mice 
fed a high fat diet for 21 days by 15.7% and 95.4% respectively (p=0.034 and p=0.003) when 
compared to the vehicle control treated mice (Fig. 4.15). 
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Fig. 4.15. CardioWise increases the expression of genes involved in transcriptional regulation in wild type 
mice. Gene transcript levels of NR1H3 (A) and PPAR-γ (B) were assessed in the livers of wild type mice after 21 
days of a high fat diet and treatment with either a vehicle control or a 1x human equivalent physiological dose of 
CardioWise. Gene transcript levels were calculated using the comparative Ct method and normalised to five 
housekeeping genes (β-actin, B2M, GAPDH, GUSB and HSP90AB1) with values from the vehicle treated cells 
given an arbitrary value of 1. The data are presented as the mean ± SEM from six control and six CardioWise mice. 
Mice with undetectable Ct readings were removed before statistical analysis. Statistical analysis was performed 
using a t-test (unequal variances) where * p≤0.05 and ** p≤0.01. 
4.3.14 CardioWise treatment reduces the number of total bone marrow cells in wild type 
mice fed a high fat diet 
The number of white blood cells within the bone marrow can be an indication of the 
inflammatory status of an individual. Wild type mice treated with CardioWise were found to 
have the proportion of white blood cells within their bone marrow reduced by 8% (p=0.039) in 
contrast to the mice treated with the vehicle control (Fig. 4.16). 
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Fig. 4.16. CardioWise decreases the proportion of total bone marrow cells. Cell populations were assessed in 
the bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a vehicle control or a 1x 
human equivalent physiological dose of CardioWise. Representative flow plots of the total cell population in the 
bone marrow (A). Numbers on the flow plots indicate the proportion of the cell population as a percentage of total 
bone marrow cell count. The forward scatter (FSC-A) is a measurement of cell size by determining the amount of 
light which passes around it. The side scatter (SSC-A) is a measurement of the amount of light which is reflected 
by particles within the cells and therefore can be used to determine the granularity of cells. Cumulative bar graphs 
showing the frequency of total bone marrow cells as a percentage of total cell count (B). The data are presented as 
the mean ± SEM from six control and six CardioWise treated mice. Statistical analysis was performed using a t-test 
(equal variances) where * p≤0.05. 
4.3.15 The number of SLAM and progenitor cells within the bone marrow of wild type 
mice fed a high fat diet following CardioWise treatment 
The flow plots for the number of SLAM and progenitor cells present in the bone marrow of wild 
type mice fed either a vehicle control or CardioWise are displayed in Fig. 4.17 and the results 
are explored in greater detail in the subsequent sections. 
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Fig. 4.17. The effect of CardioWise on the proportion of SLAM and progenitor cells present in the bone marrow. Cell populations were assessed in the bone marrow of 
wild type mice after 21 days of a high fat diet and treatment with either a vehicle control (A) or a 1x human equivalent physiological dose of CardioWise (B). Representative flow 
plots of the SLAM and progenitor populations in the bone marrow are presented. Numbers on the flow plots indicate the proportion of the cell population as a percentage of total 
bone marrow cell count. Cumulative bar graphs showing the cell populations as a percentage of total bone marrow cell count are shown in Figs. 4.18 - 4.20. The arrows indicate 
how each haematopoietic stem/progenitor cell population can be identified within the preceding gating strategy. The axis represent the various stains used to separate the cell 
populations (see Table 2.8 for further details). The forward scatter (FSC-A) is a measurement of cell size by determining the amount of light which passes around it. The side 
scatter (SSC-A) is a measurement of the amount of light which is reflected by particles within the cells and therefore can be used to determine the granularity of cells. HSC, 
haematopoietic stem cell; MPP, multipotent progenitors; HPC, hematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, 
granulocyte-macrophage progenitor; MDSC, myeloid-derived suppressor cells; CLP, common lymphoid progenitor; LIN, lineage.
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4.3.16 CardioWise treatment attenuates the number of HPC cells within the bone marrow 
of wild type mice fed a high fat diet 
All mature haematopoietic cells such as macrophages, T-cells and B-cells express lineage 
markers and are considered to be lineage-positive (Lin+). All of the remaining haematopoietic 
cells are lineage-negative (Lin-), this population contains all of the stem and progenitor cells. 
Examining the Lin- population further can reveal the effects on the multipotent blood cells within 
the bone marrow as these are found exclusively within the LSK population. The proportion of 
Lin- and LSK cells within the bone marrow of wild type mice treated with CardioWise was found 
to be unaffected when compared to the vehicle control treated mice (Fig. 4.18A and B). HSC, 
multipotent progenitor cells (MPP) and haematopoietic progenitor cells II (HPC II) give rise to 
all myeloid and lymphocyte cells within the bone marrow. The HPC II population in mice treated 
with CardioWise was reduced by 38% (p=0.222) when compared to the vehicle control mice, 
however this change was found not to be significant (Fig. 4.18C). CardioWise treatment had 
no effect on the proportion of MPP and HSC populations found within the bone marrow (Fig. 
4.18D and E). 
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Fig. 4.18. CardioWise decreases the proportion of HPC cells present in the bone marrow. Cell populations 
were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a 
vehicle control or a 1x human equivalent physiological dose of CardioWise. Cumulative bar graphs showing the 
frequency of live lineage negative (A), LSK (B), HPC II (C), MPP (D) and HSC (E) populations in the bone marrow 
as a percentage of total bone marrow cell count. Where appropriate, the data has been multiplied by powers of 10 
for ease of presenting the result clearly. The data are presented as the mean ± SEM from six control mice and 
either six (A and B) or seven (C, D and E) CardioWise treated mice. Statistical analysis was performed using either 
a t-test (equal variances; A, B, D and E) or a t-test (unequal variances; C) on either untransformed (A, B, D and E) 
or log-transformed (C) data. 
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4.3.17 CardioWise treatment does not alter the number of LK, GMP, MEP or CMP cells 
within the bone marrow of wild type mice fed a high fat diet 
The Lin- cKIT+ (LK) cell population within the bone marrow gives rise to all of the myeloid cells. 
Wild type mice treated with CardioWise had no change in the proportion of LK cells within their 
bone marrow in contrast to the mice treated with the vehicle control (Fig. 4.19A). The common 
myeloid progenitor (CMP) cells gives rise to both the granulocyte-macrophage progenitor 
(GMP) and megakaryocyte-erythroid progenitor (MEP) populations. Mature cells including 
monocytes and granulocytes are formed from GMP cells, whereas megakaryocytes and red 
blood cells are derived from the MEP population. The proportion of CMP, GMP and MEP cells 
within the bone marrow of wild type mice treated with CardioWise was found to be unaffected 
when compared to the vehicle control treated mice (Fig. 4.19B - D). 
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Fig. 4.19. CardioWise does not alter the proportion of LK, GMP, MEP or CMP cells present in the bone 
marrow. Cell populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and 
treatment with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. Cumulative bar 
graphs showing the frequency of LK (A), CMP (B), MEP (C) and GMP (D) cell populations in the bone marrow as 
a percentage of total bone marrow cell count. Where appropriate, the data has been multiplied by powers of 10 for 
ease of presenting the result clearly. The data are presented as the mean ± SEM from six control and seven 
CardioWise treated mice. Statistical analysis was performed using either a t-test (equal variances; B and D) or a t-
test (unequal variances; A and C) on either untransformed (A), log-transformed (B and D) or squared-transformed 
(C) data. 
4.3.18 CardioWise treatment reduces the number of CLP cells within the bone marrow 
of wild type mice fed a high fat diet 
The common lymphoid progenitor (CLP) cell population gives rise to B and T-cells. A non-
significant decrease in the CLP cell population of 17% (p=0.241) was observed in mice treated 
with CardioWise when compared to the vehicle control mice (Fig. 4.20). 
 Chapter 4: In Vivo study - CardioWise  
106 
 
 
Fig. 4.20. CardioWise non-significantly reduces the proportion of CLP cells present in the bone marrow. 
Cell populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment 
with either a vehicle control or a 1x human equivalent physiological dose of CardioWise. Cumulative bar graphs 
showing the frequency of the CLP populations in the bone marrow as a percentage of total bone marrow cell count. 
The data has been multiplied by 1000 for ease of presenting the result clearly. The data are presented as the mean 
± SEM from six control and seven CardioWise treated mice. Statistical analysis was performed using a t-test (equal 
variances). 
4.3.19 CardioWise treatment reduces the number of macrophages and MDSCs within 
the bone marrow of wild type mice fed a high fat diet 
Monocyte and macrophage cell populations are MAC1+ and GR1- and can be distinguished 
from the MDSC population which are MAC1+ and GR1+. Wild type mice treated with 
CardioWise showed a significant decrease in the proportion of monocytes and macrophages 
within their bone marrow by 37% (p=0.011) in contrast to the mice treated with the vehicle 
control (Fig. 4.21B). Additionally, CardioWise treatment significantly reduced the proportion of 
MDSCs by 24% (p=0.009) when compared to the vehicle control treated mice (Fig. 4.21C). 
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Fig. 4.21. CardioWise reduces the proportion of macrophages and MDSCs present in the bone marrow. Cell 
populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with 
either a vehicle control or a 1x human equivalent physiological dose of CardioWise. Representative flow plots of 
the macrophage (MAC1+) and MDSCs (GR1+MAC1+) populations in the bone marrow (A). Numbers on the flow 
plots indicate the proportion of the cell population as a percentage of total bone marrow cell count. Cumulative bar 
graphs showing the frequency of monocytes and macrophages (B) and MDSCs (C) in the bone marrow as a 
percentage of total bone marrow cell count. Where appropriate, the data has been multiplied by powers of 10 for 
ease of presenting the result clearly. The data are presented as the mean ± SEM from six control and seven 
CardioWise treated mice. Statistical analysis was performed using either a t-test (equal variances) where * p≤0.05 
and ** p≤0.01. 
4.3.20 CardioWise treatment reduces the number of B- and T-cells within the bone 
marrow of wild type mice fed a high fat diet 
The levels of B- and T-cells can be used as an indirect marker of an individual’s inflammatory 
status. Wild type mice treated with CardioWise showed a significant decrease in the proportion 
of T-cells within their bone marrow by 23% (p=0.033) in contrast to the mice treated with the 
vehicle control (Fig. 4.22B). In addition, CardioWise treatment showed a non-significant trend 
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of reduction in the proportion of B-cells by 25% (p=0.082) when compared to the vehicle control 
treated mice (Fig. 4.22C).  
 
Fig. 4.22. CardioWise reduces the proportion of T and B-cells present in the bone marrow. Cell populations 
were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a 
vehicle control or a 1x human equivalent physiological dose of CardioWise. Representative flow plots of the T and 
B-cell populations in the bone marrow (A). Numbers on the flow plots indicate the proportion of the cell population 
as a percentage of total bone marrow cell count. Cumulative bar graphs showing the frequency of T-cells (B) and 
B-cells (C) in the bone marrow as a percentage of total bone marrow cell count. Where appropriate, the data has 
been multiplied by powers of 10 for ease of presenting the result clearly. The data are presented as the mean ± 
SEM from six control and seven CardioWise treated mice. Statistical analysis was performed using a t-test (equal 
variances) where * p≤0.05. 
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4.4 Discussion 
4.4.1 The effect of CardioWise on physical parameters in wild type mice 
The results of this in vivo study show the great potential CardioWise has as a novel 
nutraceutical combinational therapy for retarding the development of atherosclerosis and 
reducing an individual’s risk of suffering a CVD-related event. In wild type mice fed a high fat 
diet for 21 days, CardioWise was found to increase both HDL cholesterol levels and improve 
the LDL/HDL ratio, while simultaneously attenuating pro-inflammatory gene expression in the 
liver and reducing pro-inflammatory cytokine levels in the blood. Furthermore CardioWise may 
exert anti-atherogenic effects on the cell populations within the bone marrow. Despite 
observing some pro-atherogenic actions of CardioWise, such as increased lipid peroxidation, 
overall it appears to exert strong anti-inflammatory effects and this study provides further 
evidence for the cardiovascular protective effects of CardioWise that were seen during the in 
vitro studies (Chapter 3). 
The effect of CardioWise on weight change was assessed as sudden changes in weight may 
imply CardioWise was exerting a detrimental effect in the mice. After 21 days of a high fat diet, 
both the vehicle control and CardioWise treated mice put on weight at the same rate, indicating 
that no detrimental effects occurred as a result of CardioWise (Fig. 4.3). However as this was 
a short term feeding study, beneficial changes in weight gain may occur gradually over time 
and should therefore continue to be explored in future long term feeding studies. Indeed a 
recent study failed to show any difference in the weight of wild type mice treated with EPA or 
DHA after 3 weeks but a decrease in body weight was observed following 10 weeks of fish oil 
supplementation (Kim et al. 2016). Another study involving wild type mice fed a high fat diet 
did not observe any changes in body weight of mice following 4 weeks of fish oil 
supplementation, however after 12 weeks the mice had gained less weight when compared to 
the vehicle control treated mice (de Sá et al. 2016). The weight gained in mice on a high fat 
diet was also unaffected by green tea extracts during short term feeding studies (Murase et al. 
2002; Sugiura et al. 2012). However a high fat diet supplemented with either 0.2% or 0.5% 
catechins resulted in reduced weight gain in mice after 42 weeks (Murase et al. 2002). 
Furthermore mice fed a high fat diet supplemented with 2% phytosterols for 32 weeks gained 
the same amount of weight as mice receiving the high fat diet only (Calpe-Berdiel et al. 2008). 
The results from this study for CardioWise shows that the combined product of ω-3 PUFAs, 
flavanols and phytosterols acts similarly to other short term studies which have investigated 
the effect of the individual components. 
The accumulation of adipose tissue in obesity is a clinical risk factor of developing CVD and 
suffering a CVD-related event. Two risk factors of atherosclerosis, systemic inflammation and 
hyperlipidaemia, have been associated with obesity (Hotamisligil 2006; Nordestgaard 2016). 
However how a build-up of fat is directly linked to atherosclerosis remains poorly understood 
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(van Dam et al. 2017). The fat deposits around the body all contribute to the hydrolysis of TG-
rich lipoproteins via LPL into FFAs and glycerol (Cinti 2009; van Dam et al. 2017). How the 
different fat deposits subsequently process the remaining lipids differs and each have unique 
functions, as a result they can be classified as white, brown and PVAT (Cinti 2009; van Dam 
et al. 2017). White fat is the most common fat type throughout the body and predominately 
maintains energy regulation by storing excess dietary fatty acids as TGs, and subsequently 
breaking them down by lipolysis in order to release FFAs for the energy needs of organs (van 
Dam et al. 2017). The regulation of lipid and glucose homeostasis has shown to be influenced 
by white fat (Kershaw and Flier 2004). During obesity, as white fat deposits continue to 
increase, they become dysfunctional due to reduced TG removal from the adipose cells and 
increased TG storage (Arner et al. 2011). If the turnover of lipids starts to decrease, it can 
result in lipids being shunted to the liver and increase plasma TG levels (Arner et al. 2011). 
Furthermore there was an indication that CardioWise treatment results in lower lipid turnover 
as an increase in circulating TG levels were also observed (Fig. 4.6). Previous studies have 
found that both ω-3 PUFAs and catechin supplementation resulted in reduced white fat 
accumulation in vivo (de Sá et al. 2016; Janovská et al. 2013; Tokimitsu 2004; Nagao et al. 
2007). However other studies have found both catechin and phytosterols had no effect on the 
size of the white fat deposits (Sugiura et al. 2012; Calpe-Berdiel et al. 2008).  
Brown adipose tissue breaks down fatty acids to generate heat in a process known as non-
shivering thermogenesis in order to maintain body temperature (van Dam et al. 2017). The 
lipolysis of TGs generates the fatty acids for brown fat to utilise (Cannon and Nedergaard 
2004). Once the lipid stores have been used, brown fat begins to take up glucose and TG-
derived fatty acids from the plasma (van Dam et al. 2017). This makes brown fat an appealing 
anti-atherogenic therapeutic target because its activation results in a reduction in circulating 
TG levels (Boon et al. 2014; Sun et al. 2014; van Dam et al. 2015; Berbée et al. 2015). However 
recently it has been shown that short term activation of brown fat is capable of increasing 
serum TG levels (Hoeke et al. 2017). In this study, CardioWise treatment in wild type mice fed 
a high fat diet for 21 days resulted in a smaller weight of brown fat (Fig. 4.4E). However perhaps 
this reduction in brown fat weight is due to its activation causing a depletion of its stored lipids 
and resulting in a smaller brown fat deposit. Indeed previous studies have shown ω-3 PUFAs 
and other GPR120 agonists (the receptor ω-3 PUFAs are thought to exert their cardiovascular 
protective effects) are capable of activating brown fat (Pahlavani et al. 2017; Quesada-López 
et al. 2016). An increase in the expression of NR1H3 and PPAR-γ are also associated with 
brown fat activation, both of which were found at increased levels in the liver following 
CardioWise treatment in this study (Fig. 4.15; Steffensen et al. 2003; Nedergaard et al. 2005; 
Laurencikiene and Rydén 2012). As previously mentioned brown fat activation is associated 
with reduced plasma TG levels. However when brown fat replenishes its lipid stores, it does 
so by taking up circulating fatty acids following lipolysis of TGs in the blood stream (Khedoe et 
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al. 2015). This means the circulating levels of glycerol would potentially increase. Every sample 
had its glycerol background level tested which were found to be increased by 22% following 
CardioWise treatment (data not shown). Furthermore the increase in TG levels observed in 
this study may be due to the short term activation of brown fat (Hoeke et al. 2017). Additionally 
brown fat activation has been shown to result in increased HDL cholesterol levels (Chen et al. 
2017b; Hoeke et al. 2017), which has also been seen in this study (Fig. 4.5). These results 
provide some evidence for the activation of brown fat following CardioWise treatment in wild 
type mice, highlighting a possible mechanism by which CardioWise exerts its cardiovascular 
protective effects. The effect of CardioWise treatment on brown fat activation requires further 
studies in vivo as well as determining the expression of brown fat related genes within the fat 
pads. 
PVAT is a unique fat deposit within the body due to its specific location surrounding systemic 
blood vessels and its ability to provide mechanical support and regulate tension within the 
blood vessels (van Dam et al. 2017). It is thought to achieve these effects by releasing 
hormones which have a paracrine effect on the vascular system (Löhn et al. 2002). However 
the phenotype of PVAT can differ depending on its location, with thoracic PVAT considered to 
be similar to brown fat whereas abdominal PVAT is thought to be like white fat (Fitzgibbons et 
al. 2011; Padilla et al. 2013). During this study, only the thoracic PVAT was harvested and 
therefore the discussion will focus on what role that PVAT within the thorax plays during 
atherosclerosis disease progression. Following 21 days of a high fat diet and CardioWise 
treatment, wild type mice were found to have increased thoracic PVAT (Fig. 4.4F). Evidence 
is emerging which suggests PVAT can influence atherosclerosis due its paracrine properties 
and its location surrounding the adventitia of blood vessels (van Dam et al. 2017). During 
obesity PVAT deposits grow in size and become dysfunctional, characterised by the 
recruitment of immune cells and the release of pro-inflammatory chemokines and cytokines 
(Greenstein et al. 2009; Police et al. 2009). Interestingly CardioWise treatment was found to 
reduce the levels of circulatory pro-inflammatory cytokines (Fig. 4.8). An increase in PVAT 
inflammation has been shown to be triggered by a high fat diet and due to its location 
surrounding blood vessels, it is also thought to have the ability to initiate an inflammatory 
response within the wall of arteries (Chatterjee et al. 2009; Lee et al. 2014; Wang et al. 2009; 
Zou et al. 2016). In a similar way to brown fat, PVAT is thought to be able to contribute to fatty 
acid clearance via thermogenesis (van Dam et al. 2017). Previous studies have shown that 
reduced thermogenesis caused by PPAR-γ deficiency can lead to a loss of PVAT and 
increased atherosclerosis (Chang et al. 2012). In this study, CardioWise was found to increase 
the expression of PPAR-γ in the liver of wild type mice (Fig. 4.15B). This increase in PPAR-γ 
expression may explain the increase in the size of the thoracic PVAT deposit if it is required 
for its proper function. These results indicate that CardioWise is able to maintain and enhance 
thoracic PVAT despite exposure to a high fat diet as shown by increased thoracic PVAT weight, 
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increased PPAR-γ expression and a reduction in circulatory pro-inflammatory cytokine levels. 
Overall it appears CardioWise exerts anti-inflammatory effects on fat deposits around the body 
by potentially increase in brown and thoracic PVAT activation, however this hypothesis needs 
to be investigated further in future in vivo studies.  
4.4.2 The effect of CardioWise on blood parameters in wild type mice 
The levels of cholesterol and TG within the blood can be used as clinical markers of CVD risk. 
HDL cholesterol is involved in the RCT process and aids in cholesterol excretion by 
transporting excess cholesterol to the liver (McLaren et al. 2011a). For this reason, increased 
levels of HDL are considered to be anti-atherogenic. This study showed CardioWise is capable 
of increasing circulating HDL levels in wild type mice fed a high fat diet for 21 days (Fig. 4.5B). 
This result implies CardioWise is capable of providing anti-atherogenic effects and protecting 
against exposure to a high fat diet. Previous studies involving ApoE deficient mice have also 
shown that EPA dietary supplementation for 28 days is capable of increasing serum HDL levels 
(Nakajima et al. 2011). Furthermore an increase in HDL levels has also been observed in rats 
and mice treated with green tea extract or phytosterols (Chisaka et al. 1988; Babu et al. 2006; 
Moghadasian et al. 1999). The increase in HDL levels following CardioWise treatment 
therefore correlates with the results of the individual nutraceutical components and the unique 
combination did not inhibit their cardiovascular protective effects. High circulating levels of LDL 
have been associated with atherosclerosis disease development, therefore low serum levels 
of LDL are considered less pro-atherogenic (McLaren et al. 2011a). Following treatment with 
a human equivalent physiological dose of CardioWise, there were no observable changes in 
LDL cholesterol levels (Fig. 4.5C). This results contradicts previous studies which have found 
that ω-3 PUFAs, catechins and phytosterols are capable of reducing serum LDL levels (Kamat 
and Roy 2016; Matsuyama et al. 2008; Moghadasian et al. 1999). Despite the lack of reduction 
in circulating LDL levels, CardioWise was able to reduce the LDL/HDL cholesterol ratio in wild 
type mice. This means CardioWise was able to reduce the amount of pro-atherogenic LDL 
cholesterol in relation to the increase in anti-atherogenic HDL cholesterol. Indeed there is 
growing evidence that LDL or HDL cholesterol levels in isolation are not always associated 
with cardiovascular health and the LDL/HDL ratio is a better clinical risk marker of 
atherosclerosis and sudden cardiac death (Millán et al. 2009; Kunutsor et al. 2017). The 
evidence from this study suggest that CardioWise is able to alter the lipid profile of mice to a 
potentially anti-atherogenic one. 
Although not presently thought to play a direct role in atherosclerosis disease development, 
TGs are a useful biomarker of TG-rich lipoproteins such as VLDL and chylomicron remnants 
which are able to enhance atherosclerosis independently of LDL (Talayero and Sacks 2011). 
CardioWise treatment caused an increase in serum TG levels in wild type mice fed a high fat 
diet (Fig. 4.6A). However this result is surprising as previous studies have shown ω-3 PUFAs 
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and phytosterols to be capable of reducing circulating TG levels (Kamat and Roy 2016; 
Schonewille et al. 2014; Perez-Ternero et al. 2017). The use of flavanols has failed to 
significantly alter TG levels in both mice and humans (Matsuyama et al. 2008; Friedrich et al. 
2012). This suggests the novel combination of CardioWise may be having interacting effects 
which cause an increase in TG levels which is not seen when the individual components are 
tested alone. However as previously discussed above, the short term activation of brown fat 
has been shown to directly increase plasma TG levels (Hoeke et al. 2017). The use of 
circulating TG levels as risk indictor for atherosclerosis and CVD has remained controversial 
since it was first proposed in 1980 (Hulley et al. 1980; Miller et al. 2011). This is because an 
increase in plasma TG levels is also correlated with a reduction in HDL levels and therefore it 
is hard to separate the two to determine the best indicator of CVD risk (Miller et al. 2011; Dron 
and Hegele 2017). Some meta-analysis studies have found that circulating TG levels is 
associated with CVD risk after controlling for changes in HDL levels (Harchaoui et al. 2009). 
However whether alterations in TG levels can be used as an independent risk marker of CVD 
or whether it is just a consequence of altered HDL levels remains debated. To overcome the 
controversy around TG levels as a CVD risk marker, the use of the TG/HDL cholesterol ratio 
has been found to be a better indicator of atherosclerosis disease progression (da Luz et al. 
2008). Although not significant, CardioWise treatment resulted in a strong trend of increased 
TG/HDL cholesterol ratio in wild type mice following a high fat diet for 21 days. Despite this 
result, as the rise in TG levels is not associated with a reduction in HDL or an increase in LDL 
levels, CardioWise appears to provide cardiovascular protective effects by increasing 
circulating levels of HDL after exposure to a high fat diet.  
Our in vitro studies showed that CardioWise treatment had the potential to increase ROS 
production (Fig. 3.14), therefore it was essential to assess the effect of CardioWise treatment 
on ROS generation in wild type mice following a high fat diet for 21 days. No significant 
changes in ROS production were observed after CardioWise treatment when compared to the 
vehicle control treated mice (Fig. 4.7A). Several recent in vivo studies have demonstrated that 
ω-3 PUFAs, flavanol and phytosterol dietary supplementation is capable of attenuating 
oxidative stress (Han et al. 2015; Ali et al. 2015; Tak et al. 2016; Firat et al. 2017; Nakamura 
et al. 2017; Wiest et al. 2017; Yu et al. 2017; Oyama et al. 2017). The increased gene 
expression of SOD1, an enzyme responsible for neutralising ROS within the body, which also 
occurred following CardioWise treatment (Fig. 4.14C) may explain why ROS species 
generation was not significantly increased in vivo. Despite no changes in ROS generation, 
CardioWise treatment did significantly increase lipid peroxidation, a consequence of increased 
ROS levels, as measured by plasma MDA levels (Fig. 4.7B). This result contradicts other 
studies in the literature which have shown that the individual nutraceuticals are capable of 
attenuating lipid peroxidation, indicating a possible interaction occurring within the novel 
mixture of CardioWise and contributing to an increase in lipid peroxidation (Kesavulu et al. 
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2002; Tak et al. 2016; Ali et al. 2015). Due to the high number of mitochondria present within 
brown fat, its activation has been associated with increased SOD1 expression and lipid 
peroxidation (Barja de Quiroga et al. 1991; Pan et al. 2005; Jastroch et al. 2010). Therefore 
the increased expression of SOD1 and increased levels of lipid peroxidation may be further 
evidence of brown fat activation in wild type mice following CardioWise treatment while 
receiving a high fat diet. 
Another blood parameter measured during the study was the level of pro- and anti-
inflammatory cytokines. After 21 days of CardioWise treatment in wild type mice fed a high fat 
diet, the levels of pro-inflammatory cytokines CXCL1, IL-2 and TNF-α all showed a trend of 
decrease (Fig. 4.8). CXCL1 plays a major role in monocyte and macrophage migration, 
therefore reductions in the circulating levels of this cytokine indicate that CardioWise would 
attenuate cell recruitment in vivo which would coincide with the in vitro result (Fig. 3.10). 
CardioWise treatment appears to attenuate the levels of IL-2 within the plasma of mice. 
However this result is based on a reduced number of mice due to undetectable assay readings 
and therefore requires further investigations before any firm conclusions can be drawn. As 
previously discussed, TNF-α is a major pro-inflammatory cytokine involved in the progression 
of atherosclerosis (Ramji and Davies 2015; Moss and Ramji 2016a). The circulating levels of 
TNF-α were reduced by a human equivalent physiological dose of CardioWise treatment in 
wild type mice. Dietary supplementation with ω-3 PUFAs, catechin and phytosterols have been 
previously shown to reduce the circulating levels of CXCL1 and TNF-α in mice 
(Guruvayoorappan and Kuttan 2008; Nordgren et al. 2014; Vaidya et al. 2017). IL-2 secretion 
was found to be reduced following ω-3 PUFA treatment whereas (+)-catechin supplementation 
has been shown to be able to induce its production (Guruvayoorappan and Kuttan 2008; Bilal 
et al. 2011). The results presented here, and from previous studies, indicate that CardioWise 
has the potential to exert strong anti-inflammatory effects. However despite CardioWise 
treatment resulting in the reduction in the circulating levels of pro-inflammatory cytokines, it 
also produced a reduction in the levels of anti-inflammatory cytokines, in particular IL-5 and IL-
10. Increased levels of IL-5 and IL-10 have been associated with reduced atherosclerosis 
disease progression (Ramji and Davies 2015). Previous studies have shown ω-3 PUFA 
treatment to reduce the levels of IL-5 and IL-10 in mice, whereas catechin treatment in mice 
receiving a high fat diet failed to alter IL-10 protein levels (Bilal et al. 2011; Cunha et al. 2013; 
Li et al. 2014a). The effects of phytosterol supplementation in mice appears to be more 
complex with IL-5 levels being attenuated following treatment while IL-10 levels were 
unaffected (Yuk et al. 2007; Vaidya et al. 2017). In this study the levels of both IL-5 and IL-10 
were non-significantly reduced following CardioWise treatment for 21 days (Fig. 4.8). The 
cytokine IL-6 has been shown to exert both pro- and anti-inflammatory effects (Ramji and 
Davies 2015). The levels of IL-6 in the plasma of wild type mice fed a high fat diet for 21 days 
were non-significantly decreased following CardioWise treatment (Fig. 4.8). This result 
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correlates with previous data within the literature which also found that ω-3 PUFAs, catechin 
and phytosterols are all capable of reducing IL-6 levels (Guruvayoorappan and Kuttan 2008; 
Nordgren et al. 2014; Vaidya et al. 2017). The results of CardioWise treatment imply a general 
dampening of immune activation and systemic inhibition of cytokine production rather than a 
specific reduction in pro-atherogenic cytokine levels. However this needs to be assessed in 
greater detail in atherosclerotic mouse models as changes in the systemic cytokine profile may 
not reflect the changes occurring at a local arterial level. 
The changes in circulating cytokine levels following CardioWise treatment also indicate that it 
may potentially promote brown fat activation. Adipose tissue is recognised as a powerful 
endocrine organ due to its ability to secrete a variety of chemokines and cytokines including 
TNF-α and IL-6 (Kershaw and Flier 2004; Coelho et al. 2013). During obesity, the adipose 
tissue becomes dysfunctional and results in the altered secretion of cytokines. Circulating 
levels of CXCL1, IL-5, IL-10 and IL-6 have all been shown to be increased in obese individuals 
(Nunemaker et al. 2014; Schmidt et al. 2015; Manna and Jain 2015). Treatment with 
CardioWise in wild type mice reduced the plasma levels of these cytokines, indicating 
CardioWise is capable of protecting against high fat diet induced obesity and restore normal 
adipose tissue function. Furthermore TNF-α is thought to play a role in the deterioration and 
dysfunction of brown fat (Nisoli et al. 2000; Markelic et al. 2011). CardioWise may protect 
brown fat and re-establish its physiological function during a high fat diet by attenuating the 
circulating levels of TNF-α. However IL-2 levels are attenuated during obesity and was also 
observed following CardioWise dietary supplementation (Vargas et al. 2016). Overall these 
results indicate that CardioWise restores the normal function of adipose tissue during a high 
fat diet. 
4.4.3 The effect of CardioWise on gene expression in the liver of wild type mice 
To determine whether the changes caused by CardioWise treatment discussed so far were 
due to changes in gene expression, a qPCR array containing 84 atherosclerosis related genes 
was used to assess gene expression changes within the liver. A total of 49 genes were found 
to have their expression altered by at least 10% (Fig. 4.9). Of those 49 genes, 8 were found to 
be significantly altered and those genes were; CFLAR, CXCL1, IFN-γ, LIF, LYPLA1, NR1H3, 
PPAR-γ and SOD1. CFLAR is considered a master regulator in preventing cell apoptosis by 
switching cell signalling from pro-apoptotic to anti-apoptotic by blocking caspase 8 activation 
and stimulating NFκB and extracellular signal-regulated kinase (ERK) signalling (Kavurma et 
al. 2008; Safa 2012; Wang et al. 2017a). The expression of CFLAR has been shown to be 
elevated in healthy hearts and reduced in individual’s with heart failure (Micheau 2003). 
Furthermore the presence of oxLDL has been shown to attenuate CFLAR expression in 
vascular endothelial cells leading to apoptosis and tissue destruction (Micheau 2003). The 
upregulation of CFLAR may therefore protect the blood vessels from oxLDL exposure and 
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retard the progression of atherosclerosis. The expression of CFLAR was found to be 
significantly upregulated following CardioWise treatment in wild type mice fed a high fat diet 
for 21 days (Fig. 4.10B). This result would indicate that CardioWise is capable of preventing 
vascular endothelial damage which may occur during exposure to oxLDL and reduce 
atherosclerosis disease development. Previous research has shown that ω-3 PUFAs are 
capable of promoting CFLAR expression, however the effects of catechin and phytosterols still 
remains unknown (Suzuki et al. 2003). The role of BCL2A1A during apoptosis and 
atherosclerosis is still unclear, however FGF2 is thought to signal through it, and BCL2A1A 
appears to play a role in B-cell maintenance (Kim et al. 2012; Ottina et al. 2012). The levels of 
BCL2A1A, FGF2 and B-cell population were all reduced following CardioWise treatment for 21 
days (Figs. 4.10A, 4.12B and 4.22C respectively). 
The expression of the chemokine CXCL1 was significantly attenuated following CardioWise 
treatment (Fig. 4.11B), which correlates with the reduced plasma CXCL1 levels previously 
seen (Fig. 4.8A). CXCL1 plays an important role in the recruitment of monocytes to the site of 
oxLDL accumulation by allowing them to attach to the activated endothelium before migrating 
into the wall of the artery (Wan and Murphy 2013; van der Vorst et al. 2015). Reductions in the 
expression of this chemokine may explain the decrease in monocyte migration observed in 
vitro (Fig. 3.9). The expression of CXCL1 is ubiquitous within human and mouse 
atherosclerotic lesions and its circulating levels have been found to be increased in patients 
with coronary artery disease (CAD; Breland et al. 2008; Wan and Murphy 2013). Furthermore 
LDLr deficient mice also lacking CXCL1 develop smaller atherosclerotic plaques, highlighting 
the major pro-inflammatory role that CXCL1 plays during atherosclerosis development 
(Boisvert et al. 2006). The gene expression levels of CD44, ITGB2 and SELPLG, which all play 
a role in cell recruitment during atherosclerosis, were also found to be reduced by CardioWise 
(Fig. 4.11; Merched et al. 2010; McEver 2015; Saha et al. 2017). These results provide 
evidence that CardioWise would be able to reduce the size of atherosclerotic lesions by 
decreasing cell recruitment to the site of oxLDL accumulation, however this needs to be studied 
in future longer term feeding studies and mouse atherosclerosis models. 
The expression levels of the cell proliferation gene LIF was also reduced by CardioWise 
treatment (Fig. 4.12D). This result is not surprising as flavanol treatment has previously been 
shown to attenuate LIF gene expression (Akhtar and Haqqi 2011). LIF is considered as an 
anti-atherogenic cytokine due to its ability to attenuate endothelial cell proliferation and induce 
vasorelaxation within arteries by increasing NO production (Demyanets et al. 2012). The 
amount of intimal thickening which occurs following blood vessel injury due to increased level 
of VSMC proliferation can be inhibited by LIF (Demyanets et al. 2012). Therefore the 
decreased expression of LIF within the liver of wild type mice due to CardioWise treatment 
would indicate that CardioWise exerts potential pro-atherogenic effects (Fig. 4.12D). However 
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reductions in the expression of other pro-atherogenic genes involved in cell proliferation 
including CSF2, FGF2 and IL-3 were observed in the CardioWise treated mice compared to 
the vehicle control treated mice (Fig. 4.12; Liu et al. 2013; Subramanian et al. 2015; Ramji and 
Davies 2015). CardioWise appears to be a strong anti-proliferative nutraceutical, however the 
effect of CardioWise on cell proliferation in vivo still needs to be determined in future studies. 
The results of reduced cell recruitment and proliferation related genes in the CardioWise 
treated mice in comparison to the vehicle control treated mice (Figs. 4.11 and 4.12) indicates 
that dietary supplementation with CardioWise would potentially reduce lesion size by 
attenuating cellular build-up within the atherosclerotic plaque. Previous studies have shown 
that ω-3 PUFAs, flavanol and phytosterol treatment is capable of decreasing lesion size within 
mice (Moghadasian et al. 1999; Yeganeh et al. 2005; Moghadasian 2006; Chyu 2004; 
Nakajima et al. 2011; Brown et al. 2012; Minatti et al. 2012; Morrison et al. 2014). The results 
presented in this study may provide a mechanism of action by which ω-3 PUFAs, catechin and 
phytosterols achieve a reduction in atherosclerotic lesion size formation in the studies 
mentioned above. Atherosclerotic plaques with reduced cellular content are considered to be 
more stable and less likely to rupture when compared to those with a high number of cells, in 
particular macrophages, within the lesion (Wilson 2010; Seneviratne et al. 2013). Furthermore 
CardioWise treatment was also found to increase the expression of the cell apoptosis inhibitor 
gene CFLAR (Fig. 4.10B). Preventing apoptosis in the macrophages present in the plaque 
would reduce the amount of lipid content and ECM modulating enzymes they release and 
therefore also contribute to improved plaque stability. These results infer that CardioWise has 
the potential to reduce atherosclerotic lesion formation and reduce the speed of disease 
development, however this needs to be assessed in greater detail in long term feeding studies 
involving atherosclerotic mouse models. 
The enzyme APT1 is encoded by the gene LYPLA1 which was found to have its expression 
enhanced by CardioWise in the livers of wild type mice fed a high fat diet (Fig. 4.13). The 
function of APT1 during atherosclerosis disease development remains unclear but it is thought 
to be involved in lipid metabolism due to its ability to remove fatty acid groups from cell surface 
proteins (Vujic et al. 2016). The removal of a fatty acid group from the proteins causes them 
to return to the Golgi apparatus in a process known as depalmitoylation (Vujic et al. 2016). As 
CardioWise results in an increase in the expression of APT1, it therefore has the potential to 
reduce the number of proteins expressed on the surface of cells due to amplified cell surface 
protein removal. This means CardioWise is capable of influencing intracellular signalling.  
The expression of several genes involved in stress responses was attenuated by CardioWise 
treatment in vivo (Fig. 4.14). As previously discussed, IFN-γ is a major pro-inflammatory 
cytokine and considered to be the main regulator of atherosclerosis disease development 
(Moss and Ramji 2015; Moss and Ramji 2016a; Ramji and Davies 2015; McLaren and Ramji 
 Chapter 4: In Vivo study - CardioWise  
118 
 
2009). CardioWise treatment significantly reduced IFN-γ expression indicating that it was 
capable of exerting strong anti-inflammatory effects. A reduction in IFN-γ expression has also 
been seen in previous studies which assessed the effect of the nutraceuticals within the 
CardioWise formulation in isolation (Nakajima et al. 2011; Leong et al. 2009; Valerio et al. 
2011). Despite changes at the gene expression level, there was no observable reduction in 
the circulating levels of IFN-γ (Fig. 4.8B). A lack of reduction in the protein levels of IFN-γ would 
imply CardioWise does not possess anti-inflammatory properties, however the mRNA 
expression and protein levels of two other pro-inflammatory genes, IL-1β and TNF-α, were 
attenuated in the mice which received treatment compared to the vehicle control receiving 
mice. Furthermore reduced IFN-γ and TNF-α signalling have been associated with improved 
brown fat activation, thereby providing additional evidence for the possible activation of brown 
fat by CardioWise (Nisoli et al. 2000; Moisan et al. 2015). The expression of SOD1 was 
significantly increased following CardioWise treatment when compared to the vehicle control 
mice (Fig. 4.14C). As previously discussed, this may explain the lack of a significant increase 
in ROS production levels in vivo that were observed during the in vitro assay (Figs. 4.7A and 
3.14). Overall the changes in the stress response gene expression observed following 
CardioWise treatment would suggest it exerts strong anti-inflammatory effects which would 
protect against atherosclerosis plaque formation. 
CardioWise treatment also increased the expression of two transcriptional regulators NR1H3 
and PPAR-γ (Fig. 4.15). NR1H3, also known as LXRα, protects against cholesterol 
accumulation within cells by enhancing the expression of genes involved in cholesterol efflux 
and transportation (Parikh et al. 2014; Michael et al. 2012a). Activation of NR1H3 has also 
been shown to attenuate the expression of pro-inflammatory genes including TNF-α and IL-1β 
(Zelcer and Tontonoz 2006). Indeed CardioWise treatment was found to increase the 
expression of NR1H3 (Fig. 4.15A) which correlated with decreases in the expression of TNF- 
α and IL-1β (Fig. 4.14). Furthermore increased NR1H3 activation is associated with reduced 
dietary cholesterol absorption from the intestine via NPLC1L1 (Alvaro et al. 2010). 
Unfortunately the levels of circulating total cholesterol were unaffected during this short term 
feeding study (Fig. 4.5). However NR1H3 is capable of increasing plasma HDL cholesterol 
levels and this was seen as a result of CardioWise treatment (Fig. 4.5B). Perhaps the 
increased expression of NR1H3 is the mechanism by which CardioWise achieves its HDL 
raising properties. The other regulator of transcription to have its expression increased by 
CardioWise treatment was PPAR-γ (Fig. 4.15B). NR1H3 and PPAR-γ are transcription factors 
that are considered to play important roles during adipocyte differentiation (Ohshima et al. 
2012; Laurencikiene and Rydén 2012). Indeed activation of NR1H3 and PPAR-γ has been 
associated with increased brown fat activation (Steffensen et al. 2003; Ohno et al. 2012). 
Furthermore increased PPAR-γ activation has been shown to reduce high fat diet induced 
inflammation in mice by decreasing the expression and secretion of IL-1β, IL-6 and TNF-α, all 
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of which were also observed in this study (Figs. 4.8 and 4.14; Seed et al. 1998; Engstrom et 
al. 2010). Increased PPAR-γ activation may possibly be the mechanism by which CardioWise 
is cable of attenuating pro-inflammatory gene expression and circulating pro-inflammatory 
cytokine levels in vivo. This result concurs with that of previous studies which have shown that 
ω-3 PUFAs and catechin are capable of activating PPAR-γ (Calder 2012; Shin et al. 2009). 
The effect of CardioWise on the expression of transcriptional regulators appears to be anti-
inflammatory and may provide a mechanism of action by which it exerts its other anti-
inflammatory effects previously discussed. 
Based on the changes in gene expression in the liver of wild type mice fed a high fat diet for 
21 days, CardioWise appears to exert strong anti-inflammatory effects. This can be seen by 
attenuating the expression of several pro-inflammatory genes which are key in the 
development of atherosclerosis including CXCL1, SELPLG, IFN-γ, IL-1β and TNF-α. 
Furthermore CardioWise was able to increase the expression levels of a variety of anti-
inflammatory genes including CFLAR, NR1H3 and SOD1. Future studies are required to fully 
evaluate these gene expression changes and their possible effects on atherosclerosis disease 
development in long term feeding studies using either ApoE or LDLr deficient mice. 
4.4.4 The possible activation of brown fat following CardioWise treatment 
As previously discussed, there is evidence to suggest that CardioWise treatment in wild type 
mice is capable of enhancing brown fat activation. CardioWise has been shown to affect 
NR1H3, PPAR-γ, SOD1 and pro-inflammatory gene expression as well as circulating levels of 
cytokines, HDL cholesterol and markers of lipid peroxidation, which have all been associated 
with brown fat activation (summarised in Fig. 4.23; Barja de Quiroga et al. 1991; Nisoli et al. 
2000; Steffensen et al. 2003; Nedergaard et al. 2005; Pan et al. 2005; Jastroch et al. 2010; 
Markelic et al. 2011; Moisan et al. 2015; Hoeke et al. 2017). It is possible that CardioWise is 
capable of activating brown fat as previous studies have shown that treatment with ω-PUFAs 
or flavanols activates brown fat (Quesada-López et al. 2016; Pahlavani et al. 2017; Yoneshiro 
et al. 2017). Since the turn of the century, research into the possible use of activating brown 
fat to protect individuals against obesity and CVD has exploded (Harms and Seale 2013; 
Peirce et al. 2014; Villarroya et al. 2016). The primary function of brown fat is to produce heat 
and maintain body temperature through a process known as non-shivering thermogenesis. 
Heat production is achieved by the high number of mitochondria present within the brown 
adipocytes and the high expression levels of uncoupling protein 1 (UCP1), which uncouples 
substrate oxidation and ATP production resulting in heat production (Harms and Seale 2013; 
Peirce et al. 2014; Villarroya et al. 2016). Brown fat activation is thought to protect against 
obesity and CVD due to non-shivering thermogenesis being a high energy dependent process 
and consequently resulting in fat being used as an energy source rather than being stored in 
white fat deposits (Harms and Seale 2013; Peirce et al. 2014; Villarroya et al. 2016). Brown fat 
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is also capable of functioning like an endocrine organ and therefore its activation may alter the 
circulating cytokine profile of an individual to a more anti-inflammatory one (Villarroya et al. 
2016). Furthermore it has been found that during brown fat activation, the levels of UPC1 
expressing, thermogenic-capable adipocytes increase within the white fat deposits (Harms and 
Seale 2013; Peirce et al. 2014; Villarroya et al. 2016; Jeremic et al. 2017). These adipocytes 
are often referred to as beige adipocytes. During brown fat activation, the number of beige 
adipocytes present in white fat deposits increases in a process known as ‘browning’ (Harms 
and Seale 2013; Peirce et al. 2014; Villarroya et al. 2016; Jeremic et al. 2017). As a result of 
the discovery of brown fat deposits within adult humans, the activation of brown fat and the 
browning of white fat have become novel therapeutic targets. Further studies are required to 
explore the possibility of CardioWise treatment activating brown fat or enhancing the browning 
of white adipose tissue. These future studies must investigate gene expression changes and 
markers such as UCP1, zic family member (ZIC)1 and myosin light chain, phophorylatable, 
fast skeletal muscle (MYLPF) which are associated with brown fat activation (Harms and Seale 
2013; Peirce et al. 2014). Additionally the gene expression levels of UCP1, CD137 and short 
stature homeobox (SHOX)2 needs to be assessed in white adipose tissue as they are 
indicators of beige adipocytes (Harms and Seale 2013; Peirce et al. 2014). Furthermore due 
to the role of brown fat in non-shivering thermogenesis, the temperature of the mice must be 
monitored as an increase in body temperature may also indicate brown fat activation (Crane 
et al. 2014; Meyer et al. 2017).  
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Fig. 4.23. The different shades of fat and the possible effects of CardioWise treatment. The above figure 
summarises the possible evidence that CardioWise treatment in wild type mice fed a high fat diet for 21 days may 
activate brown fat and enhance the browning of white adipose tissue. See text for further details. 
4.4.5 The effect of CardioWise on bone marrow cell populations in wild type mice 
A high fat diet has been associated with changes in the proportion of bone marrow cell 
populations which can lead to atherosclerosis (Chan et al. 2012; Wu et al. 2013; Adler et al. 
2014; van den Berg et al. 2016; Lang and Cimato 2014; Murphy et al. 2014; Ma and Feng 
2016). Furthermore dietary supplementation with nutraceuticals has been shown to also alter 
the cell populations within bone marrow (Takano et al. 2004a; Betiati et al. 2013; Chang and 
Deckelbaum 2013). Therefore the bone marrow of wild type mice fed a high fat diet for 21 days 
was analysed to determine whether CardioWise treatment could alter the proportion of cell 
populations and retard atherosclerosis progression. The summary of the changes within the 
bone marrow following CardioWise treatment can be found in Fig. 4.24. 
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Fig. 4.24. The CardioWise induced changes in proportions of cell populations in the bone marrow. The bone 
marrow of wild type mice were harvested after they had received either CardioWise or vehicle control treatment 
while being fed a high fat diet for 21 days. HSC, haematopoietic stem cell; MPP, multipotent progenitors; HPC, 
haematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; 
GMP, granulocyte-macrophage progenitor; MDSC, myeloid-derived suppressor cells; LMPP, lymphomyeloid 
progenitor; CLP, common lymphoid progenitor. 
The levels of an individual’s white blood cells can be seen as an indicator of their inflammatory 
state. Previous studies have shown that the levels of white blood cells normally increase during 
atherosclerosis disease progression (Ates et al. 2011; Mozos et al. 2017). A reduction in the 
proportion of bone marrow cells was observed in the bone marrow of wild type mice following 
CardioWise treatment, indicating a possible reduction in the inflammatory state and reduced 
atherosclerosis development (Fig. 4.16). This change in bone marrow cell number is a result 
of a reduction in cell populations such as macrophages, MDSCs, B-cells and T-cells which will 
be discussed in greater detail below. 
Previous studies have demonstrated a correlation between increased cholesterol levels and 
increased number of haematopoietic stem/progenitor cells (HSPCs) which leads to an increase 
in the number of white blood cells (Ma and Feng 2016). During this study, CardioWise did not 
significantly alter total serum cholesterol levels but did increase HDL cholesterol concentration 
(Fig. 4.5). Therefore FACS analysis was performed in order to determine whether CardioWise 
treatment results in altered cell population proportions within the bone marrow of wild type 
mice.  
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During atherosclerosis disease progression, it has been found that the HSCs and LK cell 
populations begin to proliferate and relocate to the spleen where they begin to differentiate into 
monocytes which specifically target the atherosclerotic lesion (Robbins et al. 2012). Previous 
studies have observed increases in CMP and GMP cell populations within the LK cell group in 
mice following a high fat diet (Gao et al. 2014). CardioWise had no effect on either the HSC 
and LK cell populations indicating no anti-atherogenic shift in cell populations within the bone 
marrow (Figs. 4.18 and 4.19). Both CSF2 and IL-3 are essential in the differentiation of HSPCs, 
especially in the formation of monocytes from its precursors (Lang and Cimato 2014; Seita and 
Weissman 2010; Schmid et al. 2010; Wu et al. 2017; Francisco-Cruz et al. 2014). The 
expression of CSF2 and IL-3 was reduced in mice receiving CardioWise (Fig. 4.12). This result 
indicated CardioWise has the potential to increase proliferation of HSPCs but attenuate their 
differentiation into monocytes and exert anti-inflammatory effects. Indeed CardioWise 
treatment results in a significant decrease in the number of monocytes and macrophages found 
within the bone marrow of wild type mice (Fig. 4.21). This reduction in monocyte and 
macrophage number could eventually result in decreased foam cell formation and smaller 
atherosclerotic plaques forming due to a smaller number of monocytes which can be recruited 
to the site of oxLDL accumulation within the artery wall (Hansson and Libby 2006). Although 
there is a decrease in the number of monocytes and macrophages, there is no indication on 
whether these macrophages are pro-atherogenic M1 macrophages or anti-atherogenic M2 
macrophages. Further studies are required to determine the consequences of the observed 
decrease in monocyte numbers following CardioWise treatment and which phenotype the 
resulting macrophage develop into. 
Increases in serum HDL levels have been shown to attenuate HPSC proliferation (Murphy et 
al. 2011; Chen et al. 2014; Yvan-Charvet et al. 2010). The circulating levels of HDL cholesterol 
was found to be increased in the mice which received CardioWise when compared to the 
vehicle control mice (Fig. 4.5). Perhaps this increase in HDL cholesterol is responsible for the 
non-significant reductions observed in the HPC and CLP progenitor cell populations (Figs. 4.18 
and 4.20).  
Changes within the haematopoietic cell populations may also arise due to changes in gene 
expression. Both B- and T-cells are rare within the atherosclerotic lesion and depending on 
their phenotype they can exert both pro- and anti-atherogenic effects (Andersson et al. 2010; 
Kyaw et al. 2011). The rate of proliferation of both the B- and T-cell populations can be 
influenced by a variety of genes including CFLAR and BCL2A1A (Safa 2012; Ottina et al. 2012; 
Métais et al. 2012). As previously discussed, dietary supplementation with CardioWise resulted 
in the altered expression of these genes (Fig. 4.10). This altered gene expression may explain 
the decrease observed in the proportion of B- and T-cells found within the bone marrow 
following CardioWise treatment (Fig. 4.22). The reduction in the expression of BCL2A1A is of 
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particular interest as decreases in the expression of this gene have been previously associated 
with attenuated early T-cell formation and reduced B-cell populations due to its role in 
preventing apoptosis (Ottina et al. 2012; Métais et al. 2012). However one of the major genes 
involved in regulating B- and T-cell proliferation is PPAR-γ. This gene negatively regulates 
both B- and T-cell proliferation, and previous studies have found that a deficiency in PPAR-γ 
expression results in the increased proliferation of B- and T-cells (Choi and Bothwell 2012; 
Garcia-Bates et al. 2009). Therefore the increase in PPAR-γ expression observed following 
CardioWise treatment might explain the changes in B- and T-cell populations. Furthermore an 
increase in the expression of PPAR-γ has been shown to promote the survival and activity of 
regulatory T-cells (Tregs), which have anti-atherogenic actions, therefore even though 
CardioWise reduces T-cell numbers it may enhance their differentiation into the anti-
atherogenic phenotype (Choi and Bothwell 2012). This altered gene expression following 
CardioWise treatment may provide a mechanism of action by which previous studies have 
shown that treatment with ω-3 PUFAs in vitro and in vivo can result in reduced T-cell 
proliferation (Calder 2015). 
Wild type mice fed a high fat diet and treated with CardioWise had reduced number of MDSCs 
within their bone marrow when compared to the vehicle control treated mice (Fig. 4.19). Not 
much is currently known about the role of MDSCs but they have been found to be capable of 
suppressing T-cell differentiation (Talmadge and Gabrilovich 2013). However CardioWise 
resulted in the decrease in the MDSC and T-cell population. This result may indicate that 
CardioWise treatment caused the reduction of both MDSCs and T-cell populations via two 
separate mechanisms. The cytokines CSF2, IL-6 and IL-10 have been shown to be involved 
in the differentiation of MDSCs (Mundy-Bosse et al. 2011; Dolcetti et al. 2009). CardioWise 
treatment reduced the gene expression and circulating levels of these cytokines which may 
explain the reduced number of MDSCs found in this study (Figs. 4.8 and 4.12). MDSCs have 
been found to be involved in the progression and metastasis of tumours by releasing a variety 
of cytokines capable of influencing cell invasion, proliferation, survival and adhesion 
(Talmadge and Gabrilovich 2013). Furthermore angiogenesis during tumour growth has been 
found to be promoted by MDSCs (Talmadge and Gabrilovich 2013). As previously discussed, 
angiogenesis within the atherosclerotic plaque can result in it becoming unstable and rupturing, 
therefore the reduction in the MDSC population as a result of CardioWise treatment may 
potentially result in improved plaque stability (Greenberg and Jin 2013). Few studies have 
investigated the role of MDSCs during atherosclerosis disease progression but those which 
did have observed that a reduction in population number was associated with an increase in 
inflammation and atherosclerosis disease progression (Xia et al. 2011; Foks et al. 2016). 
Additional studies are required to determine the specific role of MDSCs within atherosclerosis 
disease development in order to better understand the implications of CardioWise treatment 
reducing this cell population. 
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The changes in bone marrow cell populations following CardioWise treatment appear to be 
anti-atherogenic. Further studies are required to determine the consequences of these 
alterations in haematopoietic cell populations which resulted from CardioWise treatment. 
Future long term feeding studies also need to analyse the cell populations within the 
atherosclerotic plaque directly. This would overcome the limitation associated with this study 
which was restricted to only assessing the cell populations with the bone marrow. Without 
determining the cell population changes within an atherosclerotic plaque, we are unable to 
assess whether the changes within the bone marrow correlate with changes within the plaque 
or whether the changes in cell populations within this study are due to an altered secretion of 
lineage cells from the bone marrow into the blood stream. For example, decreased monocyte 
and macrophage numbers in the bone marrow may actually represent increased monocyte 
and macrophage release into the blood stream. This would alter the conclusions drawn in this 
study. The reduction in monocyte and macrophage number within the bone marrow would then 
represent a pro-inflammatory effect of CardioWise rather than an anti-inflammatory one. 
4.4.6 Summary of the effect of CardioWise in wild type mice 
This is the first in vivo study to assess the effect of a unique nutraceutical combination 
containing ω-3 PUFAs, flavanols and phytosterols at a human physiological equivalent dose 
in mice receiving a high fat diet. CardioWise appeared to exert strong anti-atherogenic effects 
by increasing serum HDL cholesterol levels, promoting anti-inflammatory gene expression and 
altering circulating levels of pro-inflammatory cytokines (summarised in Fig. 4.25). Furthermore 
this study generated a lot of indirect evidence which indicated that CardioWise is potentially 
capable of enhancing brown fat activation as indicated by changes in gene expression and 
several other blood parameters. A reduction in the number of B-, T-cells and macrophages 
present within the bone marrow of mice which received CardioWise implies an anti-atherogenic 
effect. Overall the results of this study indicate that CardioWise is capable of promoting an 
anti-inflammatory state within wild type mice receiving a high fat diet. This initial study justifies 
the use of CardioWise in longer term in vivo feeding studies which involve atherosclerotic 
mouse models such as ApoE or LDLr deficient mice to fully understand its anti-atherogenic 
potential. Using atherosclerotic mouse models would also allow the effect of CardioWise 
treatment on plaque size and formation, lesion cell composition, plaque stability and plaque 
regression to be determined. Previous studies have demonstrated that ω-3 PUFAs, flavanols 
and phytosterols are capable of attenuating plaque formation (Moghadasian et al. 1999; 
Yeganeh et al. 2005; Moghadasian 2006; Chyu 2004; Nakajima et al. 2011; Brown et al. 2012; 
Minatti et al. 2012; Morrison et al. 2014). These previous studies indicate that CardioWise 
would also result in a smaller atherosclerotic plaque. 
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Fig. 4.25. Summary of the potential anti-atherogenic properties of CardioWise in vivo. The steps potentially 
reduced in atherosclerosis disease progression following CardioWise treatment are highlighted in green. Possible 
mechanisms for these changes are also included. 
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Chapter 5: Assessing the main bioactive components of CardioWise in vitro 
Assessing the main bioactive components of CardioWise 
in vitro 
 
5.1 Introduction 
Due to CardioWise being a combination of fish oil, cocoa flavanols and phytosterols, it was 
important to investigate whether any of the individual bioactive ingredients had specific 
mechanistic actions. Studying the nutraceuticals within CardioWise would not only aid in 
explaining how it exerts its anti-atherogenic effects but it would help in refining the product by 
identifying the most effective compounds and altering the proportions of the nutraceuticals 
within the mixture. The major nutraceuticals within CardioWise were determined to be EPA, 
DHA, catechin, stigmasterol, campesterol and β-sitosterol.  
These nutraceuticals were used in a variety of initial assays at the concentrations they can be 
found within CardioWise in order to find an individual compound that would be investigated in 
further detail. Initially the levels of secreted pro-inflammatory cytokines MCP-1 and IL-1β were 
measured by ELISA. The role of MCP-1 during atherosclerosis lesion formation has been 
discussed in previous sections. The innate immune system response can be activated by IL-
1β (Moss and Ramji 2016a). The importance of IL-1β during disease progression can be 
demonstrated in atherosclerotic mouse models. ApoE deficient mice which were also lacking 
either IL-1β or its receptor were found to develop smaller atherosclerotic plaques (Kamari et 
al. 2011; Shemesh et al. 2012). Additionally, the CANTOS trial demonstrated that inhibition of 
IL-1β with a neutralising antibody was capable of reducing an individual’s risk of a recurrent 
CVD-related event (Ridker et al. 2017a). Furthermore IL-1β is a major cytokine released by 
the NLRP3 inflammasome and therefore the level of IL-1β can be used as an indirect 
measurement of inflammasome activation (Hoseini et al. 2017). The individual nutraceuticals 
were also evaluated in monocyte migration, ROS production and cholesterol efflux assays 
(details on the rationale of these assays can be found in Chapter 3). 
While assessing the individual nutraceuticals from CardioWise, an additional potential 
bioactive compound was included within the initial assays. Butyrate is a short chain fatty acid 
which is formed from dietary fibre fermentation within the gut (Moss and Ramji 2016b). 
Preclinical studies have started to observe anti-inflammatory effects following butyrate 
treatment. The expression of the pro-inflammatory cytokines IL-1β and TNF-α was significantly 
reduced by butyrate in murine macrophages (Liu et al. 2012a). Furthermore ApoE deficient 
mice fed a standard chow diet which was supplemented with 1% butyrate were found to 
develop smaller and more stable atherosclerotic plaques (Aguilar et al. 2014). The size of the 
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atherosclerotic lesions were reduced by approximately 50% due to decreased monocyte and 
macrophage accumulation, which correlated with attenuated expression of the cell recruitment 
genes MCP-1 and ICAM-1 (Aguilar et al. 2014). Furthermore the plaques were found to have 
increased ECM deposition, a sign of increased plaque stability (Aguilar et al. 2014). 
Additionally several epidemiological studies have found a correlation between increased 
dietary fibre intake and a reduced risk of suffering a CVD-related event (Liu et al. 2002; 
Merchant et al. 2003; Oh et al. 2005a). However the effectiveness of a fibre rich diet, and which 
component of the diet exerts the potential cardiovascular protective effects, is still debated 
within the literature (Moss and Ramji 2016b). Therefore butyrate was included within the initial 
assays to determine its potential as a nutraceutical. 
Following the results of the monocyte migration and ROS production assays, catechin was 
chosen as the nutraceutical which would be investigated in greater detail. It was also chosen 
as relatively little is known about its potential anti-atherogenic effects and mechanism of action 
when compared to other nutraceuticals such as ω-3 PUFAs. Therefore this study presented 
an ideal opportunity to assess catechin in greater detail using our robust in vitro models of 
atherosclerosis disease development steps. Initially a mini-dose response was performed on 
gene expression, monocyte migration and ROS generation assays to ensure an effective dose 
of catechin was being utilised. A dose of 1.5 μg/ml was selected as it is the same concentration 
of catechin found with CardioWise. Additional doses of 5, 10 and 20 μg/ml were used to provide 
a good range of catechin concentrations in the initial assays. Once an optimal dose of catechin 
had been determined, its effect on cell viability was tested with an LDH assay to ensure it did 
not exert any detrimental effects before using it in further assays. 
 
5.2 Experimental Aims 
Details of specific methodologies for each experimental aim are outlined in Chapter 2 and the 
experimental strategies for Chapter 5 are presented in Figs. 5.1 – 5.4. 
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Fig. 5.1. Strategy for assessing pro-inflammatory cytokine production. ELISA, enzyme-linked immunosorbent 
assay; ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic protein. 
 
 
Fig. 5.2. Monocyte migration experimental strategy. MCP, monocyte chemotactic protein. 
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Fig. 5.3. Strategy for assessing ROS production. A longer incubation period is required for macrophages as it 
takes more time for the DCFDA compound to diffuse into adherent cells. DCFDA, dichlorofluorescin diacetate; 
TBHP, tert-butyl hydrogen peroxide. 
 
 
Fig. 5.4. Strategy for assessing gene expression. ICAM, intercellular adhesion molecule; IFN, interferon; MCP, 
monocyte chemotactic protein. 
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5.3 Results 
5.3.1 The effect of nutraceuticals on the secreted levels of pro-inflammatory cytokines 
following IFN-γ stimulation in human macrophages 
The production of two major pro-inflammatory cytokines, MCP-1 and IL-1β, can be induced by 
IFN-γ (Moss and Ramji 2016a). PMA differentiated THP-1 macrophages were incubated with 
IFN-γ (250 U/ml) for 24 hours to induce MCP-1 and IL-1β expression. The concentration of 
secreted MCP-1 was significantly increased by 5.8 fold (p=0.050), whereas IL-1β levels 
showed a non-significant trend of increase of 1.5 fold in human THP-1 derived macrophages 
(p=0.079; Fig. 5.5). Following EPA and DHA treatment the levels of MCP-1 were reduced by 
45.6% (p=0.065) and 24.9% (p=0.417) respectively, however these changes were not 
significant (Fig. 5.5A). Furthermore catechin, stigmasterol, campesterol, β-sitosterol and 
butyrate did not affect the secretion of MCP-1. IL-1β secretion was significantly increased by 
39.5%, 48.2%, 62.0% and 67.9% after treatment with catechin, stigmasterol, campesterol and 
β-sitosterol (p=0.023, p=0.003, p<0.001 and p<0.001 respectively; Fig. 5.5B). EPA, DHA and 
butyrate failed to significantly affect IL-1β levels (p=0.995, p=0.995, p=0.999 respectively). 
Overall these results are not very informative about the active ingredient of CardioWise and 
hence monocyte migration and ROS production assays were used for subsequent studies. 
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Fig. 5.5. Bioactive compounds within CardioWise can affect MCP-1 and IL-1β protein secretion levels in 
human macrophages. The protein concentrations of MCP-1 (A) and IL-1β (B) were assessed in PMA differentiated 
THP-1 macrophages that were either treated with vehicle (vehicle control) or with IFN-γ (250 U/ml) or IFN-γ (250 
U/ml) in the presence of a variety of nutraceuticals (EPA 30 μg/ml; DHA 19.7 μg/ml; catechin 1.5 μg/ml; stigmasterol 
10 μg/ml; campesterol 13.9 μg/ml; β-sitosterol 27.2 μg/ml; butyrate 44.1 μg/ml) for 24 hours. Protein concentrations 
were assessed using an ELISA. The data are presented as the mean ± SEM from three independent experiments. 
Statistical analysis was performed using a one-way ANOVA with either a Games-Howell (A) or Dunnett (B) post-
hoc analysis where * p ≤0.05, ** p ≤0.01 and *** p ≤0.001. 
5.3.2 Key bioactive ingredients of the complete formulation can inhibit the migration of 
human monocytes towards MCP-1 
A 9.61 fold (p<0.001) increase in monocyte recruitment was observed in cells stimulated with 
MCP-1 (20 ng/ml) in comparison to the vehicle control after 3 hours (Fig. 5.6). Both EPA and 
catechin were able to significantly attenuate MCP-1-driven monocyte migration by 52.7% 
(p=0.006) and 47.5% (p=0.016) respectively. Decreased monocyte recruitment was observed 
following DHA, stigmasterol, campesterol and β-sitosterol treatment, however these changes 
were not found to be significant (p=0.192, p=0.659, p=0.143, p=0.122 respectively). Butyrate 
treatment had no effect on monocyte migration (p=1.000). 
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Fig. 5.6. Nutraceuticals within CardioWise can reduce human monocyte migration towards MCP-1. Cellular 
migration was assessed using THP-1 monocytes that were treated with either vehicle (vehicle control) or with MCP-
1 (20 ng/ml) or with MCP-1 (20 ng/ml) in the presence of a variety of nutraceuticals (EPA 30 μg/ml; DHA 19.7 μg/ml; 
catechin 1.5 μg/ml; stigmasterol 10 μg/ml; campesterol 13.9 μg/ml; β-sitosterol 27.2 μg/ml; butyrate 44.1 μg/ml) for 
3 hours. Monocyte migration was then determined as described in Materials and Methods. Monocyte migration is 
expressed as a fold-change compared to the proportion of cells that moved from the apical compartment into the 
basolateral compartment in response to MCP-1 alone, which has been arbitrarily set as 1. The data are presented 
as the mean ± SEM from four independent experiments. Statistical analysis was performed using a one-way 
ANOVA with Dunnett post-hoc analysis on Log transformed data where * p ≤0.05, ** p ≤0.01 and *** p ≤0.001.  
5.3.3 Key bioactive ingredients of CardioWise can alter ROS production in human 
monocytes and macrophages 
The level of ROS generation increased in both THP-1 monocytes and macrophages by 61% 
and 40% respectively (p<0.001 and p<0.001) following 50 μM TBHP stimulation for 3 hours 
(Fig. 5.7). In THP-1 monocytes a significant increase in ROS levels occurred following 
treatment with both EPA (192.6%; p<0.001) and DHA (53.1%; p<0.001; Fig. 5.7A). On the 
other hand treatment with Catechin and β-sitosterol reduced ROS production by 24.3% and 
12.1% respectively (p<0.001 and p=0.028). Stigmasterol, campesterol and butyrate did not 
significantly alter TBHP induced ROS generation. Comparable results were observed in THP-
1 monocyte-derived macrophages (Fig. 5.7B). EPA, DHA and campesterol treatment 
significantly increased ROS production by 141.2%, 42.1% and 10.7% respectively (p<0.001, 
p<0.001 and p=0.003). The only nutraceutical to reduce ROS generation was catechin (20.9%; 
p<0.001), whereas neither stigmasterol, β-sitosterol nor butyrate had any significant effects. 
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Fig. 5.7. Individual nutraceuticals within CardioWise can modify ROS production in human monocytes and 
macrophages. ROS production was assessed in THP-1 monocytes (A) and PMA differentiated THP-1 
macrophages (B) that were either treated with vehicle (vehicle control) or tert-Butyl hydroperoxide (TBHP; 50 μM) 
or TBHP (50 μM) and a variety of nutraceuticals (EPA 30 μg/ml; DHA 19.7 μg/ml; catechin 1.5 μg/ml; stigmasterol 
10 μg/ml; campesterol 13.9 μg/ml; β-sitosterol 27.2 μg/ml; butyrate 44.1 μg/ml) for 3 hours. ROS production was 
measured in a fluorescence microplate reader, with excitation at 485 nm and emission detected at 535 nm. Vehicle 
control was given an arbitrary value of 1. The data are presented as the mean ± SEM from three independent 
experiments. Statistical analysis was performed on the log-transformed data using a one-way ANOVA with a 
Dunnett post-hoc analysis where * p ≤0.05, ** p ≤0.01 and *** p ≤0.001. 
5.3.4 Catechin has no effect on the expression of pro-inflammatory genes following IFN-
γ stimulation in human macrophages  
Due to the positive results induced by catechin presented above, it was investigated further at 
a range of concentrations in order to assess its effects on other key stages of atherosclerosis 
progression. The expression of MCP-1 in human PMA differentiated THP-1 macrophages 
showed a non-significant increase of 35.2 (p=0.127) fold following IFN-γ stimulation for 3 hours 
(250 U/ml; Fig. 5.8A). Furthermore the transcript level of ICAM-1 was increased by 2.9 fold 
(p<0.001) when compared to the vehicle control (Fig. 5.8B). When treated with catechin at 
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doses 1.5, 5, 10 or 20 μg/ml, there were no significant alterations in IFN-γ induced expression 
of either MCP-1 or ICAM-1. 
 
Fig. 5.8. IFN-γ induced expression of MCP-1 and ICAM-1 is not affected be catechin in human macrophages. 
The expression of MCP-1 (A) and ICAM-1 (B) was assessed in PMA differentiated THP-1 macrophages that were 
either treated with vehicle (vehicle control) or with IFN-γ (250 U/ml) or IFN-γ (250 U/ml) in the presence of the 
indicated concentrations of catechin for 3 hours. Gene expression levels were assessed using qPCR and calculated 
using the comparative Ct method and normalised to GAPDH levels with values from vehicle treated cells given an 
arbitrary value of 1. The data are presented as the mean ± SEM from three independent experiments. Statistical 
analysis was performed using a one-way ANOVA with either a Games-Howell (A) or Dunnett T3 (B) post-hoc 
analysis where *** p ≤0.001. 
5.3.5 Catechin attenuates human monocyte migration 
MCP-1 (20 ng/ml) induced the recruitment of THP-1 monocytes by 5.4 fold (p<0.001) when 
compared to the vehicle control lacking MCP-1 after 3 hours (Fig. 5.9). A 36% reduction in 
monocyte recruitment occurred following treatment with catechin at a dose of 1.5 μg/ml 
(p=0.049). Decreases of 23.2% (p=0.326), 26.6% (p=0.236) and 20.0% (p=0.494) were 
observed for catechin doses 5, 10 and 20 μg/ml respectively, however none of these 
decreases were significant. 
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Fig. 5.9. The migration of human monocytes towards MCP-1 is inhibited by physiologically relevant doses 
of catechin. THP-1 monocytes were treated with vehicle (vehicle control) or treated with MCP-1 (20 ng/ml) alone 
or with MCP-1 (20 ng/ml) in the presence of one indicated concentrations of catechin for 3 hours. Monocyte 
migration was then determined as described in Materials and Methods. Data were normalised to the percentage of 
cells that migrated from the apical compartment of the modified Boyden chamber into the basolateral compartment 
in response to MCP-1 only treatment. This proportion was arbitrarily assigned as 1. The data are presented as the 
mean ± SEM from three independent experiments. Statistical analysis was performed using a one-way ANOVA 
with a Dunnett post-hoc analysis where * p ≤0.05 and *** p ≤0.001.  
5.3.6 Catechin attenuates ROS production in a dose dependent manner in human 
monocytes and macrophages 
The presence of TBHP (50 μM) induced ROS production in both THP-1 monocytes and 
macrophages by 70% and 127% respectively (p<0.001 and p<0.001) when compared to the 
vehicle control after 3 hours (Fig. 5.10). Catechin at doses 1.5, 5, 10 and 20 μg/ml was able to 
attenuate ROS production in THP-1 monocytes by 27.6%, 36.2%, 39.9% and 41.5% 
respectively when compared to cells treated with TBHP alone (all p<0.001; Fig. 5.10A). Similar 
results were seen in PMA differentiated THP-1 macrophages, decreases of 34.3%, 48.7%, 
51.4% and 53.0% were observed for the same doses of catechin (p=0.021, p=0.001, p<0.001 
and p<0.001 respectively; Fig. 5.10B). 
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Fig. 5.10. Catechin attenuates ROS production in human monocytes and macrophages in a dose dependant 
manner. ROS production was assessed in THP-1 monocytes (A) and PMA differentiated THP-1 macrophages (B) 
that were either treated with vehicle (vehicle control) or tert-Butyl hydroperoxide (TBHP; 50 μM) or TBHP (50 μM) 
and the indicated concentrations of catechin for 3 hours. ROS production was measured in a fluorescence 
microplate reader, with excitation at 485 nm and emission detected at 535 nm. Vehicle control was given an arbitrary 
value of 1. The data are presented as the mean ± SEM from three independent experiments. Statistical analysis 
was performed on the log-transformed data using a one-way ANOVA with either a Tukeys (A) or Games-Howell (B) 
post-hoc analysis where * p ≤0.05 and *** p ≤0.001. 
5.3.7 The viability of human macrophages is unaffected by catechin in vitro 
A catechin concentration of 1.5 μg/ml was used for subsequent experiments because it was 
found to effectively attenuate both monocyte migration (Fig. 5.9) and ROS production (Fig. 
5.10). Prior to subsequent experiments, the effect of the chosen concentration of catechin on 
cell viability was determined using human THP-1 monocyte-derived macrophages and a LDH 
assay. As shown in Fig. 5.11 there were no significant differences in cell viability observed 
following treatment with catechin for 24 hours in comparison to the vehicle control. 
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Fig. 5.11. No detrimental effects were observed in human macrophages following treatment with catechin 
in vitro. Cell viability was assessed by a LDH assay in PMA differentiated THP-1 macrophages that were treated 
with vehicle (vehicle control) or catechin (1.5 μg/ml) for 24 hours. Data were normalised to the vehicle control that 
has been arbitrarily assigned as 100%. The data are presented as the mean ± SEM from three independent 
experiments. Statistical analysis was performed using a t-test. 
 
5.4 Discussion 
The results of atherosclerosis-associated assays used for the numerous studies presented in 
this chapter show that the individual nutraceuticals within CardioWise had different effects on 
a variety of stages in atherosclerosis disease progression, including pro-inflammatory cytokine 
production, monocyte migration, ROS generation and cholesterol efflux in human monocytes 
and macrophages. These studies allow for a greater understanding of which compounds within 
CardioWise are potentially the most important and require further investigation. The assays 
also provide some insight into the mechanisms by which CardioWise exerts its anti-
atherogenic effects. 
As MCP-1 is a key chemoattractant during the initial atherosclerotic lesion formation and its 
expression can be induced by IFN-γ, the levels of MCP-1 secreted by THP-1 human 
macrophages was assessed by a sandwich ELISA (Moss and Ramji 2016a). In this study we 
show that both EPA and DHA are capable of reducing the concentration of MCP-1 secreted 
by human macrophages, however the result was found not to be significant (Fig. 5.5A). This 
result correlates with the reduced MCP-1 gene expression in macrophages following treatment 
with a physiologically relevant dose of CardioWise (Figs. 3.8 and 3.9). Neither catechin, 
phytosterols nor butyrate were capable of attenuating MCP-1 secretion. These results indicate 
that it is the EPA and DHA present in CardioWise which make it capable of reducing pro-
inflammatory gene expression. Previously EPA and DHA have been found to reduce MCP-1 
secretion in LPS stimulated human kidney cells, however another study found only DHA 
 Chapter 5: Identifying an individual nutraceutical  
139 
 
significantly reduced MCP-1 levels in TNF-α stimulated human adipocytes whereas EPA 
caused a non-significant trend of increase (Li et al. 2005; Romacho et al. 2015). Both in vitro 
and in vivo studies have observed decreases in MCP-1 secretion in a variety of cell types and 
in response to a range of pro-inflammatory stimuli following treatment with either catechin, β-
sitosterol or butyrate (Fusunyan et al. 1999; Bustos et al. 2008; Melgarejo et al. 2009; 
Haramizu et al. 2011; Wang et al. 2014b). These previous results in combination with the 
observations in this study may indicate that the effectiveness of ω-3 PUFAs, catechin, 
phytosterols and butyrate in reducing MCP-1 secretion may depend on cell type and pro-
inflammatory stimuli used, resulting in some of the contrasting results seen in this study and 
the literature. 
IL-1β is a major pro-inflammatory cytokine during atherosclerosis disease progression and its 
expression can be induced by oxLDL, meaning atherosclerosis disease initiation and IL-1β 
expression are closely linked (Moss and Ramji 2016a; Liu et al. 2014b). Previous studies have 
shown that IL-1β not only induces the expression of several pro-inflammatory genes but it is 
also capable of promoting the pro-inflammatory M1 macrophage phenotype (Chinetti-Gbaguidi 
et al. 2015; Leitinger and Schulman 2013; Van Tassell et al. 2013; Ridker 2016). Smaller 
atherosclerotic lesions have been observed in ApoE deficient mice that also lacked either IL-
1β or its receptor (Kamari et al. 2011; Shemesh et al. 2012). As activated inflammasomes 
convert IL-1β and IL-18 into their mature forms, measuring IL-1β secretion is an indirect way 
of measuring inflammasome activation. The results in this study show that catechin and 
phytosterols cause an increase in IL-1β secretion and therefore increase inflammasome 
activation (Fig. 5.5). Catechin and other flavanols have been shown to attenuate 
inflammasome activation in both endothelial cells and mice (Tsai et al. 2011; Wu et al. 2014; 
Jhang et al. 2015). As far as we are aware this is the first study to investigate the effects of 
stigmasterol, campesterol and β-sitosterol individually on inflammasome activation. This assay 
shows that phytosterols are capable of exerting detrimental effects during atherosclerosis 
disease progression and potentially increase the pro-inflammatory response. EPA, DHA and 
butyrate treatment had no effect on IL-1β secretion. This result contradicts previous studies in 
the literature which found ω-3 PUFAs are capable of attenuating inflammasome activation in 
both THP-1 macrophages and bone marrow-derived macrophages (BMDMs; Yan et al. 2013; 
Williams-Bey et al. 2014). The failure of butyrate to reduce inflammasome activation observed 
in this study has also been seen in LPS stimulated BMDMs (Youm et al. 2015). However due 
to the small number of studies investigating the effects of butyrate there is no consensus within 
the literature, as another study has shown that butyrate is capable of attenuating 
inflammasome activation (Bian et al. 2017). The primary limitation with our study is that IFN-γ 
was used to stimulate inflammasome activation. The major inflammasome class involved in 
atherosclerosis disease development appears to be the NLRP3 inflammasome, which is 
activated by oxLDL and cholesterol crystals (Hoseini et al. 2017). Therefore a greater insight 
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into the effects of ω-3 PUFAs, catechin, phytosterols and butyrate on inflammasome activation 
in relation to atherosclerosis would be achieved if either oxLDL or cholesterol crystals were 
used to stimulate inflammasome activation instead of IFN-γ. 
Both EPA and catechin were capable of attenuating MCP-1 driven monocyte migration (Fig. 
5.6). Furthermore DHA, stigmasterol, campesterol and β-stigmasterol showed trends of 
decrease, however none of these trends were significant. These results show all the 
components within CardioWise are capable of attenuating monocyte recruitment to some 
degree. All the nutraceuticals were used at the same concentration they are found in 
CardioWise, however when tested individually both EPA and catechin resulted in similar 
reductions in migration that were achieved by using the full combination in CardioWise (Fig. 
3.10). These results would imply that there were no additive or synergistic effects on monocyte 
migration achieved from using the nutraceuticals ω-3 PUFAs, flavanols and phytosterols in 
combination. A future study could assess this by using different combinations of EPA, DHA, 
catechin and phytosterols and comparing any reductions in monocyte recruitment to the 
nutraceuticals individually. The observations in this study are similar to those previously seen 
when assessing the effect of ω-3 PUFAs, flavanols and phytosterols on monocyte migration 
(Brown et al. 2012; Melgarejo et al. 2009; Bustos et al. 2008). Butyrate appeared to have no 
effect on monocyte migration. 
As previously discussed, the aberrant ROS production can lead to increased lipid peroxidation, 
and hence an increase in oxLDL levels and thereby more atherosclerosis disease development 
(Chen et al. 2017c). Therefore reducing ROS production would decrease one of the triggers 
of atherosclerosis disease development. As both monocyte and macrophages are present 
within the atherosclerotic plaque, ROS generation was assessed in both to ensure the effects 
of the nutraceuticals occurred in both cell types. Only catechin was found to reduce ROS 
formation in both monocytes and macrophages (Fig. 5.7). This is no surprise as catechin is a 
well-known anti-oxidant (Zielinski et al. 2014; Higdon and Frei 2003; Kumar and Pandey 2013). 
β-sitosterol decreased ROS production in macrophages which agrees with previously 
published results that show it reduced oxidative stress by increasing SOD1 expression 
(Vivancos and Moreno 2005). This result goes some way to explaining the difference in ROS 
production observed following treatment with CardioWise in the presence or absence of 
phytosterols in human macrophages (Fig. 3.14). However the reduction in ROS generation by 
β-sitosterol is not the same as the difference between CardioWise with or without phytosterols, 
implying the possibility of additive or synergistic effects occurring in the combination. Testing 
a combination of catechin and β-sitosterol as well as the other phytosterols in future studies 
would be able to establish any extra antioxidant benefits when the nutraceuticals are 
combined. Both EPA and DHA significantly increased ROS production in human monocytes 
and macrophages, indicating that these nutraceuticals were responsible for the increased ROS 
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levels following incubation with CardioWise. Previous studies have also observed increases in 
ROS production following treatment with ω-3 PUFAs (Yin et al. 2017; Di Nunzio et al. 2016). 
In this study butyrate was found to have no effect on ROS production. 
Following the results of the initial assays, catechin was chosen as the nutraceutical that would 
be investigated in further detail. Catechin was chosen as it was found to be very effective at 
reducing monocyte migration (Fig. 5.6) and ROS production (Fig. 5.7), two key steps in 
atherosclerosis disease progression. Phytosterols and butyrate were eliminated as possible 
choices due to the lack of cardiovascular protective effects being observed in the initial assays. 
Both EPA and DHA were not chosen as nutraceuticals to explore in greater detail as they were 
found to be capable of increasing ROS generation (Fig. 5.7). Furthermore EPA and DHA were 
not chosen due to the fact extensive research has already been performed on these two 
nutraceuticals. Over the last 5 years, 126 and 113 results can be found on pubmed.gov after 
searching for “EPA atherosclerosis” and “DHA atherosclerosis”, whereas only 57 can be found 
for “catechin atherosclerosis”. To ensure an optimal concentration was used for catechin, initial 
testing was performed with a mini-dose response. A dose of 1.5 μg/ml was selected as it is the 
concentration of catechin present in CardioWise. Doses of 5, 10 and 20 μg/ml were selected 
to ensure that a broad range of concentrations were tested. 
The importance of IFN-γ induced gene expression of MCP-1 and ICAM-1 has been previously 
discussed (Moss and Ramji 2016a; Moss and Ramji 2015; Ramji and Davies 2015). In this 
study we show that catechin is unable to attenuate IFN-γ stimulated expression of MCP-1 or 
ICAM-1 at any of our selected concentrations (Fig. 5.8). These results indicate that catechin 
did not play a role in reducing MCP-1 or ICAM-1 expression following CardioWise treatment 
(Figs. 3.8 and 3.9). Previous studies have shown a reduction in MCP-1 and ICAM-1 expression 
following catechin treatment, however the biggest changes in gene expression were observed 
at 50 μg/ml a concentration much higher than the highest dose used in our study (Nakanishi 
et al. 2010; Wang et al. 2014b). The effect of catechin on gene expression in response to other 
pro-inflammatory stimuli needs to be assessed to determine whether the results presented in 
this study are specific to IFN-γ or represent a general response. 
Despite catechin being unable to attenuate IFN-γ induced MCP-1 expression, it was capable 
of decreasing monocyte migration to a MCP-1 stimuli (Fig. 5.9). All doses of catechin tested 
showed a reduction in monocyte recruitment, however only the lowest dose was found to be 
significant. There is some suggestion that catechin concentration has an inverse relationship 
with monocyte migration, however the difference between the lowest and highest dose of 
catechin is minor and therefore may be as a result of natural variation within the assay. A 
previous study observed catechin attenuating LPS stimulated migration of RAW264.7 
macrophages in a dose dependent manor (Ren et al. 2014). Catechin has also been found to 
attenuate the migration of THP-1 monocytes in response to MCP-1 (Melgarejo et al. 2009). 
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Furthermore due to its antioxidant properties catechin reduced ROS production in a dose 
dependent manner (Fig. 5.10). 
The only dose of catechin found to be significant in both the monocyte migration and ROS 
production was 1.5 μg/ml, for this reason it was selected as the concentration of catechin for 
future assays. Another advantage of selecting this dose of catechin is that it is the same 
concentration of catechin found within CardioWise, therefore it will allow for comparisons to be 
made between the two treatments. Before catechin could be used in further assays, its effects 
on cell viability on human macrophages in vitro was assessed (Fig. 5.11). These results show 
that catechin has no detrimental effect on cell viability at 1.5 μg/ml, therefore all results 
observed in future assays are as a result of catechin treatment rather than due to a decrease 
in cell viability. Any potential anti-atherogenic effects of catechin are assessed in the next 
chapter.
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Chapter 6: Assessing the potential anti-atherogenic properties of catechin in vitro 
Assessing the potential anti-atherogenic properties of 
catechin in vitro 
 
6.1 Introduction 
Polyphenols are a large class of anti-oxidants which occur naturally in a wide variety of plants 
and plant products, including nuts, herbs, tea, fruit and vegetables (Moss and Ramji 2016b; 
Bahramsoltani et al. 2017). Since their discovery thousands of polyphenols have been 
uncovered, and early epidemiological studies have revealed positive associations between 
polyphenol intake and reduced risk of a CVD-related event (Moss and Ramji 2016b; 
Bahramsoltani et al. 2017). The largest trial which investigated the potential cardiovascular 
protective effects of polyphenols was a dietary intervention study known as the PREDIMED 
study (Tresserra-Rimbau et al. 2014a; Tresserra-Rimbau et al. 2014b). A total of 7,477 high 
risk Spanish CVD patients were recruited for the study and randomly assigned one of three 
diets which were either low fat control diet; Mediterranean diet supplemented with mixed nuts 
and fruit; and Mediterranean diet supplemented with extra virgin olive oil (Tresserra-Rimbau 
et al. 2014a; Tresserra-Rimbau et al. 2014b). Patients with the highest intake of polyphenols 
had a 37% reduction in their risk of all-cause mortality when compared to the patients with the 
lowest dietary intake of polyphenols (Tresserra-Rimbau et al. 2014b). Further in-depth analysis 
of the PREDIMED study has shown increased polyphenol dietary intake to be associated with 
reduced blood pressure, possibly by enhancing vasodilation via an increase in NO production, 
and reduced serum TG levels but no changes in HDL or LDL serum levels (Medina-Remón et 
al. 2015; Guo et al. 2016; Medina-Remón et al. 2017). 
Flavonoids are the largest subgroup of polyphenols found within a typical diet due to their 
ubiquity in plants (Spencer 2008). Catechin contains two chiral carbons and hence has four 
possible isomers; (+)-catechin, (-)-catechin, (+)-epicatechin and (-)-epicatechin (Fig. 6.1). Due 
to the fact there are several possible forms of the compound, catechin and epicatechin are the 
key flavanols (a major subclass of flavonoids) in fruit (Manach et al. 2004). Furthermore the 
consumption of (+)-catechin and (-)-epicatechin has been associated with a reduced CVD-
related event risk (Arts et al. 2001). The abundance and potential health benefits of flavanols 
provided Cultech Limited with the rationale for including them within their CardioWise 
formulation. (+)-catechin was determined to be the major flavanol within the complete 
CardioWise formulation and therefore this form of catechin was used throughout the study. 
After identifying catechin as a safe potential nutraceutical for atherosclerosis (Chapter 5) by 
observing reductions in both monocyte migration (Fig. 5.6) and ROS production (Fig. 5.7) it 
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was studied in greater detail in our in vitro model systems of atherosclerosis disease 
development. 
 
Fig. 6.1. The different isomers of catechin. Due to catechin having two chiral carbons, it has four possible isomers 
as shown above. 
Initially the effect of catechin on basal gene expression levels (i.e. no pro-inflammatory stimuli 
used to induce gene expression) was assessed by qPCR array. The rationale for qPCR arrays 
is discussed in Chapter 4. Unlike the qPCR arrays performed in Chapter 4 and 8 which use an 
average gene expression baseline derived from all of the control mice, the in vitro qPCR array 
performed in this Chapter used the same analysis strategy that is used for regular qPCRs. 
However due to the cost of the qPCR array plates, independent experiments could not be 
performed in triplicate for in vitro samples unlike regular qPCRs. This leads to no error bar for 
the vehicle control cells as it is always arbitrarily set to 1 during analysis. A total of six 
independent experiments were carried out, however a CT value could not be obtained for every 
repeat due to the low expression levels of some genes and therefore some of data does not 
contain the maximum possible number of independent results. Due to the variation within the 
data, resulting in a smaller chance of differences in gene expression emerging as significant, 
any difference with a p value of less than or equal to 0.1 was considered to be showing a trend 
of change and included in the results section (see Sections 6.3.1 - 6.3.7). Results of the qPCR 
array were also validated against results of regular qPCRs.  
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Due to the large volume of gene expression data generated by the qPCR arrays, it was able 
to guide the study to new areas to explore in vitro that would have previously not been 
addressed. The genes were classified by their function; apoptosis, blood coagulation, cell 
adhesion, cell proliferation, lipid metabolism, stress response and transcriptional regulation. 
These gene classes were investigated in more detail due to their functional importance in the 
progression of atherosclerosis. During early atherosclerotic lesion formation, damaged 
endothelial cells undergo cell apoptosis which results in the recruitment of monocytes 
(Stoneman and Bennett 2004). As macrophages become foam cells, their survivability is 
influenced by a variety of pro-inflammatory cytokines and eventually they undergo apoptosis 
causing their intracellularly stored lipids to become released into the intima of the artery 
(Stoneman and Bennett 2004; Moss and Ramji 2016a). The presence of oxidised lipids triggers 
further recruitment of monocytes resulting in a continuous pro-inflammatory response. As the 
plaque continues to develop, the amount of apoptosis continues to increase and contributes 
to the growth of the lipid-rich necrotic core (Stoneman and Bennett 2004). In mature plaques, 
there is some evidence that macrophage apoptosis can eventually cause VSMCs in the fibrous 
cap to also undergo apoptosis (Stoneman and Bennett 2004). As VSMC apoptosis increases, 
the fibrous cap becomes weaker and eventually ruptures. However whether macrophage 
apoptosis directly influences plaque stability was previously debated (Stoneman and Bennett 
2004). TNF-α is a major pro-inflammatory cytokine which is able to induce macrophage and 
foam cell apoptosis (Moss and Ramji 2016a). ApoE deficient mice also lacking TNF-α were 
found to develop smaller atherosclerotic lesions as a result of decreased lipid accumulation 
(Xiao et al. 2009). Furthermore previous studies have demonstrated that serum starvation 
induces THP-1 macrophage apoptosis (Iida et al. 2002), as a result a combination of serum 
starvation and TNF-α stimulation was used to induce macrophage apoptosis. The level of 
apoptosis was measured by using a fluorescently labelled annexin V protein. This protein is 
able to bind to cell markers of apoptosis, therefore the intensity of the fluorescent signal is 
proportional to the amount of cell apoptosis. Reducing cell apoptosis by catechin may lead to 
a retardation of atherosclerosis disease development. 
Unregulated cell proliferation within the intima of arterial walls can lead to the growth of 
atherosclerotic plaques (Fuster et al. 2010). Mouse models have shown that macrophage 
proliferation could contribute to lesion size and growth as much as monocyte recruitment does 
(Robbins et al. 2013). Therefore targeting macrophage proliferation within atherosclerotic 
lesions may represent a promising therapeutic target in order to slow disease progression. In 
this study, the effect of catechin on cell proliferation was determined by three in vitro assays, 
crystal violet assay, bromouridine ELISA, and cell counting for 7 days. The rationale and brief 
explanation on how the crystal violet assay works can be found in Chapter 3. Bromouridine is 
a uridine molecule with a bromine substituting the fifth carbon. It is incorporated into RNA in 
exactly the same way as uridine but it can be detected by fluorescently labelled antibodies. 
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Therefore the more the RNA is present, the greater the amount of bromouridine incorporation, 
however increased levels of RNA would also be a sign of more cells and more cell proliferation. 
Consequently the stronger the fluorescent signal from the anti-bromouridine antibodies, the 
more cell proliferation has occurred. The final method to assess cell proliferation was by 
counting the number of monocytes over 7 days. As there are two possible factors that may 
affect cell number in this assay, time and treatment type, statistical analysis was performed 
using a GLM. The advantage of using a GLM is that it is able to assess both continuous 
variables (i.e. time) and categorical variables (i.e. treatment type) simultaneously. Additionally 
it can determine if there is a significant interaction between time and treatment type and provide 
answers for more complex hypothesises, for example, the longer the cells are exposed to 
catechin the more effective it becomes. Upon further investigation, the interaction between 
time and treatment type was found to be insignificant and as a result the final statistical analysis 
is based on the effects of both variables in isolation.  
Disruption of cholesterol homeostasis to favour cholesterol uptake and reduce cholesterol 
efflux in macrophages can lead to increased intracellular cholesterol accumulation, resulting 
in the formation of foam cells (McLaren et al. 2011a; Buckley and Ramji 2015). Therefore using 
nutraceuticals to influence cholesterol homeostasis, and attenuated uptake and enhanced 
efflux, would reduce foam cell formation and retard disease progression. After determining the 
effect of catechin on cholesterol uptake and efflux, its effect on cholesterol storage was 
assessed by TLC, a technique that allows major lipid classes to be separated and the 
proportion of total intracellular lipids calculated. 
Mature plaques rely on having a strong fibrous cap, consisting of ECM and VSMCs, in order 
to prevent rupturing and triggering a thrombotic reaction and potentially causing a CVD-related 
event (Newby 2006; Schonbeck et al. 1997; Lusis 2000). If the balance of ECM production 
remains stable or in favour of deposition then the plaque would continue to be relatively stable 
and less likely to rupture and lead to a CVD-related event (Newby 2006). However a wide 
variety of pro-inflammatory cytokines including, IFN-γ and IL-18, can either activate MMPs or 
stimulate their release from macrophages and VSMCs (Schonbeck et al. 1997; Moss and 
Ramji 2016a). As MMP production continues to increase, the more ECM is destroyed in the 
fibrous cap leading to a reduction in the stability of the atherosclerotic plaque and increase the 
risk of rupture. Therefore reducing MMP activity would potentially represent a sign of improved 
plaque stability and reduced risk of a CVD-related event. 
The effect of catechin on M1 phenotype polarisation was also assessed, the rationale and 
background for this assay can be found in Chapter 3. 
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6.2 Experimental Aims 
Details of specific methodologies for each experimental aim are outlined in Chapter 2 and the 
experimental strategies for Chapter 6 are presented in Figs. 6.2 - 6.8. 
 
Fig. 6.2. Experimental strategy used to assess gene expression. Previous studies have suggested that 
differentiating THP-1 monocytes into macrophages with PMA can result in an established M1 phenotype (Park et 
al. 2007). For this reason the murine RAW264.7 macrophages were used to assess the effect of catechin on M1 
macrophage phenotype formation in this study. Arg2, arginase 2; IFN, interferon; iNOS, inducible nitric oxide 
synthase; LPS, lipopolysaccharide. 
 
 
Fig. 6.3. Apoptosis experimental strategy. TNF-α, tumour necrosis factor α. 
 Chapter 6: Catechin  
148 
 
 
 
Fig. 6.4. Strategies for cell proliferation assays. 
 
 
Fig. 6.5. Cholesterol uptake experimental strategy. PFA, paraformaldehyde. 
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Fig. 6.6. Experimental strategy for assessing cholesterol efflux. AcLDL, acetylated LDL; ApoA1, 
apolipoprotein A1. 
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Fig. 6.7. Strategy for determining the proportion of intracellular lipid classes. 
 
 
Fig. 6.8. MMP activity experimental strategy. MMP, matrix metalloproteinases. 
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6.3 Results 
6.3.1 The expression of all genes present on the qPCR array following catechin 
treatment 
Fig. 6.9 shows the global significant and non-significant gene expression changes in human 
THP-1 derived macrophages following treatment with 1.5 μg/ml of catechin for 3 hours. The 
housekeeping genes: B2M; GAPDH; hypoxanthine phosphoribosyltransferase (HPRT)1; and 
ribosomal protein lateral stalk subunit P0 (RPLP0); were found to be stable during the assay 
and were therefore used to calculate gene expression fold changes induced by CardioWise. A 
total of 37 genes were found to have their expression altered by at least 10% and 3 of those 
genes were found to be significantly altered. The genes have been classed by their function 
(according to the literature provided by Qiagen which accompanied the Atherosclerosis RT2 
Profiler PCR Arrays) and will be explored in greater detail in the subsequent sections.  
 
Fig. 6.9. Volcano plot showing global gene expression changes in human macrophages treated with 
catechin vs vehicle control cells. Gene transcript levels of 84 genes were assessed in human THP-1 derived 
macrophages which were treated with either a vehicle control or a catechin (1.5 μ/ml) for 3 hours. All genes present 
on the Qiagen RT2 profiler PCR Array were plotted. The log fold change in the treated cells versus the vehicle 
control cells is represented on the x-axis. The y-axis shows the -log10 of the p value. A p value of 0.05 (dashed 
line) and a fold changes of ±10% (solid lines) are indicated. Significantly altered gene expressions are indicated by 
a black triangle and non-significant trends of change (approximately p<0.1) are indicated by a black square. 
6.3.2 The expression of a gene involved in the regulation of apoptosis is attenuated by 
catechin in human macrophages 
First apoptosis signal (FAS) receptor is known as a death receptor present on the surface of 
cells and its activation can lead to apoptosis, therefore changes in FAS expression may 
correlate with possible changes in cell apoptosis. In the presence of catechin, there was a 
trend of decrease in the expression of FAS of 21.4% when compared to cells treated with the 
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vehicle control (Fig. 6.10). However these results are based on two independent experiments 
and must be repeated before any firm conclusions can be drawn. 
 
Fig. 6.10. Catechin attenuates the expression of a gene involved in the regulation of apoptosis. Gene 
transcript levels of FAS were assessed in PMA differentiated THP-1 macrophages that were either treated with 
vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated using the 
comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) with 
values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean from two 
independent experiments.  
6.3.3 Catechin alters the expression of genes involved in blood coagulation and 
circulation control in human macrophages 
Endoglin (ENG) and platelet-derived growth factor subunit B (PDGFB) are two genes involved 
in the regulation of blood coagulation and circulation as both are able to play key roles in 
angiogenesis. Catechin treatment increased ENG expression by 53.0% (p=0.087; Fig. 6.11A), 
whereas the expression PDGFB was attenuated by 24.7% (p=0.071; Fig. 6.11B) compared to 
the vehicle control treated cells. However neither result was found to be significant. 
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Fig. 6.11. The expression of genes involved in blood coagulation and circulation are altered by catechin. 
Gene transcript levels of ENG (A) and PDGFB (B) were assessed in PMA differentiated THP-1 macrophages that 
were either treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were 
calculated using the comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 
and RPLP0) with values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the 
mean ± SEM from three (B) or five (A) independent experiments. Statistical analysis was performed using a t- test 
(unequal variances). 
6.3.4 The expression of cell adhesion molecules is down-regulated in human 
macrophages in the presence of catechin 
Laminin subunit alpha 1 (LAMA1), E-selectin (SELE) and L-selectin (SELL) are all genes which 
are able to influence cell recruitment and migration, therefore reducing their expression may 
lead to attenuated atherosclerosis plaque formation. LAMA1 and SELE showed trends of 
decrease in expression following catechin treatment of 68.2% and 13.0% (p=0.092) 
respectively when compared to the vehicle control treated cells (Fig. 6.12A and B). The 
expression of SELL was significantly attenuated by 27.0% (p=0.015) in the presence of 
catechin (Fig. 6.12C). 
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Fig. 6.12. Catechin attenuates the expression of cell adhesion molecule genes. Gene transcript levels of 
LAMA1 (A), SELE (B) and SELL (C) were assessed in PMA differentiated THP-1 macrophages that were either 
treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated 
using the comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) 
with values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM 
from two (A) or five (B and C) independent experiments. Statistical analysis was performed using a t- test (unequal 
variances) where * p <0.05. 
6.3.5 Catechin attenuates the expression of a gene involved in regulating cell growth 
and proliferation in human macrophages 
Vascular endothelial growth factor (VEGF)A is a growth factor that can influence a variety of 
physiological processes including cell proliferation, angiogenesis and cell migration. Catechin 
attenuated VEGFA expression by 15.0% (p=0.028) when compared to the vehicle control only 
treated cells (Fig. 6.13). 
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Fig. 6.13. The expression of a gene associated with cell growth and proliferation is down-regulated by 
catechin. Gene transcript levels of VEGFA were assessed in PMA differentiated THP-1 macrophages that were 
either treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated 
using the comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) 
with values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM 
from six independent experiments. Statistical analysis was performed using a t- test (unequal variances) where * p 
<0.05. 
6.3.6 Catechin treatment decreases the expression of a lipid transport and metabolism 
gene 
The LDLr is a key receptor in LDL uptake, therefore changes in LDLr expression may represent 
changes in cholesterol metabolism. Catechin treatment reduced LDLr expression by 7.3% 
(p=0.024) when compared to the vehicle control cells (Fig. 6.14). 
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Fig. 6.14. Catechin attenuates the expression of a key gene implicated in the control of lipid transport and 
metabolism. Gene transcript levels of LDLR were assessed in PMA differentiated THP-1 macrophages that were 
either treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated 
using the comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) 
with values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM 
from six independent experiments. Statistical analysis was performed using a t- test (unequal variances) where * p 
<0.05. 
6.3.7 The expression of a gene involved in stress responses is down-regulated by 
catechin 
As previously discussed, IFN-γ is often considered a master regulator of atherosclerosis 
disease development, therefore changes in the expression of this cytokine may affect the 
speed of disease progression. The expression of IFN-γ was significantly decreased by 27.6% 
(p=0.011) following catechin treatment when compared to the vehicle control cells (Fig. 6.15). 
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Fig. 6.15. Catechin attenuates the expression of a stress response associated gene. Gene transcript levels 
of IFN-γ were assessed in PMA differentiated THP-1 macrophages that were either treated with vehicle (vehicle 
control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated using the comparative Ct method 
and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) with values from the vehicle 
treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from five independent 
experiments. Statistical analysis was performed using a t- test (unequal variances) where * p <0.05. 
6.3.8 The expression of transcriptional regulators can be reduced by catechin 
Both NR1H3 and Peroxisome proliferator activated receptor delta (PPARD) are regulators of 
transcription and have been associated with atherosclerosis disease progression (see Chapter 
4 for further details). Catechin treatment caused a non-significant trend of decrease in NR1H3 
expression of 13.0% (p=0.094; Fig. 6.16A) when compared to the vehicle control cells. On the 
other hand the expression of PPARD was significantly increased by 8.2% (p<0.001) in 
comparison to the vehicle control cells (Fig. 6.16B). 
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Fig. 6.16. The expression of transcriptional regulators is down-regulated by catechin. Gene transcript levels 
of NR1H3 (A) and PPARD (B) were assessed in PMA differentiated THP-1 macrophages that were either treated 
with vehicle (vehicle control) or catechin (1.5 μg/ml) for 3 hours. Gene transcript levels were calculated using the 
comparative Ct method and normalised to four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0) with 
values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from 
five independent experiments. Statistical analysis was performed using a t- test (unequal variances) where *** p 
<0.001. 
6.3.9 The results of the qPCR array were confirmed by regular qPCRs 
The expressions of ICAM-1 (Fig. 6.17A), MCP-1 (Fig. 6.17B) and macrophage scavenger 
receptor (MSR)-1 (Fig. 6.17C) were simultaneously assessed by regular qPCR in order to 
confirm the accuracy of the qPCR arrays. Catechin was found to attenuate ICAM-1, MCP-1 
and MSR-1 expression by 6.5%, 12.2% and 20.8% respectively. The same genes in qPCR 
array analysis were reduced by 2.1%, 6.7% and 13.3%, therefore similar trends are seen in 
the regular qPCRs and qPCR arrays. 
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Fig. 6.17. A comparison between the expression of ICAM-1, MCP-1 and MSR1 from regular qPCR and qPCR 
array results. Gene transcript levels of ICAM-1 (A), MCP-1 (B) and MSR-1 (C) were assessed in PMA differentiated 
THP-1 macrophages that were either treated with vehicle (control) or catechin (1.5 μg/ml) for 3 hours. Results on 
the left are from regular qPCRs whereas the results on the right are from qPCR arrays. The same cDNA was used 
for both qPCR techniques. Gene transcript levels were calculated using the comparative Ct method and normalised 
to either GAPDH (regular qPCR) or four housekeeping genes (B2M, GAPDH, HPRT1 and RPLP0; qPCR array) 
with values from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM 
from at least three independent experiments. Statistical analysis was performed using a t- test (unequal variances). 
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6.3.10 Cell apoptosis in human macrophages is unaffected by catechin treatment 
Due to the reduction in the expression of the cell surface death receptor FAS (Fig. 6.10), the 
effect of catechin treatment on apoptosis was assessed. During the progression of 
atherosclerotic plaque formation, the apoptosis of foam cells causes them to release their lipid-
rich contents into the wall of the artery which accumulates to form the lipid-rich necrotic core. 
A combination of serum starvation and TNF-α stimulation (100 ng/ml) was found to significantly 
increase cell apoptosis in our in vitro model by 1.39 fold (p<0.001) in comparison to the vehicle 
control (Fig. 6.18). There was no significant reduction in cell apoptosis following treatment with 
catechin. 
  
Fig. 6.18. Cell apoptosis in human macrophages is not prevented by catechin. PMA differentiated THP-1 
macrophages were treated with vehicle (vehicle control), or a combined treatment of serum starvation and 
stimulation with TNF-α (100 ng/ml; Apoptosis) or serum starved and stimulated with TNF-α (100 ng/ml) in the 
presence of catechin (1.5 μg/ml) for 3 hours to evaluate cell apoptosis. The vehicle control was arbitrarily assigned 
as 1 and remaining data normalised to this. The data are presented as the mean ± SEM from three independent 
experiments. Statistical analysis was performed using a one-way ANOVA with a Dunnett post-hoc analysis where 
*** p <0.001. 
6.3.11 The proliferation of human monocytes and macrophages is attenuated following 
catechin treatment 
Catechin treatment was found to attenuate the expression of VEGFA, a gene capable of 
stimulating cell proliferation (Fig. 6.13). As a result, the effect of catechin on macrophage 
proliferation was determined by either a crystal violet assay (Fig. 6.19A) or bromouridine ELISA 
(Fig. 6.19B). A significant reduction in cell proliferation of 12.6% and 13.8% was observed 
following treatment with catechin after 24 hours using crystal violet assay or bromouridine 
ELISA respectively (p=0.029 and p=0.034). A 24 hour time point was chosen for this assay to 
ensure sufficient time for determination of changes in the level of cell proliferation. Monocyte 
proliferation was also assessed in THP-1 monocytes which were grown for 7 days and fresh 
media containing either catechin or vehicle control added on days 0, 1, 2, 3 and 4 (Fig. 6.19C). 
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Cell proliferation had a significant positive association with time (p<0.001; adj-R2=0.57), 
furthermore cell proliferation was significantly lower in cells which had received catechin by 
21.9% (p=0.001). There was no significant effect on the interaction between time and treatment 
type. 
 
Fig. 6.19. Catechin reduces cell proliferation in human monocytes and macrophages. Cell proliferation was 
assessed by either crystal violet assay (A) or bromouridine ELISA (B) in THP-1 derived macrophages that were 
treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for 24 hours. Values from vehicle treated cells were 
given an arbitrary value of 1 and all other data are normalised to this (A - B). Cell proliferation was also assessed 
in THP-1 monocytes (C) that were either treated with vehicle (dashed line) or catechin (1.5 μg/ml; solid line) for 7 
days. Values from vehicle treated cells on day 0 were given an arbitrary value of 1 and all other data are normalised 
to this (C). The data are presented as the mean ± SEM from three (A) or four (B) independent experiments. 
Statistical analysis was performed using a t-test (equal variances) where * p ≤0.05. The prediction of average 
monocyte proliferation fold change as calculated by a generalised linear model with a Gaussian error distribution 
and log link function is displayed ± SEM from three independent experiments (C). 
6.3.12 Cholesterol uptake and efflux are unaffected by catechin in human macrophages 
Due to the attenuated expression of LDLr (Fig. 6.14), the effect of catechin treatment on 
cholesterol uptake was assessed. Human PMA differentiated THP-1 macrophages were 
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treated with Dil-oxLDL in the presence of vehicle control or catechin for 24 hours. Following 
Dil-oxLDL only treatment, the THP-1 macrophages were able increase their cholesterol uptake 
by 1.87 fold (p<0.001; Fig. 6.20A). Catechin did not significantly alter cholesterol uptake. 
Simultaneously the levels of cholesterol efflux were also measured to better understand the 
effect of catechin treatment on foam cell formation. Differentiated THP-1 macrophages, pre-
loaded with cholesterol, were treated with ApoA1 (10 µg/ml) for 24 hours to stimulate the efflux 
of their intracellular radiolabelled cholesterol. ApoA1 stimulation caused the cells to release 
19.4% of their cholesterol into the surrounding media (Fig. 6.20B), an increase of 1.44 fold 
(p<0.001). No significant changes in cholesterol efflux were observed following treatment with 
catechin. 
 
Fig. 6.20. Catechin does not alter cholesterol uptake or efflux from human macrophages. (A) PMA-
differentiated THP-1 macrophages were loaded with Dil-oxLDL for 24 hours in the presence of vehicle or catechin 
(1.5 μg/ml). The vehicle control was arbitrarily assigned as 1 and the remaining data normalised to this. The data 
are presented as the mean ± SEM from three independent experiments. Statistical analysis was performed using 
a one-way ANOVA with a Games-Howell post-hoc analysis where *** p ≤0.001. (B) PMA-differentiated THP-1 
macrophages were loaded with [4-14C]cholesterol and acLDL for 24 hours prior to a further 24 hour treatment with 
ApoA1 (10 µg/ml) in the presence of vehicle or ApoA1 in the presence of catechin (1.5 μg/ml). The data are 
presented as the mean ± SEM from three independent experiments. Statistical analysis was performed using a 
one-way ANOVA with a Dunnett post-hoc analysis on squared-transformed data where *** p ≤0.001. 
6.3.13 Catechin did not alter lipid accumulation within murine macrophages 
To determine the effect of catechin on cholesteryl ester accumulation in macrophages, the 
cells were treated with vehicle control, acLDL (25 μg/ml) or acLDL and catechin. The TLC 
assay was performed in RAW264.7 macrophages as previous work has demonstrated that 
they are capable of producing higher levels of intracellular lipids when compared to THP-1 
macrophages (Gallagher 2016). The different lipid fractions were separated by TLC and the 
activity of incorporated [14C]acetate was measured by a scintillation counter (Fig. 6.21). The 
levels of lipids present in the TPL fraction increased by 1.62 fold following stimulation with 
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acLDL, whereas FC, FFA and TG fractions were reduced by 55%, 36% and 71% respectively. 
There were no observable change in the accumulation within the CE fraction following acLDL 
treatment. Catechin did not affect the proportions of the lipid fractions when compared to the 
acLDL only treated cells. However these results are based on one independent experiment 
and must be repeated before any firm conclusions can be drawn. Due to the lack of changes 
observed in cholesterol uptake and efflux (Fig. 6.20), it was decided not to proceed further with 
this assay. 
 
Fig. 6.21. Catechin does not influence lipid accumulation or proportions in murine macrophages. Murine 
macrophages were loaded with [14C]acetate for 24 hours in the presence or absence of acLDL (25 μg/ml). Cells 
were treated with either vehicle control (grey), acLDL and vehicle control (white) or acLDL and catechin (1.5 μg/ml; 
black). The data are displayed as a percentage of the total amount of lipid extracted. The data are presented as the 
mean from one independent experiment performed in triplicate. TPL, total polar lipid; FC, free cholesterol; FFA, free 
fatty acid; TG, triacylglycerol; CE, cholesterol ester. 
6.3.14 Catechin reduces MMP activity in human macrophages 
The activity and expression of MMPs has previously been shown to be influenced by IFN-γ 
(Moss and Ramji 2015). As IFN-γ expression was attenuated following catechin treatment (Fig. 
6.15), its effects on MMP activity were determined. The stability of mature atherosclerotic 
plaques depends on the deposition of ECM in the fibrous cap which covers the lesion. If MMP 
activity become unregulated and increases ECM degradation it can lead to the plaque 
becoming unstable and rupturing. The effects of catechin on MMP activity was determined at 
both 3 and 24 hours to delineate both short-term and long-term actions. THP-1 macrophages 
were found to have reduced MMP activity of 28.8% and 29.6% respectively (p=0.036 and 
p=0.033; Fig. 6.22) when compared to the vehicle control cells. 
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Fig. 6.22. MMP activity in human macrophages is attenuated by catechin. PMA differentiated THP-1 
macrophages were treated with vehicle (vehicle control) or catechin (1.5 μg/ml) for either 3 (A) or 24 (B) hours to 
evaluate MMP activity. The vehicle control was arbitrarily assigned as 1 and remaining data normalised to this. The 
data are presented as the mean ± SEM from three independent experiments. Statistical analysis was performed 
using a t- test (equal variances) where * p ≤0.05. 
6.3.15 M1 Macrophage polarisation is not altered by catechin in murine macrophages 
The expression of five M1 macrophage markers, Arg2, IL-1β, IL-6, iNOS and MCP-1, were 
assessed in murine RAW264.7 macrophages following co-stimulation with IFN-γ (250 U/ml) 
and LPS (100 ng/ml) to determine the effect of catechin on macrophage phenotype 
polarisation. There are concerns within the literature which suggest that using PMA to 
differentiate THP-1 monocytes results in an established M1 macrophage phenotype, therefore 
this assay was performed in murine RAW264.7 macrophages (Park et al. 2007). The 
expression of Arg2 (p<0.001), IL-1β (p<0.001), IL-6 (p<0.001), iNOS (p<0.001) and MCP-1 
(p<0.001) was significantly increased following co-stimulation treatment (Fig. 6.23). Incubation 
with catechin increased Arg2 expression by 92.0% (p=0.014). No changes in IL-1β, IL-6, iNOS 
or MCP-1 expression was observed following catechin treatment when compared to the co-
stimulation only cells. 
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Fig. 6.23. M1 polarisation in murine macrophages is not influenced by catechin. The expression of Arg2 (A), 
IL-1β (B), IL-6 (C), iNOS (D) and MCP-1 (E) was assessed in murine RAW264.7 macrophages that were either 
treated with vehicle (vehicle control); with IFN-γ (250 U/ml) and LPS (100 ng/ml); with IFN-γ (250 U/ml) and LPS 
(100 ng/ml) in the presence of catechin (1.5 μg/ml) for 24 hours. Gene expression levels were assessed using 
qPCR and calculated using the comparative Ct method and normalised to β-actin levels with values from IFN-γ and 
LPS treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from three independent 
experiments. Statistical analysis was performed using a one-way ANOVA with either Games-Howell (A, B, C and 
D) or a Tukey (E) post-hoc analysis where * p ≤0.05, ** p ≤0.01 and *** p ≤0.001. 
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6.4 Discussion 
The results from this study show that catechin has some potential as a nutraceutical for 
preventing atherosclerosis disease development but the results from in vitro studies still remain 
a little mixed. Catechin was found to attenuate six pro-atherogenic actions, including; cell 
adhesion molecule expression, monocyte migration, cell proliferation, ROS production, MMP 
activity and IFN-γ gene expression. However catechin was found to have no effect on lipid 
transport, lipid storage, cell apoptosis or M1 phenotype polarisation. These assays highlight 
the possible use of catechin as a preventative or an add-on treatment to target specific steps 
within atherosclerosis plaque formation rather than as a single standalone therapy. The current 
literature remains unclear about the efficacy of catechin as an anti-atherogenic nutraceutical 
and relatively little is known about its mechanism of action (Moss and Ramji 2016b). Our study 
provided an ideal opportunity to explore the effects of catechin in our in vitro models and 
explore possible mechanisms of action. 
The qPCR array assessed the expression of 84 genes simultaneously and observed changes 
of at least 10% in 37 genes, of which 3 were found to be significant (Fig. 6.9). Those three 
genes were IFN-γ, SELL and VEGFA. The significant role IFN-γ plays during atherosclerosis 
development has previously been discussed in Chapter 1 and extensively covered in recent 
reviews (Moss and Ramji 2016a; McLaren and Ramji 2009; Moss and Ramji 2015; Ramji and 
Davies 2015). Catechin was found to significantly reduce the expression of IFN-γ and should 
be seen as a potential dampening of the whole pro-inflammatory setting which enhances 
atherosclerosis plaque formation. However this hypothesis needs to be tested in vivo before 
any conclusions can be drawn. The effect of catechin on IFN-γ gene expression in THP-1-
derived macrophages has not previously been assessed in vitro but other studies have shown 
that catechin and other flavanols in green tea are capable of attenuating IFN-γ stimulated gene 
expression, possibly via blocking IFN-γ signalling through the JAK-STAT pathway (Leong et 
al. 2009). Two key IFN-γ inducible genes are MCP-1 and ICAM-1, which were not found to 
have their expression significantly altered in the qPCR array. Furthermore there were no 
reductions observed in MCP-1 or ICAM-1 secretion following catechin treatment (Fig. 5.8). 
Despite a reduction in IFN-γ gene expression, the results of our study do not indicate any major 
cardiovascular protective effects further downstream based solely on changes in IFN-γ 
signalling through the JAK-STAT pathway. However there are a variety of JAK-STAT 
independent IFN-γ signalling pathways which should be investigated in future studies (Green 
et al. 2017). 
The second gene found to be significantly reduced in the qPCR array was SELL. Selectins are 
transmembrane protein molecules capable of influencing leucocyte adhesion and rolling on 
activated endothelial cells (McEver 2015; Galkina and Ley 2007). They also play a key role in 
the recruitment of immune cells to the initial site of atherosclerotic lesion formation (McEver 
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2015; Galkina and Ley 2007). There are a variety of selectins, however the three predominantly 
involved in cell recruitment are SELL, which is expressed on leucocytes, SELE which is 
expressed on the surface of activated endothelial cells and P-selectin (SELP) which is 
expressed on platelets (McEver 2015; Galkina and Ley 2007). Generally it is thought that SELL 
is pro-atherogenic as mice models deficient in this selectin have shown a reduction in the 
recruitment of monocytes, lymphocytes and neutrophils in an inflammatory setting (Tedder et 
al. 1995). Furthermore, the transplantation of SELL-/- lymphocytes into ApoE deficient mice 
showed that B- and T-cell migration was attenuated by 57% and 50% respectively when 
compared to transplantation of wild type lymphocytes (Galkina et al. 2006). However there are 
also other studies which have shown SELL to have cardiovascular protective effects. ApoE 
deficient mice that were also lacking SELL were found to have accelerated atherosclerosis 
development due to a 1.3 fold increase in the number of leucocytes within the aorta (Galkina 
et al. 2014). Although the study observed a decrease of 2 fold in the number of B-cells within 
the aorta, the number of macrophages present increased by 1.5 fold (Galkina et al. 2014). This 
study suggests that SELL may actually exert anti-atherogenic effects. The results of our study 
indicate that catechin is capable of attenuating SELL expression in human macrophages (Fig. 
6.12). Furthermore catechin also showed trends of decrease in the expression of SELE and 
LAMA1. Smaller atherosclerotic lesions have been found to develop in mouse model systems 
which are deficient in SELE (Collins et al. 2000). On the other hand, LAMA1 is an important 
glycoprotein within the basement membrane and provides it with structural stability, and has 
additionally been implicated in cell recruitment (Colognato and Yurchenco 2000). The reduced 
expression of LAMA1, SELE and SELL following catechin treatment may provide a mechanism 
of action by which reduced cell recruitment was achieved previously (Fig. 5.9). As the previous 
assay didn’t involve any ECM, it is therefore most likely that catechin reduces monocyte 
migration by reducing the expression of SELE and SELL. Previous studies have observed a 
reduction in SELL protein levels in obese individuals following 4 weeks of flavanol-rich cocoa 
consumption (McFarlin et al. 2015). The level of secreted SELE by HUVECs has also been 
found to be reduced following treatment with a mixture of epicatechin and catechin (Carnevale 
et al. 2014). The results of our study show similar trends to the current literature. 
VEGFA is a growth hormone which plays a major role in promoting angiogenesis (Greenberg 
and Jin 2013; Smith et al. 2015; Camaré et al. 2017). Not only is it vital for the maintenance of 
vascular function and tissue homeostasis, it has also been found to influence gene expression, 
metabolism, migration, survival and proliferation of a variety of cell types including 
macrophages (Greenberg and Jin 2013; Smith et al. 2015; Camaré et al. 2017). However 
unregulated over expression of VEGF has been implicated in a variety of diseases including 
atherosclerosis (Greenberg and Jin 2013; Camaré et al. 2017). The anaerobic conditions 
within the lipid-rich necrotic core stimulates the production and release of VEGF, which in turn 
promotes angiogenesis within the plaque (Greenberg and Jin 2013). Eventually these newly 
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formed blood vessels can either haemorrhage or cause the plaque to rupture, though it remains 
unclear if interplaque haemorrhage directly causes plaque rupturing (Greenberg and Jin 2013). 
ApoE deficient mouse models have shown VEGF to enhance atherosclerosis disease 
development (Heinonen et al. 2013; Celletti et al. 2001). In our study, we found catechin to 
significantly reduce the expression of VEGFA (Fig. 6.13), indicating possible downstream 
benefits such as reduced monocyte migration (Fig. 5.9), reduced proliferation (Fig. 6.19) and 
improved plaque stability. Although the effect of catechin on VEGFA has not been explored in 
THP-1 macrophages before, previous studies using human cells have also shown other 
flavanols to inhibit the expression of VEGFA (Nakanishi et al. 2015; Zhu 2011; Neuhaus et al. 
2004). The results from the qPCR array can be considered accurate as similar trends in gene 
expression changes were seen by regular qPCR (Fig. 6.17). The main aim of the qPCR array 
was to generate data from genes we would not normally assess with a regular qPCR in order 
to guide us into new in vitro assays to explore the possible cardiovascular protective effects of 
catechin in as greater detail as possible. 
As atherosclerotic plaques continue to mature, macrophages and foam cells undergo 
apoptosis and necrosis which causes them to expel their lipid-rich contents into the wall of the 
artery and increase the size of the lipid-rich necrotic core (Stoneman and Bennett 2004). As 
well as releasing their lipid contents, macrophages also secrete a variety of proteins and 
enzymes, including MMPs, into the intracellular space (McLaren et al. 2011a; Ruddy et al. 
2016). As well as activating MMPs, their expression is also induced by several pro-
inflammatory cytokines and lead to a weakening of the fibrous cap by degradation of the ECM 
present (Moss and Ramji 2016a; Ruddy et al. 2016). Therefore targeting both cell apoptosis 
and MMP activation may represent a potential therapeutic window to improve plaque stability. 
FAS is a cell surface receptor that causes apoptosis when activated (Peter et al. 2015). A trend 
of decrease in FAS expression was found following catechin treatment (Fig. 6.10), therefore 
the effect of catechin on cell apoptosis was assessed (Fig. 6.18). Previous studies have shown 
that catechin and other flavanols are capable of attenuating cell apoptosis both in vitro and in 
vivo (Tanigawa et al. 2014; Mohan et al. 2017; Yu et al. 2017). However this study was unable 
to observe any changes in cell survivability following catechin treatment during serum 
starvation and TNF-α induced apoptosis (Fig. 6.18). As catechin is an anti-oxidant perhaps 
apoptosis should have been induced by oxidative stress in a manner similar to the study 
performed by Tanigawa et al. (2014), which did observe improved cell survivability following 
(+)-catechin treatment of murine macrophages. 
Previous studies have demonstrated that IFN-γ is capable of inducing the expression and 
activation of MMPs in macrophages (Moss and Ramji 2015). As catechin was found to be 
capable of attenuating the expression of IFN-γ (Fig. 6.15), its effect on MMP activity was 
determined. Catechin decreased MMP activity in human macrophages after both 3 and 24 
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hours (Fig. 6.20). The reduction in MMP activity was consistent and there were no further 
reductions from prolonged exposure to catechin meaning the maximum reduction was 
achieved in the first 3 hours in vitro. The reduction in MMP activity also correlates with reduced 
IFN-γ expression (Fig. 6.15). Previous work has shown IFN-γ to be a pro-inflammatory cytokine 
capable of regulating MMP activity (Moss and Ramji 2015; Moss and Ramji 2016a). The results 
of this study fit with the current literature which shows that catechin and other flavanols are 
capable of attenuating the expression and activation of MMPs (Kim-Park et al. 2016; 
Nowakowska and Tarasiuk 2016; Wang et al. 2016; Roomi et al. 2017; Owczarek et al. 2017; 
Sato et al. 2017). MMP9, a key protease in atherosclerosis disease development, was found 
to have its production and release from PMA differentiated THP-1 macrophages reduced 
following treatment with epigallocatechin gallate (Wang et al. 2016). These results imply that 
catechin would improve plaque stability, however this still needs to be assessed in vivo. 
Furthermore, our study investigated general MMP activity and future studies should investigate 
the effect of catechin on specific MMPs. Additionally as MMP gene expression was unaffected 
in our study, it implies that the reduction of MMP activity was due to inhibition of the enzyme 
itself rather than at the expression level, therefore future assays should also explore how 
catechin achieves this and whether it exerts this effect indirectly by increasing the production 
and secretion of tissue inhibitors of metalloproteinases (TIMPs). Previous studies have found 
flavanols to increase the secretion of TIMPs and this therefore represents a possible 
mechanism by which catechin attenuates MMP expression (Garbisa et al. 2001; Lewandowska 
et al. 2013). 
The reduction in VEGFA gene expression (Fig. 6.13) implied that catechin may be able to 
attenuate cell proliferation. Uncontrolled cell proliferation within the atherosclerotic lesion can 
lead to it increasing in size, as a consequence attenuating macrophage proliferation would 
potentially retard disease progression (Fuster et al. 2010; Robbins et al. 2013). A significant 
decrease in human monocyte and macrophage proliferation was observed as a result of 
incubation with catechin (Fig. 6.19). Furthermore periodic treatment with catechin was found 
to maintain this reduction in cell proliferation, however accumulative catechin treatment did not 
affect the rate of proliferation (Fig. 6.19C). The results of this study coincide with results in the 
current literature which have found catechin and other flavanols to reduce cell proliferation in 
vitro (Baker and Bauer 2015; Papademetrio et al. 2013).  
Due to catechin being found to reduce monocyte recruitment (Fig. 5.9) and cell proliferation 
(Fig. 6.19) in vitro, it implies that catechin has the potential to reduce atherosclerotic lesion 
size in vivo by reducing the cellular content within the lesion. Indeed others have observed 
treating mice with green tea extracts results in smaller atherosclerotic lesions (Chyu 2004; 
Minatti et al. 2012; Morrison et al. 2014). ApoE deficient mice fed epigallocatechin gallate for 
either 21 or 42 days were found to have plaque formation reduced by 55% and 73% 
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respectively (Chyu 2004). A significant reduction of 35% in the area of atherosclerotic lesions 
was found in LDLr knockout mice following treatment with green tea extract after 4 weeks 
(Minatti et al. 2012). Furthermore epicatechin treatment for 20 weeks in ApoE*3-Liden mice 
resulted in smaller lesion formation (Morrison et al. 2014). Our results of reduced cell 
recruitment and proliferation may represent the mechanism behind smaller lesion formation 
following flavanol treatment in the studies mentioned above. Atherosclerotic plaques which are 
considered vulnerable to rupturing tend to have higher cellular content, especially 
macrophages, when compared to more stable plaques (Wilson 2010; Seneviratne et al. 2013). 
When considering the reduced MMP activity (Fig. 6.22) and VEGFA expression (Fig. 6.13) in 
addition to our cell recruitment and proliferation assays, the results suggest catechin has the 
potential ability to improve plaque stability and reduce the risk of rupture. However the effect 
of catechin on plaque stability in vivo remains unclear at this present time and needs to be 
assessed in future studies. 
The imbalance of cholesterol homeostasis to favour cholesterol uptake over cholesterol efflux 
in macrophages leads to increased intracellular cholesterol accumulation and foam cell 
formation (McLaren et al. 2011a). Catechin treatment of human PMA differentiated THP-1 
macrophages had no effect on either cholesterol uptake or cholesterol efflux (Fig. 6.20), 
despite a significant reduction in LDLr expression (Fig. 6.14), indicating that catechin is unable 
to attenuate foam cell formation. Few studies have assessed the effect of flavanols on 
cholesterol homeostasis in vitro. Previous studies have shown epigallocatechin gallate is 
capable of attenuating intracellular cholesterol accumulation (Bursill and Roach 2006). A more 
recent study has observed decreases in oxLDL uptake in both human THP-1 derived and 
primary macrophages following epigallocatechin gallate treatment (Chen et al. 2017d). As far 
as we are aware this is the first in vitro study to directly assess the effect of catechin on 
cholesterol uptake and efflux. Unsurprisingly as catechin did not affect cholesterol uptake and 
efflux, there were also no observable changes in the proportions of the major intracellular lipid 
classes (Fig. 6.21). However the results are based on a single independent experiment and 
requires further investigation in future studies. 
Formation of M1 phenotype macrophages should be seen as an important therapeutic target 
for retarding atherosclerosis disease progression. The expression of four markers of M1 
macrophage phenotype, IL-1β, IL-6, iNOS and MCP-1, were all unaffected following catechin 
treatment in murine macrophages (Fig. 6.23). However the expression of Arg2 was 
significantly increased (Fig. 6.23A). Earlier studies also found that (+)-catechin had no effect 
on IL-1β or IL-6 expression in primary white blood cells from cows (Sehm et al. 2005). More 
recent studies have found the expression and release of IL-1β, IL-6 and iNOS was significantly 
reduced following treatment with either polyphenol-rich cocoa or epicatechin in both THP-1 
macrophages and human neutrophils (Marinovic et al. 2015; Dugo et al. 2017). It is worth 
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noting that neither of these studies used (+)-catechin specifically as part of their treatment and 
as a result their results may be compound specific. Epicatechin has also been shown to reduce 
the expression of Arg2 after 24 hours (Schnorr et al. 2008). The significant increase in Arg2 
expression following (+)-catechin treatment appears to be gene specific rather than an 
indication of increased M1 phenotype formation as the other four genes assessed were 
unaffected. The effect of (+)-catechin on Arg2 expression should be investigated further in 
future studies. Overall catechin treatment had no effect on M1 phenotype polarisation in murine 
macrophages. 
This is the first study to assess the potential cardiovascular health benefits of (+)-catechin in 
such great detail. Although it appears affect only some steps in atherosclerosis disease 
development rather than all of them, it did attenuate monocyte migration, cell proliferation, 
ROS generation, MMP activity and IFN-γ expression (summarised in Fig. 6.24). Despite not 
preventing either cell apoptosis, M1 macrophage polarisation or foam cell formation, catechin 
never exerted any detrimental effects. Catechin was only found to have anti-inflammatory 
effects and did not appear to possess any pro-atherogenic properties, this surely makes (+)-
catechin an exciting novel nutraceutical worth pursuing. This study has also helped our 
understanding about the mechanism of action by which catechin and other flavanols may exert 
their anti-atherogenic effects. Many other studies have found flavanols to reduce 
atherosclerotic lesion size (Chyu 2004; Minatti et al. 2012; Morrison et al. 2014). This reduction 
in lesion size may be due to the reduced cell migration and proliferation observed in this study. 
Reduced circulating oxLDL levels have been seen in several in vivo studies following catechin 
and other flavanol treatment, possibly due to reduced ROS generation found within this study 
(Babu et al. 2008; Tinahones et al. 2008). The results of our study also suggest that catechin 
would improve plaque stability due to reduced cellular content within the plaque as a result of 
less cell migration and proliferation, in addition to better maintenance of the fibrous cap due to 
reduced MMP activity. Catechin treatment may also provide a systemic dampening of the 
inflammatory response to oxLDL accumulation within the wall of arteries due to a decrease in 
IFN-γ expression. However the effect of catechin on plaque stability and reduced IFN-γ 
expression still need to be explored in future in vivo studies before any conclusions can be 
drawn. These in vitro results justify further exploration of catechin, both in vitro and in vivo, to 
fully assess its potential cardiovascular protective effects. 
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Fig. 6.24. Summary of the potential anti-atherogenic properties of catechin. The steps potentially reduced in 
atherosclerosis disease progression following (+)-catechin treatment are highlighted in green. Possible 
mechanisms for these reductions are also included.
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Chapter 7: The effects of catechin in wild type mice fed a high fat diet 
The effects of catechin in wild type mice fed a high fat diet 
 
7.1 Introduction 
The in vitro results presented in Chapter 6 showed that catechin has great potential as an anti-
inflammatory nutraceutical therapy for slowing the progression of atherosclerosis disease 
development. Therefore an initial in vivo study was established to further explore the 
cardiovascular protective effects of catechin and generate more substantial evidence for the 
use of catechin as a nutraceutical which currently cannot be achieved in vitro. However due to 
the cost of using pure (+)-catechin for 21 days in 8 mice being too high (~£15,000), (+)-catechin 
hydrate was used as an alternative. Catechin hydrate is simply a catechin molecule which has 
an additional water molecule attached (Fig. 7.1). A dosage of 200 mg/kg was used in this study 
due to it being employed in previous in vivo studies which delivered catechin by gavage for a 
similar time period of 3 weeks (Potenza et al. 2007). 
 
Fig. 7.1. The structure of catechin and catechin hydrate. The structure of catechin and catechin hydrate are 
almost identical apart from an additional water molecule being present (highlighted in red). 
The same assays used to study the effect of CardioWise in vivo were employed to assess the 
potential cardiovascular protective effects of catechin. Details on their rationale can be found 
in Chapter 4. Initially both mouse and fat pad weight were recorded. Subsequently the levels 
of several risk factors, including cholesterol, TG, ROS and circulating cytokines, within the 
plasma were assessed. To determine whether changes in these parameters were brought 
about by changes in gene expression, RNA was extracted from the liver to study the effect of 
catechin on gene expression. Finally the bone marrow was harvested in order to study the 
effect of catechin on haematopoietic cell populations. Unfortunately due to unknown problems 
during cell extraction, high quality samples were only recovered from four control and four 
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catechin treated mice. Therefore the results of cell population analysis are based on a reduced 
sample size. 
 
7.2 Experimental Aims 
Details of the specific in vivo methodologies are outlined in Chapter 2 and a brief experimental 
strategy for Chapter 7 is presented in Fig. 7.2. 
 
Fig. 7.2. Experimental strategy used to assess the effect of catechin in vivo. 
 
7.3 Results 
7.3.1 The migration of human monocytes is prevented by catechin hydrate in vitro 
To ensure catechin hydrate exerted the same anti-atherogenic properties of catechin, its effect 
on monocyte migration was assessed. During the progression of atherosclerosis disease 
development, the recruitment of monocytes to the affected area is a key mechanism in lesion 
formation. Therefore using this in vitro assay could be used to compare the effects of catechin 
hydrate to catechin. The chemokine MCP-1 is capable of recruiting monocytes and this was 
confirmed in our in vitro model as a significant 498.3% increase (p<0.001) in monocyte 
migration occurred in comparison to the vehicle control (Fig. 7.3). A 1.5 μg/ml dose of catechin 
hydrate reduced monocyte recruitment to MCP-1 by 41.8% (p=0.005) in comparison to MCP-
1 only. A similar decrease in monocyte migration was seen following 1.5 μg/ml dose of catechin 
treatment of human THP-1 monocytes (Fig. 5.9). 
 
Chapter 7: In Vivo study - Catechin 
175 
 
 
Fig. 7.3. The migration of human monocytes towards MCP-1 is inhibited by catechin hydrate. THP-1 
monocytes that were treated with vehicle (vehicle control) or treated with MCP-1 (20 ng/ml) alone or with MCP-1 
(20 ng/ml) in the presence of catechin hydrate (1.5 μg/ml) for 3 hours were used to evaluate monocyte migration. 
Data were normalised to the percentage of cells that migrated from the apical compartment of the modified Boyden 
chamber into the basolateral compartment in response to MCP-1 only treatment. This proportion was arbitrarily 
assigned as 1. The data are presented as the mean ± SEM from three independent experiments. Statistical analysis 
was performed using a one-way ANOVA with a Dunnett post-hoc analysis where ** p<0.01 and *** p <0.001. 
7.3.2 Catechin caused wild type mice receiving a high fat diet to increase weight gain 
The interaction between treatment type and time was positively correlated with mouse weight 
gain (Fig. 7.4), with catechin treated mice gaining an extra 0.06 g per day compared to the 
vehicle control treated mice (p<0.001; adj-R2=0.91). After 21 days, the catechin receiving mice 
were on average 2.14 g heavier than the control mice (p=0.029). 
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Fig. 7.4. The rate of weight gain in wild type mice fed a high fat diet was increased by catechin treatment. 
The weight of mice was measured every 2 or 3 days for the entire duration of the study (21 days). Mice were fed a 
high fat diet which was either supplemented with vehicle control (triangle; dashed line) or 200 mg/kg of catechin 
hydrate (circle; solid line). The prediction of the average rate of weight gain as calculated by a generalised linear 
mixed model with a Gamma error distribution and log link function is displayed from 16 mice (control 8; catechin 8). 
To avoid pseudoreplication the identity of each mouse was included within the model as a random term. The raw 
data from each mouse is also presented to provide a visual representation of the spread within the data. 
7.3.3 Catechin significantly increases white fat accumulation in wild type mice fed a high 
fat diet 
As shown in Fig. 7.5, the increase in mouse weight gain following catechin treatment was a 
result of increased fat accumulation within the subcutaneous, gonadal and renal fat deposits. 
These fat deposits were significantly increased by 70%, 78% and 94% respectively (p=0.002, 
p=0.002 and p=0.015). This increase in fat accumulation caused a 0.78 g increase (p=0.003) 
in the total fat weight in catechin treated mice compared to the vehicle control receiving mice 
(Fig. 7.5G). The weight of the inguinal, brown and PVAT fat deposits was unaffected by 
catechin treatment.
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Fig. 7.5. White fat accumulation increased in wild type mice fed a high fat diet which received catechin treatment. Subcutaneous (A), inguinal (B), gonadal (C), renal (D), 
brown (E), PVAT (F) and total (G) fats from wild type mice were weighed after 21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin 
hydrate. The data are presented as the mean ± SEM from eight control mice and either seven (F) or eight (A, B, C, D, E and G) catechin treated mice. One mouse was removed 
from the PVAT catechin group (F) due to a possible transcription error during recording the weight of the fat pad recovered. Statistical analysis was performed using a t-test (equal 
variance) on untransformed data where * p≤0.05 and ** p≤0.01.
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7.3.4 Catechin treatment shows a trend of increase in circulating HDL cholesterol levels 
in wild type mice fed a high fat diet 
Catechin treatment in wild type mice fed a high fat diet for 21 days had no significant effect on 
the level of circulating total cholesterol and LDL cholesterol or their ratios relative to each other 
(Fig. 7.6). However a non-significant increase of 36.1% in serum HDL cholesterol levels was 
observed in mice receiving catechin compared to the vehicle control treated mice (p=0.133; 
Fig. 7.6B). This increase in HDL cholesterol levels results in a 23.1% and 23.8% non-significant 
decrease in both total cholesterol/HDL and LDL/HDL cholesterol ratios respectively (p=0.165 
and p=0.190; Figs. 7.6D and F). This result indicates that catechin is capable of reducing the 
amount of total cholesterol and LDL relative to circulating HDL levels. 
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Fig. 7.6. Wild type mice on a high fat diet and treated with catechin had increased HDL cholesterol levels. 
Total cholesterol (A), HDL (B) and LDL (C) from wild type mice was measured after 21 days of a high fat diet and 
treatment with either a vehicle control or 200 mg/kg of catechin hydrate. The ratios of total cholesterol/HDL (D), 
total cholesterol/LDL (E) and LDL/HDL (F) were also assessed. The data are presented as the mean ± SEM from 
either seven (B, D and F) or eight (A, C and E) control mice and catechin treated mice. Mice with undetectable 
assay readings were removed before statistical analysis. Statistical analysis was performed using either a t-test 
(equal variance; A, B, D, E and F) or a t-test (unequal variance; C) on untransformed data (B, C, D, E and F) or 
squared-transformed data (A). 
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7.3.5 Catechin does not affect TG levels in wild type mice fed a high fat diet 
Serum TG levels were unaffected by catechin treatment of high fat diet fed mice in comparison 
to vehicle control treatment of high fat diet receiving mice (Fig. 7.7A). Additionally no significant 
changes in TG/total, TG/HDL or TG/LDL cholesterol ratios were observed following catechin 
treatment (Figs. 7.7B, C and D). 
 
Fig. 7.7. Catechin treatment in wild type mice did not alter TG levels while receiving a high fat diet. TG (A) 
levels from wild type mice were measured after 21 days of a high fat diet and treatment with either a vehicle control 
or 200 mg/kg of catechin hydrate. The ratios of TG/total cholesterol (B), TG/HDL cholesterol (C) and TG/LDL 
cholesterol (D) were also assessed. The data are presented as the mean ± SEM from three (C) or five (A, B and D) 
vehicle control mice and either five (C) or six (A, B and D) catechin treated mice. Mice with undetectable assay 
readings were removed before statistical analysis. Statistical analysis was performed using a t-test (equal variance) 
on either untransformed data (C) or square root-transformed data (A, B and D). 
7.3.6 Catechin treatment fails to attenuate ROS production and lipid peroxidation in wild 
type mice fed a high fat diet 
Treatment with catechin did not appear to alter ROS production or lipid peroxidation, measured 
by MDA levels, in comparison to the control mice (Fig. 7.8).  
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Fig. 7.8. Catechin treatment did not alter ROS or MDA production in wild type mice receiving a high fat diet. 
ROS production (A) and MDA levels (B) were assessed in wild type mice after 21 days of a high fat diet and 
treatment with either a vehicle control or 200 mg/kg of catechin hydrate. ROS production was measured in a 
fluorescence microplate reader, with excitation at 485 nm and emission detected at 535 nm. Vehicle control was 
given an arbitrary value of 1. MDA levels were measured in a fluorescence microplate reader, with excitation at 535 
nm and emission detected at 590 nm. The data are presented as the mean ± SEM from six (B) or eight (A) control 
mice and either seven (B) or eight (A) catechin treated mice. Mice with undetectable assay readings were removed 
before statistical analysis. Statistical analysis was performed using a t-test (equal variance) on log-transformed 
data. 
7.3.7 Catechin reduces the levels of several pro- and anti-inflammatory cytokines in wild 
type mice fed a high fat diet 
The circulating serum levels of the pro- and anti-inflammatory cytokines CXCL1, IFN-γ, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-10 and TNF-α (see Table 4.1 for further details) following catechin 
treatment were measured by a Luminex Cytokine Assay via the Central Biotechnology Service 
(Figs. 7.9 and 7.10). A non-significant decrease of 45% (p=0.263) and 32% (p=0.163) was 
found in the circulating levels of CXCL1 and TNF-α respectively following catechin treatment 
when compared to the vehicle control receiving mice. All the circulating levels of the IL 
measured during this study appeared to show a trend of decrease following catechin treatment. 
The levels of IL-2 were significantly decreased by 37% (p=0.005) in mice which were treated 
with catechin (Fig. 7.10B). The levels of IL-1β, IL-4, IL-5, IL-6 and IL-10 were all non-
significantly reduced by 50% (p=0.077), 54% (p=0.180), 26% (p=0.231), 61% (p=0.456) and 
26% (p=0.060) respectively. Catechin treatment did not appear to alter circulating IFN-γ levels. 
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Fig. 7.9. Wild type mice on a high fat diet and treated with catechin had a trend of reduced levels of several 
cytokines. CXCL1 (A), IFN-γ (B), and TNF-α (C) levels within the plasma of wild type mice were measured after 
21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. The data are 
presented as the mean ± SEM from seven (B) or eight (A and C) control mice and either six (A) or eight (B and C) 
catechin treated mice. Mice with undetectable assay readings were removed before statistical analysis. Statistical 
analysis was performed using a t-test (equal variance) either on untransformed data (C) or log-transformed data (A 
and B). 
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Fig. 7.10. The levels of several interleukin cytokines are reduced in wild type mice following catechin 
treatment. IL-1β (A), IL-2 (B), IL-4 (C), IL-5 (D), IL-6 (E) and IL-10 (F) levels within the plasma of wild type mice 
were measured after 21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin 
hydrate. The data are presented as the mean ± SEM from three (C), seven (A and B) or eight (D, E and F) control 
mice and either four (C), five (B), seven (A and F) or eight (D and E) catechin treated mice. Mice with undetectable 
assay readings were removed before statistical analysis. Statistical analysis was performed using a t-test (equal 
variance) either on untransformed data (B and D) or log-transformed data (A, C, E and F). 
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7.3.8 The expression of all genes present on the qPCR array following catechin 
treatment in wild type mice fed a high fat diet 
Fig. 7.11 shows the global significant and non-significant gene expression changes in the livers 
of wild type mice fed a high fat diet for 21 days following treatment with catechin compared to 
vehicle control treated mice. The housekeeping genes GUSB and HSP90AB1 were found to 
be stable during the assay and were therefore used to calculate gene expression fold changes 
induced by catechin. A total of 55 genes were found to have their expression altered by at least 
10% and 12 of those genes were found to be significantly altered. The genes have been 
classed by their function (according to the literature provided by Qiagen which accompanied 
the Atherosclerosis RT2 Profiler PCR Arrays) and will be explored in greater detail in the 
subsequent sections. 
 
Fig. 7.11. Volcano plot showing global gene expression changes in the liver of wild type mice treated with 
catechin vs vehicle control. Gene transcript levels of 84 genes were assessed in the livers of wild type mice after 
21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. The data are 
presented as the mean catechin induced fold change when compared to the vehicle control treated mice. Results 
are based on at least three control and three catechin treated mice. All genes present on the Qiagen RT2 profiler 
PCR Array were plotted. The log fold change in the treated cells versus the vehicle control cells is represented on 
the x-axis. The y-axis shows the -log10 of the p value. A p value of 0.05 (dashed line) and a fold changes of ±10% 
(solid lines) are indicated. Significantly altered gene expressions are indicated by a black triangle and non-significant 
trends of change (p<0.1) are indicated by a black square. 
7.3.9 Catechin increases the expression of a gene involved in the regulation of blood 
coagulation and circulation in wild type mice fed a high fat diet 
The protein endoglin is encoded by the gene ENG and it is capable of influencing the formation 
of new blood vessels. Following treatment with catechin, the expression of ENG was 
significantly increased by 51.8% (p=0.011) when compared to the vehicle control treated mice 
(Fig. 7.12). 
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Fig. 7.12. Catechin treatment alters the expression of a gene involved in blood coagulation and circulation 
in vivo. Gene transcript levels of ENG was assessed in the livers of wild type mice after 21 days of a high fat diet 
and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. Gene transcript levels were calculated 
using the comparative Ct method and normalised to two housekeeping genes (GUSB and HSP90AB1) with values 
from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from eight 
control and eight catechin treated mice. Statistical analysis was performed using a t-test (unequal variances) where 
* p≤0.05. 
7.3.10 Catechin alters the expression of cell adhesion molecules in wild type mice fed a 
high fat diet 
Due to the role of cell adhesion molecules, such as ITGA2, ITGAX and thrombospondin 
(THBS)-4, during monocyte recruitment and migration in atherosclerotic plaque formation, 
altering their expression may lead to reduced atherosclerosis disease progression. Catechin 
treatment was found to reduce ITGA2 expression by 36.5% (p=0.043) when compared to mice 
treated with the vehicle control (Fig. 7.13A). However catechin treatment resulted in the 
increased expression of ITGAX and THBS4 by 100.4% (p=0.042) and 90.4% respectively 
(Figs. 7.13B and C). However due to the low expression levels of THBS4, the result is based 
on one vehicle control and two catechin treated mice and therefore requires repeating before 
any solid conclusions can be drawn. 
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Fig. 7.13. Catechin treatment alters the expression of cell adhesion molecules in vivo. Gene transcript levels 
of ITGA2 (A), ITGAX (B) and THBS4 (C) were assessed in the livers of wild type mice after 21 days of a high fat 
diet and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. Gene transcript levels were 
calculated using the comparative Ct method and normalised to two housekeeping genes (GUSB and HSP90AB1) 
with values from the vehicle treated mice given an arbitrary value of 1. The data are presented as the mean ± SEM 
from one (C) or seven (A and B) control mice and either two (C), six (A) or seven (B) catechin treated mice. Mice 
with undetectable Ct readings were removed before statistical analysis. Statistical analysis was performed using a 
t-test (unequal variances) where * p≤0.05. 
7.3.11 Catechin alteres the expression of cell growth and proliferation regulators in wild 
type mice fed a high fat diet 
The largest group of genes which were found to have their expression altered by catechin 
treatment in vivo are involved in cell growth and proliferation (Fig. 7.14). A variety of genes 
including FGF2, IL-2, IL-5, kinase insert domain receptor (KDR) and PDGFB2 were found to 
have their expression increased in the liver of catechin treated wild type mice fed a high diet. 
The levels of expression of FGF2, KDR and PDGFB2 were increased by 38.2% (p=0.044), 
48.8% (p<0.001) and 46.3% (p=0.002). On the other hand, trend of increases of 129.9% and 
262.2% were observed for IL-2 and IL-5 respectively. However due to the low expression levels 
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of IL-2 and IL-5, the assay requires repeating before any solid conclusions can be drawn. The 
only cell proliferation gene expression found to be reduced by catechin in vivo was heparin-
binding EGF-like growth factor (HBEGF) which showed a trend of decrease of 31.1% (p=0.052) 
in contrast to the vehicle control treated mice.  
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Fig. 7.14. Catechin treatment alters the expression of cell growth and proliferation regulators in vivo. Gene 
transcript levels FGF2 (A), HBEGF (B), IL-2 (C), IL-5 (D), KDR (E) and PDGFRB (F) were assessed in the livers of 
wild type mice after 21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin 
hydrate. Gene transcript levels were calculated using the comparative Ct method and normalised to two 
housekeeping genes (GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value of 
1. The data are presented as the mean ± SEM from one (C), three (D), seven (F) or eight (A, B and E) control mice 
and either one (D), two (C), seven (A and B) or eight (E and F) catechin treated mice. Mice with undetectable Ct 
readings were removed before statistical analysis. Statistical analysis was performed using a t-test (unequal 
variances) where * p≤0.05, ** p≤0.01 and *** p≤0.001. 
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7.3.12 Catechin treatment affectes the expression of ECM genes in wild type mice fed a 
high fat diet 
Fibrinogen (FG)A, FGB, MMP1A and tenascin-C (TNC) genes encode proteins which can 
influence ECM deposition and degradation as well as affecting intercellular signalling. The 
expression of both FGA and FGB was reduced in the livers of wild type mice receiving catechin 
by 42.0% and 44.0% respectively when compared to the vehicle control mice (p=0.056 and 
p=0.028; Figs. 7.15A and B). In contrast to the control mice, catechin induced the expression 
of MMP1A and TNC by 71.3% and 85.6% respectively (p=0.001 and p=0.025; Figs. 7.15C and 
D). 
 
Fig. 7.15. Catechin treatment alters the expression of genes involved in regulating ECM synthesis in vivo. 
Gene transcript levels of FGA (A), FGB (B), MMP1A (C) and TNC (D) were assessed in the livers of wild type mice 
after 21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. Gene 
transcript levels were calculated using the comparative Ct method and normalised to two housekeeping genes 
(GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value of 1. The data are 
presented as the mean ± SEM from six (D) or eight (A, B and C) control mice and either seven (A and B) or eight 
(C and D) catechin treated mice. Mice with undetectable Ct readings were removed before statistical analysis. 
Statistical analysis was performed using a t-test (unequal variances) where * p≤0.05 and *** p≤0.001. 
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7.3.13 Catechin increases the expression of genes involved in lipid transport and 
metabolism in wild type mice fed a high fat diet 
The genes APOE, LPL and LYPLA1 are all capable of influencing lipid transport and 
metabolism. An increase of 61.1% (p=0.066), 37.7% (p=0.011) and 16.0% (p=0.043) was 
observed in APOE, LPL and LYPLA1 gene expression respectively in wild type mice which 
had received catechin treatment in comparison to the vehicle control mice (Fig. 7.16). 
 
Fig. 7.16. Catechin treatment increases the expression of genes involved in the regulation of lipid transport 
and metabolism in vivo. Gene transcript levels of APOE (A), LPL (B) and LYPLA1 (C) were assessed in the livers 
of wild type mice after 21 days of a high fat diet and treatment with either a vehicle control or 200 mg/kg of catechin 
hydrate. Gene transcript levels were calculated using the comparative Ct method and normalised to two 
housekeeping genes (GUSB and HSP90AB1) with values from the vehicle treated cells given an arbitrary value of 
1. The data are presented as the mean ± SEM from eight control mice and either seven (B) or eight (A and C) 
catechin treated mice. Mice with undetectable Ct readings were removed before statistical analysis. Statistical 
analysis was performed using a t-test (unequal variances) where * p≤0.05. 
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7.3.14 Catechin increases the expression of the transcriptional regulator NR1H3 in wild 
type mice fed a high fat diet 
NR1H3 is an anti-inflammatory regulator of gene transcription, therefore increasing its 
expression with catechin would represent strong anti-inflammatory effects. There was a 
significant increase of 17.8% (p=0.033) in NR1H3 gene expression within the liver of wild type 
mice treated with catechin when compared to the control mice (Fig. 7.17). 
 
Fig. 7.17. Catechin treatment increases the expression of a gene involved in transcriptional regulation in 
vivo. Gene transcript levels of NR1H3 were assessed in the livers of wild type mice after 21 days of a high fat diet 
and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. Gene transcript levels were calculated 
using the comparative Ct method and normalised to two housekeeping genes (GUSB and HSP90AB1) with values 
from the vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM from eight 
control and catechin treated mice. Statistical analysis was performed using a t-test (unequal variances) where * 
p≤0.05. 
7.3.15 Catechin treatment increases the number of total bone marrow cells in wild type 
mice fed a high fat diet 
The inflammatory state of an individual can often be indicated by the levels of white blood cells 
within their bone marrow. Wild type mice treated with catechin were found to have the 
proportion of white blood cells within their bone marrow increased non-significantly by 1.20 
fold in contrast to the mice treated with the vehicle control (p=0.101; Fig. 7.18). 
 
 
 
 
Chapter 7: In Vivo study - Catechin 
192 
 
 
Fig. 7.18. Catechin increases the proportion of total bone marrow cells. Cell populations were assessed in the 
bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a vehicle control or 200 
mg/kg of catechin hydrate. Representative flow plots of the total cell population in the bone marrow (A). Numbers 
on the flow plots indicate the proportion of the cell population as a percentage of total bone marrow cell count. The 
forward scatter (FSC-A) is a measurement of cell size by determining the amount of light which passes around it. 
The side scatter (SSC-A) is a measurement of the amount of light which is reflected by particles within the cells and 
therefore can be used to determine the granularity of cells. Cumulative bar graphs showing the frequency of total 
bone marrow cells as a percentage of total cell count (B). The data are presented as the mean ± SEM from four 
vehicle control and four catechin treated mice. Statistical analysis was performed using a t-test (equal variances). 
7.3.16 The number of SLAM and progenitor cells within the bone marrow of wild type 
mice fed a high fat diet following catechin treatment 
The flow plots for the number of SLAM and progenitor cells present in the bone marrow of wild 
type mice fed either a vehicle control or catechin are displayed in Fig. 7.19 and the results are 
explored in greater detail in the subsequent sections.
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Fig. 7.19. The effect of catechin on the proportion of SLAM and progenitor cells present in the bone marrow. Cell populations were assessed in the bone marrow of wild 
type mice after 21 days of a high fat diet and treatment with either a vehicle control (A) or 200 mg/kg of catechin hydrate (B). Representative flow plots of the SLAM and progenitor 
populations in the bone marrow are presented. Numbers on the flow plots indicate the proportion of the cell population as a percentage of total bone marrow cell count. Cumulative 
bar graphs showing the cell populations as a percentage of total bone marrow cell count are shown in Figs. 7.20 - 7.22. The arrows indicate how each haematopoietic 
stem/progenitor cell population can be identified within the preceding gating strategy. The axis represent the various stains used to separate the cell populations (see Table 2.8 
for further details). The forward scatter (FSC-A) is a measurement of cell size by determining the amount of light which passes around it. The side scatter (SSC-A) is a 
measurement of the amount of light which is reflected by particles within the cells and therefore can be used to determine the granularity of cells. HSC, haematopoietic stem cell; 
MPP, multipotent progenitors; HPC, hematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage 
progenitor; MDSC, myeloid-derived suppressor cells; CLP, common lymphoid progenitor; LIN, lineage.
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7.3.17 Catechin treatment increases the number of Live Lin- and MPP cells within the 
bone marrow of wild type mice fed a high fat diet 
The live lineage negative cell population represent the total proportion of non-terminally 
differentiated blood cells found within the bone marrow, whereas the LSK cell population 
represents the total number of multipotent blood cells. A significant increase of 1.53 fold 
(p=0.005) was observed in the live lineage negative (Live Lin-) cell population in mice treated 
with catechin when compared to the vehicle control mice (Fig. 7.20A). The change in the 
proportion of LSK cells within the bone marrow of catechin treated mice was found to be not 
significant when compared to the vehicle control treated mice (p=0.310; Fig. 7.20B). All 
myeloid and lymphocyte cells within the bone marrow are derived from the HSC, MPP and 
HPC II cell populations. A non-significant trend of increase was seen in the MPP cell population 
of 1.45 (p=0.086) fold. The proportion of HSC and HPC II cell populations within the bone 
marrow were unaffected by catechin treatment 1.38 (p=0.329) and 1.32 (p=0.287; Fig. 7.20). 
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Fig. 7.20. Catechin increases the proportion of Live Lin-, LK, LSK, HPC, MPP and HSC cells present in the 
bone marrow. Cell populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet 
and treatment with either a vehicle control or 200 mg/kg of catechin hydrate. Cumulative bar graphs showing the 
frequency of live lineage negative (Live Lin-; A), LSK (B), HPC II (C), MPP (D) and HSC (E) populations in the bone 
marrow as a percentage of total bone marrow cell count. Where appropriate, the data has been multiplied by powers 
of 10 for ease of presenting the result clearly. The data are presented as the mean ± SEM from four control mice 
and four catechin treated mice. Statistical analysis was performed using a t-test (equal variances) on either log-
transformed (C), squared-transformed (D) or untransformed (A, B and E) data where ** p≤0.01. 
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7.3.18 Catechin treatment increases the number of CMP cells within the bone marrow 
of wild type mice fed a high fat diet 
All myeloid cells are derived from the LK cell population. Wild type mice treated with catechin 
showed no change in the proportion of LK cells within their bone marrow (Fig. 7.21A). The 
CMP, MEP and GMP cell populations are found within the LK class of cells. Catechin treatment 
resulted in a non-significant 1.33 fold increase in the proportion of CMP cells found within the 
bone marrow (p=0.112; Figs. 7.21B). No changes were observed in the proportion of MEP and 
GMP cells within the bone marrow of mice treated with catechin when compared to the vehicle 
control mice (Fig. 7.21C and D). 
 
Fig. 7.21. Catechin increases the proportion of CMP and MEP cells present in the bone marrow. Cell 
populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with 
either a vehicle control or 200 mg/kg of catechin hydrate. Cumulative bar graph showing the frequency of LK (A), 
CMP (B), MEP (C) and GMP (D) populations in the bone marrow as a percentage of total bone marrow cell count. 
Where appropriate, the data has been multiplied by powers of 10 for ease of presenting the result clearly. The data 
are presented as the mean ± SEM from four vehicle control and four catechin treated mice. Statistical analysis was 
performed using a t-test (equal variances). 
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7.3.19 Catechin treatment does not affect the number of CLP cells within the bone 
marrow of wild type mice fed a high fat diet 
Both T- and B-cells are derived from the CLP cell population. No change was observed in the 
proportion of CLP cells found within the bone marrow of catechin treated wild type mice when 
compared to the vehicle control treated mice (Fig. 7.22). 
 
Fig. 7.22. Catechin does not affect the proportion of CLP cells present in the bone marrow. Cell populations 
were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a 
vehicle control or 200 mg/kg of catechin hydrate. Cumulative bar graphs showing the frequency of the CLP 
populations in the bone marrow as a percentage of total bone marrow cell count. The data has been multiplied by 
100 for ease of presenting the result clearly. The data are presented as the mean ± SEM from four control and four 
catechin treated mice. Statistical analysis was performed using a t-test (equal variances) on square root-
transformed data. 
7.3.20 Catechin treatment reduces the number of MDSCs within the bone marrow of wild 
type mice fed a high fat diet 
Wild type mice treated with catechin showed a non-significant trend of decrease in the 
proportion of MDSCs within the bone marrow by 32% (p=0.200) in contrast to the mice treated 
with the vehicle control (Fig. 7.23C). In contrast, catechin treatment was found to have no 
effect on the proportion of granulocytes or macrophages within the bone marrow when 
compared to the vehicle control treated mice (Fig. 7.23B and D). 
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Fig. 7.23. Catechin reduces the proportion of granulocytes and MDSCs present in the bone marrow. Cell 
populations were assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with 
either a vehicle control or 200 mg/kg of catechin hydrate. Representative flow plots of the granulocyte, macrophage 
and MDSC populations in the bone marrow (A). Numbers on the flow plots indicate the proportion of the cell 
population as a percentage of total bone marrow cell count. Cumulative bar graphs showing the frequency of 
granulocytes (B), MDSCs (C) and macrophage (D) populations in the bone marrow as a percentage of total bone 
marrow cell count. Where appropriate, the data has been multiplied by powers of 10 for ease of presenting the 
result clearly. The data are presented as the mean ± SEM from four vehicle control and four catechin treated mice. 
Statistical analysis was performed using either a t-test (equal variances; B and D) or a Mann-Whitney test (C). 
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7.3.21 Catechin treatment affects the number of B- and T-cells within the bone marrow 
of wild type mice fed a high fat diet 
A non-significant trend of increase of 61% (p=0.089) was observed in the proportion of B-cells 
found within the bone marrow of wild type mice treated with catechin when compared to the 
vehicle control treated mice (Fig. 7.24C). On the other hand, catechin treatment did not 
significantly alter the proportion of T-cells within the bone marrow of wild type mice (p=0.336; 
Fig. 7.24B). 
 
Fig. 7.24. Catechin affects the proportion of B- and T-cells present in the bone marrow. Cell populations were 
assessed in the bone marrow of wild type mice after 21 days of a high fat diet and treatment with either a vehicle 
control or 200 mg/kg of catechin hydrate. Representative flow plots of the B and T-cell populations in the bone 
marrow (A). Numbers on the flow plots indicate the proportion of the cell population as a percentage of total bone 
marrow cell count. Cumulative bar graphs showing the frequency of T-cells (B) and B-cells (C) in the bone marrow 
as a percentage of total bone marrow cell count. Where appropriate, the data has been multiplied by powers of 10 
for ease of presenting the result clearly. The data are presented as the mean ± SEM from four vehicle control and 
four catechin treated mice. Statistical analysis was performed using either a t-test (equal variances; B) or a t-test 
(unequal variances; C). 
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7.4 Discussion 
7.4.1 The effect of catechin on physical parameters in wild type mice 
The possibility of using catechin as an anti-atherogenic nutraceutical and decreasing an 
individual’s chance of suffering a CVD-related event has been explored in great detail in this 
in vivo study. The levels of HDL cholesterol and LDL/HDL cholesterol ratio were found to be 
improved following catechin hydrate treatment in wild type mice fed a high fat diet. Furthermore 
the level of ROS generation and circulating level of pro-inflammatory cytokines were reduced. 
These changes could potentially be explained by catechin treatment resulting in an anti-
atherogenic gene expression profile within the livers of these mice. Mice which received 
catechin also had anti-atherogenic changes in the haematopoietic stem and progenitor cells 
within their bone marrow, including reductions in the proportion of granulocytes, MDSCs and 
T-cells. This in vivo study provides additional evidence which confirms the anti-atherogenic 
properties of catechin which were observed during our in vitro assays (Chapters 5 and 6). 
After 21 days of a high fat diet, the first notable effect of catechin treatment was its action on 
rate of weight gain. In comparison to the vehicle control treated mice, those which had received 
catechin gained weight at a faster rate and after 21 days they were found to be significantly 
heavier (Fig. 7.4). Previous studies have shown a mixed effect of flavanol dietary 
supplementation on the rate of weight gain in murine studies. Short term feeding studies have 
shown green tea extracts to have no effect on weight gain (Murase et al. 2002; Sugiura et al. 
2012). Long term studies involving dietary supplementation with green tea extracts has shown 
them to be capable of attenuating weight gain in mice (Murase et al. 2002). The increase in 
weight gain observed in this study was driven by an increased accumulation of fat within the 
subcutaneous, gonadal and renal deposits (Fig. 7.5). This result contradicts current literature 
which has found green tea extract to reduce white adipose tissue accumulation (Tokimitsu 
2004; Osada et al. 2006; Nagao et al. 2007). However these studies used a mixture of green 
tea catechins and therefore the reduction in white fat accumulation may be the result of another 
catechin present in the mixture rather than (+)-catechin. During obesity white adipose tissue 
expands and becomes dysfunctional, leading to inflammation and increased lipid levels within 
the blood (Hotamisligil 2006; Nordestgaard 2016). However white adipose tissue expansion is 
not always associated with increased atherosclerosis disease progression (van Dam et al. 
2017). Indeed during this study, catechin was found to reduce the levels of circulating pro-
inflammatory cytokines, including CXCL1, IL-5, IL-6 and IL-10, which are normally increased 
during obesity (Figs. 7.9 and 7.10; Nunemaker et al. 2014; Schmidt et al. 2015; Manna and 
Jain 2015). Additionally LPL is required for TG turnover within the fatty deposits and catechin 
treatment also significantly increased LPL expression in the liver (Fig. 7.16; Cinti 2009; van 
Dam et al. 2017). Increased LPL expression within the adipose and muscle tissue is 
considered to be anti-atherogenic, however LPL secreted by macrophages and SMCs is 
considered to be pro-atherogenic by promoting lipid accumulation and inflammation (Li et al. 
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2014b; Mead et al. 2002). Therefore the effect of catechin on LPL expression needs to be 
assessed in greater detail. The results of this study indicate that despite catechin leading to an 
increase in white fat accumulation, it is capable of maintaining its physiological function via 
increased LPL expression and therefore potentially also maintaining TG turnover. The lack of 
changes in the weight of brown fat and PVAT deposits means catechin treatment had no effect 
on brown fat activation (Figs. 7.5E and F). 
7.4.2 The effect of catechin on blood parameters in wild type mice 
The circulating levels of cholesterol, TG, ROS and cytokines within the plasma can all be used 
as risk markers of atherosclerosis disease development. An increase in serum HDL cholesterol 
is a sign of increased RCT and therefore is thought of as anti-atherogenic (McLaren et al. 
2011a). Catechin treatment in wild type mice receiving a high fat diet for 21 days was found to 
non-significantly increase HDL levels (Fig. 7.6B). A possible mechanism by which catechin 
can boost HDL cholesterol levels may be achieved through the increased expression of ApoE 
(Fig. 7.16A) and NR1H3 (Fig. 7.17). Previous studies have demonstrated that raised 
expression of ApoE and NR1H3 result in improved circulating HDL levels (Alvaro et al. 2010; 
Ramasamy 2016). Catechin treatment in rats receiving a standard chow diet has been shown 
to increase HDL cholesterol levels and simultaneously attenuate the levels of circulating LDL 
cholesterol (Chisaka et al. 1988; Babu et al. 2006; Babu et al. 2008). However in this study, 
catechin hydrate treatment failed to significantly alter serum LDL levels (Fig. 7.6C). Despite 
this lack of changes in LDL cholesterol levels, catechin treatment was found to show a trend 
of improved LDL/HDL cholesterol ratio (Fig. 7.6F). Due to the importance of the LDL/HDL 
cholesterol ratio as clinical risk indicator of CVD, changes in this marker are more important 
than assessing the levels of LDL or HDL in isolation (Millán et al. 2009; Kunutsor et al. 2017). 
Indeed previous human studies have demonstrated that catechin treatment is capable of 
enhancing the LDL to HDL cholesterol ratio (Babu et al. 2008). The results of this study show 
that catechin treatment is capable of altering a lipid profile to be more anti-atherogenic while 
receiving a high fat diet in vivo. 
The circulating levels of TGs within the plasma can be an indicator of the level of VLDL, 
chylomicron remnants and TG-rich lipoproteins, all of which are capable of exacerbating 
atherosclerosis disease progression (Talayero and Sacks 2011). This study found catechin 
was unable to affect circulating TG levels (Fig. 7.7A). This lack of reduction in TG levels 
following catechin treatment is similar to previous studies, using rats receiving a high fat diet 
or obese children, which were unable to observe decreased circulating serum TGs 
(Matsuyama et al. 2008; Friedrich et al. 2012; Ahmad et al. 2015). As previously discussed, 
the TG/HDL ratio may actually provide a clearer indication on CVD risk when compared to 
using TG levels individually (Hulley et al. 1980; Miller et al. 2011; da Luz et al. 2008). However 
catechin treatment also failed to improve the TG/HDL cholesterol ratio (Fig. 7.7C). Although 
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catechin treatment resulted in improved HDL and LDL/HDL cholesterol levels, it failed to 
attenuate TG levels following a high fat diet. Therefore additional long term studies are required 
to fully establish the potential anti-atherogenic effect of catechin treatment on the lipidomic 
profile. 
Flavanols are a well-known class of anti-oxidants, as demonstrated by previous studies and 
our in vitro results which found catechin treatment to attenuate ROS generation in human THP-
1 cells (Fig. 5.10; Moss and Ramji 2016; Bahramsoltani et al. 2017; Tak et al. 2016; Yu et al. 
2017; Oyama et al. 2017). Furthermore due to the effect of aberrant ROS production leading 
to lipid peroxidation and thrombus formation, the level of MDA within the plasma of wild type 
mice was also measured (Kinnunen et al. 2012; Ayala et al. 2014; Chen et al. 2017c). Catechin 
treatment did not reduce ROS formation in mice fed a high fat diet for 21 days (Fig. 7.8A). This 
result contradicts with the current literature which shows that flavanols are potent anti-oxidants 
(Zielinski et al. 2014; Higdon and Frei 2003; Kumar and Pandey 2013). Previous studies have 
also shown flavanols to attenuate lipid peroxidation which was not observed in this study when 
mice were treated with catechin hydrate (Fig. 7.8B; Tak et al. 2016). Thus reduction in ROS 
generation may be the mechanism by which reduced circulating oxLDL levels have been 
reported in previous human studies (Babu et al. 2008; Tinahones et al. 2008). The lack of 
reduction in ROS production following catechin treatment needs to be assessed further. 
Catechin treatment in wild type mice fed a high fat diet for 21 days showed a non-significant 
decrease in the plasma levels of pro-inflammatory cytokines CXCL1 and TNF-α (Fig. 7.9). As 
previously discussed, CXCL1 is a potent chemoattractant and plays a major role during 
monocyte recruitment and migration during atherosclerosis disease development (Wan and 
Murphy 2013). This decrease in the circulating levels of CXCL1 may explain the reduced 
monocyte migration observed following catechin treatment in vitro (Fig. 5.6). Due to its role in 
systemic inflammation, TNF-α is considered to be a key pro-inflammatory cytokine during 
atherosclerotic plaque formation (Ramji and Davies 2015; Moss and Ramji 2016a). 
Furthermore TNF-α and ApoE deficient mice have been found to develop fewer foam cells and 
as a result of reduced atherosclerotic burden (Ramji and Davies 2015). The reduction in TNF-
α levels due to catechin treatment may indicate that it is also capable of attenuating foam cell 
formation in vivo. However this requires further assessment in future in vivo studies as our in 
vitro studies failed to show any alteration in cholesterol uptake or efflux following catechin 
treatment (Fig. 6.20). The results of this study coincide with the current literature which has 
previously shown flavanol treatment in rats and mice receiving a standard chow diet to 
attenuate the circulating levels of CXCL1 and TNF-α (Takano et al. 2004b; Guruvayoorappan 
and Kuttan 2008). Despite these observed anti-inflammatory effects of catechin, it fails to lower 
the circulating levels of the major pro-inflammatory cytokine IFN-γ. 
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The serum levels of several IL cytokines including, IL-1β, IL-2, IL-4, IL-5, IL-6 and IL-10, were 
all non-significantly reduced, however IL-1β and IL-10 showed strong trends of decrease 
following catechin treatment in wild type mice (Fig. 7.10). IL-1β is a potent pro-inflammatory 
cytokine which is capable of activating the innate immune response and in turn contributes to 
the development of atherosclerosis (Ramji and Davies 2015; Moss and Ramji 2016a). Indeed 
ApoE deficient mice which also lack IL-1β or its receptor develop smaller atherosclerotic 
plaques (Kamari et al. 2011; Shemesh et al. 2012). Additionally, as previously discussed the 
circulating levels of IL-1β can be used as a marker of NLRP3 inflammasome activation. The 
NLRP3 inflammasome is associated with disease progression and plaque stability (Zheng et 
al. 2013; Zheng et al. 2014; Guo et al. 2015; Hoseini et al. 2017). Due to the pro-inflammatory 
nature of IL-1β, it is also capable of influencing macrophage polarisation into their pro-
atherogenic M1 phenotype (Moss and Ramji 2016a). The reduction in serum levels of IL-1β 
following catechin treatment observed in this in vivo study has been previously reported in 
mice receiving a standard chow diet (Tsai et al. 2011; Jhang et al. 2015). This result would 
indicate that catechin is potentially capable of attenuating atherosclerotic plaque formation, 
improve plaque stability and reduce pro-inflammatory differentiation of macrophages by 
possibly reducing inflammasome activation. However catechin treatment in vitro failed to 
attenuate inflammasome activation (measured indirectly via IL-1β release) or influence the 
expression of M1 macrophage markers (Figs. 5.5B and 6.23) and therefore requires further 
investigation in future in vivo studies. IL-2 is a cytokine shown to enhance the development of 
atherosclerosis (Ramji and Davies 2015). An increase in IL-2 production due to catechin 
dietary supplementation has been previously reported in mice receiving a standard chow diet 
(Guruvayoorappan and Kuttan 2008), however in this study catechin treatment was found to 
reduce serum IL-2 levels in wild type mice receiving a high fat diet. The role of IL-4 in 
atherosclerosis is still debated in the literature, however deficiency of the cytokine in ApoE 
atherosclerotic mouse models has been shown to result in smaller plaque formation (Lee et al. 
2010b). Therefore reductions in this cytokine following catechin treatment highlights another 
mechanism by which catechin may result in smaller atherosclerotic plaques (Morrison et al. 
2014). Indeed it has been previously observed that serum IL-4 levels are reduced following 
flavanol treatment in mice fed a standard chow diet (Liu et al. 2014a). The reductions in pro-
inflammatory cytokines found in this in vivo study indicate that dietary supplementation with 
catechin may retard atherosclerosis disease progression and attenuate lesion formation. This 
requires further investigation in future studies. 
Despite the reductions in pro-inflammatory serum cytokine levels as a result of catechin dietary 
supplementation in wild type mice receiving a high fat diet, catechin was also found to 
attenuate the levels of anti-inflammatory ILs. Both IL-5 and IL-10 are considered to be anti-
inflammatory cytokines as their genetic depletion in atherosclerotic mouse models results in 
enhanced atherosclerosis disease development (Ramji and Davies 2015). The levels of both 
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IL-5 and IL-10 were reduced following catechin treatment (Fig. 7.10D and F), which was not 
observed in previous studies (Cunha et al. 2013). Due to the anti-inflammatory effects 
associated with these two cytokines, the results of this study would suggest that catechin has 
the capacity to enhance atherosclerosis disease development. The atherosclerotic nature of 
IL-6 remains unclear as it has previously been shown to exert both pro- and anti-inflammatory 
effects (Ramji and Davies 2015). The treatment of wild type mice fed a high fat diet with 
catechin was found to decrease serum IL-6 levels (Fig. 7.10E). This result was to be expected 
as it has previously been demonstrated in mice fed a standard chow diet (Guruvayoorappan 
and Kuttan 2008; Liu et al. 2014a). Catechin appears to induce a systemic inhibition of cytokine 
production as opposed to inhibiting pro-inflammatory cytokine release. However this needs to 
be assessed in greater detail in atherosclerotic mouse models as changes in the systemic 
cytokine profile does not reflect the changes occurring at a local vascular or atherosclerotic 
plaque level. The results of the in vivo catechin study are similar to those found within 
CardioWise in vivo study (Chapter 4), possibly indicating that the changes in cytokine levels 
observed due to CardioWise treatment are due to catechin being present in the mixture. 
During obesity, the white adipose tissue deposits can expand and become dysfunctional, 
resulting in an alteration in the level of cytokines produced and released (Kershaw and Flier 
2004; Coelho et al. 2013). Previous studies have reported that obesity is associated with 
increased serum levels of CXCL1, IL-4, IL-5, IL-6 and IL-10 (Nunemaker et al. 2014; Schmidt 
et al. 2015; Manna and Jain 2015). However the level of IL-2 is normally decreased during 
obesity, a result that was also seen following catechin treatment. Overall the decrease in the 
concentration of these cytokines found within the plasma of wild type mice would suggest that 
catechin treatment maybe capable of maintaining the normal physiological function of white 
adipose tissue despite contributing to its expansion. 
7.4.3 The effect of catechin on gene expression in the liver of wild type mice 
Changes in gene expression within the liver were assessed to ascertain whether they related 
to changes in both physical and blood parameters previously discussed in this chapter. A 
qPCR array containing 84 atherosclerosis related genes was used to determine gene 
expression levels. A total of 55 genes were found to have their expression altered by at least 
10% (Fig. 7.11) and 12 genes were significantly different. Those genes were ENG, FGB, FGF2, 
ITGA2, ITGAX, KDR, LPL, LYPLA1, MMP1A, NR1H3, PDGFRB and TNC. The ENG gene 
encodes the protein endoglin, also known as CD105, which is capable of binding to the anti-
inflammatory cytokine TGF-β (Rathouska et al. 2015; Moss and Ramji 2016a). ENG is 
predominately expressed in proliferating endothelial and VSMCs within the atherosclerotic 
plaque (Conley et al. 2000; Prashar et al. 2017). This has led to both increased ENG and TGF-
β expression levels being associated with improved atherosclerotic plaque stability due to 
increased collagen and VSMC content. During this study, it was found that catechin treatment 
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significantly increased ENG expression (Fig. 7.12), suggesting that catechin treatment could 
potentially improve plaque stability. The major function of ENG appears to be its role in 
angiogenesis and vasodilation (Núñez-Gómez et al. 2017). The expression of ENG is 
increased during angiogenesis, especially at the sites of new blood vessel formation (Núñez-
Gómez et al. 2017). More importantly ENG has been implicated in vasodilation. Studies have 
demonstrated that reduced endoglin protein levels is associated with decreased NO production 
due to a reduction in the expression of endothelium NOS (eNOS; Jerkic et al. 2004; Jerkic et 
al. 2006; Park et al. 2013). The co-localisation of endoglin and eNOS proteins on the cell 
surface improves their stability and allows for the proper function of eNOS proteins to occur 
(Núñez-Gómez et al. 2017). Reduced endoglin protein levels leads to eNOS uncoupling, which 
in turn causes an increase in ROS generation and reduced NO production (Núñez-Gómez et 
al. 2017). As previously discussed, catechin treatment in wild type mice resulted in a reduction 
in ROS generation (Fig. 7.8). The increase in ENG expression may represent the mechanism 
by which catechin and other green tea extracts are capable of attenuating ROS production, 
increasing NO levels and improving vasodilation and vascular function in previously reported 
studies (Fisher et al. 2003; Babu et al. 2008; Tinahones et al. 2008; Rassaf et al. 2016; Heiss 
et al. 2015; Sansone et al. 2015). This will require further assessment in future in vivo studies 
using green tea extracts. 
Catechin treatment was found to have mixed effects on the expression of cell adhesion 
molecules (Fig. 7.13). ITGA2, also known as CD49b, is a subunit of the integrin α2β1 (Habart 
et al. 2013; Finney et al. 2017; Yurdagul et al. 2016). It is expressed in a variety of cells 
including endothelial and VSMCs and integrin α2β1 signalling is linked with the inactive 
phenotypes of both cells and allows them to interact with collagens and laminins present in the 
ECM (Yurdagul et al. 2016; Finney et al. 2017). Catechin treatment may result in improved 
plaque stability as it was found to attenuate ITGA2 expression (Fig. 7.13A), meaning reduced 
integrin α2β1 signalling may alter the VSMC phenotype from a quiescent one into an active 
migratory one and result in a thicker fibrous cap and restored vessel function. The effect of 
catechin on plaque stability needs to be assessed in future studies. Integrin α2β1 has also 
been found to be involved in platelet activation and ITGA2 deficient mice were found to have 
a reduced platelet response to collagen without any detrimental haemostatic effects (Chen et 
al. 2002; Holtkötter et al. 2002; Habart et al. 2013). Previous studies have observed an inverse 
relationship between catechin treatment and platelet activation (Mangels and Mohler 2017). 
The reduction in ITGA2 expression following catechin treatment in this study provides a 
possible mechanism by which catechin and other flavanols exert their anti-platelet activation 
effects. ITGAX is a member of the β2 integrin family and forms a heterodimeric receptor with 
CD18 (Yashiro et al. 2017). In mice ITGAX is predominately expressed by dendritic cells (DCs) 
and therefore can be used as a marker to identify this cell population (Sándor et al. 2016; 
Yashiro et al. 2017). 
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Atherosclerosis disease progression is associated with an increase in the number of DCs 
present at atherosclerotic prone sites and within lesions (Libby et al. 2008; Zernecke 2015). 
DCs are considered pro-atherogenic due to their ability to form foam cells as well as influencing 
the microenvironment within the shoulder regions of plaques to make them more vulnerable to 
rupturing (Zernecke 2015). Catechin treatment was found to increase the expression of ITGAX 
(Fig. 7.13B) which may be a marker of increased number of DCs and therefore represent a 
pro-inflammatory effect. The expression of THBS4 was found to be increased following dietary 
supplementation of catechin in wild type mice (Fig. 7.13C). THBS4 is a glycoprotein secreted 
from ECs into the ECM following TGF-β stimulation (Muppala et al. 2017). Once in the ECM, 
THBS4 is thought to be capable of influencing ECM remodelling and inducing the formation of 
new blood vessels and restoring EC function (Muppala et al. 2017). The protective role of 
THBS4 has been demonstrated by an increase in the amount of scarring which occurred in the 
hearts of pressure overloaded THBS4 deficient mice (Frolova et al. 2012; Rienks et al. 2014). 
Overall these results suggest that the altered gene expression profile of cell adhesion 
molecules due to catechin treatment would result in improved endothelial function. However 
the effect of induced expression of ITGAX needs to be assessed in greater detail in future 
studies. 
The largest class of genes to have their expression altered by catechin treatment in wild type 
mice were those that are involved in cell proliferation. Following catechin treatment, the 
expression of FGF2, IL-2, IL-5, KDR (also known as VEGFR2) and PDGFRB2 were all 
increased (Fig. 7.14). This result was unexpected as catechin treatment in vitro had been found 
to attenuate cell proliferation and decrease the expression of VEGF which is a gene capable 
of inducing cell proliferation (Fig. 6.13 and 6.19). However these results may also indicate that 
catechin treatment has different effects on hepatocytes and macrophages, which needs to be 
investigated in greater detail in future studies. Furthermore the circulating levels of IL-2 and IL-
5 were found to be attenuated following catechin dietary supplementation (Fig. 7.10). 
Interestingly all the cell proliferation related genes which were induced by catechin in vivo are 
also capable of triggering angiogenesis and maintaining endothelium function (Andrae et al. 
2008; Bouchentouf et al. 2011; Liu et al. 2013; Park et al. 2017; Camaré et al. 2017). 
As previously discussed, aberrant angiogenesis within the atherosclerotic plaque can lead to 
haemorrhaging or rupture (Greenberg and Jin 2013). Therefore these results indicate that 
catechin treatment is capable of increasing the risk of a CVD-related event or show that it 
should be limited to being used as a preventative rather than being used in those with 
established atherosclerotic plaques. However this increased expression of angiogenic genes 
may represent a mechanism by which catechin treatment is capable of restoring vascular 
function and inducing vasodilation and reducing blood pressure observed in human trials 
(Fisher et al. 2003; Babu et al. 2008; Tinahones et al. 2008; Rassaf et al. 2016; Heiss et al. 
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2015; Sansone et al. 2015). Furthermore increased KDR signalling has been found to improve 
blood supply and tissue perfusion in white fat deposits (Robciuc et al. 2016). This was 
associated with increased insulin delivery and improved adipose tissue function (Robciuc et 
al. 2016). This fits with the previously described hypothesis that despite catechin treatment 
increasing white fat accumulation, it also improved white fat function as indicated by the 
reduction in associated circulating cytokines. Perhaps catechin improves white fat function by 
increasing the amount of angiogenesis occurring within the tissue. 
The only cell proliferation related gene to have its expression attenuated by catechin treatment 
was HBEGF (Fig. 7.14B). HBEGF is actively expressed and secreted from adipocytes during 
obesity and has been shown to induce VSMC proliferation (Matsuzawa 2005). During obesity 
the plasma levels of HBEGF have been found to be increased, which has been associated 
with reduced risk of a CVD-related event due to a more stable atherosclerotic plaque 
(Matsuzawa 2005; Rattik et al. 2015). These studies suggest that HBEGF is secreted during 
obesity in order to perform a protective role. If catechin is capable of restoring white fat function 
during obesity perhaps there is no need for the protective role of HBEGF, which may explain 
its reduced expression levels. 
Dietary supplementation with catechin for 21 days was found to significantly alter the 
expression of several ECM related genes (Fig. 7.15). The genes FGA and FGB encode the 
alpha and beta peptide chains of the fibrinogen molecule. During coagulation both the alpha 
and beta chains are cleaved by thrombin, resulting in the exposure of multiple polymerisation 
sites and the formation of fibrin fibres (Davalos and Akassoglou 2012). These fibrin fibres can 
then interact with platelets and form a blood clot. Fibrinogen forms the largest component of 
blood clots as measured by mass (Davalos and Akassoglou 2012). Increased serum levels of 
fibrinogen can be an indicator of an individual’s inflammatory state as increased levels have 
been associated with inflammation, hypertension and atherosclerosis (Adams et al. 2004; 
Sándor et al. 2016). Mice deficient for fibrinogen were found to have reduced platelet activation 
and attenuated serum levels of IL-10 and TNF-α (Iwaki et al. 2006; Zacharowski et al. 2007). 
Catechin treatment was also found to attenuate the expression of both FGA and FGB, 
indicating a reduction in the formation of fibrinogen, which was also found to be associated 
with reduced IL-10 and TNF-α circulating levels (Figs. 7.9 and 7.10). A study by Rabadán-
Chávez et al. (2016) also demonstrated that epicatechin treatment was capable of reducing 
the amount of circulating fibrinogen in rats fed a high fat diet. Furthermore increased levels of 
fibrinogen are associated with vasoconstriction, therefore reductions in the expression of FGA 
and FGB may provide another mechanism by which flavanol treatment has been previously 
found to induce vasodilation (Davalos and Akassoglou 2012; Lominadze et al. 2010). 
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Another anti-atherogenic effect of catechin treatment was the increased expression of TNC 
(Fig. 7.15D). The TNC gene encodes the ECM protein tenascin-C, which is capable of 
influencing cell adhesion, inflammation and tissue remodelling (Chiquet-Ehrismann 2004; 
Franz et al. 2015). Mice lacking the TNC gene were found to have increased monocyte and 
macrophage infiltration (Song et al. 2017). The cardiovascular protective effects of TNC have 
been demonstrated in ApoE deficient mice which were also lacking TNC (Wang et al. 2012). 
These mice were found to have enhanced atherosclerosis disease progression due to larger 
lesions forming, possibly due to increased cell infiltration because of increased VCAM-1 
expression. Furthermore these mice were also found to suffer from more interplaque 
haemorrhaging in comparison to the control mice (Wang et al. 2012). Therefore catechin 
treatment may reduce atherosclerotic lesion size by attenuating cell recruitment and increase 
lesion stability by preventing interplaque haemorrhaging as a results of increased TNC 
expression. 
Despite these benefits of catechin treatment, it also appeared to exert pro-atherogenic effects 
as measured by increased MMP1A expression (Fig. 7.15C). Increased MMP expression is 
normally associated with the weakening of the fibrous cap due to the increased destruction of 
ECMs present within it (McLaren et al. 2011a; Moss and Ramji 2016a; Ruddy et al. 2016). This 
result was not expected as previous studies have demonstrated that catechin and other 
flavanol treatments are capable of attenuating MMP expression and activation (Kim-Park et al. 
2016; Nowakowska and Tarasiuk 2016; Wang et al. 2016; Roomi et al. 2017; Owczarek et al. 
2017; Sato et al. 2017). Furthermore our in vitro study observed a reduction in MMP activity 
following catechin treatment (Fig. 6.22). Catechin treatment has also been found to increase 
the expression of TIMPs and therefore although catechin treatment increased the expression 
of MMP1A, it may also increase the expression of TIMPs and actually attenuate MMP activity 
(Garbisa et al. 2001; Lewandowska et al. 2013). The effect of catechin on MMP expression 
and activity in vivo requires further exploration in future feeding studies, as the current study 
determined the gene expression levels of MMP1A in the liver rather than macrophages. 
Indirect evidence points to the possibility of catechin treatment being capable of reducing the 
size of an atherosclerotic lesion and improve its stability. The reduction in the circulating or 
expression levels of CXCL1, fibrinogen and TNC (Figs. 7.9 and 7.15) in addition to in vitro 
monocyte migration assays (Fig. 5.6) indicate that catechin treatment is capable of attenuating 
monocyte recruitment during atherosclerotic plaque formation. Furthermore cell proliferation 
was found to be attenuated in vitro (Fig. 6.19), therefore the cellular content within a plaque 
may be reduced following catechin treatment accompanied by increased plaque stability 
(Wilson 2010; Seneviratne et al. 2013). Additionally, the reduced expression of ITGA2 and 
fibrinogen following catechin treatment indicates reduction in the risk of thrombosis due to a 
reduction in platelet activation (Figs. 7.13 and 7.15). This would coincide with previous studies 
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which have observed reductions in plaque size and attenuated platelet activation following 
catechin treatment (Morrison et al. 2014). However an increase in the expression of ITGAX 
and MMP1A (Figs. 7.13 and 7.15) may be markers of an increase in the number of DCs within 
the plaque as well as increased fibrous cap degradation, both of which play a role in plaque 
destabilisation (Zernecke 2015; Ruddy et al. 2016). Furthermore raised expression of 
angiogenesis genes (Fig. 7.14) may be an indicator of increased interplaque vessel formation 
which can also contribute to plaque destabilisation (Greenberg and Jin 2013). However 
increased expression of TNC may help to protect against this (Wang et al. 2012). On the other 
hand, the increased expression of angiogenesis genes may actually represent improved 
endothelium function following catechin treatment. The effect of catechin dietary 
supplementation on atherosclerotic plaque size and stability needs to be assessed in greater 
detail in future long term feeding studies using atherosclerotic mouse models.  
Catechin treatment appeared to exert anti-atherogenic effects on lipid transport and 
metabolism related genes by increasing their expression (Fig. 7.16). ApoE is an essential 
apolipoprotein in the RCT process as it allows HDL particles to transfer excess cholesterol 
back from peripheral tissues to the liver for excretion (van der Velde 2010; McLaren et al. 
2011a). The importance of ApoE in preventing atherosclerosis development has been well 
established in mouse models which lack the apolipoprotein as they rapidly develop 
atherosclerosis plaques (Chistiakov et al. 2017). Therefore increasing ApoE expression 
following catechin treatment implies strong anti-atherogenic effects. Furthermore an increase 
in ApoE implies an increase in the RCT process which may explain the observed increase in 
HDL levels (Fig. 7.6B). However if increasing ApoE expression is a mechanism by which 
catechin treatment exerts its cardiovascular protective effects, it must be taken into account 
when using traditional atherosclerotic mouse models of atherosclerosis as they will be lacking 
either ApoE or its receptor LDLr. 
LPL is also an essential component of cholesterol metabolism and homeostasis. It is capable 
of breaking down the TGs present in chylomicrons and VLDL particles, resulting in HDL particle 
formation (Rip et al. 2005). Additionally LPL is capable of increasing the removal of pro-
atherogenic lipoproteins by the LDLr within the liver (Rip et al. 2005). For this reason, LPL 
deficiency has been associated with increased serum TG levels and reduced HDL levels, 
resulting in increased atherosclerosis and risk of a CVD-related event (Benlian et al. 1996; Rip 
et al. 2005; Ramasamy 2016). However the effect of LPL on atherosclerosis development 
depends on where it is expressed as increased levels within adipose and muscle tissue is 
considered to be anti-atherogenic, whereas it is considered to be pro-atherogenic within 
macrophages and SMCs as it promotes lipid accumulation and inflammation (Li et al. 2014b). 
The effect of catechin treatment on LPL expression needs to be assessed further in future 
studies to determine its expression levels in these tissues/cells in order to determine whether 
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it is exerting a pro- or anti-inflammatory effect. Unlike previous studies which have observed a 
decrease in the levels of LPL following catechin and green tea extract treatment, the gene 
expression levels of LPL was found to be increased within the liver of wild type mice following 
catechin treatment in our study (Auclair et al. 2009; Chen et al. 2009; Lee et al. 2009). 
Furthermore LPL is required for TG turnover in adipose tissue, therefore increasing LPL 
expression may be another indicator that catechin treatment is capable of restoring normal 
adipose tissue function during a high fat diet (Stolarczyk 2017). 
As previously discussed, the role of APT1, encoded by LYPLA1, during atherosclerosis 
disease development remains uncertain. However it is known to play a role in lipid metabolism 
and cell signalling due to its ability to influence the removal of cell surface proteins in a process 
known as depalmitoylation (Vujic et al. 2016). The observed increase in LYPLA1 gene 
expression indicates that catechin treatment results in the increased removal of receptors and 
other proteins from the cell surface, and is therefore capable of influencing cell signalling. 
Overall catechin exerts anti-atherogenic effects on cholesterol homeostasis by increasing the 
gene expression of both ApoE and LPL which potentially resulted in the observable increase 
in HDL cholesterol levels. 
The expression of the transcriptional regulator NR1H3, also known as LXRα, is capable of 
upregulating the expression of genes involved in cholesterol efflux and transportation as well 
as attenuating the expression cholesterol uptake genes (Parikh et al. 2014). Catechin 
treatment was found to increase NR1H3 gene expression within the liver of wild type mice (Fig. 
7.17). On the other hand, our in vitro studies found that catechin treatment attenuated NR1H3 
expression in THP-1 macrophages (Fig. 6.16A), however this may be a cell specific effect. 
NR1H3 is thought to alter cholesterol homeostasis by attenuating the expression of NPC1L1, 
a protein involved in the uptake of cholesterol in the intestine (Alvaro et al. 2010). However 
catechin treatment failed to alter total serum cholesterol levels (Fig. 7.6A). Increased NR1H3 
expression is associated with increased plasma HDL cholesterol levels and indeed catechin 
was found to be capable of increasing HDL cholesterol levels (Fig. 7.6B), another possible 
mechanism by which catechin exerts its anti-atherogenic effects. Furthermore NR1H3 
activation is linked to reduced TNF-α and IL-1β expression (Zelcer and Tontonoz 2006). 
Catechin treatment also resulted in the reduced circulating levels of TNF-α and IL-1β (Figs. 
7.9 and 7.10). The increased expression of NR1H3 following catechin treatment may represent 
an underlying mechanism behind some of the cardiovascular protective effects of catechin. 
Overall, it appears that catechin treatment exerts anti-atherogenic gene expression changes. 
This can be seen by its ability to attenuate the expression of several pro-inflammatory genes 
such as FGA and FGB. Furthermore catechin was also capable of increasing the expression 
of ApoE, ENG, KDR, NR1H3, THBS4 and TNC, which are all considered to be anti-atherogenic 
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genes. This altered gene expression profile may explain and provide mechanistic insight into 
the anti-atherogenic effects of catechin observed in this study. 
7.4.4 The effect of catechin on bone marrow cell populations in wild type mice 
As previously discussed a high fat diet and obesity are capable of altering the proportion of 
cell populations within the bone marrow (Chan et al. 2012; Wu et al. 2013; Adler et al. 2014; 
van den Berg et al. 2016; Lang and Cimato 2014; Murphy et al. 2014; Ma and Feng 2016). 
Furthermore the cell population profile of an individual can be altered by dietary 
supplementation with a nutraceutical (Takano et al. 2004a; Betiati et al. 2013; Chang and 
Deckelbaum 2013). As catechin resulted in an increase in weight gain and fat accumulation in 
wild type mice, it was expected that catechin treatment may induce pro-atherogenic changes 
within the cell populations. The summary of changes to the bone marrow cell populations as a 
result of catechin treatment are summarised in Fig. 7.25. 
 
Fig. 7.25. The catechin induced changes in the proportions of cell populations within the bone marrow. The 
bone marrow of wild type mice were harvested after they had received either catechin or vehicle control treatment 
while being fed a high fat diet for 21 days. HSC, haematopoietic stem cell; MPP, multipotent progenitors; HPC, 
haematopoietic progenitor cell; CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor; 
GMP, granulocyte-macrophage progenitor; MDSC, myeloid-derived suppressor cells; LMPP, lymphomyeloid 
progenitor; CLP, common lymphoid progenitor. 
Atherosclerosis disease progression is positively correlated with an increase in white blood cell 
number and therefore can be used as a marker of an individual’s inflammatory state (Ates et 
al. 2011; Mozos et al. 2017). Catechin treatment resulted in an increase in the proportion of 
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total bone marrow cells recovered from the bone marrow of wild type mice (Fig. 7.18). This 
result would imply that catechin exerts a pro-inflammatory effect and potentially contributes 
towards atherosclerosis development. Indeed this was confirmed when the level of live-lineage 
negative cell population, a population which contains all HSPCs in the bone marrow, was also 
found to be increased by catechin (Fig. 7.20A). This increase was driven by the expansion of 
the MPP cell population (Fig. 7.20). The increased expression of FGF2, IL-2, IL-5, KDR and 
PDGFRB have been implicated in stem cell proliferation and therefore the increased 
expression of these gene following catechin treatment may explain the increase observed in 
HSPC populations (Fig. 7.14; Horikawa and Takatsu 2006; Choi et al. 2008; Rodrigues et al. 
2010; Liao et al. 2011).  
The LK cell population usually expands during atherosclerosis development and relocates to 
the spleen where they differentiate into monocytes and macrophages, which are capable of 
targeting the atherosclerotic lesion (Robbins et al. 2012). Catechin treatment had no effect on 
the size of the LK population found within the bone marrow, however it did non-significantly 
increase the CMP subpopulation (Figs. 7.21). In contrast, the MEP and GMP subpopulations 
was found to be unaffected following catechin treatment (Fig. 7.21). Previous studies have 
found that a high fat diet is capable of inducing the expansion of the CMP and GMP 
subpopulation, unfortunately these results indicate that catechin is not capable of protecting 
against an obesity driven expansion of the CMP population (Gao et al. 2014).  
Although the results show no change in the monocyte and macrophage cell population (Fig. 
7.23D), it is not clear whether these macrophages are the pro-atherogenic M1 or anti-
atherogenic M2 phenotype. The expression of several pro-angiogenic genes was found to be 
increased as a result of catechin and recently M2 macrophages have been implicated in 
promoting angiogenesis (Owen and Mohamadzadeh 2013). The changes in angiogenic genes 
may provide some insight into the phenotype of the macrophages which develop following 
catechin treatment. However, the full effect of catechin treatment on macrophage phenotype 
needs to be assessed in further detail as our in vitro study found that catechin was unable to 
induce the M2 macrophage phenotype (Fig. 6.23). 
In contrast to the vehicle control treated mice, those which received catechin treatment were 
found to have a non-significant decrease in their MDSC population within the bone marrow 
(Fig. 7.23C). The role of the MDSC population during atherosclerosis disease development 
remains unclear, although they are known to supress T-cell differentiation (Talmadge and 
Gabrilovich 2013). However it is worth noting that despite a decrease in the MDSC population, 
there was no change in the size of the T-cell population (Fig. 7.24B). Previous studies have 
found that the cytokines IL-6 and IL-10 are involved in the differentiation of MDSCs and 
therefore the reduction in the circulating levels of these cytokines may explain the reduction in 
the MDSC population (Fig. 7.10; Mundy-Bosse et al. 2011; Dolcetti et al. 2009). Much of our 
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knowledge on the role of MDSCs has been generated from tumour progression studies. 
MDSCs were found to be capable of inducing invasion, proliferation, survival and adhesion of 
tumours during their development and metastasis (Talmadge and Gabrilovich 2013). 
Furthermore angiogenesis has been found to be promoted by the MDSC population, however 
this decrease in the MDSC population contradicts the increase in the expression of angiogenic 
related genes following catechin treatment (Talmadge and Gabrilovich 2013). These mixed 
and contradictory results only highlight our lack of understanding of the general function of 
MDSCs as well as their role within atherosclerosis disease development. Studies which has 
tried to assess their function found that a reduction in the MDSC population was associated 
with increased atherosclerosis and inflammation (Xia et al. 2011; Foks et al. 2016). Therefore 
studies designed to uncover the specific role of MDSCs during atherosclerosis disease 
progression are required to fully evaluate the consequences of catechin treatment in reducing 
this population. 
Catechin treatment was associated with a non-significant increase in the B-cell population (Fig. 
7.24C). Increased B-cell proliferation is associated with IL-5 levels (Horikawa and Takatsu 
2006). Catechin treatment was found to increase IL-5 gene expression, explaining the increase 
in B-cell numbers (Fig. 7.14D). Although rare within the atherosclerotic lesion, B-cells are 
capable of exerting both pro- and anti-atherogenic effects depending on the phenotype 
(Andersson et al. 2010; Kyaw et al. 2011). Without future studies determining the specific 
phenotypic changes within the B-cell population it is not possible to determine whether the 
increase in B-cell number following catechin treatment is beneficial or detrimental. 
The changes in bone marrow cell populations following catechin treatment indicates a slight 
pro-atherogenic shift. This result coincides with a previous study which found (+)-catechin 
treatment caused a significant increase in the number of white blood cells in mice receiving a 
standard chow diet (Takano et al. 2004a). Additional studies are needed to assess the effect 
of these HSPC population changes on atherosclerosis disease development. Future studies 
are required to determine the cell changes which occur directly within the atherosclerotic 
plaque to overcome the limitations associated with only assessing the populations within the 
bone marrow (discussed in Chapter 4). The major limitation of this study was the loss of four 
mice per treatment group, limiting the study to four independent values. This study needs to 
be repeated in order to achieve a better understanding of the effect of catechin treatment on 
the changes in HSPCs within the bone marrow of wild type mice. 
7.4.5 Summary of the effect of catechin in wild type mice 
As far as we are aware, this is the first in vivo study to assess the cardiovascular protective 
effects of (+)-catechin treatment in a highly rigorous and detailed manner. Catechin treatment 
was found to induce a variety of anti-atherogenic effects such as increasing HDL cholesterol 
levels, promoting anti-inflammatory gene expression and reducing circulating pro-inflammatory 
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cytokine levels (summarised in Fig. 7.26). However this study also implies a slight pro-
inflammatory state within the bone marrow cell populations by catechin treatment. Overall this 
initial study justifies the use of catechin in long term feeding studies using atherosclerotic 
mouse models to fully uncover the nutraceutical potential of catechin for attenuating the rate 
of atherosclerosis disease development. The use of atherosclerotic models would also allow 
the effect of catechin on the plaque size, cellular composition and stability to be assessed in 
vivo. Furthermore the effect of catechin on vasorelaxation needs to be assessed during future 
studies in order to link it to changes in gene expression. Previous studies have shown that 
catechin and other flavanols are capable of attenuating plaque formation (Chyu 2004; Minatti 
et al. 2012; Morrison et al. 2014). Therefore catechin holds great promise for use as a 
cardiovascular protective treatment. 
 
 
Fig. 7.26. Summary of the potential anti-atherogenic properties of catechin in vivo. The steps potentially 
involved in the reduction of atherosclerosis disease progression following catechin treatment are highlighted in 
green. Possible mechanisms for these changes are also included. 
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Chapter 8: General Discussion 
General Discussion 
 
Due to the sustained increase in the global rates of obesity and diabetes as well as the 
continual westernisation of diets in developing countries, the global prevalence of CVD-related 
events will only continue to rise (WHO 2017). Traditional pharmaceuticals, such as statins, are 
not always capable of sufficiently lowering an individual’s circulating LDL levels despite 
receiving the highest statin dosage (Leitersdorf 2001; McLaren et al. 2011a). This means some 
patients have a considerable residual cardiovascular risk despite receiving statins. Therefore 
there is a large demand for alternative anti-inflammatory therapies that could be used either in 
isolation or in combination with statins to treat or prevent atherosclerosis. 
Compounds within healthy diets have been identified as possessing additional health benefits 
that go beyond their nutritional value and have been given the term ‘nutraceutical’ (Moss and 
Ramji 2016b). The nutraceuticals ω-3 PUFAs, flavanols and phytosterols have emerged as 
compounds possessing anti-inflammatory properties and therefore may provide 
cardiovascular protective effects (extensively reviewed in Moss and Ramji 2016). Therefore 
investigating these nutraceuticals in greater detail may provide more insight into their anti-
atherogenic potential and lead to the identification of a novel preventative or treatment for 
atherosclerosis. Furthermore combining these nutraceuticals in a mixture may result in 
synergistic effects and result in stronger anti-atherogenic effects when compared to assessing 
them in isolation. CardioWise is a novel nutraceutical combination designed by Cultech 
Limited. The main aim of this project was to assess whether this nutraceutical and the 
components within it were capable of exerting anti-inflammatory effects and attenuate the key 
stages of atherosclerosis disease development. 
CardioWise was found to have many anti-atherogenic actions on monocytes/macrophages in 
vitro, including attenuated pro-inflammatory gene expression, monocyte recruitment, foam cell 
formation and M1 macrophage polarisation (see Chapter 3). These anti-atherogenic actions 
extended in vivo to mice fed a high fat diet (see Chapter 4). CardioWise treatment increased 
serum HDL levels as well as reducing the circulating levels of pro-inflammatory cytokines. 
Furthermore CardioWise produced an anti-atherogenic gene expression profile in addition to 
decreasing the proportion of macrophages found within the bone marrow. Catechin was 
identified as a key nutraceutical within CardioWise due to its anti-oxidant properties and had 
the ability to attenuate monocyte recruitment and macrophage proliferation in vitro (see 
Chapters 5 and 6). The anti-oxidant effects of catechin were also identified in vivo in mice fed 
a high fat diet (see Chapter 7). Mice treated were catechin were also found to have reduced 
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levels of pro-inflammatory cytokines and increased serum HDL cholesterol levels. Additionally 
catechin treatment induced the expression of anti-inflammatory genes as well as reducing the 
proportion of MDSCs, granulocytes and T-cells within the bone marrow of mice. 
 
8.1 The cardiovascular protective effects of CardioWise 
The results presented in Chapter 4 represent the first in vivo study to treat wild type mice fed 
a high fat diet with a novel nutraceutical combination containing ω-3 PUFAs, flavanols and 
phytosterols at a human physiological equivalent dose. The increased circulating levels of HDL 
cholesterol, reduced pro-inflammatory gene expression and reduced plasma pro-inflammatory 
cytokine levels show that CardioWise exerts strong anti-atherogenic effects in vivo 
(summarised in Fig. 4.25). Changes within the gene expression profile and altered lipid and 
cytokine levels within the mice receiving CardioWise indicate a possible activation of brown 
adipose tissue deposits and the browning of white fat (summarised in Fig. 4.23). This would 
indicate that CardioWise treatment could be used in obese individuals to activate their brown 
fat deposits and enhance lipid clearance by non-shivering thermogenesis. This hypothesis 
requires further exploration in future studies in order to gain a better understanding of the effect 
of CardioWise treatment on the function of fat deposits (see Section 8.6 for further details). As 
well as CardioWise exerting these anti-atherogenic effects, it was found to decrease the 
proportion of monocytes and macrophages found within the bone marrow when compared to 
the vehicle control treated mice, a sign of reduced inflammation (summarised in Fig. 4.24). ω-
3 PUFAs, flavanols and phytosterols have all been previously shown to be capable of 
attenuating atherosclerotic plaque formation (Moghadasian et al. 1999; Yeganeh et al. 2005; 
Moghadasian 2006; Chyu 2004; Nakajima et al. 2011; Brown et al. 2012; Minatti et al. 2012; 
Morrison et al. 2014). This reduction in lesion size may arise due to the ability of CardioWise 
treatment to reduce the expression of cell recruitment and proliferation related genes (Figs. 
4.11 and 4.12). The altered gene expression profile in combination with previous studies 
showing that ω-3 PUFAs, flavanols and phytosterols are capable of retarding atherosclerosis 
disease progression indicate that CardioWise treatment has the potential to reduce 
atherosclerotic plaque size (Moghadasian et al. 1999; Yeganeh et al. 2005; Moghadasian 
2006; Chyu 2004; Nakajima et al. 2011; Brown et al. 2012; Minatti et al. 2012; Morrison et al. 
2014). Future studies using atherosclerotic related mouse models are required to assess the 
effect of CardioWise treatment on plaque formation (see Section 8.6 for further details). Overall 
the results presented in this thesis demonstrate that CardioWise possesses anti-inflammatory 
properties in vitro using human derived macrophages as well as protecting wild type mice from 
the pro-inflammatory actions of a high fat diet. 
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8.2 The cardiovascular protective effects of catechin 
As shown in Chapter 7, catechin treatment resulted in a variety of cardiovascular protective 
effects, including increased HDL cholesterol levels, enhanced anti-inflammatory gene 
expression and reduced circulating pro-inflammatory cytokine levels (summarised in Fig. 7.26). 
Furthermore the study also revealed that catechin induces the expression of several genes 
involved in maintaining the function of the endothelium (Fig. 7.14). Previous studies have 
observed improved vascular function, vasodilation and reduced blood pressure following 
catechin treatment (Fisher et al. 2003; Babu et al. 2008; Tinahones et al. 2008; Rassaf et al. 
2016; Heiss et al. 2015; Sansone et al. 2015). The increased expression of these gene may 
represent the underlying mechanism by which catechin and other flavanol treatments are 
capable of inducing vascular function improvements seen in previous human trials (Fisher et 
al. 2003; Babu et al. 2008; Tinahones et al. 2008; Rassaf et al. 2016; Heiss et al. 2015; 
Sansone et al. 2015). Additional in vivo studies are required to confirm the potential link 
between altered gene expression and reduced blood pressure following catechin treatment 
(see Section 8.6 for further details). Although catechin treatment resulted in several anti-
atherogenic effects, it was also found to shift the bone marrow cell populations to a slightly 
pro-inflammatory one (summarised in Fig. 7.25). However due to unforeseen problems with 
the cell extraction from the bone marrow, the results of the cell population analysis are based 
on a reduced sample size and therefore requires repetition to fully evaluate the effect of 
catechin on haematopoietic cell populations. Catechin treatment was found to attenuate the 
circulation and expression of a variety of monocyte recruitment factors in vivo (Figs. 7.9 and 
7.15) in addition to decreasing the amount of monocyte migration in vitro (Fig. 5.6). This may 
represent the mechanism by which previous studies have shown that catechin and other 
flavanols are capable of reducing atherosclerotic plaque size (Chyu 2004; Minatti et al. 2012; 
Morrison et al. 2014). The direct link between the effect of catechin on circulating cytokine 
levels as well as the expression of cell adhesion molecules and the size of the plaque needs 
to be assessed in future studies to confirm the mechanism of action (see Section 8.6 for further 
details). This study has shown that catechin treatment is capable of exerting cardiovascular 
protective effects in both human macrophages and wild type mice. 
 
8.3 Similarities and differences between CardioWise and catechin treatment 
As catechin is a major component within the CardioWise combination, it is useful to compare 
and contrast the cardiovascular protective effects generated by each treatment. This would aid 
in determining the role of catechin within the mixture or identifying additional protective effects 
which cannot be achieved by catechin treatment in isolation. A comparison of the effects of 
CardioWise and catechin treatment on foam cell formation in vivo is summarised in Fig. 8.1. 
There is indirect evidence to suggest that CardioWise and catechin treatment are capable of 
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restoring the physiological function of brown and white fat respectively (see Chapters 4 and 
7). Previous studies have demonstrated that ω-3 PUFAs and other GPR120 agonists are 
capable of activating brown fat, which explains the additional benefit of brown fat activation 
following treatment with the mixture (Quesada-López et al. 2016; Pahlavani et al. 2017). The 
CardioWise mixture was also capable of increasing circulating HDL levels and improving the 
LDL/HDL cholesterol ratio (Fig. 4.5). This result was expected as ω-3 PUFAs, flavanols and 
phytosterols have all been found to increase serum HDL levels in murine studies (Chisaka et 
al. 1988; Babu et al. 2006; Moghadasian et al. 1999; Nakajima et al. 2011). Catechin treatment 
in isolation was also found to improve HDL levels and the LDL/HDL ratio (Fig. 7.6), however 
the changes were comparable to the combined treatment indicating that there were no 
additional benefits on circulating cholesterol levels from the extra nutraceuticals. Catechin 
treatment also resulted in a reduction in the circulating levels of several atherosclerosis related 
cytokines (see Chapter 7). CardioWise treatment resulted in similar trends of reduction in 
circulating cytokine levels which were observed following catechin treatment (see Chapter 4), 
therefore it indicates that main compound capable of reducing cytokine levels within the 
mixture is catechin. However this requires further exploration in future studies. 
 
Fig. 8.1. The similarities and differences between CardioWise and catechin treatment on foam cell formation 
in vivo. The steps altered by both CardioWise and catechin treatment during atherosclerosis disease progression 
are highlighted in green. The steps altered by CardioWise treatment only during atherosclerosis disease 
progression are highlighted in blue. The steps altered by catechin treatment only during atherosclerosis disease 
progression are highlighted in purple. 
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Both catechin and CardioWise treatment resulted in a decrease in the proportion of MDSCs 
within the bone marrow of wild type mice, whereas CardioWise treatment also reduced the 
number of macrophages (Fig. 4.21 and 7.23). 
As well as exerting similar effects, catechin and CardioWise treatments resulted in 
cardiovascular protective effects that were unique to each treatment. An anti-atherogenic gene 
expression profile was induced by both catechin and CardioWise treatment but interestingly 
the genes which were found to be altered by catechin treatment were not the same genes 
altered by CardioWise treatment (see Chapters 4 and 7). These results suggest that either 
another component within the mixture masked the effects of catechin or an interaction between 
the nutraceuticals caused changes in the expression of different genes. This may be due to 
the increased PPAR-γ expression observed following CardioWise treatment which was not 
seen when catechin was used in isolation (Fig. 4.15B and 7.17). This coincides with previous 
studies which have shown that ω-3 PUFAs cause the activation of PPAR-γ (Calder 2012). As 
PPAR-γ is a key regulator of transcription, its activation following CardioWise treatment may 
explain why different genes are either activated or attenuated when compared to the mice 
receiving catechin only (Derosa et al. 2013; Derosa et al. 2018). 
Previous studies have demonstrated that flavanols are unable to alter circulating TG levels and 
this was confirmed in our study (Fig. 7.7; Matsuyama et al. 2008; Friedrich et al. 2012). 
However both ω-3 PUFAs and phytosterols have been found to reduce the serum levels of 
TGs (Kamat and Roy 2016; Schonewille et al. 2014; Perez-Ternero et al. 2017). It was 
therefore unexpected when CardioWise treatment resulted in an increase in TG levels (Fig. 
4.6A). As previously discussed there is evidence that CardioWise potentially induces brown 
fat activation which in turn can raise TG levels (Hoeke et al. 2017). Another possible 
explanation for this increase in TG levels is due to an interaction between all of the 
nutraceuticals present within the mixture which therefore requires further investigation. 
Furthermore CardioWise resulted in a decrease in the number of B- and T-cell present within 
the bone marrow, whereas catechin treatment used in isolation only resulted in a reduction in 
the number of T-cells (Fig. 4.22). This change may be a result of the altered gene expression 
changes observed following dietary supplementation with CardioWise (see Chapter 4) or it is 
a result of an additional nutraceutical present within the mixture. Indeed previous studies have 
demonstrated that ω-3 PUFAs are capable of reducing the number of T-cells and therefore is 
the most likely nutraceutical responsible for the decrease in B- and T-cells (Calder 2015). As 
previously discussed MDSCs reduce the proliferation of T-cells, however in CardioWise 
treated mice both the MDSC and T-cell population were found to be decreased. This led to the 
hypothesis that the two populations had their numbers reduced by two independent 
mechanisms (see Chapters 4).  
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The ω-3 PUFAs and phytosterols present within the CardioWise mixture prevented the weight 
gain which occurred in mice receiving the dietary supplementation of catechin only (Figs. 4.3 
and 7.4). However as this was a short term feeding study, a longer time period is required to 
fully assess the effects of CardioWise and catechin treatment on weight gain in wild type mice. 
Previous studies have demonstrated that flavanols are strong anti-oxidants which are capable 
of attenuating ROS generation (Moss and Ramji 2016b; Bahramsoltani et al. 2017; Tak et al. 
2016; Yu et al. 2017; Oyama et al. 2017). However ROS generation was not attenuated in 
mice receiving CardioWise or catechin (Fig. 4.7 and 7.8). Overall these results demonstrate 
that the unique mixture of ω-3 PUFAs, flavanols and phytosterols present in CardioWise has 
different and additional cardiovascular protective effects when compared to catechin only 
treatment in wild type mice. This study shows that combinations of nutraceuticals can be used 
as potential therapies for CVD and atherosclerosis and should therefore should be assessed 
in greater detail in future studies. Studies are required to explore the potential effects of mixing 
previously known cardiovascular protective nutraceuticals to try and establish a potent anti-
inflammatory therapy for retarding the progression of atherosclerosis in a similar manner to the 
development of CardioWise. 
 
8.4 From bench to mouse to bedside? 
This study has demonstrated that both CardioWise and catechin treatment are effective anti-
inflammatory nutraceuticals which have the potential to exert anti-atherogenic effects in our 
atherosclerotic related in vitro models and wild type mice (see Chapters 3- 7). The results from 
these initial studies justify the further exploration of CardioWise and catechin dietary 
supplementation in atherosclerotic related mice models. Both ApoE and LDLr deficient mice 
have previously been used to show that the individual components of CardioWise, ω-3 PUFAs, 
flavanols and phytosterols, are capable of retarding atherosclerosis disease development 
(Table 1.2; Moss and Ramji 2016). Therefore it is predicted that both CardioWise and catechin 
treatment would be capable of attenuating atherosclerosis plaque formation. 
As the majority of nutraceutical therapies are most likely going to be used to treat individuals 
who are already receiving statins, the effect of CardioWise and catechin dietary 
supplementation needs to be assessed in atherosclerotic mice also receiving statins. This 
would determine whether there were any additional cardiovascular protective effects or any 
detrimental effects associated with receiving a combination of traditional pharmaceuticals and 
nutraceutical therapies for atherosclerosis as add on treatments for statins. Only once 
CardioWise and catechin dietary supplementation have been found safe and effective in these 
studies should it progress into preliminary human clinical trials for assessment as add-on 
therapies for statins. Results will be able to determine whether CardioWise and catechin are 
most effective when used as a preventative (i.e. in low to medium risk patients who do not 
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initially qualify for statin treatment but will in the future without some form of intervention) or 
used in combination with statins to achieve greater cardiovascular protective effects which 
cannot be achieved by statins in isolation. Furthermore as CardioWise is a combination of 
nutraceuticals, results from the in vivo murine and human studies should always be used to 
determine whether the mixture would benefit from additional nutraceuticals being added, or 
changing the concentrations of the individual components within the emulsion to result in a 
more effective combination. These changes could easily be assessed within our in vitro 
atherosclerotic models before use in clinical trials in an effective bench-to-bedside approach 
to anti-atherogenic nutraceutical research. 
Another issue to consider when designing potential nutraceutical therapies for the prevention 
or treatment of atherosclerosis is the bioavailability of the compounds. The bioavailability of all 
nutrients can be affected by a variety factors including, their physicochemical properties, the 
presence or absence of other nutrients which may boost or attenuate absorption, and how they 
are metabolised once taken up by the body (Schuchardt and Hahn 2013). Studies have shown 
that following the consumption of EPA or DHA, plasma levels rapidly increase and they also 
begin to aggregate in mononuclear cells and adipose tissue (Browning et al. 2012; Browning 
et al. 2014). Furthermore, the half-life of EPA has been shown to be approximately 3 days 
(Braeckman et al. 2013). These studies show that ω-3 PUFAs are able to reach the target 
tissues and at high concentrations for a prolonged period of time. 
On the other hand, the bioavailability of flavonoids is extremely variable (Thilakarathna and 
Rupasinghe 2013). Catechin is known to be efficiently absorbed within the gut following 
consumption, as demonstrated by an increase in the concentration of catechin metabolites in 
urine (Manach et al. 2004; Manach et al. 2005; Del Rio et al. 2010). The plasma concentrations 
of flavanols has been show to peak approximately 1.5 hours after consumption and they have 
a half-life of 2 to 3.5 hours (Lee et al. 2002). Relatively little is known about what concentrations 
catechin or its metabolites are able to reach in different tissues around the body. This needs 
to be investigated in greater detail in future studies to ensure catechin reaches the target 
tissues at sufficient concentrations. The bioavailability of phytosterols is extremely poor as 
there is relatively little absorption within the gut (Ostlund 2002), however this is how they exert 
their potential cardiovascular health benefits. As phytosterols attenuate cholesterol uptake in 
the gut by out competing its ability to bind to the necessary receptors, its bioavailability within 
the body is not as important as the ω-3 PUFAs and catechin. 
 
8.5 The use of nutraceuticals for other inflammatory based diseases  
Chronic inflammation is not limited to atherosclerosis and is involved in several diseases 
including arthritis, asthma and inflammatory bowel disease (IBD). Therefore the anti-
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inflammatory effects observed following CardioWise and catechin treatment both in vitro and 
in vivo means they also have the potential to be used as nutraceutical therapies for these 
diseases. Several studies have explored the use of nutraceuticals, especially ω-3 PUFAs, for 
a variety of inflammatory based conditions with success (Tanaka and Takahashi 2013; Calder 
2015). A brief overview of the role of the inflammatory response in arthritis, asthma, IBD and 
Abdominal aortic aneurysm is discussed below along with evidence for the protective effects 
of nutraceuticals. 
8.5.1 Arthritis 
There are many forms of arthritis but the two most prevalent forms are osteoarthritis (OA) and 
rheumatoid arthritis (RA). Arthritis occurs when the cartilage and neighbouring bone are broken 
down within the joint, disrupting the protected smooth movement of the joint which leads to 
joint pain. OA is an age related condition and is usually triggered by mechanical stress, 
whereas RA is a chronic inflammatory autoimmune disorder (Hoxha 2018). RA is characterised 
by the increased production and secretion of pro-inflammatory cytokines and cell adhesion 
molecules within the joint (Hoxha 2018). The major cytokine thought to be involved in 
promoting the destruction of the joint is TNF-α (Hoxha 2018). Current therapies for RA which 
target the cytokines TNF-α and IL-6 are beyond the scope of this project but have been 
extensively reviewed in Chaabo and Kirkham (2015) and Kim et al. (2015). Furthermore an 
increase in the number of B- and T-cells infiltrating the joint is also associated with RA (Hoxha 
2018). 
CardioWise treatment in wild type mice receiving a high fat diet was found to be capable of 
attenuating the expression and secretion of cytokines and cell adhesion molecules, including 
TNF-α (Figs. 4.8, 4.11 and 4.14). Furthermore the proliferation of B- and T-cells was reduced 
in mice treated with CardioWise (Fig. 4.22). These results indicate that CardioWise also has 
the potential to be used as a nutraceutical therapy for RA. Indeed some of the components of 
CardioWise, ω-3 PUFAs and flavanols, have been shown to attenuate RA development in 
mice (Tang et al. 2007; Ierna et al. 2010; Calder 2015). Dietary supplementation with EPA and 
DHA in the form of fish or krill oil was found to attenuate the formation of arthritis in mice when 
compared to the vehicle control diet (Ierna et al. 2010). A reduction in arthritis score, joint 
pathology, inflammatory cell invasion and paw swelling was observed in mice receiving ω-3 
PUFAs compared to the control mice (Ierna et al. 2010). Catechin treatment in rats with 
induced arthritis was found to reduce secondary inflammatory paw swelling in addition to 
attenuating the levels of TNF-α (Tang et al. 2007).  
The RA protective benefits of ω-3 PUFAs dietary supplementation has also been observed in 
human trials (Boe and Vangsness 2015; Calder 2015; Fattori et al. 2016). The most common 
treatment for RA is the use of non-steroidal anti-inflammatory drugs (NSAIDs). These drugs 
work by targeting the inflammatory reaction which occurs during the destruction of the articular 
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cartilage (Boe and Vangsness 2015). After treatment with ω-3 PUFAs, patients were found to 
need less NSAID treatment (Boe and Vangsness 2015; Calder 2015; Fattori et al. 2016). 
Furthermore randomised clinical trials have shown that patients who receive ω-3 PUFA 
treatment for 3 to 4 months reported less joint pain, reduced joint swelling and improved grip 
strength (Boe and Vangsness 2015; Calder 2015; Fattori et al. 2016). These anti-RA health 
benefits are thought to be due to a reduction in the levels of pro-inflammatory cytokines which 
occurred as a result of ω-3 PUFA treatment (Boe and Vangsness 2015). The changes in 
cytokine levels following CardioWise treatment presented in this study in combination with the 
evidence of the benefits of ω-3 PUFA dietary supplementation from previous studies, indicate 
that CardioWise has the potential to relieve joint pain in RA suffers. 
8.5.2 Asthma 
Asthma is a chronic inflammatory disease within the airways of the lung. It can be characterised 
by airway spasms and a reversible obstruction of airflow due to an increase in the contractility 
of the surrounding smooth muscles. This means asthma can result in coughing, wheezing and 
shortness of breath, therefore it is important that all possible therapies are explored to relieve 
asthma suffers of their discomfort. The inflammatory reaction during asthma is primarily 
associated with an increase invasion of eosinophils within the lung (Calder 2015). Additionally 
mast cells, neutrophils, macrophages and T-cells are all present in increased numbers. 
Furthermore the levels of several pro-inflammatory cytokines including TNF-α, IL-5 and IL-6 
are known to be increased in asthma sufferers (Calder 2015). 
CardioWise treatment in wild type mice receiving a high fat diet results in decreased monocyte 
proliferation (Fig. 4.21), in addition to reducing the number of T-cells present within the bone 
marrow (Fig. 4.22). Furthermore a reduction in the circulating levels of TNF-α, IL-5 and IL-6 
was observed in mice following treatment with CardioWise when compared to the vehicle 
control treatment mice (Fig. 4.8). Catechin treatment was also found to attenuate the circulating 
levels of these cytokines (Figs. 7.9 and 7.10). These results would indicate that both 
CardioWise and catechin dietary supplementation have the potential to reduce the 
inflammatory response which occurs during asthma. Previous studies using the Fat-1 mouse 
model (mice which should have a ω-3:ω-6 ratio of 1:1) have reduced airway inflammation, 
white blood cell invasion and IL levels including pro-inflammatory IL-5 when compared to wild 
type mice (Bilal et al. 2011). 
A small clinical trial involving 23 participants was found to have reduced airway inflammation 
following 5 weeks of ω-3 PUFA dietary supplementation (Schubert et al. 2008). Patients were 
pre-treated with ω-3 PUFAs before being challenged with low level mite allergen for the 
remaining 2 weeks. However lung function was shown to be unchanged between the two 
groups, indicating that despite a reduction in inflammatory biomarkers there was not a 
significant improvement in airflow in the lung (Schubert et al. 2008). Furthermore meta-analysis 
 Chapter 8: General Discussion  
224 
 
of 6 and 9 randomised clinical trials has shown that ω-3 PUFA dietary supplementation has 
little benefit in child or adult sufferers of asthma (Thien et al. 2002; Anandan et al. 2009). Early 
studies may have suggested that ω-3 PUFA treatment was capable of relieving the symptoms 
of asthma, however recent studies have questioned their efficacy and therefore further 
research is required to fully understand the effects of ω-3 PUFA supplementation in asthma 
sufferers (Calder 2015). 
A limited number of studies have also explored the effect of flavanol treatment in asthma 
sufferers. Both epidemiological and cross-sectional studies have demonstrated a correlation 
between diets rich in fruit and vegetables, which contain flavonoids, and reduced asthma 
severity (Tanaka and Takahashi 2013). Mice treated with flavanols have also shown reduced 
levels of IL-4 and IL-5 which was associated with reduced symptoms of asthma (Tanaka and 
Takahashi 2013). Large clinical trials are needed to assess the effectiveness of both ω-3 
PUFAs and flavanol treatment in reducing the inflammatory response in asthma patients. As 
previous studies have only been able to inconsistently demonstrate the anti-asthmatic benefits 
of ω-3 PUFA and flavanol treatment in isolation, CardioWise treatment should also be explored 
due it being a combination of potentially beneficial nutraceuticals and therefore may be more 
effective. 
8.5.3 IBD 
IBD is a general term for ulcerative colitis and Crohn’s disease which are two chronic 
inflammatory diseases which affect the digestive system. Colitis primarily affects the colon and 
is frequently associated with increased neutrophil invasion and increased production of IL-5 
and IL-10 (Calder 2015). In contrast the entire digestive system can be affected by Crohn’s 
disease, which is also accompanied by an increased invasion of neutrophils and elevated 
levels of IFN-γ, IL-1β, IL-6 and TNF-α (Calder 2015). The treatment for IBD typically involves 
constant pharmaceutical and surgical intervention to improve a patient’s quality of life (Vezza 
et al. 2016). However long term pharmaceutical intervention is associated with several side 
effects and therefore there is a need to develop alternative therapeutics (Vezza et al. 2016). 
CardioWise and catechin treatment in wild type mice receiving a high fat diet was found to 
attenuate the levels of several pro-inflammatory cytokines, including those associated with 
colitis and Crohn’s disease (Figs. 4.8, 7.9 and 7.10). Therefore they represent potential 
nutraceuticals which could be used to reduce the inflammatory response in IBD. 
A variety of murine studies have demonstrated that ω-3 dietary supplementation induced a 
reduction in chemically triggered colitis inflammation in comparison to those mice treated with 
ω-6 PUFAs (Calder 2015). Fat-1 mouse models have shown to have reduced gut inflammation 
and damage compared to wild type mice following 10 weeks of a ω-6 rich diet (Hudert et al. 
2006). Furthermore these mice were found have reduced expression of TNF-α and IL-1β within 
the gut. Green tea extract has also been used to reduce in the inflammatory response in murine 
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models of colitis by attenuating the level of ROS production and subsequent lipid peroxidation 
(Brückner et al. 2012; Oz et al. 2013). ROS generation was also found to be reduced by 
catechin treatment in our study (Fig. 7.8). 
The beneficial effects of ω-3 PUFA dietary supplementation for the treatment of IBD remains 
controversial. Several clinical trials have shown that a diet enriched with EPA and DHA is 
capable of reducing gut inflammation, in addition to improving a variety of markers including 
clinical score and gut mucus histology (Calder 2008; Calder 2015). The patients receiving the 
dietary supplementation were also able to reduce their need for traditional pharmaceutical 
intervention (Calder 2008; Calder 2015). However other studies have observed no change in 
the levels of gut inflammation following ω-3 PUFA treatment (Calder 2008; Calder 2015). 
Therefore further clinical trials are required to fully evaluate the effectiveness of ω-3 PUFA and 
catechin dietary supplementation on gut inflammation. 
8.5.4 Abdominal aortic aneurysms 
Abdominal aortic aneurysm is an inflammatory condition which results in the enlargement of 
the aorta by at least one and a half times its original diameter (Meital et al. 2017). The aorta 
continually expands due to the weakening of the arterial wall caused by ECM degradation until 
it eventually ruptures and results in death (Meital et al. 2017). The inflammatory reaction during 
aortic aneurysm formation is primarily associated with an increased accumulation of 
macrophages, granulocytes, B- and T-cells within the walls of the artery (Meital et al. 2017). 
Furthermore the levels of several pro-inflammatory cytokines including IL-1β, IL-6 and TNF-α 
are known to be increased in patients with an aortic aneurysm (Meital et al. 2017). 
CardioWise treatment in wild type mice receiving a high fat diet results in decreased monocyte 
proliferation (Fig. 4.21), whereas catechin treatment resulted in a reduction in proportion of 
granulocytes found within the bone marrow (Fig. 7.23). Additionally both treatments reduced 
the number of T-cells present within the bone marrow (Figs. 4.22 and 7.24). Furthermore a 
reduction in the circulating levels of IL-1β, IL-6 and TNF-α was observed in mice treated with 
CardioWise when compared to the vehicle control treatment mice (Fig. 4.8). Catechin 
treatment was also found to attenuate the circulating levels of these cytokines (Figs. 7.9 and 
7.10). These results would indicate that both CardioWise and catechin dietary supplementation 
have the potential to reduce the inflammatory response which occurs during aortic aneurysm. 
At the time of writing there has only been one human clinical trial performed which investigated 
the effect of ω-3 PUFA dietary supplementation on aortic aneurysm formation (Berger et al. 
2008). The small trial involved 24 patients recovering from abdominal aortic aneurysm surgery 
receiving either ω-3 PUFA supplementation or a vehicle control for 4 days (Berger et al. 2008). 
The dietary intervention was found to be ineffective as both sets of patients had increased 
serum CRP and lipid peroxidation levels after 4 days, indicating no difference in their 
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inflammatory state (Berger et al. 2008). However the study did not investigate the effect of ω-
3 PUFA supplementation on the circulating levels of pro-inflammatory cytokines, which would 
have provided more information about the patient’s inflammatory state (Meital et al. 2017). 
A recent study using rats fed a standard chow diet found that green tea extract is capable of 
attenuating abdomen aortic aneurysm development (Setozaki et al. 2017). The rats were fed 
green tea extract for 2 weeks before an aortic aneurysm was surgically induced. Dietary 
supplementation continued for a further 4 weeks (Setozaki et al. 2017). In comparison to the 
vehicle control receiving rats, those which received the green tea extract had a smaller aortic 
diameter and a thicker arterial wall (Setozaki et al. 2017). Furthermore these rats had 
attenuated TNF-α, IL-1β and MMP9 gene expression levels, as well as reduced MMP activity 
(Setozaki et al. 2017). Catechin was found to exert similar effects in our study as it was capable 
of reducing the serum levels of IL-1β and TNF-α (Figs. 7.9 and 7.10), in addition to decreasing 
MMP activity (Fig. 6.22). Due to the limited number of studies which have investigated the 
potential benefits of using nutraceutical to retard the development of abdominal aortic 
aneurysms, both CardioWise and catechin should be used in future in vivo studies to explore 
their potential benefits in greater detail.  
 
8.6 The limitations and future directions of this study 
The major limitation associated with this study is the lack of a standard chow diet control mice 
during the in vivo assays. This was due to the limited availability of mice at the time of the 
study. Mice fed a chow diet would establish a baseline by which the high fat diet mice could 
be compared to. It would provide a better understanding of the effect of a high fat diet on all in 
vivo parameters measured, especially the effect of a high fat diet on cell populations within the 
bone marrow. A baseline would also allow a better interpretation of the changes induced by 
CardioWise and catechin treatment (i.e. Do the nutraceutical therapies reverse the impact of 
a high fat diet on wild type mice?). Therefore all future studies using CardioWise and catechin 
treatment should also include chow fed mice. 
This study was performed using wild type mice. Although this is not strictly a limitation as this 
study was designed to generate initial data to evaluate the potential of performing long term 
feeding studies. However future studies should use atherosclerotic mouse models, either ApoE 
or LDLr deficient mice, as these mice are capable of developing plaques unlike wild type mice. 
The CardioWise and catechin treatment period should also be increased from 3 to 12 weeks. 
This is to allow adequate time for plaques to develop as this time point has been shown to be 
effective in previous studies (Chen et al. 2017a; Shamsuzzaman et al. 2017; Tang et al. 2017). 
The number of weeks also needs to be increased as patients will be expected to receive 
nutraceutical therapy for a prolonged period of time. Therefore it is essential to determine no 
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detrimental effects occur from sustained CardioWise and catechin treatment. By using 
atherosclerosis prone mice, it would allow the effects of CardioWise and catechin treatment to 
be assessed on several other parameters of atherosclerosis development that could not be 
determined in this study. For example the effect of CardioWise and catechin treatment on 
plaque size, stability and cellular composition could be assessed. This would provide a greater 
insight into the cardiovascular protective effects of CardioWise and catechin as well as develop 
a better understanding of their mechanism of action. 
Another aspect which could be changed in future studies is the time point at which CardioWise 
and catechin treatment is delivered. As one of the possible use of nutraceutical therapy is to 
delay a patient’s need for traditional pharmaceutical interventions, studies need to be designed 
with this aspect in mind. CardioWise and catechin treatment should be given to atherosclerotic 
prone mice for a short time period while receiving a standard chow diet before switching to a 
high fat diet. A delay in the development of atherosclerotic plaques would represent a 
preventative effect. Other studies should do the reverse and move mice onto a high fat diet for 
several weeks before CardioWise or catechin intervention (Chistiakov et al. 2017). This would 
allow plaques to develop to equal size. Once atherosclerotic lesions have formed, treating the 
mice with either CardioWise or catechin would determine whether either nutraceutical 
intervention is capable of inducing plaque regression and restore blood vessel function in 
individuals with advanced atherosclerosis. 
Another potential use of nutraceutical therapies is to use them in combination with traditional 
pharmaceuticals as an additional way to achieve health targets. For this reason studies should 
also treat atherosclerotic mice with CardioWise or catechin in combination with statins. In all 
likelihood, this scenario would represent the majority of patients who would use nutraceutical 
therapies. Therefore it is essential to assess the effects of CardioWise and catechin as an 
additional add-on therapy to statins to ensure there are no detrimental effects and whether 
further reductions in atherosclerosis development can be achieved. 
Throughout this study, indirect evidence showed that CardioWise treatment is capable of 
activating non-shivering thermogenesis in brown adipose tissue. Therefore studies should also 
be designed to investigate this aspect by testing the levels of markers of brown fat activation 
within the fat deposits of mice (Harms and Seale 2013; Peirce et al. 2014). The body 
temperature of the mice should also be measured routinely throughout the study as an 
increase in body temperature can be a sign of increased brown fat activation (Crane et al. 
2014; Meyer et al. 2017). Furthermore due to the ability of catechin to lower blood pressure, 
future studies should determine the blood pressure of the mice periodically over the entire time 
course of the trial by using a tail cuff (Wang et al. 2017b). 
 Chapter 8: General Discussion  
228 
 
Some of the results produced during this study were only found to result in non-significant 
trends of change. Therefore care must be taken when interpreting these results and drawing 
conclusions. Future studies should investigate these trends further in order to produce more 
definitive conclusions. 
Once these studies have been performed, the anti-atherogenic properties of CardioWise and 
catechin and their mechanism of action should be well established. However to fully determine 
the efficacy of CardioWise and catechin treatment for atherosclerosis, long term human trials 
need to be conducted in participants who are and are not receiving statins over an extensive 
treatment time period. Only after randomised clinical trials can the effectiveness of CardioWise 
and catechin treatment be fully determined. 
 
8.7 The limitations within the nutraceutical field and future directions 
Research into the cardiovascular protective effects of nutraceuticals has grown over the years. 
Nutraceuticals have emerged from both preclinical and clinical studies as possible anti-
atherogenic compounds which have the potential to reduce an individual’s risk of suffering a 
CVD-related event such as MI or stroke (Moss and Ramji 2016b). It is essential that the health 
benefits of nutraceuticals continue to be explored as current and emerging pharmaceutical 
therapies are either not fully effective or fail to progress from clinical trials to approval. 
However, research on nutraceuticals has often lagged behind pharmaceutical therapies for a 
variety of reasons. 
Clinical trials for nutraceuticals often occur on a small scale and within a population from a 
single country, which fails to account for differences in lifestyle and diets (Moss and Ramji 
2016b). This heterogeneity within the populations used for different nutraceutical clinical trials 
may explain why some are found to be successful while others fail to find any additional health 
benefits from dietary supplementation. To overcome this issue, large, robust randomised 
clinical trials which recruit participants from multiple countries should be performed. This is 
currently the rationale behind the REDUCE-IT and STRENGTH clinical trials which are 
assessing the cardiovascular protective effects of ω-3 PUFAs (U.S. National Institutes of 
Health 2017a; U.S. National Institutes of Health 2017c). Furthermore consistency is essential 
in human trials. Studies often differ in nutraceutical composition, concentration and duration of 
intervention, which only contributes to the discrepancy that often occurs within the published 
literature in relation to nutraceutical’s effects and efficacy.  
To reduce the failure rate at the human clinical trial level, an improvement in the design of 
preclinical studies would aid in the identification of the most effective nutraceuticals. The major 
limitation of preclinical nutraceutical research is the dosage used as they are often too high. 
Therefore studies should perform experiments with a concentration of the desired nutraceutical 
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at a dosage which would be found within the target tissue after consumption. Furthermore the 
use of dose-response experiments should be utilised whenever possible to ensure the most 
effective dosage is delivered to patients. Additionally preclinical studies should also focus on 
the mechanism of action behind potential cardiovascular protective effects of nutraceuticals. 
Developing a better understanding of how nutraceuticals are capable of exerting their anti-
atherogenic effects may aid in the development of novel pharmaceutical therapies which are 
capable of mimicking the key responses. For example, GPR120 was identified as the potential 
receptor by which ω-3 PUFAs mediated their anti-inflammatory and insulin sensitising effects 
(Oh et al. 2010). This led to the development of an orally administered cpdA, which is a highly 
selective small molecule GRP120 agonist capable of improving insulin resistance and chronic 
inflammation in obese mice (Oh et al. 2014).  
 
8.8 Conclusion 
Using our in vitro models of atherosclerosis disease progression, we were able to show that 
CardioWise, which is a unique nutraceutical combination of ω-3 PUFAs, flavanols and 
phytosterols, was capable of exerting anti-atherogenic effects. These anti-atherogenic effects 
were also observed in wild type mice fed a high fat diet. The major flavanol, (+)-catechin, was 
identified as a potent anti-atherogenic compound in vitro and in vivo. Future studies are 
required to explore the effect of both CardioWise and catechin as add-on therapies for statins 
in atherosclerotic mouse models. This study has shown that nutraceuticals are effective anti-
inflammatory therapies capable of providing cardiovascular protective effects and therefore 
represent promising emerging therapies for atherosclerosis. We are entering an exciting phase 
in nutraceutical research. 
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S.1 CardioWise attenuates the expression of pro-inflammatory genes following IFN-γ 
stimulation in murine macrophages 
IFN-γ is capable of inducing the expression of two key markers of inflammation, MCP-1 and 
ICAM-1, which also play major roles in the development of atherosclerosis development (Moss 
and Ramji 2016a; Li et al. 2010). The expression of MCP-1 in RAW264.7 macrophages was 
significantly increased by 32.39 and 6.17 fold (p=0.006 and p=0.004) following IFN-γ 
stimulation (250 U/ml; Supplementary Fig. S.1A and S.1C). Furthermore the transcript levels 
of ICAM-1 were increased by 9.04 and 23.54 fold (p<0.001 and p<0.001) when compared to 
the vehicle control (Supplementary Fig. S.1B and S.1D). When treated with either a 1x or 4x 
physiological dose of the complete CardioWise formulation, the IFN-γ stimulated MCP-1 
expression was attenuated by 96.6% (p=0.010) and 95.2% (p=0.021) respectively 
(Supplementary Fig. S.1A). A decrease of 70.1% (p=0.009) in IFN-γ induced expression of 
ICAM-1 was observed when cells were incubated with 2x dose of complete CardioWise, 
whereas the 4x dose reduced ICAM-1 expression by 75.5% (p=0.001; Supplementary Fig. 
S.1B). Similar observations were apparent in murine RAW264.7 macrophages which were 
treated with CardioWise in the absence of phytosterols. The expression of MCP-1 was reduced 
by 82.3% (p=0.004), 86.7% (p=0.001) and 84.1% (p=0.003) when treated with the 0.25x, 0.5x 
or 1x physiological dose respectively (Supplementary Fig. S.1C). In comparison to the IFN-γ 
stimulated cells, the expression of ICAM-1 was attenuated in the presence of CardioWise 
lacking phytosterols at the 0.25x, 0.5x, 1x and 4x dose by 78.0% (p=0.001), 74.9% (p=0.014), 
80.0% (p<0.001) and 80.1% (p<0.001) respectively (Supplementary Fig. S.1D).  
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Supplementary Fig. S.1. CardioWise can inhibit the IFN-γ induced expression of MCP-1 and ICAM-1 at 
physiologically relevant doses in murine macrophages. The expression of MCP-1 (A and C) and ICAM-1 (B 
and D) was assessed in RAW264.7 macrophages that were either treated with vehicle (vehicle control) or with IFN-
γ (250 U/ml) or IFN-γ (250 U/ml) in the presence of the complete CardioWise formulation (+PS; A and B) or with 
IFN-γ (250 U/ml) in the presence of CardioWise lacking phytosterols (-PS; C and D) for 3 hours. Gene expression 
levels were assessed using qPCR and calculated using the comparative Ct method and normalised to β-actin levels 
with values from vehicle treated cells given an arbitrary value of 1. The data are presented as the mean ± SEM 
from four (A and C) or five (B and D) independent experiments. Statistical analysis was performed on the log-
transformed data using a one-way ANOVA with either a Dunnett (D) or Games-Howell (A, B and C) post-hoc 
analysis where * p ≤0.05, ** p ≤0.01 and *** p ≤0.001. 
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S.2 First authored publications 
The following publications were written and accepted during the project time period. 
S.3.1 Interferon-γ: Promising therapeutic target in atherosclerosis 
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S.3.2 A Unique Combination of Nutritionally Active Ingredients Can Prevent Several Key 
Processes Associated with Atherosclerosis In Vitro 
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S.3.3 Cytokines: Roles in atherosclerosis disease progression and potential therapeutic 
targets 
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S.3.4 Nutraceutical therapies for atherosclerosis 
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